
<SEC-DOCUMENT>0001185185-16-005234.txt : 20160815
<SEC-HEADER>0001185185-16-005234.hdr.sgml : 20160815
<ACCEPTANCE-DATETIME>20160815165314
ACCESSION NUMBER:
CONFORMED SUBMISSION TYPE:
PUBLIC DOCUMENT COUNT:
CONFORMED PERIOD OF REPORT:
FILED AS OF DATE:
DATE AS OF CHANGE:
10-Q
45
20160630
0001185185-16-005234
20160815
20160815
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME:
CENTRAL INDEX KEY:
STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000]
IRS NUMBER:
STATE OF INCORPORATION:
FISCAL YEAR END:
Bio-AMD Inc.
0001370030
205242826
1231
NV
FILING VALUES:
FORM TYPE:
SEC ACT:
SEC FILE NUMBER: 000-52601
FILM NUMBER:
10-Q
1934 Act
161833546
BUSINESS ADDRESS:
STREET 1:
CITY:
STATE:
ZIP:
BUSINESS PHONE:
MAIL ADDRESS:
STREET 1:
CITY:
STATE:
ZIP:
FORMER COMPANY:
SCI-TECH DARESBURY, KECKWICK LANE
DARESBURY
X0
WA4 4FS
44(0)8445-861910
SCI-TECH DARESBURY, KECKWICK LANE
DARESBURY
X0
WA4 4FS
FORMER CONFORMED NAME: Flex Fuels Energy, Inc.
DATE OF NAME CHANGE:
20070806
FORMER COMPANY:
FORMER CONFORMED NAME: Malibu Minerals Inc.
DATE OF NAME CHANGE:
20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bio-amd10q063016.htm
<DESCRIPTION>10-Q
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-BOTTOM: black 1px 
solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: 
#ffffff; MARGIN-RIGHT: auto" align="center">
 UNITED STATES</div>
<div style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">SECURITIES AND EXCHANGE 
COMMISSION</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Washington, 
D.C.&#160;&#160;20549</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">&#160;</div>
<div>
<hr style="HEIGHT: 1px; WIDTH: 12%; COLOR: #000000; TEXT-ALIGN: center; MARGIN-
LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" 
noshade="noshade">
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center"><font style="FONT-SIZE: 16pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">FORM 10-
Q</font>&#160;&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">
<hr style="HEIGHT: 1px; WIDTH: 12%; COLOR: #000000; TEXT-ALIGN: center; MARGIN-
LEFT: auto; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" 
noshade="noshade">
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<table id="z2fb70e25da77458ba90be37fdef1e2ec" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 6.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">&#9746;</div>
</td>
<td style="WIDTH: 93.8%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">For the quarterly period ended <font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold"><u>June 30, 2016</u></font></div>
<div><br>
</div>
<table id="zb4e2acffe6e2471da779d2ea6b89cb6d" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 6.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">&#9744;</div>
</td>
<td style="WIDTH: 93.74%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">TRANSITION REPORT PURSUANT TO SECTION 13 OR 
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: middle" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">For the transition period from _______ to 
_______</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">Commission File Number:&#160;&#160;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold"><u>000-52601</u></font></div>
<div><br>
</div>
<div style="FONT-SIZE: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center"><u>BIO-AMD, INC.</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">(Exact name of registrant as specified in 
its charter)</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<table id="z4993b30f233641e583ffa3a5c612521e" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
VARIANT: normal; WIDTH: 50%; VERTICAL-ALIGN: middle; FONT-WEIGHT: bold; COLOR: 
#000000; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ">
<div style="TEXT-ALIGN: center"><u>Nevada</u></div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
VARIANT: normal; WIDTH: 50%; VERTICAL-ALIGN: middle; FONT-WEIGHT: bold; COLOR: 
#000000; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ">
<div style="TEXT-ALIGN: center"><u>20-5242826</u></div>
</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">(State or other jurisdiction of 
incorporation)&#160;</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">(I.R.S. Employer Identification No.)</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center"><u>Sci-Tech Daresbury, 
Keckwick Lane, Daresbury, WA4 4FS, UK</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">(Address of principal executive 
offices)</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center"><u>+ 44 (0) 8445 
861910</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">(Registrant&#8217;s telephone number, 
including area code)</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Indicate by check mark whether the 
registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for 
such shorter period that the registrant was required to file such reports), and 
(2) has been subject to such filing requirements for the past 90 
days.&#160;&#160;Yes&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
Wingdings">x </font>No&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif">&#9744;</font></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: justify">Indicate by check mark whether the 
registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 
12 months (or for such shorter period that the registrant was required to submit
and post such files).&#160;&#160;Yes <font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif">&#9746;</font>&#160;&#160;No <font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Indicate by check mark whether the 
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of &#8220;large 
accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller 
reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<table id="zf63f0ac34df948658cf245e15f09d184" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 19.61%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">Large accelerated filer <font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>
</td>
<td style="WIDTH: 6.97%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">Accelerated filer <font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>
</td>
<td style="WIDTH: 6.98%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 20.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">Non-accelerated filer <font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>
</td>
<td style="WIDTH: 6.98%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 23.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">Smaller reporting company <font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9746;</font></div>
</td>
</tr>
<tr>
<td style="WIDTH: 19.61%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 6.97%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 6.98%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 20.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">(Do not check if a smaller</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">Reporting company)</div>
</td>
<td style="WIDTH: 6.98%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 23.34%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Indicate by check mark whether the 
registrant is a shell company (as defined in Rule 12b-2 of the Exchange 
Act).&#160;&#160;Yes&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif">&#9744;</font>&#160;&#160;No&#160;&#160;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">&#9746;</font></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">There were 45,975,966 shares of the 
issuer&#8217;s common stock outstanding as of August 8, 2016.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">BIO-AMD, INC.</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">FORM 10-Q</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2016</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt"><a name="TABLEOFCONTENTS"><!--Anchor--></a>TABLE OF CONTENTS</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>
<table id="zf35ee63dc7af4f899aa223ff1163614c" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">PAGE</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">PART I - FINANCIAL 
INFORMATION</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr style="HEIGHT: 13px">
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 1.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM1.FINANCIAL">Financial 
Statements</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">3</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 2.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a 
href="#ITEM2.MANAGEMENTS">Management&#8217;s Discussion and Analysis of 
Financial Condition and Results of Operations</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">17</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 3.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM3.QUANTITATIVE">Quantitative and
Qualitative Disclosures About Market Risk</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">28</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 4.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM4.CONTROLS">Controls and 
Procedures</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">28</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">PART II - OTHER 
INFORMATION</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 1.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM1.LEGAL">Legal 
Proceedings</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 1A.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM1A.RIS">Risk Factors</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr style="HEIGHT: 13px">
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 2.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM2.UNREGISTERED">Unregistered 
Sales of Equity Securities and Use of Proceeds</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 3.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM3.DEFAULTS">Defaults Upon Senior
Securities</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 4.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM4.MINE">Mine Safety 
Disclosures</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 5.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM5.OTHER">Other 
Information</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Item 6.</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#ITEM6.EXHIBITS">Exhibits</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 10.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 81.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left"><a 
href="#SIGNATURES">SIGNATURES</a></div>
</td>
<td style="WIDTH: 7.7%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">30</div>
</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">PART I &#8211; FINANCIAL INFORMATION</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 
3pt"><a name="ITEM1.FINANCIAL"><!--Anchor--></a>ITEM 1.&#160;&#160;FINANCIAL 
STATEMENTS</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>
<table id="z995b51e827d943dc8297d1b0358455a8" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">PAGE</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#BALANCESHEETS">Condensed 
Consolidated Balance Sheets as of June 30, 2016 (unaudited) and December 31,
2015</a></div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">4</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#OPERATIONS">Condensed Consolidated 
Statements of Operations and Comprehensive Loss for the three month and six 
month&#160;periods ended June 30, 2016 and 2015 (unaudited)</a></div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">5</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#EQUITY">Condensed Consolidated 
Statement of Equity for the&#160;six month period ended June 30, 2016 
(unaudited)</a></div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">6</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#CASHFLOWS">Condensed Consolidated 
Statements of Cash Flows for the&#160;six month periods ended June 30, 2016 and 
2015 (unaudited)</a></div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">7</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 94.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="#Notes">Notes to Condensed 
Consolidated Financial Statements (unaudited)</a></div>
</td>
<td style="WIDTH: 5.52%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">8</div>
</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">3</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD, INC.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">CONDENSED CONSOLIDATED <a 
name="BALANCESHEETS"><!--Anchor--></a>BALANCE SHEETS</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">EXPRESSED IN US DOLLARS</div>
<div style="TEXT-ALIGN: left"><br>
</div>
<table id="z38b57b23f5b14d52b022da388ec65969" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">June 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN:
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom" 
colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">(Unaudited)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" 
valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" 
valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">ASSETS</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" 
valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" 
valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;Cash</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">68,754</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">437,400</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;Amounts receivable</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">5,359</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">12,972</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;Prepaid expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">8,068</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">12,251</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;Deferred charges (Note 1)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">645,534</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total Current Assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">82,181</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,108,157</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;Property and equipment, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">140</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">157</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;Patents (Note 3)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">165,573</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">165,848</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total Assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,274,162</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">LIABILITIES AND STOCKHOLDERS' EQUITY</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Current Liabilities:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;Accounts payable</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">34,114</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">62,149</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;Accrued liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif">17,575</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">23,239</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;Other liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">761</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">17,316</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;Deferred revenue (Note 1)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">950,402</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total Liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">52,450</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,053,106</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Nature of Operations and Continuation of Business (Note 1)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Subsequent Event and Commitment (Note 7)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Stockholders' Equity:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 9pt">Preferred stock, 10,000,000 shares authorized, 
$0.001 par value, </div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">nil shares issued and outstanding</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">-</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">-</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom"></td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 9pt">Common stock, 500,000,000 shares authorized, 
$0.001 par value,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">45,975,966 shares issued and outstanding</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,976</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,976</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 9pt">Additional paid-in capital</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">42,611,186</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">42,589,759</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 9pt">Accumulated other comprehensive income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">35,571</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">73,243</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 9pt">Deficit</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(41,384,326</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(41,331,858</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total Bio-AMD, Inc. Stockholders' Equity</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,308,407</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,377,120</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Non-controlling interest</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(1,112,963</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(1,156,064</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total Stockholders' Equity</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">195,444</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">221,056</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total Liabilities and Stockholders' Equity</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,274,162</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP: 3pt">&#160;(The 
accompanying notes are an integral part of these unaudited condensed 
consolidated financial statements)</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">4</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="FONT-WEIGHT: bold; TEXT-ALIGN: center">Bio-AMD, INC.</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">CONDENSED CONSOLIDATED STATEMENTS OF <a name="OPERATIONS"><!--Anchor--
></a>OPERATIONS AND COMPREHENSIVE LOSS</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">EXPRESSED IN US DOLLARS</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">(Unaudited)</div>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<table id="z6763fa60b4b9472b949124d2bdb97bce" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">For the three months</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">For the six months</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">ended June 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">ended June 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
center" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
center" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
center" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 44%; VERTICAL-
ALIGN: bottom" valign="bottom">
<div>Operating expenses:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" 
valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" 
valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" 
valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" 
valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;General and administrative charges (Note 4)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">103,847</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">354,863</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">257,594</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">578,496</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total operating expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">103,847</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">354,863</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">257,594</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">578,496</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net loss before other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(103,847</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(354,863</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(257,594</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(578,496</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Other income:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;Gain on termination of research agreement (Note 
5)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">248,074</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">248,074</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">490</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">731</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">962</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,524</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">144,717</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(354,132</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(8,558</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(576,972</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net loss (income) attributable to the non-controlling 
interest</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(48,574</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">7,502</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(43,910</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">13,554</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net loss attributable to Bio-AMD, Inc. common shareholders</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">96,143</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(346,630</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(52,468</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(563,418</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Comprehensive Loss:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">144,717</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(354,132</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(8,558</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(576,972</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Foreign currency translation adjustment, net of tax</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(14,848</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">26,402</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(17,054</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(2,875</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Total other comprehensive income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif">129,869</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(327,730</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(25,612</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(579,847</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Comprehensive (income)/loss attributable to the non-controlling 
interest</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(62,547</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">19,990</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(64,529</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">16,484</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Comprehensive loss attributable to the Bio-AMD, Inc. common 
shareholders</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">67,322</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(307,740</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif">(90,141</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(563,363</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net loss per common share attributable to Bio-AMD, Inc. common 
shareholders - basic and diluted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">0.00</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(0.01</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(0.00</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif">(0.01</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 44%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Weighted average number of common</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">shares outstanding - basic and diluted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,975,966</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,103,998</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,975,966</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">44,906,076</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(The 
accompanying notes are an integral part of these unaudited condensed 
consolidated financial statements)</div>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">5</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">Bio-AMD, INC.</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">CONDENSED CONSOLIDATED STATEMENT OF <a name="EQUITY"><!--Anchor--
></a>EQUITY</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">FOR THE THREE MONTH PERIOD ENDED JUNE 30, 2016</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">EXPRESSED IN US DOLLARS</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">(Unaudited)</div>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<table id="zdde48feacbcf4c7ea8a9af6a6e534721" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Accumulated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Other</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Common Stock</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: " 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Additional</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: " 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Comprehensive</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: " 
valign="bottom" colspan="2">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: " 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Non-controlling</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: " 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Stockholders'</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Shares<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif"><br>
</font> #</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Amount<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif"><br>
</font> $</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px"
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Paid-in Capital<font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> $</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Income<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif"><br>
</font> $</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Deficit<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif"><br>
</font> $</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Interest<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif"><br>
</font> $</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Equity (Deficit)<font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> $</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Balance at December 31, 2015</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,975,966</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,976</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">42,589,759</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">73,243</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(41,331,858</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(1,156,064</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">221,056</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Comprehensive income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(37,672</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">20,618</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(17,054</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Subsidiary preferred dividend</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">8,914</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(8,914</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Change in ownership interest of subsidiary</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">12,513</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(12,513</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(52,468</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">43,910</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(8,558</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 16%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Balance at June 30, 2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,975,966</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">45,976</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">42,611,186</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">35,571</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(41,384,326</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(1,112,963</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">195,444</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(The 
accompanying notes are an integral part of these unaudited condensed 
consolidated financial statements)</div>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">6</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">Bio-AMD, INC.</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">CONDENSED CONSOLIDATED STATEMENTS OF <a name="CASHFLOWS"><!--Anchor--
></a>CASH FLOWS</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">EXPRESSED IN US DOLLARS</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP:
3pt">(Unaudited)</div>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<table id="zb4e869e24ccc4f7484f25dbac6de4338" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">For the six months ended June 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">$&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Cash flows from operating activities:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(8,558</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(576,972</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Adjustments to reconcile net loss to net cash used in operating 
activities:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amortization of 
prepaid stock based fees</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">24,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain on termination
of research agreement</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(248,074</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock based 
consulting fees</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">184,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in 
operating assets and liabilities:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;Amounts receivable</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">7,613</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">5,323</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Prepaid expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">4,402</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(7,834</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Deferred charges</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(46,878</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(397,301</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN:
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Security deposit and other assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(19,594</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Accounts payable</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(28,035</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">102,777</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Accrued liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(5,664</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Other liabilites</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(16,555</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(3,420</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Deferred revenue</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">978,076</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net cash (used in) provided by operating activities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(341,749</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">289,055</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Cash flows from investing activities:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: 
left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#
160;&#160;Patent expenditures</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(18,824</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Net cash used in Investing Activities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(18,824</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN:
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Effects of exchange rate changes on cash</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(8,073</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; 
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid;
TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">16,944</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Change in Cash</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">(368,646</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">305,999</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Cash, beginning of period</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">437,400</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">717,144</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Cash, end of period</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">68,754</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double;
TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">1,023,143</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: 
left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Non-cash Investing and Financing activities:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">&#160;&#160;Common stock issued for prepaid services</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">54,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Supplementary disclosure of cash flow information:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Interest</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 72%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Income tax</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(The 
accompanying notes are an integral part of these unaudited condensed 
consolidated financial statements)</div>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">7</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="FONT-WEIGHT: bold; TEXT-ALIGN: center">Bio-AMD, Inc.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center"><a name="Notes"><!--Anchor--
></a>Notes to Unaudited Condensed Consolidated Financial Statements</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">June 30, 2016</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Expressed in US 
dollars)</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Note 1&#160;&#8211; Nature of
Operations and Continuance of Business</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">General</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The accompanying unaudited condensed 
consolidated financial statements have been prepared pursuant to the rules and 
regulations of the Securities and Exchange Commission (the 
&#8220;SEC&#8221;).&#160;Certain information and note disclosures normally 
included in annual consolidated financial statements prepared in accordance with
generally accepted accounting principles have been condensed or omitted pursuant
to those rules and regulations, although the Company believes that the 
disclosures made are adequate to make the information not misleading.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In the opinion of management, the unaudited
condensed consolidated financial statements have been prepared on the same basis
as the annual consolidated financial statements and reflect all adjustments, 
which include only normal recurring adjustments, necessary to present fairly the
consolidated financial position as of June 30, 2016 and the results of 
operations and cash flows for the six month periods ended June 30, 2016 and 
2015. The financial data and other information disclosed in the notes to the 
interim condensed consolidated financial statements related to these periods are
unaudited.&#160;The results for the three and six month period ended June 30, 
2016 are not necessarily indicative of the results to be expected for any 
subsequent quarter or the entire year ending December 31, 2016.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">These unaudited condensed consolidated 
financial statements should be read in conjunction with our audited consolidated
financial statements and the notes thereto for the year ended December 31, 2015,
included in the Company&#8217;s annual report on Form 10-K filed with the 
SEC&#160;on March 30, 2016.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Nature of Operations</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Bio-AMD, Inc. (&#8220;Bio-AMD&#8221; the 
&#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) 
(formerly known as Flex Fuels Energy, Inc. and Malibu Minerals, Inc.) was 
incorporated in the State of Nevada on March 10, 2006 to engage in the business 
of exploration and discovery of gold, minerals, mineral deposits and 
reserves.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On April 15, 2011, we entered into an 
Agreement and Plan of Merger (the "Merger Agreement") pursuant to which we 
merged with our newly formed, wholly owned subsidiary, Bio-AMD, Inc., a Nevada 
corporation ("Merger Sub" and such merger transaction, the "Merger"). Upon the 
consummation of the Merger, the separate existence of Merger Sub ceased and 
shareholders of the Company became shareholders of the surviving company named 
Bio-AMD, Inc. As permitted by Chapter 92A.180 of Nevada Revised Statutes, the 
sole purpose of the Merger was to effect a change of our name to Bio-AMD, Inc. 
to better reflect our core business area. Upon the filing of Articles of Merger 
(the "Articles of Merger") with the Secretary of State of Nevada on April 15, 
2011 to effect the Merger, our Articles of Incorporation were deemed amended to 
reflect the change in our corporate name.&#160;&#160;We are quoted on OTC 
Markets and the OTC Bulletin Board under the symbol &#8220;BIAD&#8221;.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">During the fourth quarter of our 2006 
fiscal year, for the purpose of diversifying our business, acquiring capital, 
gaining greater access to the capital markets and with the assistance of newly 
acquired capital, we entered into an Agreement with Flex Fuels Energy Limited 
(&#8220;FFE Ltd&#8221;) and the stockholders of FFE Ltd by which FFE Ltd became 
our wholly-owned subsidiary effective on May 29, 2007. FFE Ltd engaged in the 
development of the business of manufacturing and distributing Oil Seed Rape 
(&#8220;OSR&#8221;) products.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Effective September 5, 2009, after having 
carefully evaluated all options, we abandoned our proposed oil seed business, as
we no longer considered the business to be economically viable on either a go 
alone or partnered basis.&#160;&#160;The proposed project initiated by prior 
management involved building an oil seed crushing plant at Cardiff, Wales was 
compromised by delays, sub-optional design and substantial legal 
costs.&#160;&#160;We were unable to raise the necessary financing, to locate a 
project partner, or to divest our interest in the project for 
value.&#160;&#160;Accordingly, we determined that our best course of action was 
to preserve value by winding down the oil seed operations of FFE Ltd.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">8</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">From our inception through the date of 
these unaudited condensed consolidated financial statements, we have not 
generated any revenues and have incurred significant expenses. The Company 
intends to fund its development of the currency risk technology, diagnostic 
technology and on-going operations through equity and/or debt financing 
arrangements.&#160;&#160;However, there can be no assurance that these 
arrangements will be sufficient to fund its ongoing capital expenditures, 
working capital, and other cash requirements. Consequently, our operations are 
subject to all the risks and uncertainties inherent in the establishment of a 
new business enterprise.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">WOCU Limited 
Acquisition</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On May 1, 2009, we entered into an 
Investment Agreement (the &#8220;Investment Agreement&#8221;) with WDX 
Organisation Limited, a corporation incorporated under the laws of England and 
Wales, and the founding shareholders of WDX Organisation Limited (the 
&#8220;Founders&#8221;), the owners of all of the issued and outstanding shares 
of WDX Organisation Limited.&#160;&#160;On the same date, we entered into a 
related Loan Agreement (the &#8220;Loan Agreement&#8221;) and a related Option 
and Funding Agreement (the &#8220;Funding Agreement&#8221;) with WDX 
Organisation Limited.&#160;&#160;The Investment Agreement, Loan Agreement and 
Funding Agreement are hereinafter collectively referred to as the 
&#8220;Agreements&#8221;. Pursuant to the Agreements, we acquired 51% ownership 
of WDX Organisation Limited. WDX Organisation Limited changed its name to WOCU 
Limited (&#8220;WL&#8221;) effective January 29, 2013.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">WL is the developer of the WOCU technology,
an algorithm and system of providing reference data for its WOCU global currency
unit, designed to mitigate currency risk. On August 14, 2009, we provided a 
further &#163;150,000 (approximately $247,800) to WL by way of a loan and have 
exercised certain call options. On November 20, 2009, we loaned an additional 
&#163;150,000 (approximately $249,840) to WL and increased our equity position
in WL.&#160;WL has been working to develop contracts with a variety of banks, 
currency exchange networks, data providers, and derivative exchanges in an 
effort to commercialize its WOCU technology through licensing 
agreements.&#160;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On March 8, 2010, we loaned an additional 
&#163;150,000 (approximately $224,055) to WL and executed certain call options 
to further increase our equity position in WL. The loans were the result of our 
ongoing investment in WL as contemplated by our May 1, 2009 Investment Agreement
with WL.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Altogether, these transactions resulted in 
a total loan of &#163;600,000 (approximately $904,000) to WL and the ownership 
of 93% of WL by the Company on March 8, 2010.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On July 23, 2010, we entered into a 
Subscription Agreement with WL and the founders of WL under which we purchased 
500,000 preference shares of WL (the &#8220;Preference Shares&#8221;) at a price
of one British Pound per share (approximately $750,000). &#160; The Preference 
Shares earn in priority to any other class of stock of WL, a cumulative dividend
equal to 5% of the subscription price of such Preference Shares per annum. These
Preference Shares carry a preference over all other classes of WL stock in the 
event of a sale, liquidation or listing of WL. Upon liquidation, sale or listing
and after repayment of the outstanding loans made by us to WL, other liabilities
of WL and related transaction costs, the holder of the Preference Shares is 
entitled to a payment equal to three times the subscription price (the 
&#8220;Preference Shares Payment&#8221;) paid for such Preference 
Shares.&#160;&#160;The Preference Shares are redeemable upon a sale, listing or 
winding down of WL.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Subscription Agreement also provided 
for WL to allot up to an aggregate of 16,900 C Ordinary Shares of WL to 
employees, directors and consultants of WL to secure their continued service to 
WL and incentivize them in the performance thereof.&#160;&#160;An aggregate of 
14,061 C Ordinary Shares were issued, for nominal consideration, to three 
employees and Robert Galvin, our former Chief Financial Officer on July 23, 
2010. The issuance of the 14,061 C Ordinary Shares reduced our ownership in WL 
from 93% to 77.54%.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Effective June 30, 2011, WL agreed with all
three of its employees to terminate existing employment agreements so as to 
reduce the monthly cash outflows. As a result of the termination of employment 
contracts, and in accordance with the WL Articles of Association, terminated 
employees gave up 9,243 C Ordinary Shares. This increased our ownership in WL to
87.13%.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">During November 2011, we loaned an 
additional &#163;50,000 (approximately $77,000) to WL as a short-term unsecured 
intercompany loan. On July 12, 2012, it was agreed that this loan would be 
settled through the issuance of 5,000,000 common shares, increasing our 
ownership in WL to 99.81%.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">9</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Since January 2013, the Company has 
provided further advances totaling &#163;196,000 (approximately $260,000) into 
WL to fund its operations based on the prospective pipeline of opportunities 
that have been generated.</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 0.1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; 
MARGIN-RIGHT: 0.1pt">As at June 30, 2016, there were no commercial agreements in
place, and no revenues had been generated by WL. Given the Company&#8217;s 
limited resources, it is unlikely that the Company can support WL operations 
going forward, as a contractor to WL vital to its technical operation has 
indicated it is not willing to continue to provide its services at the current 
much reduced rate of payment and accordingly further investment will be required
to support WL. The Company will consider any option that might preserve any 
value in WL.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Bio-AMD Holdings Limited 
Acquisition</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On February 25, 2010, we entered into a 
Subscription and Shareholders Agreement with Bio-AMD Holdings Limited 
(&#8220;Bio-AMD Holdings&#8221;), a United Kingdom company, and the managers of 
Bio-AMD Holdings, under which we acquired a 63% interest in Bio-AMD Holdings for
&#163;865,000 British Pounds (approximately $1,335,000) through the purchase of 
preferred shares.&#160;&#160;The preferred shares accrue dividends at the rate 
of 5% per year and provide for a preference in liquidation equal to 
&#163;865,000, plus accrued unpaid dividends (the preference on a sale is 
&#163;850,000, plus accrued and unpaid dividends). Bio-AMD Holdings is a 
development stage company, formed in February 2010, which, through its operating
subsidiary, Bio Alternative Medical Devices Ltd. (&#8220;Bio-Medical&#8221;), 
principally operates in the Medical Point of Care (&#8220;POC&#8221;) diagnostic
space. Where context requires, reference to Bio-AMD Holdings also includes 
reference to Bio-Medical. Bio-AMD Holdings owns a portfolio of patent 
applications on technologies, which it expects to enable it to develop highly 
accurate, low cost, hand held electronic diagnostic devices capable of reading 
certain third party assays. Since 2010 Bio-AMD Holdings has been developing its 
technology into three initial product types (1) a digital strip reader targeted 
initially into the &#8220;over the counter&#8221; female well-being market 
(including digital pregnancy, ovulation and fertility testing, (2) a blood 
coagulation device and (3) early stage development work into a POC immunoassay 
detection system based on magnetic nanoparticle manipulation.&#160;&#160;In 
addition, Bio-AMD Holdings is working to develop various commercial 
relationships with manufacturers, bio-chemistry companies and sales 
distributions partners to enable commercialization of its products through 
licensing agreements.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Since January 2014, the Company has 
provided additional working capital by way of cash injections via intercompany 
loans amounting to &#163;100,000 (approximately $132,000) to Bio-AMD Holdings to
further fund operations. These loans are secured against the assets of Bio-AMD 
Holdings and its wholly owned operating subsidiary, Bio-Medical.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Restructuring of Bio-AMD 
Holdings and Bio-Medical operations</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On June 1, 2016, the 
intellectual property relating to the Company's DSR, COAG and MIDS projects (the
"IP") and depreciated physical equipment assets (together the IP, the "Assets"),
formerly under the control of Bio-AMD Holdings and Bio-Medical, were brought 
into the full control of Bio-AMD, Inc. under loan security agreements put in 
place by the Company during 2015.</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On June 17, 2016, the Company
entered into a Subscription and Shareholders' Agreement with Bio-AMD UK Holdings
Limited ("UKH"), a United Kingdom company, and the managers of UKH, under which 
we acquired a 70% interest in UKH in exchange for the Assets. See exhibit
10.1.</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">UKH is a development stage 
company, formed in May 2009 by the Company's two principal and key scientists 
formerly contracted to Holdings, Dr. Nasser Djennati and Dr. Andrew Mitchell. 
UKH was formerly dormant and has never traded. Immediately prior to the 
transaction UKH formed a new subsidiary, MIDS Medical Limited ("MML") as a 
dedicated vehicle to develop our MIDS universal immunoassay detection technology
in a joint venture, further described below. UKH has taken over the operations 
of Holdings and Bio-Medical.</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The 30% of UKH not owned by 
the Company is owned by Dr. Nasser Djennati (15%) and Dr. Andrew Mitchell (15%),
whose experience and qualifications were reported on Form 8K filed on March 3, 
2010. The board of directors of both UKH and MML consists of Drs. Djennati and 
Mitchell, and Mr Barr, the Company's CEO.</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The effect of the 
restructuring was to beneficially increase the Company's interest in its UK 
medical operations from 63% to 70%, to simplify and gain better voting control 
of its UK subsidiaries, and to eliminate two employee profit share 
arrangements.</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">10</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">As a result of the 
incremental increase in the ownership of the Assets, the Company recorded a 
charge to Additional Paid-in Capital and the Non-controlling Interest of
$12,513. The amount represents the Company&#8217;s additional interest in the 
net book value of the group of Assets determined by voting control.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">MIDS 
Medical Limited Operations</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On June 20, 2016, the
Company and its UKH and MML subsidiaries entered into a joint venture by way of 
a Subscription and Shareholders&#8217; Agreement (&#8220;Agreement&#8221;) with 
a third party medical detection device developer (&#8220;Partner&#8221;) a 
Nevada corporation, under which the Partner, in exchange for its participation 
and funding to support MML during a Phase 1 development, owns a 40% interest in 
MML as of July 1, 2016, The Partner also prospectively agreed to fund a Phase 2 
development of our MIDS universal immunoassay detection technology within the 
MML vehicle. MML will have the right to use the MIDS Intellectual Property 
(&#8220;MIDS IP&#8221;) under license during the development and the MIDS IP 
will be transferred to MML in the event that MML concludes a commercial deal for
MIDS with a third party. See exhibit 10.2.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Agreement 
provides for a series of payments (&#8220;Phase 1 Payments&#8221;) in an 
aggregate amount of &#163;450,500 (approximately $650,000 based on the current 
rate of exchange). The Partner made a Phase 1 Payment to MML, of $130,000 (the 
&#8220;First Payment&#8221;), which was received on August 2, 2016 and converted
to &#163;92,857. Subsequent Phase 1 Payments are expected to be received as 
follows; (a) on or before September 20, 2016, a payment &#163;106,093, (b) on or
before November 20, 2016, a payment of &#163;100,640; (c) on or before January 
20, 2017 a payment of &#163;100,640; and (d) on or before March 20, 2016 a 
payment of &#163;50,320.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Agreement also 
provides for a contingency funding (&#8220;Contingency&#8221;) to be made 
available by the Partner after March 31, 2017 in an aggregate amount of up to 
&#163;45,000 (approximately $64,000) to be paid by the Partner within 20 days of
receiving a written notice from&#160; MML.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The parties to the 
Agreement envisage a second phase of development (&#8220;Phase 2&#8221;) to 
follow Phase 1. This is expected to be broadly over a similar timeframe and at a
similar cost. MML may independently obtain funding for Phase 2 at MML&#8217;s 
option, or invite the Partner to fund.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Agreement 
contains various provisions to govern the funding obligations of the Partner: if
any Phase 1 Payment is not made within 14 days of it falling due 
(&#8220;Default&#8221;), the Partner&#8217;s shareholding in MML may be reduced 
to zero; if no Contingency is drawn during Phase 1, UKH will be awarded an 
enduring 2.5% profit after tax right in MML (&#8220;Override&#8221;) which will 
increase to a 15% Override if the Partner declines to fund Phase 2; if the 
Partner declines to fund Phase 2 and any Contingency has been drawn, UKH will be
awarded a 15% Override decreased by 0.5% for each &#163;7,500 tranche of 
Contingency drawn down during Phase 1. Any Override will convert pro rata into 
ordinary shares in the event of a sale of MML.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Provided that each 
Phase 1 Payment is made within 14 days of falling due, the Partner also has 
additional control rights over MML, including representation on the MML board of
directors, rights over the appointment and employment of senior management 
persons, indebtedness, major transactions, budget approval rights, accounting 
practices and general operational management supervisory rights.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">As a condition of the
Agreement, MML has entered into Supply of Services Agreements under which it 
receives the services of Drs. Djennati and Mitchell, being key personnel related
to the MIDS development.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Initial development 
project planning has commenced on the MIDS project, including the specification 
of a bench rig printed circuit board designed to support first stage testing of 
a sample of Hall Effect Sensors already supplied to MML in order to examine 
their behavior in the detection of magnetic nanoparticles &#8211; the core MIDS 
technology &#8211; and to determine how these Hall Effect Sensors should be 
optimized prior to integration in a micro fluidic test strip.</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company has 
agreed, pursuant to a letter agreement (the &#8220;Warrant Agreement&#8221;), to
prospectively issue 3,000,000 five year warrants in the Company exercisable at 
$0.10, to certain third parties (or their nominees) who have introduced the 
Partner to the Company (&#8220;Introducer Warrants&#8221;). The Warrant 
Agreement provides for the Introducer Warrants to be issued at the discretion of
the Company at any time up to MML receiving the final Phase 1 Payment, and may 
not be exercised prior to June 15, 2017. In the event the Phase 1 Payments are 
not made in full, the Company will have the right to cancel the issuance of the 
Introducer Warrants, or to negotiate revised terms, at the Company&#8217;s sole 
option. No other fees have been paid in regard to the Agreement. See exhibit 
4.1.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">11</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Going Concern</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The accompanying unaudited condensed 
consolidated financial statements have been prepared on a going concern basis,
which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business.&#160;&#160;The Company has not commenced its 
planned principal operations. As shown in the accompanying unaudited condensed 
consolidated financial statements, the Company has not generated any revenue and
has incurred recurring losses through June 30, 2016.&#160;&#160;Additionally, 
the Company has recurring negative cash flows from operations and has an 
accumulated deficit of $41,384,326 as at June 30, 2016.&#160;&#160;These factors
raise substantial doubt about the Company&#8217;s ability to continue as 
a&#160;going concern.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company's ability to continue its 
existence is dependent upon commencing its planned operations, management's 
ability to develop and achieve profitable operations and/or upon obtaining 
additional financing to carry out its planned business. The Company intends to 
fund the development of its diagnostic technology and on-going operations 
through equity and debt financing arrangements.&#160; However, there can be no 
assurance that these arrangements will be sufficient to fund its ongoing capital
expenditures, working capital, and other cash requirements.&#160; The outcome of
these matters cannot be predicted at this time.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">There can be no assurance that any 
additional financings will be available to the Company on satisfactory terms and
conditions, if at all.&#160; In the event we are unable to continue as a going 
concern, we may elect or be required to seek protection from our creditors by 
filing a voluntary petition in bankruptcy or may be subject to an involuntary 
petition in bankruptcy. To date, management has not considered this 
alternative.</div>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The accompanying unaudited condensed 
consolidated financial statements do not include any adjustments related to the 
recoverability or classification of asset-carrying amounts or the amounts and 
classification of liabilities that may result should the Company be unable to 
continue as a going concern.&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Note 2&#160;&#8211; Summary 
of Significant Accounting Policies</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Use of estimates</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The preparation of consolidated financial 
statements in conformity with generally accepted accounting principles requires 
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at 
the date of the consolidated financial statements and the reported amounts of 
revenue and expenses during the reporting period. Actual results could differ 
from those estimates.&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Principles of 
consolidation</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The unaudited condensed consolidated 
financial statements include the accounts of Bio-AMD, Inc., WOCU Limited (a 
99.81% owned subsidiary as of June 30, 2016), Bio-AMD Holdings Limited (a 63% 
owned subsidiary as of June 30, 2016), along with Bio-AMD Holdings 
Limited&#8217;s wholly owned subsidiary Bio-Medical, and&#160;Bio-AMD UK 
Holdings Limited (a 70% owned subsidiary effective June 30, 2016), along with 
its then wholly owned subsidiary MIDS Medical Limited. All significant 
intercompany transactions and balances have been eliminated in 
consolidation.&#160;&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The third party ownerships of 0.19% of WL, 
37% of Bio-AMD Holdings, and 30% of UKH are recorded as non-controlling 
interests in the unaudited condensed consolidated financial 
statements.&#160;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Patents</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Patents are stated at cost less accumulated
amortization and are comprised of patent applications on technologies which the 
Company expects to enable it to develop highly accurate, low cost, hand held 
electronic diagnostic devices capable of reading third party assays. The patents
are amortized straight-line over the estimated useful life but not to exceed 17 
years.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Revenue Recognition</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company recognizes revenue when the 
following criteria have been met: persuasive evidence of an arrangement exists, 
no significant Company obligations remain, collection of the related receivable 
is reasonably assured, and the fees are fixed or determinable. The Company acts 
as a principal in its revenue transactions as it is the primary obligor in the 
transactions.</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">12</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Deferred Revenue and Deferred 
Costs</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company defers revenue on contracts 
which contain a performance commitment until such time as the services have been
completed and no significant Company obligations remain.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The costs associated with contracts for 
which revenue is deferred, including personnel costs and incremental contract 
costs, are initially capitalized as deferred costs. Subsequently these costs are
recognized as a component of cost of revenue when the associated revenue is 
recognized.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In May 2016, the Company received formal 
written notice of termination of its Master Agreement with Sysmex Corporation 
(&#8220;Sysmex&#8221;) in a letter dated April 22, 2016. As a result of the
termination, the Company has no further obligations with respect to the research
agreement and related funding received.&#160; Due to the unexpected termination 
by Sysmex, the Company recorded a gain from the contract termination of 
$248,074.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Foreign currency 
translation</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company's reporting and functional 
currency is US Dollars. The accounts of the Company's 99.81% owned subsidiary, 
WL, and the Company's 63% owned subsidiary, Bio-AMD Holdings, and Bio-AMD 
Holdings' wholly owned subsidiary, Bio-Medical, and the Company's 70% owned 
subsidiary UKH and its wholly owned subsidiary MML, are maintained using the 
local currency (Great British Pounds) as the functional currency. All assets and
liabilities are translated into US Dollars at the balance sheet date, equity is 
translated at historical rates, and revenue and expense accounts are translated 
at the average exchange rate for the year or the reporting period.&#160;The 
translation adjustments are recorded as accumulated other comprehensive 
income.&#160;&#160;Transaction gains and losses arising from exchange rate 
fluctuation on transactions denominated in a currency other than the functional 
currency are included in the unaudited condensed consolidated statements of 
operations.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The relevant translation rates are as 
follows: For the six month period ended June 30, 2016 closing rate at 1.3242 
US$:GBP, average rate at 1.4319 US$:GBP and for the six month period ended June 
30, 2015 closing rate at 1.5717 US$:GBP, average rate at 1.5233 US$:GBP.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Recently Issued Accounting 
Standards</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In February 2015, the FASB issued ASU No. 
2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, 
which is intended to improve targeted areas of consolidation guidance for legal 
entities such as limited partnerships, limited liability corporations, and 
securitization structures (collateralized debt obligations, collateralized loan 
obligations, and mortgage-backed security transactions). The ASU focuses on the 
consolidation evaluation for reporting organizations that are required to 
evaluate whether they should consolidate certain legal entities. In addition to 
reducing the number of consolidation models from four to two, the new standard 
simplifies the FASB Accounting Standards Codification and improves current US 
GAAP by placing more emphasis on risk of loss when determining a controlling 
financial interest, reducing the frequency of the application of related-party 
guidance when determining a controlling financial interest in a variable
interest entity (&#8220;VIE&#8221;), and changing consolidation conclusions for 
companies in several industries that typically make use of limited partnerships 
or VIEs. The ASU will be effective for fiscal years, and interim periods within 
those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-
02 did not have any effect on our financial position, results of operations or 
cash flows.</div>
<div style="MARGIN-BOTTOM: 0.1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In August 2014, the FASB issued ASU No. 
2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-
40)". ASU 2014-15 provides guidance related to management's responsibility to 
evaluate whether there is substantial doubt about an entity's ability to 
continue as a going concern and to provide related footnote disclosure. ASU 
2014-15 is effective for annual periods ending after December 15, 2016, and for 
interim and annual periods thereafter. Early application is permitted. We do not
expect the adoption of ASU 2014-15 to have a material effect on our financial 
position, results of operations or cash flows.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; MARGIN: 0.1pt">In June 2014, the FASB 
issued ASU No. 2014-12, &#8220;Compensation &#8211; Stock Compensation (Topic 
718): Accounting for Share-Based Payments When the Terms of an Award Provide 
That a Performance Target Could Be Achieved after the Requisite Service 
Period.&#8221; This ASU requires that a performance target that affects vesting 
and that could be achieved after the requisite service period be treated as a 
performance condition. ASU 2014-12 is effective for fiscal years, and interim 
periods within those fiscal years, beginning after December 15, 2015. The 
adoption of ASU 2014-12 did not have any effect on our financial position, 
results of operations or cash flows.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">13</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="MARGIN-BOTTOM: 0.1pt; MARGIN-TOP: 0.1pt"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In May 2014, the FASB issued ASU No. 2014-
09, &#8220;Revenue from Contracts with Customers (Topic 606).&#8221; ASU 2014-09
affects any entity using US GAAP that either enters into contracts with 
customers to transfer goods or services or enters into contracts for the 
transfer of nonfinancial assets unless those contracts are within the scope of
other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is 
effective for fiscal years, and interim periods within those fiscal years, 
beginning after December 15, 2016. We are still evaluating the effect of the 
adoption of ASU 2014-09. On April 1, 2015, the FASB voted to propose to defer 
the effective date of the new revenue recognition standard by one year.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Recent accounting pronouncements issued by 
the FASB and the SEC did not or are not believed by management to have a 
material impact on the Company's present or future consolidated financial 
statements.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Note 3 &#8211; Patents</div>
<div><br>
</div>
<table id="z05feb8420eb24d37b0fe0737aef813ff" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.65%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Cost</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Accumulated amortization</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div>&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Foreign currency translation 
adjustment</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 13.68%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">June 30,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Net carrying value</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">December 31,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Net carrying value</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
</tr>
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.65%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.11%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 13.68%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Patents</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">174,810</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 2.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 11.04%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">&#8211;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px double;
BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">(9,237)</div>
</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px double;
BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 1.66%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">165,573</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">165, 848</div>
</td>
</tr>
</table>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Bio-AMD currently has eight patent 
applications covering its three proprietary technology platforms, the Company 
having elected to abandon one redundant patent relating to DSR which was due for
renewal in April 2016 (other patents relating to DSR are being 
maintained).&#160;We continue to review our intellectual property strategy with 
the intention of sufficiently protecting our key intangible assets, and that any
new IP generated is reviewed as far as possible to optimize the novel nature of 
the IP and freedom to operate in key jurisdictions.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In June 2015, Bio AMD Holdings Limited 
received a grant of U.S. patent dated June 2, 2015, under U.S. Patent No. US 
9,046,512 protecting twenty one claims central to the Company&#8217;s 
microfluidic strip and reader technology designed to test PT/INR by a POC 
device.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In January 2016, the Company received a 
grant of patent from the State Intellectual Property Office of the 
People&#8217;s Republic of China (&#8220;PRC&#8221;) for our MIDS technology. 
The Company has made similar MIDS technology patent applications in the U.K. and
in more than 145 Contracting States under the international Patent Cooperation 
Treaty, and separately in the USA, the European Union and India.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In March 2016, the Company received notice 
of grant of patent from the State Intellectual Property Office of the PRC 
relating to our microfluidic strip and reader technology designed to test PT/INR
by a POC device.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Note 4&#160;&#8211; Related 
Party Transactions</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">During the three months ended June 30, 
2016, we paid $nil (2015 - $49,156), to The ARM Partnership (&#8220;ARM&#8221;),
a partnership in which Robert Galvin, our former Chief Financial Officer and 
Treasurer is a partner, for services provided to us by Mr. Galvin in all 
capacities. During the six month period ended June 30, 2016, we paid an 
aggregate of $10,030 (2015 - $99,319) to ARM. Mr. Galvin owns 12.33% of the 
outstanding share capital of Bio-AMD Holdings. In addition, during the six 
months ended June 30, 2016, the Company paid $nil (2015 - $11,500 (&#163;7,500))
for the use of ARM&#8217;s offices in central London located at 3rd Floor, 14 
South Molton Street, London, UK. The rental expense was set at &#163;500 per
month for Bio-AMD Inc. (approximately $760), this ceased on July 31, 2015 and 
&#163;750 per month for Bio-AMD Holdings (approximately $1,150), reduced to 
&#163;500 (approximately $760) for each of the months of August and September 
2015, and which ceased in October, 2015.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">During the three month period ended June 30, 
2016, we paid an aggregate of $24,138 (2015 - $36,461) to Thomas Barr, our Chief
Executive Officer, for services provided to us by Mr. Barr in all 
capacities.&#160;&#160;During the six month periods ended June 30, 2016, we paid
an aggregate of $59,290 (2015 - $72,351) to Mr. Barr.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">14</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">During the 
three month period ended June 30, 2016, we paid an aggregate of $15,733 (2015 - 
$23,614) to David Miller, our Chief Financial Officer, for services provided to 
us by Mr. Miller in all capacities.&#160;During the six month period ended June 
30, 2016, we paid an aggregate of $38,563 (2015 - $46,988) to Mr. Miller.</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 0px">&#160;</div>
<div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-
TOP: 0px">Note 5 &#8211; Deferred Revenue</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Deferred revenue consists of funds received
in advance of services being performed. The Company&#8217;s revenue recognition 
policy dictates that revenues will be recognized when the services have been 
completed and no significant Company obligations remain. As at June 30, 2016, 
the Company had $nil (December 31, 2015 - $950,402 (&#163;642,077)) of deferred 
revenues.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The costs directly associated with the
performance of services for which revenue has been deferred are initially 
capitalized as deferred costs. These costs will be recognized as a component of 
cost of revenue when the associated revenue is recognized.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">As at June 30, 2016, the Company had $nil 
(December 31, 2015 - $645,534 (&#163;436,113)) of deferred costs.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In May 2016, the Company received notice of
termination of its Master Agreement with Sysmex. Upon receiving notice, 
management has determined that the Company has no further material obligations 
under the research agreement. The net difference between the deferred revenues 
and deferred costs of $248,074 has been recognized as a gain on termination of 
research agreement in the statement of operations.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Note&#160;6&#160;&#8211; 
Segmented Information</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We currently operate in two segments: 1) 
the development of a technology designed to mitigate currency risk through our 
99.81% owned subsidiary, WL as of June 30, 2016, and 2) the development of 
highly accurate, low cost, hand held, electronic medical diagnostic devices 
capable of reading third party assays through our 63% and 70% owned 
subsidiaries, Bio-AMD Holdings and Bio-AMD UK Holdings Limited, respectively. 
Segment information for the three and six months ended June 30, 2016 and 2015 
consists of the following:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Three months ended June 30, 2016:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<table id="za5916a89e4b5433bb13a2c9eeaaed5a7" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center" border="0">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings &amp; </div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD UK Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000">427</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">63</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">490</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(2,168</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">239,041</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(92,156</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">144,717</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">3,319</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">177,543</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">67,032</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Three months ended June 30, 2015:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<table id="zb89655d2886c416e8c52632fd0212a51" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">463</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">268</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">731</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(12,025</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(20,213</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(321,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(354,132</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">2,672</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,168,133</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">483,272</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,654,077</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">15</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Six months ended June 30 2016:</div>
<div><br>
</div>
<table id="z4d16ef951bf2413ab42d38ccb77c1ffa" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings &amp; </div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD UK</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">860</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">102</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">962</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(4,018</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">226,444</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(230,984</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(8,558</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">3,319</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">177,543</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">67,032</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Six months ended June 2015:</div>
<div><br>
</div>
<table id="zc4bd26c045b24edd8822a1d59ce1cb64" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">921</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">603</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,524</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(33,524</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(36,459</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(506,989</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(576,972</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">2,672</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,168,133</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">483,272</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,654,077</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Note&#160;7 &#8211; Subsequent 
Event and Commitment</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">As previously described in Note 1, 
effective July 1, 2016, the Company has formed a joint venture agreement for the
Phase 1 development of MIDS technological application.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company has agreed, to prospectively 
issue 3,000,000 five year warrants in the Company exercisable at $0.10 per 
share, to certain third parties (or their nominees) who have introduced the 
joint venture partner to the Company. The warrants may&#160; be issued at any 
time up to MML receiving the final Phase 1 Payment and they may not be exercised
prior to June 15, 2017.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Management evaluated all activities of the 
Company through the issuance date of the Company's interim unaudited condensed 
consolidated financial statements and concluded that no further subsequent 
events have occurred that would require adjustments or disclosure into the 
interim unaudited condensed consolidated financial statements.</div>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">16</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="TEXT-ALIGN: left"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left"><a name="ITEM2.MANAGEMENTS"><!--
Anchor--></a>ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF 
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Statement Regarding Forward-Looking 
Information</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">This report contains forward-looking 
statements within the meaning of Section 27A of the Securities Act of 1933, as 
amended, Section 21E of the Securities Exchange Act of 1934 and the Private 
Securities Litigation Reform Act of 1995. All statements other than statements 
of historical facts included in this Quarterly Report on Form 10-Q, including 
without limitation, statements in this Management&#8217;s Discussion and 
Analysis of Financial Condition and Results of Operations regarding our 
financial position, estimated working capital, business strategy, the plans and 
objectives of our management for future operations and those statements preceded
by, followed by or that otherwise include the words &#8220;believe&#8221;, 
&#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;intends&#8221;, 
&#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;target&#8221;, 
&#8220;goal&#8221;, &#8220;plans&#8221;, &#8220;objective&#8221;, 
&#8220;should&#8221;, or similar expressions or variations on such expressions 
are forward-looking statements. We can give no assurances that the assumptions 
upon which the forward-looking statements are based will prove to be correct. 
Because forward-looking statements are subject to risks and uncertainties, 
actual results may differ materially from those expressed or implied by the 
forward-looking statements. There are many risks, uncertainties and other 
important factors that could cause our actual results to differ materially from 
the forward-looking statements, including, but not limited to, the availability 
and pricing of additional capital to finance operations.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Except as otherwise required by the federal
securities laws, we disclaim any obligations or undertaking to publicly release 
any updates or revisions to any forward-looking statement contained in this 
Quarterly Report on Form 10-Q to reflect any change in our expectations with 
regard thereto or any change in events, conditions or circumstances on which any
such statement is based.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The following discussion should be read in 
conjunction with our unaudited condensed consolidated financial statements and 
the accompanying notes included elsewhere in this Quarterly Report on Form 10-
Q.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Overview</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We were incorporated in the State of Nevada
under the name Malibu Minerals, Inc. on March 10, 2006, to engage in the 
business of exploration and discovery of gold, minerals, mineral deposits and 
reserves. On July 6, 2007 we changed our name to Flex Fuels Energy, Inc. through
a merger effected for that sole purpose. On April 15, 2011 we changed our name 
to Bio-AMD, Inc. through a merger effected for that sole purpose. During the 
fourth quarter of 2006, we acquired a 15% interest in Flex Fuels Energy Limited 
(&#8220;FFE Ltd.&#8221;). In May 2007 we completed the acquisition of the 
remaining 85% of FFE Ltd., making FFE Ltd. a wholly owned subsidiary of
ours.&#160;&#160;FFE Ltd. was formed on November 26, 2006 under the laws of 
England and Wales to engage in the business of manufacturing and distributing 
Oil Seed Rape (&#8220;OSR&#8221;) products. Effective September 5, 2009, we 
determined to abandon FFE Ltd.&#8217;s proposed OSR business and related 
projects as we no longer considered the business to be economically viable on 
either a go alone or partnered basis. FFE Ltd was dissolved in February 2011 and
the final winding down accounting transaction took place in May 2011.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On May 1, 2009 we acquired stock of WDX 
Organisation Limited, a corporation incorporated under the laws of England and 
Wales representing a 51% interest in the company. WDX Organisation Limited 
changed its name to WOCU Limited (&#8220;WL&#8221;) effective January 29, 2013. 
Since May 1, 2009, we have acquired additional stock of WL and since July 12, 
2012 we have owned 99.81% of WL making it a majority owned subsidiary of ours. 
WL is the developer of a technology designed to mitigate currency risk.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On February 25, 2010, we entered into a 
Subscription and Shareholders Agreement with Bio AMD Holdings Limited 
(&#8220;Bio-AMD&#8221;), a UK limited company, and the managers of Bio-AMD, 
under which we acquired 63% of the fully diluted equity in Bio-AMD for 
&#163;865,000 GBP (approximately $1,287,000 at the time of purchase). Bio-AMD is
a technology company focused in the rapidly expanding medical diagnostic Point 
Of Care (&#8220;POC&#8221;) market. Bio-AMD currently has eight patent 
applications pending or granted covering its three technology platforms.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Restructuring of Bio-AMD 
Holdings and Bio-Medical operations</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; 
MARGIN-RIGHT: 0.1pt">On June 1, 2016 the intellectual property relating to the 
Company&#8217;s DSR, COAG and MIDS projects (the &#8220;IP&#8221;) and 
depreciated physical equipment assets (together the &#8220;Assets&#8221;), 
formerly under the control of Bio-AMD Holdings and Bio-Medical, into the full 
control of Bio-AMD, Inc. as a result of the loan security put in place by the 
Company during 2015.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">17</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On June 17, 2016 the Company entered into a
Subscription and Shareholders' Agreement with Bio-AMD UK Holdings Limited 
("UKH"), a United Kingdom company, and the managers of UKH, under which we 
acquired a 70% interest in UKH in exchange for the Assets.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">UKH is a development stage company, formed 
in May 2009 by the Company's two principal and key scientists formerly 
contracted to Holdings, Dr. Nasser Djennati and Dr. Andrew Mitchell. UKH was 
formerly dormant and has never traded. Immediately prior to the transaction UKH 
formed a new subsidiary, MIDS Medical Limited ("MML") as a dedicated vehicle to 
develop our MIDS universal immunoassay detection technology in a joint venture, 
further described below. UKH has taken over the operations of Holdings and Bio-
Medical.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The 30% of UKH not owned by the Company is 
owned by Dr. Nasser Djennati (15%) and Dr. Andrew Mitchell (15%). The board of 
directors of both UKH and MML consists of Drs. Djennati and Mitchell, and Mr 
Barr, the Company's CEO.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The effect of the restructuring was to 
beneficially increase the Company's interest in its UK operations from 63% to 
70%, to simplify and gain better voting control of its UK subsidiaries, and to 
eliminate two employee profit share arrangements.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">MIDS Medical Limited 
Operations</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: normal; COLOR: #000000; TEXT-ALIGN: justify">On June 20, 2016 the 
Company and its UKH and MML subsidiaries entered into a joint venture by way of 
a Subscription and Shareholders&#8217; Agreement (&#8220;Agreement&#8221;) with 
a third party medical detection device developer (&#8220;Partner&#8221;) a 
Nevada corporation, under which the Partner, in exchange for its participation 
and funding to support MML during a Phase 1 development, owns a 40% interest in 
MML as of July 1, 2016, The Partner also prospectively agreed to fund a Phase 2
development of our MIDS universal immunoassay detection technology within the 
MML vehicle. MML will have the right to use the MIDS Intellectual Property 
(&#8220;MIDS IP&#8221;) under license during the development and the MIDS IP 
will be transferred to MML in the event that MML concludes a commercial deal for
MIDS with a third party.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: normal; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: normal; COLOR: #000000; TEXT-ALIGN: justify">The Agreement provides for 
a series of payments (&#8220;Phase 1 Payments&#8221;) in an aggregate amount of 
&#163;450,500 (approximately $597,000 based on the current rate of 
exchange).</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: normal; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Business Overview</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: normal; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: normal; COLOR: #000000; TEXT-ALIGN: justify">During the quarter ended 
June 30, 2016, we were engaged in the following sectors:</div>
</div>
<div>
<table id="z01bc2bdda6cb43518e045243289c225f" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; COLOR: #000000; TEXT-
ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">developing our POC 
medical diagnostic business; and</div>
</td>
</tr>
</table>
</div>
<div><br>
</div>
<div>
<table id="z1f214134faab4034b513f41e505e66c2" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; COLOR: #000000; TEXT-
ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">developing our currency 
risk mitigation business.</div>
</td>
</tr>
</table>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Operations - Medical</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The trend toward greater POC testing is 
driven by the faster diagnostic benefits it provides.&#160; Other reasons have 
also emerged for the high demand of POC testing, including clinical staff 
shortages, an ageing population, long-term healthcare cost savings and a 
decrease in reliance on conventional laboratory services.</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">18</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We believe that Bio-AMD is an innovator in 
the field of diagnostic sensor technology, with the attributes of its technology
platform fitting well with these key trends:</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#183;&#160; &#160; &#160; &#160; 
&#160;&#160; A disposable micro-fluidic test strip which has been adapted to 
measure prothrombin time (PT/INR) and designed to be capable of performing 
additional coagulation related tests such as APTT and DTI, through a POC blood 
coagulation monitoring device (&#8220;COAG&#8221;) enabling patient based, 
anticoagulant drug therapy monitoring;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#183;&#160; &#160; &#160; &#160; 
&#160;&#160; A Digital Strip Reader (&#8220;DSR&#8221;) able to read a wide 
variety of lateral flow based immunoassay diagnostic test strips already in the 
POC market including, but not limited to, cardiac markers, infectious diseases, 
drugs of abuse and female wellbeing (pregnancy/ovulation testing) to provide 
semi-quantitative results; and</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#183;&#160; &#160; &#160; &#160; 
&#160;&#160; A disposable test strip combining micro-fluidics and &#8216;lab-on-
chip&#8217; technology providing fully quantitative measurement into a highly 
sensitive and accurate immunoassay POC platform that detects nanoparticles 
through magnetic manipulation using a novel magnetic and optical double 
detection technique &#8211; Magnetic Immunoassay Detection System 
(&#8220;MIDS&#8221;).</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">COAG</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Bio-AMD&#8217;s micro-fluidic strip 
technology has been applied for use in a POC hand-held device to detect 
prothrombin time (&#8220;PT&#8221;)/International Normalized Ratio 
(&#8220;INR&#8221;), or the speed of blood coagulation. In 2013, the POC 
coagulation market for PT/INR measurement was estimated to be worth 
approximately US$870 million globally and projected to grow to an estimated 
US$1.1 billion by 2017.&#160; Market growth is driven by the rising number of 
patients using anti-coagulation therapy, growing clinical evidence supporting 
the use of such testing and strong patient demand for patient self-testing. The 
market is dominated by a small number of major players including Alere, Roche, 
Siemens and Philips who have either developed products internally or have 
acquired exclusive rights to license appropriate technologies from smaller 
companies.&#160; Patients with cardiac problems are often on life-long oral 
anticoagulation therapy, for example Warfarin. Frequent testing and careful 
monitoring of the PT/INR or blood coagulation to regulate the doses of 
anticoagulation therapy is a necessity.&#160; A patient taking too much 
anticoagulant is at risk of serious bleeding events and if too little is taken 
they may be at risk of thrombosis.&#160;&#160; PT/INR measurement products 
currently in the market are often cited as being expensive and complicated to 
use.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Bio-AMD has established a design that 
allows for low cost manufacture of the disposable strip whilst ensuring 
scalability and repeatability.&#160; We have performed extensive in-house bench 
tests at our laboratory and further tested in an initial hospital study 
producing comparable results to the current &#8216;best in market&#8217; 
devices, which we believe validates the feasibility of our design.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In late 2013, we filed a patent application
for a multi-chamber microfluidic strip design, incorporating a novel locking 
mechanism that allows for the control of fluid flow through the strip.&#160; In 
addition to being able to test for PT/INR which requires the presence of a 
single reagent in the immunoassay testing process this enhanced strip design 
enables additional coagulation based tests requiring the use of multiple 
reagents in the immunoassay process, e.g. Activated Partial Thromboplastin Time 
(&#8220;APTT&#8221;), a laboratory based test used to measure the activity of 
direct thrombin inhibitors.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In June 2015 we received notice of the 
grant of a U.S. patent dated June 2, 2015, under U.S. Patent No. US 9,046,512 
protecting twenty one claims central to the Company&#8217;s microfluidic strip 
and reader technology designed to test PT/INR by a POC device.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We plan to apply the new strip design to 
multiple, different coagulation specific tests utilizing a common hand held 
reader device to display the results.&#160; For example, a clinician testing for
PT/INR would use a specific PT/INR strip and record the result from the reader. 
The clinician would then be able to test for APTT using a separate APTT specific
strip using the same reader device. The test strips would use a common plastic 
component design, which we believe will reduce overall production costs.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Launching a product into the coagulation 
market that incorporates our COAG technology will require us to partner with a 
much larger, suitable business with the requisite capital resources and skills 
including distribution and sales channels, and ideally global marketing 
expertise in sectors such as hematology and immunochemistry.&#160; Our strategy 
for commercialization of COAG has centered on attracting a suitable partner that
fits this profile, and which is keen to add coagulation based POC system to its 
existing product line.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">19</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On December 17, 2014, Bio-Medical entered 
into a Master Agreement (the &#8220;Agreement&#8221;) with Sysmex Corporation 
(&#8220;Sysmex&#8221;) pursuant to which the parties planned to jointly conduct 
a feasibility study (the &#8220;Study&#8221;) for the potential development of 
our POC COAG system including a reader device with disposable test strips for 
PT-INR assays and potentially new future assays in the field of hemostasis (the 
&#8220;Products&#8217;).&#160; An expense advance of &#163;642,067 
(approximately $980,000) was made to Bio-Medical by Sysmex in 2015. The Study, 
we believe, was successfully completed and the preliminary results were 
presented to Sysmex in late 2015. Notwithstanding the conclusions of the Study, 
Sysmex decided in April 2016 to discontinue funding the Study and indicated that
it would not proceed with it in the future. No new intellectual property was 
developed during the Study and the temporary research license granted to Sysmex 
by the Company to use the Company&#8217;s intellectual property has been 
automatically terminated.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company believes that its COAG 
technology is now well advanced and performs better than expected when compared 
to gold standard lab analyzers and the market-dominant POC PT/INR self-test 
device, CoaguChekXS. The Company believes that COAG broadly matches the accuracy
performance of those tests even in an un-optimized device. Our data suggest that
a finalized, optimized COAG device is expected to be a leader on POC accuracy, 
with a sub 5% coefficient of variance, in an environment where the FDA is 
seeking higher PT/INR self-test accuracy requirements. We believe that COAG has 
been proven to operate on a patient-friendly, minimal 5 microliter pin prick 
blood sample, which is materially smaller than any other device available in the
market. Accordingly the Company believes that COAG will be of interest to major 
POC providers.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We are in the process of contacting and 
exchanging information with major medical companies with a view to obtaining a 
new development deal for COAG. Whilst we have received some interest there can 
be no assurance that we will enter into any new agreement to jointly develop 
COAG or to otherwise commercialize COAG.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">DSR</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The DSR technology platform utilizes a 
patented proprietary method for reading and quantifying traditional 
chromatography based, nitro-cellulose, lateral-flow immunoassay tests, centered
on what we believe to be a unique optical sensor arrangement.&#160; The DSR 
technology comprises a proprietary design incorporating sensors, diagnostics, 
display and power management capabilities.&#160; We believe that a key feature 
of the DSR technology is that its platform can be adapted and applied to 
numerous and disparate lateral flow diagnostic tests.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Bio-AMD has created designs for both single
and multi-test versions of the DSR hand-held reader device and laboratory based 
bench tests have been performed by us in our premises using a variety of third 
party lateral flow strips.&#160; The DSR device is designed to be fully 
disposable and can be powered by solar power cells, although traditional battery
power sources can also be used.&#160; Our multi-test device utilizes a 
replaceable cap system in which a new test strip is fitted, thereby enabling the
hand-held reader to be used multiple times for the same test.&#160; By way of 
example, existing over the counter (&#8220;OTC&#8221;) home fertility testing 
packs normally contain up to 20 separate identical tests; for this fertility 
application our device would require just one reader device with 20 caps, each 
cap containing the test strip, thereby reducing the number of component parts 
and manufacturing cost.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The market for female well-being, which 
includes digital home pregnancy and fertility testing, was estimated to be worth
approximately $1.5 billion globally in 2012.&#160; Whilst the market for 
pregnancy testing is very competitive and dominated by a small number of large 
global brands e.g. Clearblue, Predictor and First Response, in several regions, 
particularly Asia, there is demonstrated demand from local distributors for OEM 
produced digital pregnancy test kits (&#8220;PTK&#8221;), the key factors being 
price and marketability by way of unique product features. Options for DSR might
include creating our own branded and/or OEM digital pregnancy testing kit, or 
partnering with a qualified distributor aiming to launch a branded product into 
the region.&#160; This will entail our finalizing a product manufacturing design
file and obtaining appropriate territorial regulatory approval specifically for 
the Asian market. Such a strategy will require additional capital, which we 
cannot guarantee would be available on terms acceptable to us or at all.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We have also been exploring, at an early 
stage, the potential to add value to diagnostic screening campaigns led by the 
National Health Service (&#8220;NHS&#8221;) in the UK.&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">20</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH:
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">MIDS</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Demand is increasing for POC tests that can
detect very low concentrations of a target analyte and to quantify the 
result.&#160; Current lateral flow based immunoassays can detect analyte at high
levels of concentration.&#160; However, at low concentration levels, the assay 
system requires amplification either of the signal or the target, which will 
typically increase the complexity and the costs of the testing device.&#160; 
Consequently, current POC tests remain largely unreliable for targets that 
require quantification.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We believe there to be an opportunity to 
develop a universal immunoassay based POC testing system which:</div>
<div><br>
</div>
<div style="TEXT-ALIGN: justify">
<table id="z8ccbdb9d099d42409da68d43a432bdc6" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Is capable of 
detecting biomarkers at a nanoparticle level, providing fully quantitative 
measurement of results i.e. giving a numerical value for each biomarker detected
and not just an indication on whether a specified biomarker is actually 
present,</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="zba27be39b3b6474294d0abf0cb9c18a8" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Is capable of
multiplexing i.e. performing multiple types of test from the same sample,</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="zf46d4e246ba14e32b37036eec6d0cc4b" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Provides full 
connectivity and networking for collection, storage and transfer of data and 
results,</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="z6dd8a87eeffe453f9e9048a365208446" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Displays test 
results in minutes (less than 8 minutes for a panel of up to 3 tests),</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="z63415cc9eae44f9a9336c0f30771a76b" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Requires a 
finger prick sample size for a single test,</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="z1939a117d77c401ab331a256ccbd0630" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Utilizes a 
handheld reader and single disposable cartridge designed to be operated by a 
minimally trained person, requiring modest manual operation, other than for 
sample collection,</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="zc0fd9631265846d38090fba042408a0f" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Contains all 
necessary reagents and where all steps are automated into an integrated 
encompassing pre-treatment, analyte specific reaction, signal production, signal
reaction and final result: from sample to result in one step,</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="z7ba2d889aca64ce986f09604f686ea8c" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Can be adapted 
to perform different immunoassays for testing in areas such as infectious 
diseases, drugs of abuse or oncology, especially where rapid diagnosis is 
critical, and</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify">
<table id="zfa6ac2d878d8440cb67c4de206f0c95f" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
27pt; VERTICAL-ALIGN: top; COLOR: #000000; align: right">&#9679;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH:
auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify">Has a simple 
system design, requiring minimal direct input costs and inline manufacturing 
processes to keep unit costs as low as possible.</td>
</tr>
</table>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The technology will incorporate what we 
believe to be a novel microfluidic strip design, magnetic nanoparticle 
manipulation and a unique double detection technique using bespoke &#8216;Hall 
Effect&#8217; sensors and bespoke optical sensor which, when combined, will 
increase significantly the sensitivity and accuracy of the result.&#160; We are 
not aware that this method is being used in products currently being offered in 
the market or in development.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We plan to develop the immunoassay platform
initially for the high sensitivity cardiac marker POC testing market, which are 
measured to evaluate heart function.&#160; Cardiac markers are used in the 
diagnosis and risk stratification of patients with chest pain and suspected 
acute coronary syndrome.&#160; The detection of these markers is used to 
diagnose myocardial infarction and its severity, typically troponin (cTnI or 
cTnT), myoglobin and Creatine kinase MB isoenzyme (CK-MB). Our ultimate aim is 
to commercialize a product for the multiple cardiac marker testing market which 
was estimated by BCC Research to be worth US $1.3 billion globally in 2013 
(including device, reagent and supply sales), and is expected to grow to $2.4 
billion by 2018.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Additionally, we envisage the technology 
platform to be adaptable and be extended into new test areas, e.g. infectious 
diseases, drugs of abuse and oncology; having potential to expand into a 
multifunctional device, i.e. one analyzer using different strips for different 
tests; and can be introduced into high growth areas such as companion 
diagnostics (where POC devices are used to optimize the personalized dosage of a
therapeutic drug).</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We believe that our MIDS technology has 
considerable potential to create a next generation of POC test devices. Our 
proposed method aims to bring together biology, chemistry, nano-fluidics, and 
electronics and, 'lab-on-chip' technology together into what we believe can be 
unique, economically viable products.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">To date some very early stage work has been
completed in conjunction with the Science, Technology and Facilities Council, 
one of Europe&#8217;s largest independent scientific research public body 
organizations in-part funded by the UK Government.&#160;.&#160; In April 2011 we
made an initial patent application for the technology and in October 2012 we 
entered into the national phase stage, making applications in Europe, US, India 
and China, with a Chinese patent being granted in March 2016</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">21</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On June 20, 2016 the Company 
and its UKH and MML subsidiaries entered into a joint venture by way of a 
Subscription and Shareholders&#8217; Agreement (&#8220;Agreement&#8221;) with a 
third party medical detection device developer (&#8220;Partner&#8221;) a Nevada 
corporation, under which the Partner, in exchange for its participation and 
funding to support MML during a Phase 1 development, owns a 40% interest in MML 
as of July 1, 2016, The Partner also prospectively agreed to fund a Phase 2 
development of our MIDS universal immunoassay detection technology within the 
MML vehicle. The Agreement provides for a series of payments (&#8220;Phase 1 
Payments&#8221;) in an aggregate amount of &#163;450,500 (approximately $596,500
based on the current rate of exchange).</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Initial development project 
planning has commenced on the MIDS project, including the specification of a 
bench rig printed circuit board designed to support first stage testing of a 
sample of Hall Effect Sensors already supplied to MML in order to examine their 
behavior in the detection of magnetic nanoparticles &#8211; the core MIDS 
technology &#8211; and to determine how these Hall Effect Sensors should be 
optimized prior to integration in a micro fluidic test strip.</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Since January 2014, the 
Company has provided additional working capital by way of cash injections via 
intercompany loans amounting to &#163;100,000 (approximately $133,000) to Bio-
AMD Holdings to further fund operations. These loans were secured against the 
assets of Bio-AMD Holdings and its wholly owned operating subsidiary, Bio 
Medical. These assets have now been transferred to UKH as a result of the 
security.</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">To date, no revenues had been
generated by Bio-AMD Holdings or UKH.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font></div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Operations
- WL - Currency Risk Mitigating Business</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">WL is the creator of a proprietary 
algorithm that produces a global currency derivative quotation known as the 
WOCU&#174;.&#160;&#160;The WOCU can be applied to financial products provided by
third parties such as index structure products, exchange traded funds or 
derivate contracts, with a view to mitigating any currency risk inherent within 
those products. The WOCU algorithm was completed in June 2009, with further work
including back-testing using historical foreign exchange data, to prove the 
attributes of the WOCU design, taking place throughout 2010 until the 
WOCU&#8217;s launch late that year.&#160;&#160;Since that time, the WL 
management team has sought to achieve licensing deals with a variety of 
financial institutions that are seeking to create financial products denominated
in WOCU.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: justify">The WOCU&#8217;s generally low volatility 
against fiat currencies offers huge commercial advantages as a unit of account 
for the denomination of world trade, compared to the status quo of cross border 
trade denominated in fiat currency pairs, or in US 
Dollars.&#160;&#160;Transactions across currencies (except in isolated cases 
where one exchange rate is &#8220;pegged&#8221; to the other) inevitably involve
potential foreign exchange risk caused by movements in exchange rates. The 
advantage of denominating a transaction involving foreign exchange in 
WOCU&#8217;s is that can lower the foreign exchange (&#8220;FX&#8221;) 
volatility as compared to traditional exchange rate pairs.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The WOCU, subject to the achievement of the
WL corporate strategy and business model described below, is expected to have 
application to:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Multinational corporate treasury operations;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Reference pricing for general global trade;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Reference pricing for currency, fixing, including virtual, online 
currencies;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Commodity pricing and trade;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Currency balanced savings accounts;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Fund management, including Exchange Traded Funds;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;FX and derivative trading and speculation;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Global index calculations; and</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;Reserve ratio applications (similar to the IMF&#8217;s Special Drawing Right or
SDR).</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">22</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The WOCU&#8217;s apolitical, bank-
independent, transparent, instant availability and universal nature are believed
to be a key differentiator compared to alternative methods of hedging against 
currency risk.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: justify">The WOCU quotation is calculated and 
published by WL as daily and hourly fixed reference prices for a total of 169 
fiat currencies, digital currencies and commodities. In addition WOCU Foreign 
Exchange (&#8220;FX&#8221;) 1, 2, 3, 6, 9 and 12 month Forward quotations will 
be produced by WL against the USD, from which a Forward WOCU rate can be 
calculated for any currency for which Forward rates are currently quoted, plus 
WOCU Interest Rate forward quotations covering the Overnight 1, 2, 3, 6, 9 and 
12 month money market periods. The WOCU reference price is fixed daily at 16:00 
UTC against all major currencies and is also available as an hourly reference 
price, from 00:00 Monday to 23:00 Friday, and as hourly price captures for gold,
silver and oil.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The WOCU quotation is available (non-
exclusively) from WL&#8217;s re-seller Interactive Data Corporation 
(&#8220;IDC&#8221;) via its data terminals and data feeds under the ticker 
symbol XCU. IDC currently calculates and offers quotations for 47 WOCU based 
currency pairs, and 6 commodities, as cross rates and supplies a stand-alone 
WOCU real-time charting package application via IDC&#8217;s PrimePortal&#8482; 
application. WOCU rates are also available on the professional Thompson Reuters 
platform and on the UK&#8217;s leading retail price data platform ADVFN.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The WOCU quotation is also available via a 
mobile application for Apple mobile devices known as &#8220;WOCU&#8221;. This 
application supports five languages; English, simplified Chinese, traditional 
Chinese, Japanese and Korean.&#160;&#160;The WOCU quotation is also available as
an hourly reference price available directly from WL by RSS feed, e-mail and via
WL&#8217;s FTP server. The WOCU quotation as an hourly updated price is also 
available from the Company&#8217;s corporate website www.wocu.com</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">WL has established relationships with a 
number of individuals and organizations authorized to serve as introducing 
agents ("IAs") to the WL business, charged with identifying suitable prospects 
that fit the WL target profile.&#160;&#160;&#160;These IAs are remunerated 
purely on a contingent basis linked only to successful results and each IA 
generally is responsible for its own expenses. The exact terms of any IA 
arrangement is agreed between WL and the IA on a case by case 
basis.&#160;&#160;IAs are chosen based on their experience and knowledge of the 
financial markets and their deep contact network. To date six such IAs have been
appointed.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Since January 2013, the Company has 
provided further advances totaling &#163;196,000 (approximately $260,000) into 
WL to fund its anticipated operations based on the prospective pipeline of 
opportunities that have been generated.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">WL has not achieved any operating revenues 
to date and does not expect to achieve operating revenues until such time, if 
ever, that the WOCU is successfully marketed.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Given the Company&#8217;s limited 
resources, it is unlikely that the Company can support WL operations going 
forward, as a contractor to WL vital to its technical operation has indicated it
is not willing to continue to provide its services at the current much reduced 
rate of payment and accordingly further investment will be required to support 
WL. The Company will consider any option that might preserve any value in 
WL.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Results of Operations</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify"><u>Losses from Operations</u></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We incurred losses from operations of 
$103,847 and $257,594 for the three and six month periods ended June 30, 2016, 
respectively, compared to losses from operations of $354,863 and $578,496 for 
the three and six month periods ended June 30, 2015, respectively.&#160;</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">23</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: left">The main components of the recorded operating 
loss during the three and six month periods ended June 30, 2016 compared to 
losses from continuing operations during the three and six month periods ended 
June 30, 2015 were as follows:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-RIGHT: 
0.1pt">&#160;&#160;</div>
<table id="z03a1853445524a868e6572639e3570b9" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="WIDTH: 37%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">3 months ended June 30,</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">6 months ended June 30,</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 37%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Note</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 37%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div>Consulting expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">1</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>$</div>
</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">74,343</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>$</div>
</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">96,021</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>$</div>
</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">174,505</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>$</div>
</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">226,054</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 37%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div>Legal Fees</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">2</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">5,965</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">5,780</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">6,483</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">6,275</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 37%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div>Professional Fees</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">3</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">6,038</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">9,369</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">30,057</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">72,389</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 37%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div>Rent, Office related, Telecoms and Miscellaneous</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">4</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">6,993</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">25,245</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">21,576</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">46,445</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 37%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div>Stock-based compensation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">5</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">199,000</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11.05%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div>
<div></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">208,000</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Co
nsulting expenses decreased by $21,678 to $74,343 for the three month period 
ended June 30, 2016, compared to $96,021 for the three month period ended June 
30, 2015 and decreased by $51,549 to $174,505 for the six month period ended 
June 30, 2016 compared to $226,054 for the six month period ended June 30, 2015.
Consulting expenses includes consultants engaged with the management and 
administration of the Company utilized in the course of our operations and those
of our subsidiaries. These officers/consultants have recently received a reduced
fee which commenced at the beginning of March 2016.&#160; However the majority 
of the decrease was primarily due to certain consulting costs initially 
capitalized as deferred costs and which are directly associated with the 
performance of services for which revenue has been previously deferred. These 
costs have been netted in the gain on termination of research agreement due to 
the termination of the Master Agreement by Sysmex.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;&#160;&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Le
gal fees increased by $185 from $5,780 for the three month period ended June 30,
2015 to $5,965 for the three month period ended June 30, 2016 and increased by 
$208 to $6,483 for the six month period ended June 30, 2016 from $6,275 for the 
six month period ended June 30, 2015. We continue to monitor all advisor related
expenditure to ensure maximum value at minimal cost</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: 
justify">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pr
ofessional fees comprised primarily of audit and financial compliance related 
costs, decreased by $3,331 from $9,369 for the three month period ended June 30,
2015 to $6,038 for the three month period ended June 30, 2016 and decreased by 
$42,332 from $72,389 for the six month period ended June 30, 2016 to $30,057 for
the six month period ended June 30, 2015. The reduction was primarily due to a 
change of auditor.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; MARGIN-RIGHT: 
0.1pt">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Rent
, Office related, Telecoms and Travel expense was $6,993 for the three month 
period ended June 30, 2016 compared to $25,245 for the three month period ended 
June 30, 2015 and was $21,576 for the six month period ended June 30, 2016 
compared to $46,445 for the six month period ended June 30, 2015. The decrease 
of $24,869 for the six month period ended June 2016 can mainly be attributed to 
a decrease in rent expense incurred in Bio-AMD and a decrease in travel expenses
in Bio-Medical.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; MARGIN-RIGHT: 
0.1pt">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stoc
k-based compensation was $nil for the three month period ended June 30, 2016 
compared to $199,000 for the three month period ended June 30, 2015 and was $nil
for the six month period ended June 30, 2016 compared to $208,000 for the six 
month period ended June 30, 2015. The decrease of $208,000 for the six month 
period ended June 2016 can mainly be attributed to that fact the Company did not
issue any stock-based compensation during the six month period ended June 30, 
2016 whereas the Company issued 1,150,000 restricted shares of common stock with
a fair value of $184,000 in relation to a consulting agreement dated June 9, 
2015 as well as recognizing $24,000 for the six month period ended June 30, 2015
in relation to 300,000 restricted shares of stock options issued for investor 
relationship services provided to the Company over a period of twelve 
months.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify"><u>Revenues</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We have not generated any revenues from 
operations for the three and six month periods ended June 30, 2016 and 
2015.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify">Other Income</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-RIGHT: 0.1pt">We
recorded other income during the three and six month periods ended June 30, 2016
of $248,564 and $249,036, respectively, as compared to $731 and $1,524 for the 
three and six month periods ended June 30, 2015, respectively.&#160; The 
increase in other income over the three and six month periods relates to a 
$248,074 gain on termination of research agreement due to the termination of the
Master Agreement by Sysmex.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">24</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify">Net Losses</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We generated net income in the amount of 
$144,171 and a net loss of $8,558 ($0.00 and ($0.00) per share) for the three 
and six month periods ended June 30, 2016, respectively, as compared to a net 
loss of $354,132 and $576,972 (($0.01) and ($0.01) per share) for the three and 
six month periods ended June 30, 2015, respectively, for the reasons discussed 
above.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Liquidity and Capital
Resources</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We have limited cash reserves and may need 
substantial amounts of capital to implement our planned business 
strategies.&#160;&#160;Given the currently unsettled state of the capital 
markets and credit markets, there is no assurance that we will be able to raise 
the amount of capital that we may seek to support our working capital 
requirements or for further investment in current and future 
operations.&#160;&#160;If we are unable to raise the necessary capital at the 
times we require such funding, we may have to materially change our business 
plan, delaying implementation of aspects of our business plan or curtailing or 
abandoning our business plan.&#160;&#160;Investing in us is a speculative 
investment and investors may lose all of their investment.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Since our inception, we have been financed 
primarily by the sale of equity in private placements.&#160;&#160;We raised 
$10,000 for shares issued to founders in 2006, $1,635,000 on December 29, 2006 
(net of expenses of $20,000), $13,391,879 on May 29, 2007 (net of expenses of 
$1,492,000), and $3,940,189 on July 29, 2007 (net of expenses of $444,654) by 
way of three separate private placements of shares of common 
stock.&#160;&#160;At June 30, 2016, we had cash of $68,754; other current assets
of $13,427 consisting of amounts receivable, and prepaid expenses, and we had 
current liabilities of $52,450, consisting of accounts payable, accrued 
liabilities, and other liabilities.&#160;&#160;We attribute our operating loss 
to having no operating revenues to sustain our operating costs.&#160;These 
factors raise substantial doubt about our ability to continue as a going 
concern.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left"><u>Net Cash Provided 
by/Used in Operating Activities</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Net cash used in operating activities of 
operations was $341,750 for the six months ended June 30, 2016, as compared to 
net cash provided of $289,055 for the six months ended June 30, 2015. The 
increase is primarily attributable to our net loss from operations of $8,558 and
the net change in the balances of operating assets and liabilities in the 
aggregate amount of $612,176.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify"><u>Net Cash Used in 
Investing Activities</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">During the six months ended June 30, 2016, 
the Company paid $18,824 for patent applications. During the six months ended 
June 30, 2015, the Company paid $nil for patent applications.&#160;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
STYLE: italic">&#160;</font></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify"><u>Net Cash Provided by
Financing Activities</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We did not raise any funds through 
financing activities of operations during the six month periods ended June 30, 
2016 and 2015.&#160;&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Critical Accounting Policies 
and Estimates</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify"><u>Significant 
Accounting Policies</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="MARGIN-BOTTOM: 0.1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; 
MARGIN-RIGHT: 0.1pt">Financial Reporting Release No. 60, published by the SEC, 
recommends that all companies include a discussion of critical accounting 
policies used in the preparation of their financial statements. While all these 
significant accounting policies impact our consolidated financial condition and 
results of operations, we view certain of these policies as 
critical.&#160;&#160;Policies determined to be critical are those policies that 
have the most significant impact on our consolidated financial statements and 
require management to use a greater degree of judgment and estimates. Actual 
results may differ from those estimates.</div>
<div style="MARGIN-BOTTOM: 0.1pt"><br>
</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">We believe that given current
facts and circumstances, it is unlikely that applying any other reasonable 
judgments or estimate methodologies would cause a material effect on our 
unaudited condensed consolidated results of operations, financial position or 
liquidity for the periods presented in this report.&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">25</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-STYLE: 
italic"><u>General</u></font>&#160;</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company&#8217;s 
consolidated financial statements are prepared in accordance with U.S. generally
accepted accounting principles, which require management to make estimates, 
judgments and assumptions that affect the reported amounts of assets, 
liabilities, net revenue, if any, and expenses, and the disclosure of contingent
assets and liabilities.&#160;&#160;Management bases its estimates on historical 
experience and on various other assumptions that it believes to be reasonable 
under the circumstances, the results of which form the basis for making 
judgments about the carrying values of assets and liabilities that are not 
readily apparent from other sources.&#160;&#160;Senior management has discussed 
the development, selection and disclosure of these estimates with the Board of 
Directors.&#160;&#160;Management believes that the accounting estimates employed
and the resulting balances are reasonable; however, actual results may differ 
from these estimates under different assumptions or conditions.&#160;</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">An accounting policy is 
deemed to be critical if it requires an accounting estimate to be made based on 
assumptions about matters that are highly uncertain at the time the estimate is 
made, if different estimates reasonably could have been used, or if changes in 
the estimate that are reasonably possible could materially impact the 
consolidated financial statements. Management believes the following critical 
accounting policies reflect the significant estimates and assumptions used in 
the preparation of the consolidated financial statements.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify"><u>Revenue 
Recognition</u></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company recognizes revenue when the 
following criteria have been met: persuasive evidence of an arrangement exists,
no significant Company obligations remain, collection of the related receivable 
is reasonably assured, and the fees are fixed or determinable. The Company acts 
as a principal in its revenue transactions as the Company is the primary obligor
in the transactions.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left"><u>Deferred Revenue and 
Deferred Costs</u></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company defers revenue on contracts 
which contain a performance commitment until such time as the services have been
completed and no significant Company obligations remain.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify"><u>Foreign Currency 
Translation</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The Company&#8217;s reporting and 
functional currency is US Dollars. The accounts of the Company&#8217;s 99.81% 
owned subsidiary, WL, and the Company&#8217;s 63% owned subsidiary, Bio-AMD 
Holdings, and Bio-AMD Holdings Limited&#8217;s wholly owned subsidiary, Bio-
Medical, and the Company&#8217;s 70% owned Subsidiary UKH and its 60% owned 
subsidiary MML, are maintained using the local currency (Great British Pound) as
the functional currency. All assets and liabilities are translated into US 
Dollars at balance sheet date, equity is translated at historical rate and 
revenue and expense accounts are translated at the average exchange rate for the
year or the reporting period. The translation adjustments are deferred as a 
separate component of stockholders&#8217; equity, captioned as accumulated other
comprehensive (loss) gain.&#160;&#160;Transaction gains and losses arising from 
exchange rate fluctuation on transactions denominated in a currency other than 
the functional currency are included in the consolidated statements of 
operations.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The relevant translation rates are as 
follows: For the six month period ended June 30, 2016 closing rate at 1.3242 
US$:GBP, average rate at 1.4319 US$:GBP and for the six month period ended June 
30, 2015 closing rate at 1.5717 US$:GBP, average rate at 1.5233 US$:GBP.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">26</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: justify"><u>Recent accounting 
pronouncements</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="MARGIN-BOTTOM: 0.1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; 
MARGIN-RIGHT: 0.1pt">In February 2015, the FASB issued ASU No. 2015-02, 
Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is 
intended to improve targeted areas of consolidation guidance for legal entities 
such as limited partnerships, limited liability corporations, and securitization
structures (collateralized debt obligations, collateralized loan obligations, 
and mortgage-backed security transactions). The ASU focuses on the consolidation
evaluation for reporting organizations that are required to evaluate whether 
they should consolidate certain legal entities. In addition to reducing the 
number of consolidation models from four to two, the new standard simplifies the
FASB Accounting Standards Codification and improves current U.S. GAAP by placing
more emphasis on risk of loss when determining a controlling financial interest,
reducing the frequency of the application of related-party guidance when 
determining a controlling financial interest in a variable interest entity 
(&#8220;VIE&#8221;), and changing consolidation conclusions for companies in 
several industries that typically make use of limited partnerships or VIEs. The 
ASU will be effective for fiscal years, and interim periods within those fiscal 
years, beginning after December 15, 2015. The adoption of ASU 2015-02 did not 
have any effect on our financial position, results of operations or cash 
flows.&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif"><br>
</font> In August 2014, the FASB issued ASU No. 2014-15, "Presentation of 
Financial Statements - Going Concern (Subtopic 205-40)". ASU 2014-15 provides 
guidance related to management's responsibility to evaluate whether there is 
substantial doubt about an entity's ability to continue as a going concern and 
to provide related footnote disclosure. ASU 2014-15 is effective for annual 
periods ending after December 15, 2016, and for interim and annual periods 
thereafter. Early application is permitted. We do not expect the adoption of ASU
2014-15 to have a material effect on our financial position, results of 
operations or cash flows.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In June 2014, the FASB issued ASU No. 2014-
12, &#8220;Compensation &#8211; Stock Compensation (Topic 718): Accounting for 
Share-Based Payments When the Terms of an Award Provide That a Performance 
Target Could Be Achieved after the Requisite Service Period.&#8221; This ASU
requires that a performance target that affects vesting and that could be 
achieved after the requisite service period be treated as a performance 
condition. ASU 2014-12 is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2015. The adoption of ASU 2014-
12 did not have any effect on our financial position, results of operations or 
cash flows.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In May 2014, the FASB issued ASU No. 2014-
09, &#8220;Revenue from Contracts with Customers (Topic 606).&#8221; ASU 2014-09
affects any entity using U.S. GAAP that either enters into contracts with 
customers to transfer goods or services or enters into contracts for the 
transfer of nonfinancial assets unless those contracts are within the scope of 
other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is 
effective for fiscal years, and interim periods within those fiscal years, 
beginning after December 15, 2016. We are still evaluating the effect of the 
adoption of ASU 2014-09. On April 1, 2015, the FASB voted to propose to defer 
the effective date of the new revenue recognition standard by one year.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Other recent accounting pronouncements 
issued by the FASB and the SEC did not, or are not believed by management to 
have a material impact on the Company's present or future unaudited condensed 
consolidated financial statements.&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify"><u>Off-Balance Sheet Arrangements</u></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We have no off-balance sheet 
arrangements.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><u>Inflation</u></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We believe that inflation has not had, and 
is not expected to have, a material effect on our operations.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><u>Climate Change</u></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We believe that neither climate change, nor
governmental regulations related to climate change, have had, or are expected to
have, any material effect on our operations.&#160;</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">27</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="TEXT-ALIGN: left"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a 
name="ITEM3.QUANTITATIVE"><!--Anchor--></a>ITEM 3.&#160;&#160;QUANTITATIVE AND 
QUALITATIVE DISCLOSURES ABOUT MARKET RISK</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Not applicable.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a name="ITEM4.CONTROLS"><!--
Anchor--></a>ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Evaluation of Disclosure 
Controls and Procedures</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">We maintain disclosure controls and 
procedures that are designed to ensure that material information required to be 
disclosed in our periodic reports filed under the Securities Exchange Act of
1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported 
within the time periods specified in the SEC's rules and forms and to ensure 
that such information is accumulated and communicated to our management, 
including our chief executive officer and chief financial officer as 
appropriate, to allow timely decisions regarding required disclosure. During the
quarter ended June 30, 2016, we carried out an evaluation, under the supervision
and with the participation of our management, including the principal executive 
officer and the principal financial officer, of the effectiveness of the design 
and operation of our disclosure controls and procedures, as defined in Rule 
13(a)-15(e) under the 1934 Act.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times
New Roman', Times, serif">&#160;</font>Based on this evaluation, our chief 
executive officer and chief financial officer have concluded that as of June 30,
2016, our disclosure controls and procedures were not effective because (1) the 
Company lacks a functioning audit committee and there is a lack of independent 
directors on the board of directors, resulting in reduced oversight in the 
establishment and monitoring of required internal controls and procedures; (2) 
the Company has inadequate segregation of duties consistent with control 
objectives; and (3) the Company has ineffective controls over its period end 
financial disclosure and reporting processes. The Company operations are also 
ineffective due to the lack of operating funding.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Limitations on Effectiveness 
of Controls and Procedures</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Our management, including our Chief 
Executive Officer (Principal Executive Officer) and Chief Financial Officer 
(Principal Financial Officer), does not expect that our disclosure controls and 
procedures will prevent all errors and all fraud. A control system, no matter 
how well conceived and operated, can provide only reasonable, not absolute, 
assurance that the objectives of the control system are met. Further, the design
of a control system must reflect the fact that there are resource constraints 
and the benefits of controls must be considered relative to their costs. Because
of the inherent limitations in all control systems, no evaluation of controls 
can provide absolute assurance that all control issues and instances of fraud, 
if any, within the Company have been detected. These inherent limitations 
include, but are not limited to, the realities that judgments in decision-making
can be faulty and that breakdowns can occur because of simple error or mistake. 
Additionally, controls can be circumvented by the individual acts of some 
persons, by collusion of two or more people, or by management override of the 
control. The design of any system of controls also is based in part upon certain
assumptions about the likelihood of future events and there can be no assurance 
that any design will succeed in achieving its stated goals under all potential 
future conditions. Over time, controls may become inadequate because of changes 
in conditions, or the degree of compliance with the policies or procedures may 
deteriorate. Because of the inherent limitations in a cost-effective control 
system, misstatements due to error or fraud may occur and not be detected.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Changes in Internal 
Controls</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">During the fiscal quarter ended June 30, 
2016, there has been a change in our internal control over financial reporting 
due to the reduced cash and other liquid assets to fund the operations of the 
Company that have materially affected or are reasonably likely to materially 
affect our internal controls over financial reporting.</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">28</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">PART II &#8211; OTHER 
INFORMATION</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a name="ITEM1.LEGAL"><!--
Anchor--></a>ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">From time to time we may be a defendant or 
plaintiff in various legal proceedings arising in the normal course of our 
business. We are currently not a party to any material legal proceedings or 
government actions, including any bankruptcy, receivership, or similar 
proceedings. In addition, we are not aware of any litigation or liabilities 
involving the operators of our properties that could affect our operations. 
Furthermore, as of the date of this Quarterly Report, our management is not 
aware of any proceedings to which any of our directors, officers, or affiliates,
or any associate of any such director, officer, affiliate, or security holder is
a party adverse to our company or has a material interest adverse to us.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a name="ITEM1A.RIS"><!--
Anchor--></a>ITEM 1A.&#160;&#160;RISK FACTORS</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Not applicable.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a 
name="ITEM2.UNREGISTERED"><!--Anchor--></a>ITEM 2.&#160;&#160;UNREGISTERED SALES
OF EQUITY SECURITIES AND USE OF PROCEEDS</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">None</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a name="ITEM3.DEFAULTS"><!--
Anchor--></a>ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">None.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a name="ITEM4.MINE"><!--
Anchor--></a>ITEM 4.&#160;&#160;MINE SAFETY DISCLOSURES</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Not applicable.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><a name="ITEM5.OTHER"><!--
Anchor--></a>ITEM 5.&#160;&#160;OTHER INFORMATION</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">None.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left"><a name="ITEM6.EXHIBITS"><!--
Anchor--></a>ITEM 6.&#160;&#160;EXHIBITS</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The following exhibits are included as part
of this report:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<table id="z37a6e742bf5e4d00a81b107c5b27140d" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px 
solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left">Exhibit 
No.</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px 
solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: 
left">Description</div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr style="HEIGHT: 13px">
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle; TEXT-ALIGN: center">4.1</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 87.9%; VERTICAL-
ALIGN: top">
<div><a href="ex4-1.htm">Form of warrants agreement letter</a></div>
</td>
</tr>
<tr style="HEIGHT: 13px">
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle; TEXT-ALIGN: center">10.1</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 87.9%; VERTICAL-
ALIGN: top">
<div></div>
<div><a href="ex10-1.htm">Subscription and Shareholders&#8217; Agreement dated 
June 17, 2016 among Bio-AMD UK Holdings, the persons named on Schedule 1 Part A 
thereto and Bio-AMD, Inc.</a></div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">10.2</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">&#160;</td>
<td style="FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 87.9%; VERTICAL-
ALIGN: top">
<div></div>
<div><a href="ex10-2.htm">Subscription and Shareholders&#8217; agreement dated 
June 20, 2016, among MIDS Medical Limited, Zenosense, Inc.,Bio-AMD UK Holdings 
Limited and Bio-AMD Inc.</a></div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">31.1</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="ex31-1.htm">Certification of 
Principal Executive Officer pursuant to Section 302 the Sarbanes-Oxley Act of 
2002</a></div>
</td>
</tr>
<tr style="HEIGHT: 12px">
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">31.2</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="ex31-2.htm">Certification of 
Principal Financial Officer pursuant to Section 302 the Sarbanes-Oxley Act of 
2002</a></div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">32.1</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="ex32-1.htm">Certification of Chief 
Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to 
Section 906 of the Sarbanes-Oxley Act of 2002</a></div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">32.2</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left"><a href="ex32-2.htm">Certification of Chief 
Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to 
Section 906 of the Sarbanes-Oxley Act of 2002</a></div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">101.INS</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">XBRL Instance Document</div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">101.SCH</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">XBRL Taxonomy Extension Schema Document</div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">101.CAL</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">XBRL Taxonomy Extension Calculation Linkbase 
Document</div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">101.DEF</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">XBRL Taxonomy Extension Definition Linkbase 
Document</div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">101.LAB</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">XBRL Taxonomy Extension Label Linkbase 
Document</div>
</td>
</tr>
<tr>
<td style="WIDTH: 9.13%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: center">101.PRE</div>
</td>
<td style="WIDTH: 2.98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 87.9%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">XBRL Taxonomy Extension Presentation Linkbase 
Document</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageFooter"></div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">29</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 
100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; 
BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
<div id="DSPFPageHeader" style="WIDTH: 100%">
<div><a href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>
<div style="TEXT-ALIGN: left"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center"><a name="SIGNATURES"><!--
Anchor--></a>SIGNATURES</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In accordance with the requirements of the 
Securities Exchange Act of 1934, the Registrant has caused this report to be 
signed on its behalf by the undersigned, thereunto duly authorized.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">
<div><br>
</div>
<table id="zf9ee4f398bc54c119af72bfb97ab35f6" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">BIO-AMD, 
INC.</td>
<td style="WIDTH: 38%; VERTICAL-ALIGN: top" colspan="2"></td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-LEFT-
COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">August 15, 2016&#160;</div>
</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">By:</div>
</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">/s/&#160;Thomas Barr</div>
</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Thomas Barr, Chief Executive Officer</div>
</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">August 15, 2016&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">/s/&#160;David Miller</div>
</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">David Miller, Chief Financial Officer</div>
</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
</div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">30 </font>
<div id="DSPFPageFooter"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: 
normal">&#160; </font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div>
<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 4.1</div>
<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; TEXT-ALIGN: left">&#160;</div>
<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; TEXT-ALIGN: left">
<table id="z5a292b42d633466580796de372a40820" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="WIDTH: 643px"><img src="image00001.jpg">
<div>&#160;</div>
</td>
<td style="WIDTH: 932px">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">Sci-Tech Daresbury</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">Keckwick lane,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">Daresbury WA4 4FS</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">T: +44(0)1925606 471</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">www.bioamd.com</div>
</div>
</td>
</tr>
</table>
</div>
</div>
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">June 14, 2016</div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Re:</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><u>Services Performed</u></font></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Dear XXXXX and&#160; XXXXX,</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000">This letter agreement (the 
&#8220;Agreement&#8221;) confirms the terms and conditions previously agreed 
between Bio-AMD Inc.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000">a Nevada corporation with IRS 
Employer Identification Number 20-5242826 having an address at Sci-Tech 
Daresbury, Keckwick Lane, Daresbury, Cheshire WA4 4FS UK (together with its 
affiliates, subsidiaries, predecessors, and successors, the 
&#8220;Company&#8221;) and XXXXX, an individual having an address at XXXXX and 
XXXXX, an individual having an address at XXXXX, the introducing agents 
(&#8220;Introducers&#8221;) in connection with the Phase 1 staged payments in an
aggregate amount of &#163;450,500 payable in tranches over a period of nine 
months (the &#8220;Investment&#8221;), and an optional Phase 2 funding, of the 
Company&#8217;s MIDS technology.</font></div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Services</u></font>.</font></div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Work 
Performed</u></font>.&#160; The Company hereby acknowledges that the Introducers
were solely responsible for making the introduction to the company which intends
to make the Investment and have played an essential and very substantial role in
negotiations and other work to facilitate the transaction.</div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Compensation</u></font>.&#160; As consideration for
the services provided under this Agreement, the Company will pay fees as 
follows:</font></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt">&#160;</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">a.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Introducer Fee</u></font>. The Company and the 
Introducers hereby agree that there will be no cash fees due 
whatsoever.</font><br>
</div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">b.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Introducer&#160; Financing 
Warrants</u></font>.&#160; Company shall sell to the Introducers or their 
nominee(s) a total in aggregate of 3,000,000 warrants (&#8220;Introducer 
Warrants&#8221;) in proportions to be instructed by the Introducers, the form of
which is to be agreed, subject to certain terms listed in (c) below, to purchase
equity securities (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-STYLE: italic">i.e.</font> Common Stock), for the purchase 
price of $1 in total (excluding any additional cost to exercise the 
warrants).&#160; The Introducer Warrants will contain a provision whereby 
Introducer will provide 61 calendar days written notice prior to the exercise of
the Introducer Warrants, and no exercise will be permitted prior to June 15,
2017. Such Introducer Warrants will be for a term of five (5) years. The 
Introducer Warrants issued hereunder will have an exercise price of $0.10 (10 
U.S. cents).&#160; The Introducer Warrants will be either cashless or cash 
exercise, at the sole discretion of the Introducers and contain regular anti-
dilution provisions and representations and warranties normal and customary for 
warrants issued to introducers, including a market standoff provision, and will 
not be callable or terminable prior to the expiration date. For clarity, there 
will be no &#8220;ratchet&#8221; adjustment made to the exercise price or number
of shares underlying the Introducer Warrants in the event of subsequent 
financings The Introducer Warrants may be issued to any persons or entities 
designated by Introducer.</font></div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">c.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Terms</u></font>. The Company has the right to make
the sale of the Introducer Warrants at any time after the closing of the 
Investment and before the last Phase 1 Payment. In the event the Investment is 
not made in full, the Company will have the right to cancel the sale of the 
Introducer Warrants, or to negotiate revised terms, at the Company&#8217;s sole 
option.</font></div>
<div><br>
</div>
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 70.9pt"><font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000">d.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 37.1pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE:
10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Legends.</u></font> The 
shares of Common Stock (the &#8220;Shares&#8221;) underlying the Introducer 
Warrants and all certificates representing such Shares shall bear a restrictive 
legend to the effect that the Shares represented by such certificate have not 
been registered under the Securities Act, and that the Shares may not be sold or
transferred in the absence of such registration or an exemption 
therefrom.</font></div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
<div>&#160;</div>
<div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000">&#160;3.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 36pt">&#160;</font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Complete Agreement;
Amendments; Assignment</u></font>. This Agreement sets forth the entire 
understanding of the parties relating to the subject matter hereof and 
supersedes and cancels any prior communications, understandings and agreements, 
whether oral or written, between the Introducers and the Company. This Agreement
may not be amended or modified except in writing. The rights of Introducers 
hereunder shall be freely assignable to any affiliate of the Introducers, and 
this Agreement shall apply to, inure to the benefit of and be binding upon and 
enforceable against each of the parties and their successors and 
assigns.</font></div>
<div><br>
</div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">4.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000"><u>Governing Law; Jurisdiction; 
Venue</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000">.&#160; All aspects of the relationship created by
this Agreement shall be governed by and construed in accordance with the laws of
the State of New York.&#160; All actions and proceedings which are not submitted
to arbitration pursuant to Section 13 hereof shall be heard and determined 
exclusively in the state and federal courts located in the</font> State of New 
York, and the Company and Kairos hereby submit to the jurisdiction of such 
courts and irrevocably waive any defense <font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">or objection to such 
forum, on forum non conveniens grounds or otherwise.&#160; The parties agree to 
accept service of process by mail, to their principal business address, 
addressed to the chief executive officer and secretary thereof.&#160; The 
parties hereby agree that this Section 12 shall survive the termination and/or 
expiration of this Agreement.</font></font></div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">5.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Severability</u></font>.&#160; Should any one or 
more covenants, restrictions and provisions contained in this Agreement be held 
for any reason to be void, invalid or unenforceable, in whole or in part, such 
unenforceability will not affect the validity of any other term of this 
Agreement, and the invalid provision will be binding to the fullest extent 
permitted by law and will be deemed amended and construed so as to meet this 
intent.&#160; To the extent any provision cannot be so amended or construed as a
matter of law, the validity of the remaining provisions shall be deemed 
unaffected and the illegal or invalid provision will be deemed stricken from 
this Agreement.</font></div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Section Headings</u></font>.&#160; The section 
headings herein are for convenience of reference only, and shall not limit or 
otherwise affect the meaning hereof.</font></div>
<div><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Counterparts</u></font>.&#160; This Agreement may 
be executed via facsimile transmission and may be executed in separate 
counterparts, each of which shall be deemed to be an original and all of which 
together shall constitute a single instrument.</font></div>
<div style="TEXT-ALIGN: left"><br>
</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8.</font><font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
36pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif"><u>Notice</u></font>.&#160; All notices, demands, and 
other communications to given pursuant to this Agreement shall be in writing and
shall be personally delivered, sent by overnight delivery using a nationally 
recognized courier service, sent by facsimile transmission, or emailed.&#160; 
Notice shall be deemed received: (a) if personally delivered, upon the date of 
delivery to the address of the receiving party; (b) if sent by overnight 
courier, the date actually received by the recipient; (c) if sent by facsimile 
or email, when sent.&#160; The parties will each promptly notify the other of 
any changes to the following contact information.</font></div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt">&#160;</div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt">&#160;</div>
<div>
<table id="zf08412d7c1634649b0ccd3294e269f8a" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Notices to Introducers shall be sent to:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 51.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Notices to the Company shall be sent to:</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.81%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 51.19%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">XXXXX.com</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; WIDTH: 51.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">tom.barr@bioamd.com</div>
</td>
</tr>
</table>
<div><br>
</div>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
VARIANT: small-caps; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center">[Signature Pages Follow]</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
<div>&#160;</div>
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">If the above accords with your understanding 
and agreement, kindly indicate your consent hereto by signing below.&#160; We 
look forward to a long and successful relationship with you.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 36pt">Very truly yours,</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Bio-AMD Inc.</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="TEXT-ALIGN: left"><br>
<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: 
normal"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#1
60;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&
#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#1
60;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&
#160; </u></font></div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">By: Thomas Barr</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">CEO</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">ACCEPTED AND AGREED TO</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">AS OF THE DATE FIRST ABOVE WRITTEN</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 36pt">XXXXX</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 
36pt">__________________________________</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 36pt">By: XXXXX</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 36pt">XXXXX</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 
36pt">__________________________________</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 36pt">By: XXXXX</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 10.1</div>
<div>&#160;</div>
<div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify"><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center"><u>DATED&#160; &#160; &#160; &#160; &#160; 
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 
&#160; &#160; &#160; June 17, 2016</u></div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">BIO-AMD UK HOLDINGS LIMITED</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">-and-</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">THE MANAGERS</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">-and-</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">BIO-AMD, INC.</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">___________________________________</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 120.95pt; MARGIN-RIGHT: 
120.95pt">SUBSCRIPTION AND SHAREHOLDERS&#8217; AGREEMENT</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 120.95pt; MARGIN-RIGHT: 
120.95pt">relating to BIO-AMD UK HOLDINGS LIMITED</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">___________________________________</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">1 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 
6pt">Contents</div>
<div style="MARGIN-BOTTOM: 6pt; MARGIN-TOP: 6pt"><br>
</div>
<div style="MARGIN-BOTTOM: 2.4pt; MARGIN-TOP: 2.4pt">
<table id="zcf658f33381044329fdad9d9463563f1" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; WIDTH: 3%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: left">Clause&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: right">Page</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Definitions</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">3</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Interpretation</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">5</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Conditions</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">7</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Completion</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">7</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Warranties</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">8</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Covenants</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">11</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">ITEPA</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">12</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Board</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">13</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">9</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Consents etc</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">14</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">10</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Announcements and confidentiality</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">14</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">11</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Variation of this Agreement and the Articles</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">15</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">12</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Notices</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">15</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">13</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">General</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">16</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">14</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Governing law and jurisdiction</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">18</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">20</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part A &#8211; Managers&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">20</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part B - Issued share capital immediately before
and following Completion&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">20</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part C - The Company&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">21</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Conditions&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">22</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 3&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">23</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Warranties&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">23</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 4&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">25</div>
</td>
</tr>
<tr style="HEIGHT: 13px">
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part A - Matters requiring Investor 
Consent&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">25</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part B - Conduct of Group&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">27</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part C &#8211; Provision of 
Information&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">27</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part D &#8211; Manager Covenants&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">28</div>
</td>
</tr>
<tr style="HEIGHT: 12px">
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 5&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Deed of Adherence&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">29</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 6&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">30</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Assets to be transferred&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">30</div>
</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 8pt"><br>
</div>
<br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">2 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 2.4pt; TEXT-ALIGN: left; MARGIN-TOP: 2.4pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">THIS AGREEMENT is made on</font><font id="TRGRRTFtoHTMLTab" 
style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 396pt">&#160;</font><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">17 June 
2016</font></div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">BETWEEN</font>:</div>
<div style="MARGIN-BOTTOM: 6pt; MARGIN-TOP: 6pt"><br>
</div>
<div>
<table id="z34aba535175347dc92b077e433f8bb24" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Bio-AMD UK Holdings 
Limited </font>(company number&#160;06909826) whose registered office is at Sci-
Tech Daresbury, Keckwick Lane, Daresbury, WA4 4FS, UK (&#8220;<font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Company</font>&#8221;);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z2addf53c4b1b4db2ade49cdf51ea0aa2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">(2)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">The Persons</font> 
whose names and addresses are set out in Schedule&#160; 1, Part A (the 
&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-WEIGHT: bold">Managers</font>&#8221; and individually a &#8220;<font
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Manager</font>&#8221;); and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zcd283d51c03c4886bc44408c2e5cd817" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">(3)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Bio-AMD, Inc.</font>
(I.R.S. Employer Identification No 20-5242826) having principal executive 
offices at&#160; Sci-Tech Daresbury, Keckwick Lane, Daresbury, WA4 4FS, UK (the 
&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-WEIGHT: bold">Investor</font>&#8221;)</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">NOW IT IS 
AGREED</font> as follows:</div>
<div>
<table id="z74deb56e9bd0440384a17dd1bd94c930" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Definitions</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">In this Agreement,
unless the context otherwise requires:</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#160;&#8220;<font
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Articles</font>&#8221; means the articles of association of the 
Company or as subsequently amended from time to time;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Board</font>&#8221; means the board of directors of the 
Company;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Business</font>&#8221; means the business of the development and 
exploitation of intellectual property and products for use in the healthcare
sector or the holding or companies similarly engaged therein (as the same may be
changed from time to time in accordance with the provisions of this 
Agreement);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Business Day</font>&#8221; means any day on which banks are open 
for business in London (excluding Saturdays, Sundays and public holidays);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Companies Act 1985</font>&#8221;<font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#160;</font>means Companies Act 1985;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Companies Act 2006</font>&#8221;<font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#160;</font>means Companies Act 2006;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Companies Acts</font>&#8221; means the Companies Act 1985 and the 
Companies Act 2006 in each case to the extent to which the provisions of the 
same are for the time being in force;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Completion</font>&#8221; means completion of the Investment in 
accordance with Clause 4;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; COLOR: #000000;
FONT-STYLE: normal; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-WEIGHT: bold">Completion Board Minutes</font>&#8221; means minutes 
of a meeting of the Board comprising resolutions to be passed on or before 
Completion;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Completion Date</font>&#8221; means the date of Completion;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Conditions</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY:
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means the 
conditions referred to Clause 3 and set out in Schedule 2;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">3 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Confidential Information</font>&#8221;<font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#160;</font>means save in so far as such information is already in the 
public domain (other than by breach of any duties of confidentiality) or is 
required to be disclosed by reason of any legal requirement or any rule or 
regulation of any Recognised Investment Exchange or any government or regulatory
authority, all knowledge and information (whether or not recorded in documentary
or machine readable form) which is secret or confidential to the business or 
affairs of the Group;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Deed of Adherence</font>&#8221; means a deed contemplated by 
Clause 13.5 and substantially in the form set out in Schedule 5;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Directors</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">&#160;</font>the directors of the Company from time to time;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Disclosure Letter</font>&#8221;, if any,<font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#160;</font>means a letter of even date from the Warrantors to the 
Investor specifying disclosures to the Warranties given at Completion and 
includes the documents attached to it;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Encumbrance</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means 
any claim, mortgage, lien, pledge, charge, encumbrance, hypothecation, trust, 
right of pre-emption or any other restriction or third party right or interest 
(legal or equitable) or any other security interest of any kind however created 
or arising (or any agreement or arrangement to create any of them);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Managers</font>&#8221; means Nasr-Eddine Djennati and Andrew 
Mitchell as listed in Schedule 1;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#160;&#8220;<font
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Group</font>&#8221; means the Company, each holding company for 
the time being of the Company and all the subsidiaries or subsidiary 
undertakings for the time being of any one of them;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Group Company</font>&#8221; means any member for the time being of
the Group;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">ICTA</font>&#8221; means the Income and Corporation Taxes Act 
1988;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Indebtedness</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#160;</font>means<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>the total of: (a) amounts 
borrowed by the Group; (b) any actual or contingent liability under a guarantee 
given by a Group Company; (c) amounts due by the Group under any credit sale, 
hire purchase, and equipment leasing agreements, insofar as any of these can 
properly be attributed to capital; but excluding loans, and guarantees, from one
Group Company to another;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Intellectual Property Rights</font>&#8221; means all intellectual 
property rights subsisting at any time in any part of the world including 
patents (including patent applications, any continuation applications, 
divisional applications, or continuation in part applications that claim 
priority to the patents and/or applications, any patents that issue from any of 
the foregoing, and any reissues, re-examinations, renewals, substitutions, and 
extensions of any of the foregoing) trade marks, trade names, marks, design 
rights, data base rights and copyrights (whether any of such rights are 
registered or unregistered) all rights in, to or in connection with confidential
information and all know how, business information (including technical, 
process, clinical or other information, business plans, procedures), technical 
information (including knowledge, research, techniques, designs, science data, 
specifications, practices, procedures, assays, formulae, processes, systems, 
improvements, methods, skill, test and other data including chemical, 
pharmacological, toxicological and clinical tests and other data, analytical and
quality control data, and laboratory notes), regulatory information and 
applications, authorizations, permits and licenses, trade secrets, computer 
programs and domain names and registrations and applications for any of the 
foregoing;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">4 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Investment</font>&#8221; means the subscription by the Investor 
and the transferred assets made for the Ordinary Shares under this 
Agreement;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Investor Consent</font>&#8221; means the prior written consent of 
such of the holders of Ordinary Shares holding for the time being over 50% in 
nominal value of Ordinary Shares then in issue;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Investor Director</font>&#8221; means a person nominated by any of
the Investor to be a director of any Group Company pursuant to this Agreement 
(including his alternate);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">ITEPA</font>&#8221; means the Income Tax (Earnings and Pensions) 
Act 2003;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Ordinary Shares</font>&#8221; means the ordinary shares of &#163;1
each in the capital of the Company, having the rights set out in the 
Articles;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#8220;Recognised Investment Exchange&#8221;</font> shall have the meaning
defined in section 285(1)(a) of the Financial Services and Markets Act 
2000;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Remuneration</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means 
all payments of salary, expenses, fees, value of any benefits in pension 
contributions and all such other taxable benefits (in each case, in cash or 
otherwise);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#160;&#8220;<font
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Shareholders</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means 
the holders of the Shares from time to time;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Subscription Monies</font>&#8221; means the sum that the Investor 
has agreed to subscribe for the Ordinary Shares under this Agreement;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Warranties</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY:
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means the 
Warranties referred to in Clause&#160;5 and set out in Schedule 3;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Warrantors</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY:
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: italic">&#160;</font>the Company and the 
Managers.</div>
<div>
<table id="ze7be9d03eb43407ca5ebd056f8ec49fd" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: 
justify">Interpretation</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3acc009f1dee4168ac0bf4a468fe3ab0" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Agreement unless the context 
otherwise requires:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z4a7f221d0e8f49cc9488bb90461285e2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any recitals and Schedules form part 
of this Agreement and references to this Agreement include them and references 
to recitals, Clauses and Schedules are to recitals and clauses of, and schedules
to, this Agreement and references in a Schedule or part of a Schedule to 
paragraphs are to paragraphs of that Schedule or that part of that
Schedule;</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">5 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="ze8ff09212bb84c58b4aa277e1b57165e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">references to this Agreement or any 
other document are to this Agreement or that document as in force for the time 
being and as amended from time to time in accordance with this Agreement or that
document (as the case may be);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5c7c7d078d4e4171a4dd84a584dec172" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">words importing a gender include 
every gender, references to the singular include the plural and vice versa and 
words denoting persons include individuals and bodies corporate, partnerships, 
unincorporated associations and other bodies (in each case, wherever resident 
and for whatever purpose) and vice versa;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z677c3b02787249a7b72c829b7e0dc472" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">a person is deemed to be connected 
with another if that person is so connected within the meaning of 
section&#160;839 ICTA (as in force and construed at the date of this 
Agreement).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z530cca9e2d094b299bbfa664c061de89" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Agreement, unless the context
otherwise requires:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z04e25ca5af6643b2bcd1711c57c9e32c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">a reference to a statute or statutory
provision shall be construed as including a reference to any subordinate 
legislation (as defined by section&#160;21(1) Interpretation Act 1978) made from
time to time under that statute or provision (whether before or after the date 
of this Agreement); and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zff2b1ee38d4e4a72a2637c03915115a3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">a reference to a statute, statutory 
provision or subordinate legislation (as so defined) shall be construed as 
including a reference to:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z63b0704f1fa94f5aae0b186c281a3efc" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(i)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">that statute, provision or 
subordinate legislation as in force at the date of this Agreement and as from 
time to time modified or consolidated, superseded, re-enacted or replaced 
(whether with or without modification) after the date of this Agreement);&#160; 
and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zadbcea831c2c4d488819758e47bc5f40" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(ii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any statute, statutory provision or 
subordinate legislation (as so defined) which it consolidates, supersedes, re-
enacts or replaces (whether with or without modification).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z52a09cf810eb410f890587037e4d6b5c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Terms used or defined in the 
Companies Acts or in the Articles shall have the same meanings in this Agreement
unless the context otherwise requires provided that company (if not a reference
to the Company) shall mean any body corporate wheresoever situated and howsoever
incorporated and the other expressions in Companies Act 2006 shall be construed 
accordingly.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z4431dbf448d64d8cba8f6318205c61c7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Agreement references to any 
provision in Companies Act 1985 shall be treated (where and when applicable) as 
being a reference to the corresponding provision (or the provision(s) most 
nearly corresponding to it) in the Companies Act 2006 or in any subordinate 
legislation made under the Companies Act 2006 which replaces it (with or without
modification).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zb21a4c43901e42b78032b7eb75c31c4d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The headings and contents table and 
the brief description of one clause or one paragraph that is cross referenced 
within the text of another clause or paragraph in this Agreement are for 
convenience only and do not affect its interpretation.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">6 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z3827c902f7a9473691d35a3c39059a90" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Agreement the words "<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">other</font>", "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif; FONT-WEIGHT: bold">includes</font>", "<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">including</font>" and "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">in particular</font>" do not
limit the generality of any preceding words and any words which follow them 
shall not be construed as being limited in scope to the same class as the 
preceding words where a wider construction is possible.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z04b7b65779a64d348ba5a3aecb232cbb" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">References to an &#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Investor</font>&#8221; shall be deemed to include respectively the
Investor, its nominee, its assigns, its transferees and its successors.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8f5971dcc3784448b49371428690dbba" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In the Agreement, unless the context 
otherwise requires or the terms of any adherence express the contrary, the 
expressions &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold">Investor</font>&#8221; or &#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Manager</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>includes any 
party adhering to this Agreement as an Investor or Manager (as the case may be)
pursuant to a Deed of Adherence.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za26db868eb8d40a1bf309565f78c4d7d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.9</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">References in this Agreement to any 
party shall, except where the context otherwise requires, include his successors
in title and personal representatives.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zbc287544a0b342deb0e305fdfbc17c4d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Conditions</div>
</td>
</tr>
</table>
</div>
<div>
<table id="ze7a8bc0fd49a4db7a26eb1841a4bd216" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">3.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor's obligation to make the
Investment at Completion is conditional upon the Conditions being satisfied to 
the satisfaction of the Investor (in its absolute discretion) or waived (in 
whole or in part) in writing by it or on its behalf (in its absolute 
discretion).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zd033064524f244fabac4bfd639eb2739" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">3.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If the Conditions have not been 
fulfilled to the satisfaction of the Investor or waived in writing by the 
Investor (in each case in its absolute discretion) then this Agreement shall 
lapse and cease to have effect unless the Investor otherwise agrees or requires 
in writing and no party shall have any claim against any other party under this 
Agreement or in respect of any claims by the Investor which have arisen prior to
such lapse and cessation.&#160;&#160; Accordingly, the provisions of Clauses 1 
and 2, this Clause 3, Clauses 10, 12, 13 and&#160;14 and such of the other 
provisions of this Agreement as are necessary to give efficacy to those Clauses 
or are relevant to the enforcement of those Clauses shall continue to have 
effect notwithstanding any lapse or cessation under Clause 3.2.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zba69eb516d304a67a7356a17ef2761a6" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">3.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Save for any claims for arrears of 
Remuneration, each of the Managers irrevocably waives any claims against the 
Company, or any of its officers and employees and consultants, which he may have
outstanding prior to the Completion Date.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z535c6679cf2843538f427524d3295d23" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Completion</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc81e22d584584c2383dec08f7ddf5660" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">4.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">On satisfaction or waiver of each of 
the Conditions in accordance with Clause 3, on Completion:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za8f941a89bb34ee9a18e8929d10fd1d1" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the business set out in the 
Completion Board Minutes shall be transacted;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5bbf5efbb30245a69282f4dc7621dba8" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Investor shall be deemed to apply
and shall subscribe &#163;70 in cash for 70 Ordinary Shares at a price of 
&#163;1 per share, and the Managers will be deemed to subscribe for 14 shares 
each, to reflect and produce the prior and resultant shareholdings as listed in 
Schedule 1 Part B and the Investor shall assign or otherwise transfer the assets
listed in Schedule 6, all parties acknowledging the IP assets listed in Schedule
6 are effectively worthless absent the Managers&#8217; skills and expertise to 
bring them out of development into commercialisation, and the tangible assets 
are of nominal value;</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">7 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z3086e868c4da4b6fa8dbadd5765fa4b6" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company shall:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5fd398dc024f4fe6a898e321153ba3da" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(i)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">allot and issue the Ordinary Shares 
to the Investor and the Managers free from all Encumbrances;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zdc565fb720ab4373a2780f9f8c62c6b0" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(ii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">issue a share certificate to the 
Investor and the Managers for those Ordinary Shares so subscribed;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="ze440c0315ce14da8b8e4fe04a3935ef5" class="DSPFListTable"
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(iii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">enter the name of the Investor and 
the Managers in the register of Members in respect of the Ordinary Shares so 
subscribed;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3788144411b54f1ea049a98e6e0746bc" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(iv)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">appoint Thomas Barr as the first 
Investor Director.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z62f0e8864f564f3abf261c6a3076cd9a" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Warranties</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5d1a15ae89634085b987784eede729ea" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In consideration of the Investor
making the Investment at Completion each of the Warrantors severally warrants to
the Investor in the terms of the Warranties.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z997730498b6a442f8824c34b42874da5" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Where a Warranty is given or a 
statement is made in the Disclosure Letter &#8220;<font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">so far as the 
Warrantors</font>&#8221; (or any similar expression) such Warranty or statement 
shall be deemed to include an additional statement to the effect that the 
Warrantors have made all due and careful enquiries of each other.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z81e0f078031f43429522d5836e680a2d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">A matter shall be regarded as 
&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-WEIGHT: bold">fairly disclosed</font>&#8221; only to the extent that
the information in the Disclosure Letter gives to the Investor sufficient 
information to form a reasonable opinion as to the nature and extent of the 
matter is disclosed and its effect or likely effect on the business of the 
Company.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6d3f036764364affb307cac2a749d169" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Warrantors acknowledge to the
Investor that the Investor has entered into this Agreement in reliance on the 
Warranties. Each of the Warranties shall be construed separately and 
independently from the others.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z7955d2668e04403c81bc295563ee6cb8" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Each of the Warranties shall be 
construed as a separate Warranty and shall not be limited or restricted by 
reference to or inference from the terms of any other Warranty or any other term
of this Agreement, nor shall any Warranty be qualified by any knowledge (whether
actual, constructive or implied) of the Investor.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z2d365b74718f476e8837e97830d677f5" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Each Warrantor:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z0f5508cc8cb04175b535c692bb4bdd5b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">agrees that the giving by the Company
or any of its officers, employees, agents or advisers (past or present) to any 
of the Warrantors or their agents or advisers (past or present) of any 
information or opinion in connection with the Warranties or the Disclosure 
Letter or otherwise in relation to the business or affairs of the Company in 
connection with the negotiation and preparation of this Agreement or the 
Disclosure Letter shall not be deemed to be a representation, warranty or
guarantee to the Warrantors of the accuracy of such information or 
opinion;</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">8 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z7b3802967e5b45d0a0570f69694ec459" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">waives and releases any right which 
he may have against the Company and/or any director or employee of the Company 
for any error, omission or misrepresentation (other than fraud) in the 
information and opinions given by them to such Warrantor in connection with the 
negotiation and preparation of the Warranties or this Agreement or the 
Disclosure Letter;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z86eed68f450446bead21a87bbc9d806f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">agrees not at any time without 
Investor Consent to enter into any contract or arrangement or insurance whereby 
any other person (including, without limitation, any other Warrantor) agrees to 
indemnify, hold him harmless or contribute towards or otherwise share or 
discharge (in whole or part and whether or not conditional) any liability of his
or claim against him relating to or under this Agreement; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z798519b28a244f4b842d6c9fe97c571f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">acknowledges that any such rights 
shall not constitute a defence to any claim by the Investor relating to this 
Agreement.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3adbbde37b904f54a4e070ac36d0eb5f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If any payment is made by any Manager
in respect of the Warranties or under this Clause 5 the payers thereof shall 
have no right and shall not claim any right of counter indemnity or subrogation 
or other right of recovery of any sum so paid or any part thereof against or 
from the Company save to the extent expressly permitted in this Agreement.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z95ef74111da9409b9c0a9d0552364ec6" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Subject to Clause&#160;5.18, the 
Investor shall not be entitled to make a claim under the Warranties in respect 
of any matter which is fairly disclosed in the Disclosure Letter but no other 
information relating to the Company of which the Investor have (or later obtain)
implied or constructive knowledge shall prejudice or affect any claim made by 
the Investor under the Warranties or operate to reduce any amount 
recoverable.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zb78fc50969664f45a7b98334076fb707" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.9</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The maximum aggregate liability of 
each Warrantor in respect of claims for breach of the Warranties shall not 
exceed, the amount set opposite his or its name in the table below:</div>
</td>
</tr>
</table>
</div>
<table id="z22391cd726e644d1a8064f73def071c3" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 60%" cellspacing="0" 
cellpadding="0" align="center" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; WIDTH: 37%" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Warrantor</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%" 
valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 21%" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">Amount</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH:
1%" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 37%" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Nasr-Eddine Djennati</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 21%" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">&#163;1</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 37%" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Andrew Mitchell</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 21%" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">&#163;1</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 37%" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Company</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 21%" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">Subscription Monies</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
<div>
<table id="z833f5e6d00a847c99c59aaff99dc92b3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.10</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Any and all liability under the 
Warranties shall absolutely cease and determine in the case of any Warranties on
30 June 2016 (the &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold">End Date</font>&#8221;).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zb66be2dcfd304bcaa8d56cd1d15bc034" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.11</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">A Warrantor shall not be liable for 
breach of the Warranties unless:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9051fb6ed85a4c79a2c6036122bed41b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Warrantors shall have been served
with written notice providing reasonable details of the facts then known to the 
Investor of the basis for the claim by the Investor of a specific breach of any 
Warranty prior to the relevant End Date; and</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">9 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z8dbbfe7a1e0a4b9ebc01ba24057ded7a" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">proceedings shall have been commenced
and served upon the Warrantors giving the relevant Warranty in connection with 
such breach within the period of 12 months (or such longer period as is agreed 
in writing between the parties from time to time) from the date of written 
notice of the breach has been given to the Warrantors who gave the relevant 
Warranty.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z4fa742340d2f4e5986c69362e02cc573" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.12</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Warrantors shall not be liable 
for a breach of the Warranties to the extent that the claim arises from or is
increased as a result of:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zdc16d27c3ee34890b0b3e306e318f923" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any legislation not in force at the 
Completion Date which takes effect retrospectively;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z1ef1f16af1914a90bdc3f3243e0ba3f2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any change (with the Investor 
Consent) after the Completion Date in the accounting reference date of the 
Company;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8caca36f9c8247febeb800b0bb0abefe" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any change (with the Investor 
Consent) after the Completion Date in the accounting policies adopted by the 
Company or in the accounting bases upon which (i) the Company; or (ii) to the 
extent it relates directly to Business, in each case prepares its accounts save 
where such change is required to conform such policy or practice with generally 
accepted policies or practices or where such change is necessary to correct an 
improper policy or practice.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6a5edcbf68c04cd899e4e79cbf167618" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.13</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If the Warrantors (or any of them) 
pay to the Investor an amount representing satisfaction in full of any claim for
breach of the Warranties and the Investor subsequently recovers from a third 
party a sum which is referable to it (after payment of any expenses incurred in 
recovering it), the Investor shall, as soon as reasonably practicable 
thereafter, repay to the applicable Warrantor or Warrantors the sum so recovered
less all reasonable costs of recovery.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5bffe72da22b41d1ac5fa309b298c379" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.14</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor shall not be entitled to
recover any sum in respect of any claim for breach of any of the Warranties more
than once in respect of the same subject matter which gives rise to the same 
loss.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zee0cd33ed8984f7681f12ce694cc678f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.15</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Without limiting the Investor&#8217;s
right to claim against any of the Warrantors, the Investor may claim in whole or
in part in respect of any breach of the Warranties against any of the other 
Warrantors.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z26848a23e7ae4c2686cc4842ef4a65f0" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.16</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Warrantors shall not be liable 
for any claim under the Warranties to the extent that the fact, matter, event or
circumstance giving rise to such claim is remediable and is remedied in full by 
or at the expense of the Warrantors without cost to the Company or the Investor 
(or any of their Connected Persons) within ten Business Days of the date on 
which written notice of such claim is given to the Warrantors.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3c24552d023a49cf99dd20ff83ac23ee" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.17</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Nothing in this Agreement shall be 
deemed to relieve the Investor from any common law duty to mitigate any loss or 
damage suffered by any of them.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc31b584dee29467da62e06b6837449af" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.18</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Disclosure Letter shall not 
qualify or limit nor shall any of the preceding provisions of this Clause 5 
qualify or limit:</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber"
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">10 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="za34406e8cd964d5fa88cef29cc29b922" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any of the Warranties at paragraphs 
2, 3.1 and 4.1 of Schedule 3;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zde6784be4d644c5caa852e151eb080a1" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any claim for breach of any Warranty 
arising (or any delay in the discovery of which arises) as a result of fraud or 
wilful or dishonest non-disclosure or wilful or dishonest misrepresentation on 
the part of any Warrantor.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3108ee5214064ab5805cba8a1af78e30" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">5.19</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor warrants to the Company 
and each of the Managers that it is duly authorised to enter into this Agreement
and the obligations of the Investor under this Agreement and each document to be
executed by it at or before Completion are or when the relevant document is 
executed, will be enforceable on the Investor in accordance with their
terms.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z20c0a4da73ed4d6fa60c72c898c4fe73" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Covenants</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z04200fb4284b48aeabc4dbc2b4bd3124" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">6.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">From Completion:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z7270e4d61fb2459da7728534b266930d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company shall not, and the 
Managers shall exercise all rights and powers lawfully available to them to 
procure that the Group shall not, take any of the actions set out in Schedule 4,
Part A without Investor Consent, unless the action is expressly required or 
permitted by this Agreement;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9cc936235d40418da82338e4ea1a32be" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company shall, and the Managers 
shall exercise all rights and powers lawfully available to them&#160; to procure
that the Group shall, conduct its business in accordance with, and observe the 
covenants set out in, Schedule 4, Part B (whether or not as a matter of law such
covenants are enforceable against the Group Company in question) unless with 
Investor Consent;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z1772882e80eb40c5a1fc7ab4eb6d31f6" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company and the Managers will 
comply with their respective obligations set out in Schedule 4, Part C regarding
the provision of information to the Investor; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z871eaa288c5e431f81261d611a3fdf2c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">each of the Managers severally 
undertakes to, and covenants with, the Investor in the terms of Schedule 4, Part
D,</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">(together the 
&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-WEIGHT: bold">Covenants</font>&#8221; which term shall, for the 
avoidance of doubt, include each of the covenants, obligations and undertakings 
set out in, and each of the paragraphs of, Schedule 4).</div>
<div>
<table id="z04f4fe5057804c7aacae88bf2b7501e8" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">6.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Where any action would be prohibited 
by Clause 6.1 but for the fact that the action is expressly stated in an 
approved Budget the Company and the Managers shall continue to be bound by 
Clause 6.1 and shall seek the necessary consents (as applicable).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z10dce82d540c4cca8aa86bf4cfc8ef63" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">6.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">It is acknowledged for the purposes 
of section 173 Companies Act 2006 that the Covenants in Schedule 4, Part D and 
other provisions of this Agreement may restrict the future exercise of 
discretion by Directors and the parties intend that,&#160; to the extent 
permitted by that section, the discretion of such directors should be so 
restricted.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">11 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="zc6a63dc4553e4387992f11979faae5d4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">6.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If the Company or any of the Managers
are in breach of any of the Covenants, and, if such breach is capable of remedy,
it is not remedied within 10 Business Days of the Investor giving notice 
requiring such breach to be remedied, the Company and the Managers (as the case 
may be) shall:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z350bf7dd6a5841898c85ebca28ca7f29" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">provide the Investor with a full 
explanation for the delay or breach and assist in investigations;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8ac076229dc44cb5b2d82cf0a8904b74" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if the Investor so requires the 
Investor may instruct a firm of chartered accountants to prepare or help in 
preparing the accounts or any of such reports plans budgets forecasts or 
statements the costs of which will be borne by the Company;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5a61fded3702499881072312dfe09aa2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">allow such advisers to make extracts 
from and take copies of its accounting books and records and to discuss any 
matter with any of its personnel and officers.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zbb05a822a95d49d18a3e6782b0672882" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">6.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Each of the Covenants shall be 
construed independently of each of the others so that if one or more of them 
shall be held to be invalid as an unreasonable restraint of trade or for any 
other reason whatsoever then the remaining Covenants shall be valid to the 
extent that they are not held to be so invalid.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3bf06eb210144f5c9ad92d09f7b9f760" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">ITEPA</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zb26fc267aff04cbc97f407232cc43bdb" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Subject to Clause 7.3, each Manager 
hereby covenants to pay to, or at the direction of, the Company on demand an 
amount equal to all income tax and national insurance contributions and any 
related penalties or interest for which the Company (or any member of the Group)
is required to account in connection with the acquisition or disposal of any 
shares issued to, or acquired by, the Manager (or any associated person (as 
defined in section 421C ITEPA) of the Manager) or with the occurrence of any 
event giving rise to a charge under any of the provisions of Part 7, ITEPA in 
relation to such shares.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z893c1030c37f47cab1020bc1d18aaab4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Subject to Clause 7.3, if any payment
required to be made by a Manager pursuant to the covenant in Clause 7 is not 
made within the period specified in section 222(1)(c) ITEPA, the Manager shall 
in addition pay to the Company an amount equal to all income tax and national 
insurance contributions and any related penalties or interest for which the 
Company (or any other company referred to in Clause 7) is required to account as
a result of any amount of tax being treated as earnings from an employment of 
the Manager whether pursuant to section 222 of ITEPA or otherwise.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za1f890d43bdd4442a02c4d810c8c897d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The covenants in Clause 7 and 7.2 
shall only extend to any secondary Class 1 national insurance contributions to 
the extent that the agreement of the Manager to meet any such liability, and any
payment in respect of any such liability pursuant to such covenants, is not 
contrary to paragraph 3A(1) schedule 1 Social Security Contributions and 
Benefits Act 1992.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za6147f53ca6d4ff19d04453e181ffeb3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If the Company (or any member of the 
Group) is liable to tax on any sum paid under any of Clauses 7 to 7.3 
(inclusive), the amount so payable shall be increased by such amount as will
ensure that, after payment of the tax liability, the Company (and/or and member 
of the Group) is left with a net sum equal to the sum it would have received and
retained had no such tax liability arisen.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">12 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="zfb620f49f328420bb95ee1fb8a36e6e7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Board</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z97c9835914df43499ec40a6596d553a3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In addition to any other Shareholder 
right the Investor may in its absolute discretion appoint any one person to be a
Director (the &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold">Investor Director</font>&#8221;) who 
may also, at the request of the Investor so appointing him, be appointed as a 
director of any other Group Company.&#160; The Investor may also remove any such
person(s) so appointed and appoint another person in his place.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z275f8fbc4d274ac39f4aa9d274cad1f1" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If at any time there is no Investor 
Director in office, the Investor may in its absolute discretion appoint an 
observer to the Board who shall have the same rights as an Investor Director 
except that he shall not be entitled to vote at Board meetings.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3c53b55a0e384b599b6021a123b8934f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Board shall meet as appropriate 
or if required by the Investor Director at a venue in the United Kingdom to be 
decided by the Board or by remote means such as teleconference.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8376d11711844713a907a438fc011629" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Company and the Investor will 
agree the appointment of a mutually acceptable chairman within 24 months 
following Completion.&#160; In the absence of agreement within such time, the 
Investor will have the right to nominate a suitable candidate who shall be 
appointed as chairman.&#160;&#160; Pending such appointment, the parties agree 
that Nasr-Eddine Djennati will act as interim chairman.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8bc6c15fa39b4ad085b95f9766909120" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If requested by Investor Consent, the
Company will establish a remuneration committee (the &#8220;<font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Remuneration Committee</font>&#8221;) and/or an audit committee (the 
&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-WEIGHT: bold">Audit</font>&#160;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Committee</font>&#8221;), both consisting solely of such non-executive 
directors and executive directors (if any) (one of whom must be the Investor 
Director) and chaired by such person as may be approved by Investor 
Consent.&#160; The Remuneration Committee and an Audit Committee shall have such
powers and terms of reference as may be agreed between the Company and Investor 
Consent.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="ze5e223c9998c4216b8cb6277af728956" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Parties agree that (i) the 
Investor Director, and (ii) any observer appointed by the Investor are each duly
authorised to disclose and consult together with the Investor and their 
professional advisers for the purpose of monitoring the Investment, and the 
Company and the Managers shall permit the Investor and the Investor Director (if
any) and the observer (if any) to consult fully together and exchange 
information relating to the Group for the purpose only of reviewing or 
appraising the business and affairs of the Group and/or for purposes relating to
the Investment.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z2e3b3bb083084420ba4c776a81fa229b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor confirms and the Company
and the Managers acknowledge that (i) neither the appointment of, nor the giving
of any of advice by, an Investor Director or any observer appointed by the 
Investor to any Group Company shall constitute the giving of investment advice 
or constitute any Group Company as a customer of the Investor within the meaning
of the Financial Services Authority handbook of rules and guidance as modified, 
supplemented or replaced from time to time (the &#8220;<font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">FSA 
Handbook</font>&#8221;); and (ii) none of the Parties expects the Investor, the 
Investor Director or their observer to owe to any Group Company any duties or 
responsibilities as a customer within the meaning of the FSA Handbook.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">13 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z698cbeae0c8e45649420e90d1987f495" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">9</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Consents etc</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc3f261bf9f064d9bace3d2bdc6be0235" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">No consent or approval to be given by
the Investor or by Investor Consent under this Agreement shall be valid unless 
given in writing.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za761fb7ef6c54f27bb9e31bf6caf5f02" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The carrying out of such duties and 
powers and the giving (or not) of such consents by the Investor or Investor 
Consent shall not (unless otherwise expressly stated) constitute a variation of 
this Agreement or remove the need to seek a similar consent for a subsequent 
similar matter.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z220c1a0886ce4bc0a338fcb8f9267436" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Where any consent or approval of the 
Investor or an Investor Director is required or sought in respect of any 
provision of this Agreement, the Investor or, as the case may be, an Investor 
Director shall have a complete and unfettered discretion as to whether or not to
give the consent or approval and whether or not to impose any terms, conditions 
or limitations on any such consent or approval.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z08dc27b8798e4596a38f444dda69c4b5" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">10</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Announcements and 
confidentiality</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3b1a6cabbdb044f3a34ecab7d07a70ce" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; TEXT-ALIGN: left">10.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Subject to Clauses 10.2 and 10.3, the
terms of this Agreement shall be confidential to the parties.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zebba8fc1c6824ae385d05aaabd1b8d9d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">10.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Company and each of the Managers 
undertakes to the Investor that the Investor and the Investor Director are free 
to disclose (on a confidential basis) to:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zbd2e7af3d86c401ab3569a261060835a" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Investor or any parent 
undertaking of the Investor or any subsidiary undertaking of the Investor;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zd2c71e2108a04e8e8c3c6e3fa566af13" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any professional adviser to, trustee 
or manager of or investor or prospective investor in any fund on behalf of which
the Investor (or their nominees or custodian) holds shares in the capital of the
Company;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z678dd9b0dd3d40159a5bc7aa214757c2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any professional adviser or auditor 
to any such company or fund;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z81fd2565d4b44687a54a12c443b3dd66" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any regulatory body responsible for 
any such company or fund (to the extent that such regulatory body requires 
it);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z64fd8c09bedb4080b12ff4fe9e1f2968" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any actual or prospective provider of
finance to any Group Company;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zbf77a14a3e8d4da58cb7552841893044" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any professional adviser to any of 
the foregoing; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z08686a13784747f78899589007d02dc4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(g)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any person to whom they may disclose 
information under Clause 8.6;</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">any information it
or he receives relating to the Group, any Group Company or its businesses and 
affairs.</div>
<div>
<table id="zd278156ab6ca400b95e97c6fd074c20a" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">10.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The obligations of confidentiality in
Clause 10.2 or otherwise shall not apply to the Investor or the Investor 
Director&#160; in the event that:</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">14 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z39b8385701454c74a743cb4977dfb228" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any of them is expressly obliged by 
law or by the rules and regulations of any recognised investment exchange or by 
the terms upon which the Investor has raised finance (whether debt or equity) to
disclose or divulge any such information;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z98fae2cd690d4e5d9845874f99ccf25c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if the information concerned shall 
have come into the public domain otherwise than by virtue of a prior breach by 
them of such obligations of confidentiality; or</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zaa9417cb55c7441a997ed3c629f623e9" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">as expressly permitted by the Board 
(with the approval of the Investor Director).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3d01ec82c707414bbe1cd3ed28f03e13" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">10.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Each Manager and the Company 
undertakes to the Investor to keep confidential the terms of the Investment and 
all matters contemplated by this Agreement.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8630aaae397c44f9b5e9758ed2bd1051" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">11</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Variation of this 
Agreement and the Articles</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z10ebc5d1d43f4ff690fb9970593e7f75" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">11.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If the Board and with Investor 
Consent concludes that any changes need to be made to the Articles so as to give
effect to the provisions of the Companies Act 2006, to the extent that the 
effectual changes do not alter the commercial effect intended by the Articles 
nor, as an overriding provision, conflict with the provisions of this Agreement,
if so requested by the Board and the Investor, the parties to this Agreement 
shall, so far as are able in their capacity as Directors and/or Shareholders, 
approve the necessary changes to the Articles, and the Managers shall use their 
reasonable endeavours to recommend to the other Shareholders that they also 
approve those changes<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000">.</font></div>
</td>
</tr>
</table>
</div>
<div>
<table id="ze47fb2e2e6e24aa38916cabfb1f739dc" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">11.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If any Manager ceases to be employed 
or engaged by or contracted to provide services to the Company or another Group 
Company in any such capacity or ceases to hold Shares (whichever is the later) 
then, as from the date of such cessation, this Agreement may be varied without 
reference to (or the need for the signature on any relevant document of) such 
Manager provided that (for the avoidance of doubt) such variation shall not give
rise to any new or increased liability of that Party.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z09805c6a88bc4e36b63515a088b42335" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">12</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Notices</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf29d1657085246ee8ba3d17efb2d89f2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">12.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">All notices to be given to a party 
under this Agreement shall be in writing in English and shall be marked for the 
attention of the person, and delivered by hand or sent by first class prepaid 
post (or by air mail if to an address outside the United Kingdom) or by email 
addressed to the party below:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5a2fb246b710434fa97cf8a2166e1849" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">in the case of the Company:</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">
<table id="z82c484d959e54224bdfb0ed999d8c905" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.16%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Address:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.08%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">its registered office</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.16%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.95%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.08%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.16%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">email:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.08%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">nasser.djennati@bioamd.com</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.16%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.95%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.08%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.16%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Attention:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.08%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Nasser Djennati</div>
</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 8pt">&#160;</div>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">15 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z7b3cf5b8de3e4a95886aa1cd13059845" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">in the case of each Manager:</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">
<table id="z1b9707f4b0d14ba99df2e6400115b1d2" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Address:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">his address appearing in part A of Schedule
1</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">email:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: justify">such email as may be notified from time to 
time</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Attention:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">to the relevant Manager</div>
</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif">&#160;</div>
</div>
<div>
<table id="zb9bc8a8f1da642449c15686b3dab7aef" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">in the case of the Investor:</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">
<table id="z197b13bb89e4462b9143be1615b5544b" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Address:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">its address appearing on page 1</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">email:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">tom.barr@bioamd.com</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 13%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Attention:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Tom Barr</div>
</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 8pt">&#160;</div>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">A party may change
the details recorded for it in this Clause by notice to the other in accordance 
with this Clause&#160;12.</div>
<div>
<table id="zb375aff769c540a687cf87238ce408c9" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">12.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">A notice shall be treated as having 
been received:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9b66f1203ff94895b4b1e038f16ed5d3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if delivered by hand between 
9.00&#160;am and 5.00&#160;pm on a Business Day (which time period is referred 
to in this Clause&#160;12 as &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">Business 
Hours</font>&#8221;), when so delivered; and if delivered by hand outside 
Business Hours, at the next start of Business Hours;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zce7105ea38e942a28713cfdcc5d15272" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if sent by first class post, at 
9.00&#160;am on the second Business Day after posting if posted on a Business 
Day and at 9.00 am on the third Business Day after posting if not posted on a 
Business Day;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5baa072802af47d8be367f9fc828a4d7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if sent by air mail, at 9.00&#160;am 
on the fifth Business Day after posting if posted on a Business Day and at 
9.00&#160;am on the sixth Business Day after posting if not posted on a Business
Day; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5f6bd2e899bb46ad893428a6b633680b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if sent by email, when sent if sent 
during Business Hours and if sent by email outside Business Hours, at the next 
start of Business Hours.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf30418218ccf4ba68746449654478ac5" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">12.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In proving that a notice has been 
given it shall be conclusive evidence to prove that delivery was made, or that 
the envelope containing the notice was properly addressed and posted or that the
email was properly addressed and despatched and confirmation of full 
transmission was received (as the case may be).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zb939bb79f5e74bbda697ea7149e36902" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">General</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zbf55c25cfa2f435d8dea5aaf5491d320" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Entire agreement:
</font>This Agreement (together with all documents entered into or referred to 
in this Agreement and all other documents to be entered into pursuant to, or in 
connection with, the Agreement) sets out the entire agreement and understanding 
between the parties, and supersedes all proposals and prior agreements, 
arrangements and understandings between the parties, relating to its subject 
matter.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za219f93a3624496583f7be3041ef1373" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Acknowledgment:</font> Each party acknowledges that in entering into this 
Agreement (and any other document to be entered into pursuant to it) it does not
rely on any representation, warranty, collateral contract or other assurance of 
any person (whether party to this Agreement or not) that is not set out in this 
Agreement or the documents referred to in it.&#160; Nothing in this Agreement 
shall, however, limit or exclude any liability for fraud.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">16 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z5f9430f69b6c4f238aa6fe6c6deee9d2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Further 
assurance:</font>&#160; Each party shall do and execute, or arrange for the 
doing and executing of, any other act and document reasonably requested of it by
the other party to implement and give full effect to the terms of this
Agreement.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8cc339f3bb344a8d86a6d3d27bee6c1d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Survival of 
rights:</font>&#160; Neither Completion nor termination of this Agreement for 
any reason shall affect any rights or liabilities that have accrued prior to 
Completion or termination (as the case may be) or the coming into force or 
continuance in force of any term that is expressly or by implication intended to
come into or continue in force on or after Completion or termination.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za784046a8b2443529e9fa52e8d4764a7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Assignment</font>: 
The parties undertake to each other that it shall be a condition of any sale or 
transfer or other disposal of any Share (or any interest in it) and of any issue
of Shares to any person who is not a party to this Agreement or who has not 
already entered into a Deed or Adherence that prior to it being effected, if so 
requested by the Investor, such person shall have entered into a Deed of 
Adherence. The Company will also join into such Deed of Adherence.&#160; The 
Company is irrevocably authorised by all other persons who are for the time 
being parties to this Agreement to enter into on their behalf any Deed of 
Adherence so approved by the Investor.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zcb0ad700474f41f4888ab385d0a580b7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Variation:</font> 
Subject to clause 11.1, no variation of this Agreement shall be effective unless
it is in writing and is signed by or on behalf of each of the parties.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf007d79657fb4fbab57572a8b517e30e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Waiver and 
Severability:</font>&#160; No single or partial exercise, or failure or delay in
exercising any right, power or remedy by the Investor shall constitute a waiver 
of, or impair or preclude any further exercise of, that or any right, power or 
remedy arising under this Agreement or otherwise. The parties intend each 
provision of this Agreement to be severable and distinct from the others.&#160; 
If a provision of this Agreement is held to be illegal, invalid or 
unenforceable, in whole or in part, the parties intend that the legality, 
validity and enforceability of the remainder of this Agreement shall not be 
affected.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3d30cef8797749e6841a3f025bfea0f4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Rights 
cumulative:</font>&#160; The rights and remedies of the Investor in connection 
with this Agreement are cumulative and, except as expressly stated in this 
Agreement, are not exclusive of any other rights or remedies provided by law or 
equity or otherwise.&#160; Except as expressly stated in this Agreement (or at 
law or in equity in the case or rights and remedies provided by law or equity) 
any right or remedy may be exercised (wholly or partially) from time to 
time.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z77272e687e9643b1862a71e319679791" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.9</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Rescission: 
</font>No party to this Agreement shall be entitled to rescind this Agreement 
after Completion.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc752c0313efd4071b20203347b247df4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.10</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Obligations: </font>Where more than one person takes on any obligation 
such obligation shall, unless otherwise expressly stated, be several.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z468eb027be0a4b9495fc5c34ece602da" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.11</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Conflict:</font> If there is any conflict between this Agreement and the 
Articles, this Agreement shall as between the parties prevail, and, if required 
by the Investor, the parties shall take all steps necessary to amend the 
Articles so as to remove such conflict.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">17 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="zb6e08ca4712e4f12a3deffb6a9676386" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.12</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Third party rights</font>: Unless this Agreement expressly states 
otherwise:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8d5ce437291241cdaa9c09ab15591250" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">a person who is not a party to this 
Agreement has no right to enforce any of its terms under the Contracts (Rights 
of Third Parties) Act 1999; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z83845258405240e38e8da3b7f2e16b25" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if a person who is not a party to 
this Agreement is stated to have the right to enforce any of its terms under the
Contracts (Rights of Third Parties) Act 1999, the parties may rescind or vary
this Agreement (and any documents entered into pursuant to or in connection with
it) without the consent of that person.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z94657b2f278b498c979aca6764810eac" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13.13</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Counterparts:</font> The parties may enter into this Agreement in any 
number of counterparts and on separate counterparts, all of which taken together
shall constitute one and the same instrument.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z462d36653e8d4393b25e5940b3632a9c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">14</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Governing law and 
jurisdiction</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zaef8bf3eb9c9479bb483029b52ecfb1e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">14.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">This Agreement will be governed by 
and construed in accordance with English law and all claims and disputes 
(including non-contractual claims and disputes) arising out of or in connection 
with this Agreement, its subject matter, negotiation or formation will be 
determined in accordance with English law.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3e7847a8988e47c7bb5c5f6888870a48" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">14.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Each party irrevocably submits to the
exclusive jurisdiction of the English courts in relation to all matters 
(including non-contractual matters) arising out of or in connection with this 
Agreement.</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Executed</font> and 
delivered as a deed by the parties or their duly authorised representatives as a
deed on the date of this Agreement.</div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify"><br>
</div>
<table id="zacbcc26ff67a4243816f433117a39c9a" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%" rowspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: justify">Bio-AMD UK Holdings Limited</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">acting by a director in the presence of</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Nasser Djennati, Director</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Name<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Address<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.27%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.76%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">18 Page</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div><br>
</div>
<table id="z8de4fcea693d4edb95e0890e78ebc449" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%" rowspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Nasr-Eddine Djennati</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">in the presence of</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">
<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif">Name</font><font id="TRGRRTFtoHTMLTab" 
style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 216pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">
<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif">Address</font><font id="TRGRRTFtoHTMLTab" 
style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 216pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div><br>
</div>
<table id="z7ac2f2acdd574db39b492a64abf50209" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%" rowspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Andrew Mitchell</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">in the presence of</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr style="HEIGHT: 5px">
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">
<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif">Name</font><font id="TRGRRTFtoHTMLTab" 
style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 216pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">
<div style="TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif">Address</font><font id="TRGRRTFtoHTMLTab" 
style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 216pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.97%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.06%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div><br>
</div>
<div><br>
</div>
<table id="zfeb7c7b107044700a537f6fe140b66e2" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%" rowspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: justify">Bio-AMD Inc.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">acting by a director in the presence of</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Tom Barr, CEO &amp; Director</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.52%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 32.51%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div><br>
</div>
</div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: left"><font id="DSPFPageNumber" 
style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; FONT-STYLE: normal">19 Page</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ex10-2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div>
<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 10.2</div>
<div style="MARGIN-BOTTOM: 8pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; TEXT-ALIGN: left"><br>
 &#160;</div>
</div>
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center"><u>DATED&#160; &#160; &#160; &#160; &#160; 
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; 
&#160; &#160; &#160; June 20, 2016</u></div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">MIDS Medical Limited</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">and</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Zenosense, Inc.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">and</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Bio-AMD UK Holdings Limited</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">and</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">Bio-AMD, Inc.</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">___________________________________</div>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 120.95pt; MARGIN-RIGHT: 
120.95pt">SUBSCRIPTION AND SHAREHOLDERS&#8217; AGREEMENT</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 120.95pt; MARGIN-RIGHT: 
120.95pt">relating to a MIDS Medical Limited Joint Venture</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: center">___________________________________</div>
<div><br>
 &#160;</div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 
6pt">Contents</div>
<div style="MARGIN-BOTTOM: 2.4pt; TEXT-ALIGN: left; MARGIN-TOP: 2.4pt">
<table id="z7e29bdac19de4f969c486a6d1cc21d9f" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; WIDTH: 2.59%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: left">Clause&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: right">Page</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Definitions</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">1</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Interpretation</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">3</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Conditions</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">4</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Completion and during Phase 1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">5</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Phase 2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">6</div>
</td>
</tr>
<tr style="HEIGHT: 18px">
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Phase 2 shall be funded by these options, in this order of 
optionality:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">6</div>
</td>
</tr>
<tr style="HEIGHT: 14px">
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Conversion of Override(s)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">7</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Shareholding Changes</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">7</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Protection in the event of Insolvency</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">8</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">10</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">MIDS License and Developed IP</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">9</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">11</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Warranties</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">10</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">12</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Covenants</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">10</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">13</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Board</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">11</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">14</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Announcements and confidentiality</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">11</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">15</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Notices</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">12</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">16</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">General</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">13</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 2.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">17</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 91.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Governing law and jurisdiction</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">15</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">17</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Budget Phase 1&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">17</div>
</td>
</tr>
<tr style="HEIGHT: 13px">
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part A - The Company</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">18</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part B - Issued share capital immediately before
Completion&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">18</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 2&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">20</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Conditions</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">20</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 3&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">21</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Warranties&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">21</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 4&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">22</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Covenants&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">22</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part A - Matters requiring Investor 
Consent&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">22</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part B - Conduct of Company&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">24</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">Part C &#8211; Provision of 
Information&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">24</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Schedule 5&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">25</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 60.31%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left; TEXT-INDENT: 18pt">ESCROW AGREEMENT&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: right">25</div>
</td>
</tr>
</table>
</div>
<div><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div><br>
</div>
<div style="MARGIN-BOTTOM: 2.4pt; TEXT-ALIGN: left; MARGIN-TOP: 2.4pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">THIS AGREEMENT is made on</font><font id="TRGRRTFtoHTMLTab" 
style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 432pt">&#160;</font><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[<font 
id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: inline-block; WIDTH: 
12pt">&#160;</font>] 2016</font></div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 6pt"><font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">BETWEEN</font>:</div>
<div style="MARGIN-BOTTOM: 6pt; MARGIN-TOP: 6pt"><br>
</div>
<div>
<table id="z08a5c8e38c17428d848aa9afd1389f27" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MIDS Medical 
Limited</font> (company number&#160;10229764)<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>whose 
registered office is at is at Sci-tech Daresbury, Keckwick Lane, Daresbury, 
Cheshire WA4 4F (&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold">Company</font>&#8221;);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z76e8187328404f03b7a213acd92ceb22" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">(2)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Zenosense, 
Inc.</font> (I.R.S. Employer Identification No. 26-3257291) whose principal 
executive office is at Avda Cortes Valencianas 58, Planta 5 46015 Valencia, 
Spain (the &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold">Investor</font>&#8221;);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z1ae1967d0a5e4515b073984b49279ea7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Bio-AMD UK Holdings 
Limited </font>(company number&#160;06909826) whose registered office is at Sci-
Tech Daresbury, Keckwick Lane, Daresbury, WA4 4FS, UK (&#8220;<font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Parent One</font>&#8221;);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zef25b63fca084f44beda12439b400a93" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">(2)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Bio-AMD, Inc.</font>
a Nevada Corporation having I.R.S. Employer Identification No. 20-5242826 having
principal executive offices at Sci-Tech Daresbury, Keckwick Lane, Daresbury, WA4
4FS, UK (&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold">Parent Two</font>&#8221;);</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Together, <font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">the 
&#8220;Parties&#8221;</font></div>
<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">NOW IT IS 
AGREED</font> as follows:</div>
<div>
<table id="z5d191b6946644f1aa3b6d8adbb67ff4c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Definitions</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">In this Agreement,
unless the context otherwise requires:</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Agreed Form</font>&#8221; means, in relation to any document, that
document in the form agreed by the parties and, for the purposes of 
identification, signed or initialled by or on behalf of the parties or their 
solicitors;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Articles</font>&#8221; means the articles of association of the 
Company in the Agreed Form or as subsequently amended from time to time;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Board</font>&#8221; means the board of directors of the 
Company;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Budget Phase 1</font>&#8221; means the development budget for the 
first phase of the Company&#8217;s MIDS project referred to in Schedule 1;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Business</font>&#8221; means the business of the development of 
the MIDS Project;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Business Day</font>&#8221; means any day on which banks are open 
for business in London (excluding Saturdays, Sundays and public holidays);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Business Plan</font>&#8221; means the Company&#8217;s plan for the
future development of the MIDS project;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Company&#8217;s Intellectual Property Rights&#8221; </font>or<font
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold"> &#8220;MIDS IP</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means 
all the Intellectual Property Rights which the Company and any new MIDS IP 
developed;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">1</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Completion</font>&#8221; means completion of the Investment in 
accordance with Clause 4;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Completion Date</font>&#8221; means the date of Completion;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Conditions</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY:
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means the 
conditions referred to Clause 3 and set out in Schedule 2;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Confidential Information</font>&#8221;<font style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#160;</font>means save in so far as such information is already in the 
public domain (other than by breach of any duties of confidentiality) or is 
required to be disclosed by reason of any legal requirement or any rule or 
regulation of any Recognised Investment Exchange or any government or regulatory
authority, all knowledge and information (whether or not recorded in documentary
or machine readable form) which is secret or confidential to the business or 
affairs of the Company;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#8220;Contingency Funding&#8221;</font> means the &#163;45,000 that may 
be drawn down in accordance with clause 4.4;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Directors</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">&#160;</font>the directors of the Company from time to time;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Encumbrance</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means 
any claim, mortgage, lien, pledge, charge, encumbrance, hypothecation, trust, 
right of pre-emption or any other restriction or third party right or interest 
(legal or equitable) or any other security interest of any kind however created 
or arising (or any agreement or arrangement to create any of them);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Equity Shares</font>&#8221; has the meaning given to it in the 
Articles;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Intellectual Property Rights</font>&#8221; means all intellectual 
property rights subsisting at any time in any part of the world including 
patents (including patent applications, any continuation applications, 
divisional applications, or continuation in part applications that claim 
priority to the patents and/or applications, any patents that issue from any of 
the foregoing, and any reissues, re-examinations, renewals, substitutions, and 
extensions of any of the foregoing), trade marks, trade names, marks, design 
rights, data base rights and copyrights (whether any of such rights are 
registered or unregistered) all rights in, to or in connection with confidential
information and all know how, business information (including technical, 
process, clinical or other information, business plans, procedures), technical 
information (including knowledge, research, techniques, designs, science data, 
specifications, practices, procedures, assays, formulae, processes, systems, 
improvements, methods, skill, test and other data including chemical, 
pharmacological, toxicological and clinical tests and other data, analytical and
quality control data, and laboratory notes), regulatory information and 
applications, authorizations, permits and licenses, trade secrets, computer 
programs and domain names and registrations and applications for any of the 
foregoing;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Investment</font>&#8221; means the subscription by the Investor 
for the Ordinary Shares under this Agreement;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Investor Director</font>&#8221; means a person nominated by any of
the Investor to be a director the Company pursuant to this Agreement;</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">2</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Listing</font>&#8221; shall have the meaning ascribed to it in the
Articles;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#8220;MIDS Project&#8221;</font> means the prospective development of a 
universal immunoassay diagnostic device initially targeted at cardiac 
markers;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#8220;MIDS IP&#8221; </font>means any Intellectual Property Rights, 
including patents, patent applications or trademarks that relate to the MIDS 
project;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#8220;MIDS&#8221;</font> means any development related to the MIDS 
project as carried out by the Company whatsoever, including but not limited to 
prototypes, know-how, documentation, licences, patents, patent applications, 
trademarks, agreements,&#160; test equipment and consumables;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Ordinary Shares</font>&#8221; means the ordinary shares of 
&#163;0.05 each in the capital of the Company, having the rights set out in the 
Articles;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Override</font>&#8221; means an enduring share of PAT payable 
within one month following approval and adoption by the Company of the 
Company&#8217;s annual audited accounts for each relevant financial year;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">PAT</font>&#8221; means the profit on the Company&#8217;s ordinary
activities after tax, interest and depreciation, prior to any dividend being 
paid, as shown in the audited profit and loss account of the Company for a 
relevant financial year (to the nearest whole &#163;1);</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#8220;Phase 1&#8221;</font> means the first phase of MIDS Project as 
contemplated in Schedule 1;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">&#8220;Phase 2&#8221; </font>means a second phase of MIDS Project to be 
determined and agreed but expected to be on broadly the same budget and&#160; 
timeline as Phase 1;</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Subscription Monies</font>&#8221; means the sum that the Investor 
has agreed to subscribe for the Ordinary Shares under this Agreement; and</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">&#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Warranties</font>&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY:
'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means the 
Warranties referred to in Clause&#160;11.</div>
<div>
<table id="z7e72a70bb379490a948666a145f80c0e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: 
justify">Interpretation</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z82fee76090704191b23d1a99f635092d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Agreement unless the context 
otherwise requires:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z2bad5e006b78450d86063a8dfc8f10e5" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any recitals and Schedules form part 
of this Agreement and references to this Agreement include them and references 
to recitals, Clauses and Schedules are to recitals and clauses of, and schedules
to, this Agreement and references in a Schedule or part of a Schedule to 
paragraphs are to paragraphs of that Schedule or that part of that 
Schedule;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z040f988ed14444ff8d8dd469932130a8" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">references to this Agreement or any 
other document are to this Agreement or that document as in force for the time 
being and as amended from time to time in accordance with this Agreement or that
document (as the case may be);</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">3</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z68e4abb9879341f2a81e265783a7a533" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">words importing a gender include 
every gender, references to the singular include the plural and vice versa and 
words denoting persons include individuals and bodies corporate, partnerships, 
unincorporated associations and other bodies (in each case, wherever resident 
and for whatever purpose) and vice versa;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zd9ae0ecae9cc4edea1b11c7e16fadafd" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Agreement, unless the context
otherwise requires:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z555b16bd2f7e498285289acbc39e6c6b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">a reference to a statute or statutory
provision shall be construed as including a reference to any subordinate 
legislation (as defined by section&#160;21(1) Interpretation Act 1978) made from
time to time under that statute or provision (whether before or after the date 
of this Agreement); and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z427e8a282df84989b87ba272ba5d8904" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">a reference to a statute, statutory 
provision or subordinate legislation (as so defined) shall be construed as 
including a reference to:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za35e7b3e734949c7934093674a25d339" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(i)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">that statute, provision or 
subordinate legislation as in force at the date of this Agreement and as from 
time to time modified or consolidated, superseded, re-enacted or replaced 
(whether with or without modification) after the date of this Agreement);&#160; 
and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z5941c143416945348a55c5a445198095" class="DSPFListTable"
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(ii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any statute, statutory provision or 
subordinate legislation (as so defined) which it consolidates, supersedes, re-
enacts or replaces (whether with or without modification).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z2e06e2837d22417c991423206aa62aca" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Terms used or defined in the 
Companies Acts or in the Articles shall have the same meanings in this Agreement
unless the context otherwise requires provided that company (if not a reference 
to the Company) shall mean any body corporate wheresoever situated and howsoever
incorporated and the other expressions in Companies Act 2006 shall be construed 
accordingly.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc6d3fe19d3eb45f3bae9712a6e57d76a" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The headings and contents table and 
the brief description of one clause or one paragraph that is cross referenced 
within the text of another clause or paragraph in this Agreement are for 
convenience only and do not affect its interpretation.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z7b662b1518e84bb2b0957edaf78f1c06" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Agreement the words "<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">other</font>", "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif; FONT-WEIGHT: bold">includes</font>", "<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">including</font>" and "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">in particular</font>" do not
limit the generality of any preceding words and any words which follow them 
shall not be construed as being limited in scope to the same class as the 
preceding words where a wider construction is possible.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z80282602e0434e48a174d675ebc617a7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">References to an &#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">Investor</font>&#8221; shall be deemed to include respectively the
Investor, its nominee, its assigns, its transferees and its successors.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z676881f4558e4517a97bd0f9675dd832" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">2.7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">References in this Agreement to any 
party shall, except where the context otherwise requires, include his successors
in title and personal representatives.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z39472226fd334836b93a49331689a645" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Conditions</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zbccacc6167fe4e8fbab89983e1d39588" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">3.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor's obligation to make the
Investment at Completion is conditional upon the Conditions being satisfied to 
the satisfaction of the Investor (in its absolute discretion) or waived (in 
whole or in part) in writing by it or on its behalf (in its absolute 
discretion).</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">4</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="zf1893d80c027453e824c12f37bd805e6" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">3.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If the Conditions have not been 
fulfilled to the satisfaction of the Investor or waived in writing by the 
Investor (in each case in its absolute discretion) then this Agreement shall 
lapse and cease to have effect unless the Investor otherwise agrees or requires 
in writing and no party shall have any claim against any other party under this 
Agreement or in respect of any claims by the Investor which have arisen prior to
such lapse and cessation.&#160;&#160; Accordingly, the provisions of Clauses 1 
and 2, this Clause 3, Clauses 14, 15, 16 and&#160;17 and such of the other 
provisions of this Agreement as are necessary to give efficacy to those Clauses 
or are relevant to the enforcement of those Clauses shall continue to have 
effect notwithstanding any lapse or cessation under Clause 3.2.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z81015b23ddce492eb8166a9bd85aa0d2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Completion and 
during Phase 1</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z53306614a14c45c8a727917ba3167155" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">4.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">On satisfaction or waiver of each of 
the Conditions in accordance with Clause 3, on Completion:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zaf505c1b1d504584a7d0cf3442c6ec4c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the business set out in this 
Agreement shall be transacted;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z0ecba4c261574bebaf83eb8e3ba4d3d3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Investor shall be deemed to apply
for and shall subscribe in advance the pound sterling equivalent of US$130,000 
in cash for 80 Ordinary Shares having a par value of &#163;0.05 per share, 
resulting in the Investors 40 per cent initial ownership in the Company to 
reflect and produce the prior and resultant shareholdings as listed in Schedule 
1 Part B, such ownership and share issuance commencing from July 1, 2016;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z470d4e38dd714b4d8dea560059275b31" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor shall remit the payment 
in 4.1(b) above to the account listed here, it being the Parent Two&#8217;s 
foreign exchange provider&#8217;s account, marking it with the reference 
&#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Bio-AMD Inc</font>.&#8221;:</div>
</td>
</tr>
</table>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 98.95pt">Account Name: City Forex Ltd USD Client 
Account</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 98.95pt">IBAN: GB79 RBOS 1663 0000 4337 41</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 98.95pt">Swift Code: RBOSGB2L</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 98.95pt">Bank: Royal Bank of Scotland PLC</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 98.95pt">62/63 Threadneedle Street</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 98.95pt">London</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 98.95pt">EC2R 8LA, and</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt">Parent Two will control, 
exchange from USD into Sterling, and hold those funds in trust for the Investor 
under the terms of the Escrow Agreement in Schedule 5 until Completion and such 
time MIDS Medical Limited is able to receive the payment in 4.1(b) above and 
Parent Two shall disburse the payment for application solely to the MIDS Project
in line with the Budget Phase 1 until such time MIDS Medical Limited is able to 
receive the payment. In the event Completion does not occur, the funds will be 
immediately returned by Parent Two to the Investor.</div>
<div><br>
</div>
<div>
<table id="zd4e58476476441a3a050e87a0e01c97a" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company shall on 1 July, 
2016:</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">5</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="zdf2e0cdd3bcd45bf9c6bdd20b1752524" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(i)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">allot and issue the Ordinary Shares 
to the Investor free from all Encumbrances;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z2fb48d9afd2945dea39d7af9be75e584" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(ii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">issue a share certificate to the 
Investor for those Ordinary Shares so subscribed or cause UK Companies House to 
evidence the subscription;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z91a9ed6d1d9b400f8721e4ba48e50f60" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(iii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">enter the name of the Investor in the
register of Members in respect of the Ordinary Shares so subscribed; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zfe349991a8eb4de284bf1a3427e404a7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(iv)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">appoint Carlos Gil as the first 
Investor Director.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z89bc7c65ad7b4700b5b612d3d79efcab" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; TEXT-ALIGN: left">4.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Company undertakes to the 
Investor that the Subscription Monies will be applied for the general Company 
funding to achieve the purpose set out in the Business Plan or any Budget (as 
the case may be).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z31a34dcb04ae47d69531616eb7144506" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">4.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">During Phase 1 the Investor will 
further invest in accordance with the Budget Phase 1 payment schedule set out in
Schedule 1.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z99c30396f643426c9ef416f1315c3519" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">4.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">After March 31, 2017 the Investor 
will make Contingency Funding payments if required by the Company at the 
Company&#8217;s sole discretion, of up to a further &#163;45,000 to be drawn 
down, in whole or part, in tranches of &#163;7,500. Any Contingency Funding 
payment will require the Company to provide written notice to the Company and 
will be due within 20 days of such notice.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z167b4203c56e44d8a5b602d94932db16" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">4.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor&#8217;s 40 per cent 
initial shareholding will be subject to;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6bf2de5fb0274d17858ec7a237e5dd2d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if the Investor fails to make any 
further Budget Phase 1 scheduled payment within 14 days of its due date, the 
Company may, in its sole discretion, purchase from the Investor all of its 
ordinary shares at a par value of &#163;0.05 per share;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3191b222652c4359bd98afd528a056d0" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if the Contingency Funding is not 
used in any part during Phase 1, Parent One will be entitled to receive an 
Override calculated as a sum equal to 2.5 per cent of PAT.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zfdffb3cc7272419ca73d86d0becd4a4d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Phase 2</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">Phase 2 shall be 
funded by these options, in this order of optionality:</div>
<div>
<table id="z3b7412597a2742dca6da0be92b1bd77b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Parent One may, in its sole 
discretion, elect, by 31 January, 2016, to fund Phase 2, in which event Parent 
One will be entitled to receive an Override calculated as a sum equal to 15 per 
cent of PAT; subject to that Override being decreased by 0.5 per cent for each 
&#163;7,500 tranche of Contingency Funding demanded and drawn down by the 
Company;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc8e0c36e4a76408fbd73e54b7af05bc1" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If Phase 2 is not elected to be 
funded as in 5(a) above the Company will invite the Investor to fund Phase 2 by 
supplying the Investor with a Phase 2 project plan by 31 January, 2016 and the 
Investor will decline or irrevocably commit to fund Phase 2 by 28 February, 
2017;&#160;if the Investor does not fund Phase 2 in full on the same or similar 
terms to Phase 1, Parent One will be entitled to receive an Override calculated 
as a sum equal to 15 per cent of PAT; subject to that Override being decreased 
by 0.5 per cent for each &#163;7,500 tranche of Contingency Funding demanded and
drawn down by the Company;</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">6</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="za8090844dac84ee6a7c8af8f89f5e736" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If Phase 2 is not funded by the 
Investor as in 5(a) or 5(b) above, and after the Override therein is granted to 
Parent One,&#160; the Parties agree, notwithstanding the Investor Consent rights
in 9 below, that the Company may accept funding from a third party provided 
that;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6a4531a821fb4f5bbbd851cd246af9aa" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(i)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Parent One and the Investor&#8217;s 
interests are diluted pro rata in all respects; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z4103fde2d1734f9fac44867f8bda5f2f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(ii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Any necessary Override adjustment is 
made to effect the provisions of 7.3 below.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za0c5f7707a1a48adb7ef8ea10ccade38" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Conversion of 
Override(s)</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zee0f352213bc429f9ee9a3115fc03d6e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">6.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In the event of a Sale of the Company
as defined in 6.1 below, any Override shall, immediately before any Sale, be 
converted, by way of a sale of Ordinary Shares by the Investor to Parent One and
the concurrent cancellation of the Override,&#160; into Parent One Ordinary 
Shares of the Company, each 1 per cent of Override or part thereof converting 
into each 1 per cent of Ordinary Shares or part thereof, the Investor hereby 
irrevocably agreeing to sell a number of its ordinary shares in the Company to 
Parent One at par value of &#163;0.05 per share to effect that conversion, 
immediately prior to the Sale.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9237b78d0c354df2b6da5a83e6f7a454" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">6.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In this Clause 6 &#8220;Sale&#8221; 
shall mean the making of one or more agreements (whether conditional or not but 
which agreement(s) become(s) unconditional) for the disposal, transfer, 
purchase, subscription or renunciation of any part of the share capital of the 
Company giving rise to a Change in Control and for the purposes of this 
definition &#8220;disposal&#8221; shall mean a sale, transfer, assignment or 
other disposition whereby a person ceases to be the absolute beneficial owner of
the share in question or of voting rights attached thereto or an agreement to 
enter into such disposal or the grant of a right to compel entry into such an 
agreement.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z0c2c5b9b45404f7c97632c4d603bfd26" class="DSPFListTable"
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Shareholding 
Changes</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zedcda4d43ca741f9820ec57c55bd8401" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Parties hereby agree from the 
outset, as if it were embodied in a preference share structure or otherwise, the
intention of the contemplated shareholding changes in 4.5(a) and 6.1 above, and 
8.1(a) and 8.1(b) below, and irrevocably agree to take any action necessary to 
ensure a relevant Party&#8217;s sale and purchase, and irrevocably agree to 
authorise the Company to alternatively issue ordinary shares to effect the 
contemplated changes, should a Party not promptly effect a relevant sale and 
purchase as required by any relevant clause.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z452553f05ce44e5e82a39eeaba6c0b6d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">During Phase 1 other than in 7.1 
above the Company will not, without the written consent of the Investor;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z304b7c7a65184cd1a6b97d1cb3f15324" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Make any change to its memorandum or 
articles of association;</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">7</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="za793a009aa2f433990a091a4bc331ae3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Make any change in its authorised or 
issued share capital of the Company or grant any Encumbrance over any Shares, 
grant any rights to subscribe for or to convert any instrument into Shares or 
securities or waive any right to receive payment on any of its shares issued 
partly paid or cancel or accept the surrender of any such right to subscribe or 
convert;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9793d5d6a338413aa17c5751dc34a5f2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Reduce and capitalise any part of its
share capital, share premium account or capital redemption reserve or vary the 
rights attaching to any class of shares or redeem, purchase or otherwise acquire
any shares or other securities of that company.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zd9d1f45408a6406a9388e2340480de4e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor&#8217;s ownership shall 
not fall below 30per cent per cent as a result of any future investment in the 
share capital in the Company. The Parties agree that, should an investment be 
made that would breach this level, an Override adjustment shall be made so that 
any ordinary shareholding given up by any other shareholder to allow the 
Investor to maintain its shareholding at 30 per cent or above will be 
compensated for by an equivalent percentage Override being granted to those 
other shareholders; by way of a calculation example the 15 per cent Override 
adjustments contemplated in 5(a) and 5(b) above are in exchange for the Investor
not transferring 15 per cent&#160; of the Company equity to Parent One.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zae79b0a6c46d41e29618874b687e75c3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">7.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If the Board with Investor Consent 
concludes that any changes need to be made to the Articles so as to give effect 
to the provisions of the Companies Act 2006, to the extent that the effectual 
changes do not alter the commercial effect intended by the Articles nor, as an 
overriding provision, conflict with the provisions of this Agreement, if so 
requested by the Board and the Investor, the parties to this Agreement shall, so
far as are able in their capacity as Directors and/or Shareholders, approve the 
necessary changes to the Articles, and the Managers shall use their reasonable 
endeavours to recommend to the other Shareholders that they also approve those 
changes.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zcf7f0815bca54fed893ac3a8881b76e6" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Protection in the 
event of Insolvency</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za939556745704e538cb77de754be8c05" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">8.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In the event of an Insolvency Event 
defined as the inability of a party to pay its debts as they fall due within the
meaning of section&#160; 123 of the Insolvency Act 1986 (the &#8220;Act&#8221;);
or the issue of an application for an administration order or a notice of 
intention to appoint an administrator in relation to the company; or the passing
of a resolution or order for the Company&#8217;s winding-up, dissolution, 
administration or reorganization; or the declaration of a moratorium in relation
to any of the Company&#8217;s indebtedness; or the making of any arrangement or 
any proposal for any arrangement with any of the Company&#8217;s creditors; or 
the appointment of a liquidator, receiver, administrator, supervisor or other 
similar officer in respect of any of the Company&#8217;s assets, or any similar 
arrangement, the following shall apply;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc9caa144517a4198a5e913436fc89cf9" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If affecting the Company or Parent 
Two, Parent One shall sell the MIDS IP to the Investor for $1;</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">8</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="zd02ba5ebc7ea4827b1a9e5e22001386e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">If affecting the Investor; the 
Investor shall be deemed to have sold its Ordinary Shares in the Company back to
the Company at par value of &#163;0.05 per share.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za8314e7124ca4e399c77df8ff6537f23" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Consents 
etc.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z583e60af092645f7901b44843cda145b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor will have the right to 
prevent or approve by consent any of the matters listed in in Schedule 4. This 
right of consent, notwithstanding&#160; 16.4 below, may be extinguished at the 
sole discretion of Parent One if;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z93872789f78547218eeba9ad469dbed4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(i)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor does not make a Phase 1 
Payment within 14 days of it falling due;</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt; TEXT-INDENT: 
36pt">or</div>
<div>
<table id="z7aa98d8e2cf44accba3415c81cccbfa8" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(i)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor does make all the Phase 
1 payments but declines to fund Phase 2;</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt; TEXT-INDENT: 
36pt">and</div>
<div>
<table id="z4462837867df4f848dfd2f3ac4a0694b" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 108pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">(ii)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Any further investment into the 
Company affects both Parent One and the Investor pro rata in all respects. Any 
adjustment by Override as laid out in 7.3 above is deemed to be pro rata.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf442c60fe44f4f9abd3ba08dc560a979" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">No consent or approval to be given by
the Investor or by Investor Consent under this Agreement shall be valid unless 
given in writing.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zfc1893c22a754f62b83032b81e37243f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The carrying out of such duties and 
powers and the giving (or not) of such consents by the Investor or Investor 
Consent shall not (unless otherwise expressly stated) constitute a variation of 
this Agreement or remove the need to seek a similar consent for a subsequent 
similar matter.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z47c46b497c6a46e28a53758015e63f55" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">9.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Where any consent or approval of the 
Investor or an Investor Director is required or sought in respect of any 
provision of this Agreement, the Investor or, as the case may be, an Investor 
Director shall have a complete and unfettered discretion as to whether or not to
give the consent or approval and whether or not to impose any terms, conditions 
or limitations on any such consent or approval.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6f9348f4537549799040b51d61c01835" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">10</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">MIDS License and 
Developed IP</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf094d48656eb45db85d8b8078d380a7a" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">10.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Parent One shall initially grant the 
Company, a limited, exclusive, world-wide, royalty free, non-transferable 
research license to use and utilize the MIDS IP and will transfer the MIDS IP 
directly to the Company in the event that the Company concludes a commercial 
deal with a third party.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zfff67838281342ec9e8b387547dcc1fe" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">10.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Any additional Intellectual Property 
(&#8220;New IP&#8221;) developed by the Company in relation to the MIDS IP will 
vest as the sole property of the Company, and the Investor shall have no other 
right, other than its ordinary shareholding in the Company, in any Intellectual 
Property so developed. In the event that New IP is developed the Parties will 
reasonably agree as to any requirement for patented protection and if any 
payment is required this will be contributed pro rata with respective 
shareholdings, including and taking into account any Override rights, at 
relevant times.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">9</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z74073ec6bd564ea3854ef5c1b4d9b793" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">10.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Prior to transfer as in 10.1 above to
Parent One will invoice the Company for patent costs and administration in line 
with the Budget Phase 1.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z038ed00d65e046b1a0beff8931a5113c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">11</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Warranties</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3c8486889c5542679c67796f913adcf7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">11.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In consideration of the Investor 
making the Investment at Completion the Company and / or Parent One warrants to 
the Investor that;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za997e823575f412aa5b7f13316e0e7c1" class="DSPFListTable"
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Parent One&#160; will licence the 
MIDS IP to the Company in accordance with 10 above, and will maintain those 
patents as far as it can;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z648c6f2919874db5a1c6c9d0cdf3cb33" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Parent One will cause the MIDS IP to 
come into the direct registration and control of the Company in the event that 
the Company concludes a commercial deal with a third party; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z99260d0cb03b452d8ab35a9e516311c9" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Budget Phase 1 will be applied as
contemplated, subject only to necessary operational variations at the 
Company&#8217;s sole discretion, provided that variation is deemed by the 
Company as reasonably necessary to achieve the Phase 1 objectives.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc1bf21ad7b0e4da1af37d4e5ae33ed8c" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">11.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">The Company acknowledges to the Investor that the Investor has 
entered into this Agreement in reliance on the Warranties. Each of the 
Warranties shall be construed separately and independently from the 
others.</div>
</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><br>
</div>
<div>
<table id="zee0d5c62653b4eb58e3a14abe928f39c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">11.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Any and all liability under the 
Warranties shall absolutely cease at the end of Phase 1 (the &#8220;<font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold">End Date</font>&#8221;).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf6321aa26fc941888e8eb3bdd94820e1" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">11.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor warrants to the Company 
that it is duly authorised to enter into this Agreement and the obligations of 
the Investor under this Agreement and each document to be executed by it at or 
before Completion are or when the relevant document is executed, will be 
enforceable on the Investor in accordance with their terms.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8352fa37a0094c5abdf41a85ec10ace2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">12</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Covenants</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 6pt; TEXT-INDENT: 36pt">From 
Completion, unless modified by 9.1 above:</div>
<div>
<table id="ze596e1e1757747718bffaa44e2714f54" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company shall not take any of the
actions set out in Schedule 4, Part A without Investor Consent, unless the 
action is expressly required or permitted by this Agreement;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z1ec90a7c837f482e91ff5f00793131d6" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company shall exercise all rights
and powers lawfully available to them to procure that it conducts its business 
in accordance with, and observe the covenants set out in, Schedule 4, Part B 
(whether or not as a matter of law such covenants are enforceable against the 
Company in question) unless with Investor Consent;</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">10</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z71c49c3297ce4aa4902273111de9dfdf" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">the Company will comply with their 
respective obligations set out in Schedule 4, Part C regarding the provision of 
information to the Investor; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z550a9fc10fa64c5b9d51952f8b158be2" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">12.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">It is acknowledged for the purposes 
of section 173 Companies Act 2006 that the Covenants in Schedule 4, Part D and 
other provisions of this Agreement may restrict the future exercise of 
discretion by Directors and the parties intend that,&#160; to the extent 
permitted by that section, the discretion of such directors should be so 
restricted.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zaec5d92db1df4bf1bfa74c6a9b8c24b7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">12.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Each of the Covenants shall be 
construed independently of each of the others so that if one or more of them 
shall be held to be invalid as an unreasonable restraint of trade or for any 
other reason whatsoever then the remaining Covenants shall be valid to the 
extent that they are not held to be so invalid.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="ze632bae0cacb4ff8ae27aeea8b198288" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">12.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Company shall not, and the 
Investor shall exercise all rights and powers lawfully available to them to 
procure that the Company shall not, take any of the following actions without 
the prior written consent of the holders of not less than 76per cent of the 
issued Ordinary Shares (an &#8220; Ordinary Majority &#8221;):</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9eb85f59795249f7b932c688c5d0c2d9" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">make any change in its issued share 
capital;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z246a4be6ee9a427d9157e9c14335a7bd" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">appoint or remove any director of the
Company (other than the appointment or removal of the Investor Director);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6c300f3d0b04431f85491a01ac7c7ae8" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">take any steps to wind-up or 
liquidate or obtain an administration order in respect of the Company.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zbef04291982b498c8fa69f9d14adadda" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">13</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Board</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z1de6c397637a442ca7d12ebddb162f9d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">13.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor will appoint any one 
person to be a Director (the &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">Investor 
Director</font>&#8221;) of the Company.&#160; The Investor may also remove any 
such person(s) so appointed and appoint another person in his place.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z527bbf58b9cc47169f374530355f6824" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">13.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The number of Investor Directors 
shall be increased, as far as it practicable, so that the number of Investor 
Directors is broadly maintained as a proportion of one in three directors of the
Company.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z1ffa4b28ae5c445bba57c1819c73b7dd" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">13.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor and its Investor 
Director(s) shall be actively involved in the management of the Company, its 
CEO, Carlos Gil, will be initially appointed to the board as Investor Director 
and act as Sales Director. Mr Gil will provide his services to the Company under
a contract to be agreed during Phase 1, the Investor funding the cost of those 
services to the Company by payments directly to Mr Gil.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8d29799237664054aeaecb71a18afd5f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">13.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Investor Director will always 
maintain a director in office.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z0a060a721cf346c88416c63f65b22e2d" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">13.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">The Board shall meet at as it determines or as required by the 
Investor Director.</div>
</td>
</tr>
</table>
</div>
<div style="TEXT-ALIGN: justify; MARGIN-LEFT: 36pt"><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">11</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z3c5872b49a694ca5be8a42d5df156154" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">14</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Announcements and 
confidentiality</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z17db93ae62b74bfb98ac94bb34a334af" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">14.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Subject to Clauses 14.2 and 14.3, the
terms of this Agreement shall be confidential to the parties.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc130ad4451da47c3a5255557f2bc172e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">14.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Company undertakes to the 
Investor that the Investor and the Investor Director are free to disclose (on a
confidential basis) to:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zfa613e3f37074f9c90e582d77a5500aa" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any professional adviser to, trustee 
or manager of or investor or prospective investor in any fund on behalf of which
the Investor (or their nominees or custodian) holds shares in the capital of the
Company;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zd6c3e0204dcb417cb46e2a6a30dc3b08" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any professional adviser or auditor 
to any such company or fund;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zb4fde857267a457fb43e1d01c4d2638d" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any regulatory body responsible for 
any such company or fund (to the extent that such regulatory body requires 
it);</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc2db866522b54023ba198a829a6bb67c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any actual or prospective provider of
finance to the Company;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf7f3f83c804348f487560a5a7a5aeb32" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any professional adviser to any of 
the foregoing; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z3728910c97a141f7ad97b6baef6a40b3" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any person to whom the Investor may 
make a permitted transfer under Article 13 (Permitted Transfers) of the 
Articles,</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">any information it
or he receives relating to the Company or its businesses and affairs.</div>
<div>
<table id="z309034587504497ab9065b298e3c538c" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">14.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The obligations of confidentiality in
Clause 14.2 or otherwise shall not apply to the Investor or the Investor 
Director&#160; in the event that:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zd048573a1cf2457fa94a5ef11154b2e7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">any of them is expressly obliged by 
law or by the rules and regulations of any recognised investment exchange or by 
the terms upon which the Investor has raised finance (whether debt or equity) to
disclose or divulge any such information;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9141242e65574855b21c5a4415921b99" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if the information concerned shall 
have come into the public domain otherwise than by virtue of a prior breach by 
them of such obligations of confidentiality; or</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z69a84317c7574471abb07133b3faabb9" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">as expressly permitted by the Board
(with the approval of the Investor Director).</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z8d4b4dafda6d41638a497e7626f243e4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">14.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Company undertakes to the 
Investor to keep confidential the terms of the Investment and all matters 
contemplated by this Agreement.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z699879f7624a49e7944559a384de3171" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">14.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">The Company and the Investor agree it
is in their mutual interest to seek to publicise the Company&#8217;s progress 
with the MIDS project in order to maximise commercial interest and the prospects
for partnering, and will from time to time agree to release such non-
confidential information to achieve this aim, and will work together to produce 
a MIDS specific website to promote this commercial aim.</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">12</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z6c95976d78024ceabd4caba322a530d1" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">15</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Notices</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z2cc814d22b1b44c9bf18ee58312a84de" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">15.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">All notices to be given to a party 
under this Agreement shall be in writing in English and shall be marked for the 
attention of the person, and delivered by hand or sent by first class prepaid 
post (or by air mail if to an address outside the United Kingdom) or by email to
the address or email account detailed for the party below:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zf691c98577324a309e49ce40f0b49dc8" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">in the case of the Company, Parent 
One and Parent Two:</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">Address:</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 108pt">&#160;</font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif">the relevant address appearing on 
page 1</font></div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">email</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 144pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif">Tom Barr</font></div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">Attention:</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 108pt">&#160;</font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif">tom.barr@bioamd.com</font></div>
<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
<div>
<table id="zb2271f884444423c92100b8bade04442" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">in the case of the Investor:</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">Address:</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 108pt">&#160;</font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif">its address appearing on page 
1</font></div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">email</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 144pt">&#160;</font><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif">cgil@zenosense.net</font></div>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, 
serif">Attention:</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 108pt">&#160;</font><font style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif">Carlos Gil</font></div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">A party may change
the details recorded for it in this Clause by notice to the other in accordance 
with this Clause&#160;15.</div>
<div>
<table id="z7942016b5ba04702a8b31d28fc877907" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">15.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">A notice shall be treated as having 
been received:</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za9944dcbe4504a55b45ecb39bbaa8f07" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if delivered by hand between 
9.00&#160;am and 5.00&#160;pm on a Business Day (which time period is referred 
to in this Clause&#160;15 as &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold">Business 
Hours</font>&#8221;), when so delivered; and if delivered by hand outside 
Business Hours, at the next start of Business Hours;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za2cff4f402374aa4ad3392feb194bb23" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if sent by first class post, at 
9.00&#160;am on the second Business Day after posting if posted on a Business 
Day and at 9.00 am on the third Business Day after posting if not posted on a 
Business Day;</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zb0a0ecae796347769373b2bd071b7399" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if sent by air mail, at 9.00&#160;am 
on the fifth Business Day after posting if posted on a Business Day and at 
9.00&#160;am on the sixth Business Day after posting if not posted on a Business
Day; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zd13de16af10745589ef4e1b01280de33" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if sent by email, when sent if sent 
during Business Hours and if sent by fax outside Business Hours, at the next 
start of Business Hours.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6b79452cee05452eaca2164789e29f74" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">15.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">In proving that a notice has been 
given it shall be conclusive evidence to prove that delivery was made, or that 
the envelope containing the notice was properly addressed and posted or that the
email was properly addressed and despatched and confirmation of full 
transmission was received (as the case may be).</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">13</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="za7599ad137dd42a6a24fc960dc8e0fe0" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">General</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zc4848177991d47ca8b42c57fed031597" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Entire agreement: 
</font>This Agreement (together with all documents entered into in the Agreed 
Form referred to in this Agreement and all other documents to be entered into 
pursuant to, or in connection with, the Agreement) sets out the entire agreement
and understanding between the parties, and supersedes all proposals and prior 
agreements, arrangements and understandings between the parties, relating to its
subject matter.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z04af9c13598d453fa499be5c22c889b1" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Acknowledgment:</font> Each party acknowledges that in entering into this 
Agreement (and any other document to be entered into pursuant to it) it does not
rely on any representation, warranty, collateral contract or other assurance of 
any person (whether party to this Agreement or not) that is not set out in this 
Agreement or the documents referred to in it.&#160; Nothing in this Agreement 
shall, however, limit or exclude any liability for fraud.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="zfdbcd13c263943ef9e44fa8c77559475" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.3</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Further 
assurance:</font>&#160; Each party shall do and execute, or arrange for the 
doing and executing of, any other act and document reasonably requested of it by
the other party to implement and give full effect to the terms of this 
Agreement.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6854897273ec40b0a5fd7455741eb2a5" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: left">16.4</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold">Survival of rights:</font>&#160; Neither 
Completion nor termination of this Agreement for any reason shall affect any 
rights or liabilities that have accrued prior to Completion or termination (as 
the case may be) or the coming into force or continuance in force of any term 
that is expressly or by implication intended to come into or continue in force 
on or after Completion or termination.</div>
</td>
</tr>
</table>
</div>
<div><br>
</div>
<div>
<table id="z9ae7e9905a1d4abba1ce51fcb4699b5c" class="DSPFListTable" style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" 
cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: left">16.5</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold">Waiver and Severability:</font>&#160; No single
or partial exercise, or failure or delay in exercising any right, power or 
remedy by the Investor shall constitute a waiver of, or impair or preclude any 
further exercise of, that or any right, power or remedy arising under this 
Agreement or otherwise. The parties intend each provision of this Agreement to 
be severable and distinct from the others.&#160; If a provision of this 
Agreement is held to be illegal, invalid or unenforceable, in whole or in part, 
the parties intend that the legality, validity and enforceability of the 
remainder of this Agreement shall not be affected.</div>
</td>
</tr>
</table>
</div>
<div><br>
</div>
<div>
<table id="z79aa47d5737445ea89e350c69623518e" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.6</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Rights 
cumulative:</font>&#160; The rights and remedies of the Investor in connection 
with this Agreement are cumulative and, except as expressly stated in this 
Agreement, are not exclusive of any other rights or remedies provided by law or 
equity or otherwise.&#160; Except as expressly stated in this Agreement (or at 
law or in equity in the case or rights and remedies provided by law or equity) 
any right or remedy may be exercised (wholly or partially) from time to 
time.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z20469ea47f4546a79a2ad137694c256f" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.7</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Rescission: 
</font>No party to this Agreement shall be entitled to rescind this Agreement 
after Completion.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="za81a0efa3024442486b63b0fff69e4d9" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.8</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Conflict:</font> If
there is any conflict between this Agreement and the Articles, this Agreement 
shall as between the parties prevail, and, if required by the Investor, the 
Company shall take all steps necessary to amend the Articles so as to remove 
such conflict.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z9e112fbee952456ba416c440b3f3ff25" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.9</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third party 
rights</font>: Unless this Agreement expressly states otherwise:</div>
</td>
</tr>
</table>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">14</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<div>
<table id="z63c1e0396f0244a1a82ba78456a5a4c7" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">a person who is not a party to this 
Agreement has no right to enforce any of its terms under the Contracts (Rights 
of Third Parties) Act 1999; and</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z871c5a3220c6420cac8d62b766b8f600" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 72pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">if a person who is not a party to 
this Agreement is stated to have the right to enforce any of its terms under the
Contracts (Rights of Third Parties) Act 1999, the parties may rescind or vary 
this Agreement (and any documents entered into pursuant to or in connection with
it) without the consent of that person.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z71965642bf544f6dac5c035136c69684" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">16.10</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: 
bold">Counterparts:</font> The parties may enter into this Agreement in any 
number of counterparts and on separate counterparts, all of which taken together
shall constitute one and the same instrument.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z20f3a073e0724cbdb38239ebb00f5717" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">17</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Governing law and 
jurisdiction</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6dfcd52fb9d04f04b7908a9a7d677bc4" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">17.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">This Agreement will be governed by 
and construed in accordance with English law and all claims and disputes 
(including non-contractual claims and disputes) arising out of or in connection 
with this Agreement, its subject matter, negotiation or formation will be 
determined in accordance with English law.</div>
</td>
</tr>
</table>
</div>
<div>
<table id="z6d550b80cb4c4175a26cb5cc51345286" class="DSPFListTable" 
style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 36pt; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: left">17.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: auto">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify">Each party irrevocably submits to the
exclusive jurisdiction of the English courts in relation to all matters 
(including non-contractual matters) arising out of or in connection with this 
Agreement.</div>
</td>
</tr>
</table>
</div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Executed</font> and 
delivered as a deed by the parties or their duly authorised representatives as a
deed on the date of this Agreement.</div>
<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
<table id="zbf264fc2c9ad445f94b519b58b941298" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%" rowspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: justify">MIDS Medical Limited</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">acting by its duly authorised Officer</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000">in the presence of</font>:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Tom Barr - Director</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Name<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Address<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.74%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP:
10pt">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">15</font></div>
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-
BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-
WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
<table id="z61fb133cc4b7419fa24fd9c6ff7a6faa" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%" rowspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: justify">Zenosense Inc.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">acting by its duly authorised Officer</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000">in the presence of</font>:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Carlos Gil - CEO</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Name<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Address<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
<table id="zbf3be9de7a4d4430aeb358576a6295d5" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%" rowspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: justify">Bio-AMD UK Holdings Limited.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">acting by its duly authorised Officer</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000">in the presence of</font>:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Nasser Djennati - Director</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Name<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Address<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
<table id="zb93e1c06411a4588b665fab29519f123" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" 
cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%" rowspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left">Executed as a deed by</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; TEXT-ALIGN: justify">Bio-AMD Inc.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">acting by its duly authorised Officer</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000">in the presence of</font>:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: center">)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Tom Barr - CEO</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Signature of witness</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Name<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; DISPLAY: 
inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-
ALIGN: justify">Address<font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 1px; 
DISPLAY: inline-block; WIDTH: 12pt">&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.61%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 28.41%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.91%">&#160;</td>
</tr>
</table>
<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify"><br>
</div>
</div>
<div>&#160;</div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font 
id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">16</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">Exhibit 31.1</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">CERTIFICATION OF PRINCIPAL 
EXECUTIVE AND FINANCIAL OFFICER</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">I, Thomas Barr, 
Principal Executive Officer of Bio-AMD, Inc., certify that:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed 
this quarterly report on Form 10-Q of Bio-AMD, Inc. for the quarterly period 
ended June 30, 2016;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my 
knowledge, the quarterly report does not contain any untrue statement of 
material fact or omit to state a material fact necessary to make the statements 
made, in light of the circumstances under which such statements were made, not 
misleading with respect to the period covered by this quarterly report;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my 
knowledge, the financial statements, and other financial information included in
this quarterly report, fairly present in all material respects the financial 
condition, results of operations and cash flows of the registrant as of and for 
the periods presented in this quarterly report;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The 
registrant&#8217;s other certifying officers and I are responsible for 
establishing and maintaining disclosure controls and procedures (as defined in 
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial 
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the 
registrant and have:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such 
disclosure controls and procedures, or caused such disclosure controls and 
procedures to be designed under our supervision, to ensure that material 
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the 
period in which this quarterly report is being prepared;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such 
internal control over financial reporting, or caused such internal control over 
financial reporting to be designed under our supervision, to provide reasonable 
assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally 
accepted accounting principles;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the 
effectiveness of the registrant&#8217;s disclosure controls and procedures; and 
presented in this report our conclusions about the effectiveness of the 
disclosure controls and procedures, as of the end of the period covered by this 
report based on such evaluation; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this
report any change in the registrant&#8217;s internal control over financial 
reporting that occurred during the registrant&#8217;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the 
registrant&#8217;s internal control over financial reporting; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The 
registrant&#8217;s other certifying officers and I have disclosed, based on our 
most recent evaluation of internal control over financial reporting, to the 
registrant&#8217;s auditors and the audit committee of the registrant&#8217;s 
board of directors (or persons performing the equivalent function):</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant 
deficiencies and material weaknesses in the design or operation of internal 
control over financial reporting which are reasonably likely to adversely affect
the registrant&#8217;s ability to record, process, summarize and report 
financial information; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, 
whether or not material, that involves management or other employees who have a 
significant role in the registrant&#8217;s internal controls.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<table id="zbe4e35472db3426bb2940d5493527243" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 80%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 45%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Date:&#160;&#160; August 15, 2016&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 
30%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">/s/ Thomas Barr</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 45%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 30%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Thomas Barr, Principal Executive Officer</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">Exhibit 31.2</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">CERTIFICATION OF PRINCIPAL 
EXECUTIVE AND FINANCIAL OFFICER</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">I, David Miller, 
Principal Financial Officer of Bio-AMD, Inc., certify that:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed 
this quarterly report on Form 10-Q of Bio-AMD, Inc. for the quarterly period 
ended June 30, 2016;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my 
knowledge, the quarterly report does not contain any untrue statement of 
material fact or omit to state a material fact necessary to make the statements 
made, in light of the circumstances under which such statements were made, not 
misleading with respect to the period covered by this quarterly report;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my 
knowledge, the financial statements, and other financial information included in
this quarterly report, fairly present in all material respects the financial 
condition, results of operations and cash flows of the registrant as of and for 
the periods presented in this quarterly report;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The 
registrant&#8217;s other certifying officers and I are responsible for 
establishing and maintaining disclosure controls and procedures (as defined in 
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial 
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the 
registrant and have:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such 
disclosure controls and procedures, or caused such disclosure controls and 
procedures to be designed under our supervision, to ensure that material 
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the 
period in which this quarterly report is being prepared;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such 
internal control over financial reporting, or caused such internal control over 
financial reporting to be designed under our supervision, to provide reasonable 
assurance regarding the reliability of financial reporting and the preparation 
of financial statements for external purposes in accordance with generally 
accepted accounting principles;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the 
effectiveness of the registrant&#8217;s disclosure controls and procedures; and 
presented in this report our conclusions about the effectiveness of the 
disclosure controls and procedures, as of the end of the period covered by this 
report based on such evaluation; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this
report any change in the registrant&#8217;s internal control over financial 
reporting that occurred during the registrant&#8217;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the 
registrant&#8217;s internal control over financial reporting; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The 
registrant&#8217;s other certifying officers and I have disclosed, based on our 
most recent evaluation of internal control over financial reporting, to the 
registrant&#8217;s auditors and the audit committee of the registrant&#8217;s 
board of directors (or persons performing the equivalent function):</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 
36pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant 
deficiencies and material weaknesses in the design or operation of internal 
control over financial reporting which are reasonably likely to adversely affect
the registrant&#8217;s ability to record, process, summarize and report 
financial information; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT:
36pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, 
whether or not material, that involves management or other employees who have a 
significant role in the registrant&#8217;s internal controls.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>
<table id="z4db01565dedb4f30ad80b7c865740bce" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 80%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 45%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Date:&#160;&#160; August 15, 2016</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 
30%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">/s/&#160;David Miller</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 45%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 30%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">David Miller, Principal Financial 
Officer</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">Exhibit 32.1</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">CERTIFICATION PURSUANT TO 18 
U.S.C. SECTION 1350,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">AS ADOPTED PURSUANT TO</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">SECTION 906 OF THE SARBANES-
OXLEY ACT OF 2002</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In connection with the Quarterly Report of 
Bio-AMD, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended 
June 30, 2016 as filed with the Securities and Exchange Commission on the date 
hereof (the &#8220;Report&#8221;), I, Thomas Barr, Chief Executive Officer of 
the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">(1)<font style="FONT-SIZE: 1pt; FONT-
FAMILY: 'Times New Roman', serif">&#160;</font>The Report fully complies with 
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 
1934; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">(2)<font style="FONT-SIZE: 1pt; FONT-
FAMILY: 'Times New Roman', serif">&#160;</font>The information contained in the 
Report fairly presents, in all material respects, the financial condition and 
results of operations of the Company.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">A signed original of this written statement
required by Section 906 has been provided to the Company and will be retained by
the Company and furnished to the Securities and Exchange Commission or its staff
upon request.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<table id="z23e2e62aecea41279eb455ad2527e898" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 80%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 45%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Date:&#160;&#160; August 15, 2016</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 
30%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">/s/ Thomas Barr&#160;</div>
</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 45%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 30%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Thomas Barr, Principal Executive Officer</div>
</td>
</tr>
</table>
<div><br>
</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">A signed original of this written statement 
required by Section 906 of the Sarbanes- Oxley Act of 2002 has been provided to 
Bio-AMD, Inc. and will be retained by Bio-AMD, Inc. and furnished to the 
Securities and Exchange Commission or its staff upon request. This written 
statement accompanies the Form 10-Q to which it relates, is not deemed filed 
with the Securities and Exchange Commission, and will not be incorporated by 
reference into any filing of Bio-AMD, Inc. under the Securities Act of 1933 or 
the Securities Exchange Act of 1934, irrespective of any general incorporation 
language contained in such filing.</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Federal Filings
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" 
bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: right">Exhibit 32.2</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">CERTIFICATION PURSUANT TO 18 
U.S.C. SECTION 1350,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">AS ADOPTED PURSUANT TO</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">SECTION 906 OF THE SARBANES-
OXLEY ACT OF 2002</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">In connection with the Quarterly Report of 
Bio-AMD, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended 
June 30, 2016 as filed with the Securities and Exchange Commission on the date 
hereof (the &#8220;Report&#8221;), I, David Miller, Chief Financial Officer of 
the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">(1)<font style="FONT-SIZE: 1pt; FONT-
FAMILY: 'Times New Roman', serif">&#160;</font>The Report fully complies with 
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 
1934; and</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">(2)<font style="FONT-SIZE: 1pt; FONT-
FAMILY: 'Times New Roman', serif">&#160;</font>The information contained in the 
Report fairly presents, in all material respects, the financial condition and 
results of operations of the Company.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: justify">A signed original of this written statement
required by Section 906 has been provided to the Company and will be retained by
the Company and furnished to the Securities and Exchange Commission or its staff
upon request.</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>
<table id="z0b780fdca890467cbbb97868cf4b372d" style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; WIDTH: 80%" cellspacing="0" 
cellpadding="0" border="0">
<tr>
<td style="WIDTH: 45%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Date:&#160;&#160; August 15, 2016</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px 
solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">/s/ David Miller&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 45%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">David Miller, Principal Financial 
Officer</div>
</td>
</tr>
</table>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
<div><br>
</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">A signed original of this written statement 
required by Section 906 of the Sarbanes- Oxley Act of 2002 has been provided to 
Bio-AMD, Inc. and will be retained by Bio-AMD, Inc. and furnished to the 
Securities and Exchange Commission or its staff upon request. This written 
statement accompanies the Form 10-Q to which it relates, is not deemed filed 
with the Securities and Exchange Commission, and will not be incorporated by 
reference into any filing of Bio-AMD, Inc. under the Securities Act of 1933 or 
the Securities Exchange Act of 1934, irrespective of any general incorporation 
language contained in such filing.</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>biad-20160630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by iC(tm) - CompSci Interactive Converter - 
http://www.compsciresources.com -->
<!-- Created: Mon Aug 15 16:32:52 EDT 2016 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" 
xmlns:xl="http://www.xbrl.org/2003/XLink" 
xmlns:iso4217="http://www.xbrl.org/2003/iso4217" 
xmlns:compsci="http://compsciresources.com" xmlns:us-gaap="http://fasb.org/us-
gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" 
xmlns:biad="http://www.bioamd.com/20160630" 
xmlns:xbrli="http://www.xbrl.org/2003/instance" 
xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:us-
types="http://fasb.org/us-types/2016-01-31" 
xmlns:xbrldi="http://xbrl.org/2006/xbrldi" 
xmlns:link="http://www.xbrl.org/2003/linkbase" 
xmlns:xlink="http://www.w3.org/1999/xlink" 
xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="biad-20160630.xsd"/>
  <context id="c0_AsOf30Jun2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c1_AsOf31Dec2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="c2_From1Apr2016To30Jun2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c3_From1Apr2015To30Jun2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c4_From1Jan2016To30Jun2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
</entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c5_From1Jan2015To30Jun2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c6_AsOf31Dec2015_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Dec2015_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2015_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2015_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
<instant>2015-12-31</instant>
    </period>
  </context>
  <context id="c10_AsOf31Dec2015_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="c11_From1Jan2016To30Jun2016_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c12_From1Jan2016To30Jun2016_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c13_From1Jan2016To30Jun2016_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context 
id="c14_From1Jan2016To30Jun2016_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c15_AsOf30Jun2016_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c16_AsOf30Jun2016_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c17_AsOf30Jun2016_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c18_AsOf30Jun2016_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c19_AsOf30Jun2016_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
<segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementEquityComponentsAxis">us-
gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c20_AsOf31Dec2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="c21_AsOf30Jun2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="c22_AsOf8Aug2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <instant>2016-08-08</instant>
    </period>
  </context>
  <context id="c23_AsOf1May2009_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-05-01</instant>
    </period>
  </context>
  <context 
id="c24_From14Aug2009To14Aug2009_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-08-14</startDate>
      <endDate>2009-08-14</endDate>
    </period>
  </context>
  <context 
id="c25_From20Nov2009To20Nov2009_WOCULimitedWLFormerlyWDXOrganizationMember">
<entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-11-20</startDate>
      <endDate>2009-11-20</endDate>
    </period>
  </context>
  <context 
id="c26_From8Mar2010To8Mar2010_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-03-08</startDate>
      <endDate>2010-03-08</endDate>
    </period>
  </context>
  <context id="c27_AsOf8Mar2010_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-03-08</instant>
    </period>
  </context>
  <context id="c28_AsOf23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-07-23</instant>
    </period>
  </context>
  <context 
id="c29_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
<period>
      <startDate>2010-07-23</startDate>
      <endDate>2010-07-23</endDate>
    </period>
  </context>
  <context 
id="c30_AsOf23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember_SeriesCPreferre
dStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-
gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-07-23</instant>
    </period>
  </context>
  <context 
id="c31_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember_Seri
esCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-
gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-07-23</startDate>
      <endDate>2010-07-23</endDate>
    </period>
  </context>
  <context 
id="c32_From30Jun2011To30Jun2011_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-30</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context 
id="c33_From1Nov2011To30Nov2011_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
</entity>
    <period>
      <startDate>2011-11-01</startDate>
      <endDate>2011-11-30</endDate>
    </period>
  </context>
  <context 
id="c34_From12Jul2012To12Jul2012_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-12</startDate>
      <endDate>2012-07-12</endDate>
    </period>
  </context>
  <context 
id="c35_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c36_AsOf25Feb2010_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-02-25</instant>
    </period>
  </context>
  <context id="c37_From25Feb2010To25Feb2010_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-02-25</startDate>
      <endDate>2010-02-25</endDate>
    </period>
  </context>
  <context id="c38_AsOf25Feb2010">
<entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <instant>2010-02-25</instant>
    </period>
  </context>
  <context id="c39_From1Jan2016To30Jun2016_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c40_AsOf17Jun2016_BioAMDUKHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:BioAMDUK
HoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-17</instant>
    </period>
  </context>
  <context id="c41_AsOf30Jun2016_BioAMDUKHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:BioAMDUK
HoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context 
id="c42_AsOf30Jun2016_DrNasserDjennatiMember_BioAMDUKHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember 
dimension="biad:NoncontrollingOwnerAxis">biad:DrNasserDjennatiMember</xbrldi:exp
licitMember>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:BioAMDUK
HoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
<context 
id="c43_AsOf30Jun2016_DrAndrewMitchellMember_BioAMDUKHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember 
dimension="biad:NoncontrollingOwnerAxis">biad:DrAndrewMitchellMember</xbrldi:exp
licitMember>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:BioAMDUK
HoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c44_AsOf16Jun2016_InterestInUKMedicalOperationsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Interest
InUKMedicalOperationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-16</instant>
    </period>
  </context>
  <context id="c45_AsOf17Jun2016_InterestInUKMedicalOperationsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Interest
InUKMedicalOperationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-17</instant>
    </period>
  </context>
  <context id="c46_From1Jan2016To17Jun2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-17</endDate>
    </period>
  </context>
  <context 
id="c47_AsOf1Jul2016_ThirdPartyMedicalDetectionDeviceDevloperMember_MIDSMedicalL
imitedMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember 
dimension="biad:NoncontrollingOwnerAxis">biad:ThirdPartyMedicalDetectionDeviceDe
vloperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:MIDSMedi
calLimitedMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-
gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-07-01</instant>
    </period>
  </context>
  <context 
id="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentureMember
">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-
gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-
gaap:CorporateJointVentureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-07-01</endDate>
    </period>
  </context>
  <context 
id="c49_AsOf1Jul2016_SubsequentEventMember_CorporateJointVentureMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-
gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-
gaap:CorporateJointVentureMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-07-01</instant>
    </period>
  </context>
  <context id="c50_AsOf30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:WOCULimi
tedWLFormerlyWDXOrganizationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c51_AsOf30Jun2016_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
</period>
  </context>
  <context id="c52_AsOf30Jun2016_GBP">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c53_AsOf30Jun2016_AverageRateMember_GBP">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember 
dimension="biad:ForeignTranslationAxis">biad:AverageRateMember</xbrldi:explicitM
ember>
        <xbrldi:explicitMember dimension="us-
gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c54_AsOf30Jun2015_GBP">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="c55_AsOf30Jun2015_AverageRateMember_GBP">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember 
dimension="biad:ForeignTranslationAxis">biad:AverageRateMember</xbrldi:explicitM
ember>
        <xbrldi:explicitMember dimension="us-
gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="c56_From30Jun2016To30Jun2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
    </entity>
    <period>
      <startDate>2016-06-30</startDate>
      <endDate>2016-06-30</endDate>
    </period>
</context>
  <context id="c57_From1Apr2015To30Jun2015_AffiliatedEntityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:AffiliatedEntityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c58_From1Jan2016To30Jun2016_AffiliatedEntityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:AffiliatedEntityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c59_From1Jan2015To30Jun2015_AffiliatedEntityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:AffiliatedEntityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c60_AsOf30Jun2016_ChiefFinancialOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context 
id="c61_From1Jan2015To31Jul2015_AffiliatedEntityMember_BioAMDIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:AffiliatedEntityMember</xbrldi:explicitMember>
<xbrldi:explicitMember 
dimension="dei:LegalEntityAxis">biad:BioAMDIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-07-31</endDate>
    </period>
  </context>
  <context id="c62_From1Jan2015To31Jul2015_AffiliatedEntityMember_Bio-
AMDHoldingsLimitedMember_BioAMDIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:AffiliatedEntityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember 
dimension="dei:LegalEntityAxis">biad:BioAMDIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-07-31</endDate>
    </period>
  </context>
  <context id="c63_From1Aug2015To30Sep2015_AffiliatedEntityMember_Bio-
AMDHoldingsLimitedMember_BioAMDIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:AffiliatedEntityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-
gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember 
dimension="dei:LegalEntityAxis">biad:BioAMDIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-08-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="c64_From1Apr2016To30Jun2016_ChiefExecutiveOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c65_From1Apr2015To30Jun2015_ChiefExecutiveOfficerMember">
<entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c66_From1Jan2016To30Jun2016_ChiefExecutiveOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c67_From1Jan2015To30Jun2015_ChiefExecutiveOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c68_From1Apr2016To30Jun2016_ChiefFinancialOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c69_From1Apr2015To30Jun2015_PresidentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:PresidentMember</xbrldi:explicitMember>
      </segment>
    </entity>
<period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c70_From1Jan2016To30Jun2016_ChiefFinancialOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c71_From1Jan2015To30Jun2015_ChiefFinancialOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-
gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context 
id="c72_From1Apr2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:WOCULimitedWLFormerlyWDXOrganizationMem
ber</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c73_From1Apr2016To30Jun2016_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c74_From1Apr2016To30Jun2016_CorporateMember">
    <entity>
<identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">us-
gaap:CorporateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c75_AsOf30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:WOCULimitedWLFormerlyWDXOrganizationMem
ber</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c76_AsOf30Jun2016_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="c77_AsOf30Jun2016_CorporateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">us-
gaap:CorporateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context 
id="c78_From1Apr2015To30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:WOCULimitedWLFormerlyWDXOrganizationMem
ber</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
</period>
  </context>
  <context id="c79_From1Apr2015To30Jun2015_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c80_From1Apr2015To30Jun2015_CorporateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">us-
gaap:CorporateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c81_AsOf30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:WOCULimitedWLFormerlyWDXOrganizationMem
ber</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="c82_AsOf30Jun2015_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="c83_AsOf30Jun2015_CorporateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">us-
gaap:CorporateMember</xbrldi:explicitMember>
      </segment>
</entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context 
id="c84_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:WOCULimitedWLFormerlyWDXOrganizationMem
ber</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c85_From1Jan2016To30Jun2016_Bio-AMDHoldingsLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="c86_From1Jan2016To30Jun2016_CorporateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">us-
gaap:CorporateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context 
id="c87_From1Jan2015To30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:WOCULimitedWLFormerlyWDXOrganizationMem
ber</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c88_From1Jan2015To30Jun2015_Bio-AMDHoldingsLimitedMember">
<entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">biad:Bio-
AMDHoldingsLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="c89_From1Jan2015To30Jun2015_CorporateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001370030</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-
gaap:StatementBusinessSegmentsAxis">us-
gaap:CorporateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="gbp">
    <measure>iso4217:GBP</measure>
  </unit>
  <unit id="gbpPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:GBP</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">68754</us-
gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">437400</us-
gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">5359</us-
gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">12972</us-
gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">8068</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">12251</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">0</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">645534</us-gaap:DeferredCostsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">82181</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">1108157</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">140</us-
gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">157</us-
gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">165573</us-
gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">165848</us-
gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:Assets unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">247894</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">1274162</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">34114</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">62149</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf30Jun2016"
decimals="0">17575</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2015"
decimals="0">23239</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">761</us-
gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">17316</us-
gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">0</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">950402</us-gaap:DeferredRevenueCurrent>
  <us-gaap:Liabilities unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">52450</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">1053106</us-gaap:Liabilities>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">45976</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2015"
decimals="0">45976</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">42611186</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">42589759</us-gaap:AdditionalPaidInCapital>
  <us-
gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax unitRef="usd" contextRef="c0_AsOf30Jun2016" decimals="0">35571</us-
gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax>
  <us-
gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax unitRef="usd" contextRef="c1_AsOf31Dec2015" decimals="0">73243</us-
gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">-41384326</us-
gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">-41331858</us-
gaap:RetainedEarningsAccumulatedDeficit>
  <us-
gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 
unitRef="usd" contextRef="c0_AsOf30Jun2016" decimals="0">1308407</us-
gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-
gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 
unitRef="usd" contextRef="c1_AsOf31Dec2015" decimals="0">1377120</us-
gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:MinorityInterest unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">-1112963</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterest unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">-1156064</us-gaap:MinorityInterest>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c0_AsOf30Jun2016" 
decimals="0">195444</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2015" 
decimals="0">221056</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">247894</us-
gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">1274162</us-
gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" 
contextRef="c0_AsOf30Jun2016" decimals="INF">10000000</us-
gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" 
contextRef="c1_AsOf31Dec2015" decimals="INF">10000000</us-
gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" 
contextRef="c0_AsOf30Jun2016" decimals="3">0.001</us-
gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" 
contextRef="c1_AsOf31Dec2015" decimals="3">0.001</us-
gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" 
contextRef="c0_AsOf30Jun2016" decimals="0">0</us-
gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" 
contextRef="c1_AsOf31Dec2015" decimals="0">0</us-
gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" 
contextRef="c0_AsOf30Jun2016" decimals="0">0</us-
gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding unitRef="shares" 
contextRef="c1_AsOf31Dec2015" decimals="0">0</us-
gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" 
contextRef="c0_AsOf30Jun2016" decimals="3">0.001</us-
gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" 
contextRef="c1_AsOf31Dec2015" decimals="3">0.001</us-
gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" 
contextRef="c0_AsOf30Jun2016" decimals="INF">500000000</us-
gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" 
contextRef="c1_AsOf31Dec2015" decimals="INF">500000000</us-
gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" 
contextRef="c0_AsOf30Jun2016" decimals="INF">45975966</us-
gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" 
contextRef="c1_AsOf31Dec2015" decimals="INF">45975966</us-
gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" 
contextRef="c0_AsOf30Jun2016" decimals="INF">45975966</us-
gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" 
contextRef="c1_AsOf31Dec2015" decimals="INF">45975966</us-
gaap:CommonStockSharesOutstanding>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">103847</us-
gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">354863</us-
gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">257594</us-
gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">578496</us-
gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">103847</us-
gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">354863</us-
gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">257594</us-
gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">578496</us-
gaap:OperatingExpenses>
  <us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">-103847</us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments>
  <us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">-354863</us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments>
  <us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-257594</us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments>
  <us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-578496</us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments>
  <us-gaap:GainLossOnContractTermination unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">248074</us-
gaap:GainLossOnContractTermination>
  <us-gaap:GainLossOnContractTermination unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">0</us-
gaap:GainLossOnContractTermination>
  <us-gaap:GainLossOnContractTermination unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">248074</us-
gaap:GainLossOnContractTermination>
  <us-gaap:GainLossOnContractTermination unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">0</us-
gaap:GainLossOnContractTermination>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">490</us-
gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">731</us-
gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">962</us-
gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">1524</us-
gaap:InterestAndOtherIncome>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c2_From1Apr2016To30Jun2016" 
decimals="0">144717</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c3_From1Apr2015To30Jun2015" 
decimals="0">-354132</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" 
decimals="0">-8558</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" 
decimals="0">-576972</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">48574</us-
gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">-7502</us-
gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">43910</us-
gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-13554</us-
gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">96143</us-
gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">-346630</us-
gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-52468</us-
gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-563418</us-
gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c2_From1Apr2016To30Jun2016" 
decimals="0">144717</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c3_From1Apr2015To30Jun2015" 
decimals="0">-354132</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" 
decimals="0">-8558</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" 
decimals="0">-576972</us-gaap:ProfitLoss>
  <us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax unitRef="usd" contextRef="c2_From1Apr2016To30Jun2016" decimals="0">-
14848</us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax>
  <us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax unitRef="usd" contextRef="c3_From1Apr2015To30Jun2015" 
decimals="0">26402</us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax>
  <us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-
17054</us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax>
  <us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-
2875</us-
gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax>
  <us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest unitRef="usd" contextRef="c2_From1Apr2016To30Jun2016" 
decimals="0">129869</us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest>
  <us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest unitRef="usd" contextRef="c3_From1Apr2015To30Jun2015" decimals="0">-
327730</us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest>
  <us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-
25612</us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest>
  <us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-
579847</us-
gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest>
  <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest 
unitRef="usd" contextRef="c2_From1Apr2016To30Jun2016" decimals="0">62547</us-
gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest 
unitRef="usd" contextRef="c3_From1Apr2015To30Jun2015" decimals="0">-19990</us-
gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest 
unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" decimals="0">64529</us-
gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest 
unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-16484</us-
gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="0">67322</us-
gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="0">-307740</us-
gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-90141</us-
gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-563363</us-
gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" 
contextRef="c2_From1Apr2016To30Jun2016" decimals="2">0.00</us-
gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" 
contextRef="c3_From1Apr2015To30Jun2015" decimals="2">-0.01</us-
gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="2">0.00</us-
gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="2">-0.01</us-
gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted 
unitRef="shares" contextRef="c2_From1Apr2016To30Jun2016" 
decimals="INF">45975966</us-
gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted 
unitRef="shares" contextRef="c3_From1Apr2015To30Jun2015" 
decimals="INF">45103998</us-
gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted 
unitRef="shares" contextRef="c4_From1Jan2016To30Jun2016" 
decimals="INF">45975966</us-
gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted 
unitRef="shares" contextRef="c5_From1Jan2015To30Jun2015" 
decimals="INF">44906076</us-
gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" 
contextRef="c6_AsOf31Dec2015_CommonStockMember" decimals="INF">45975966</us-
gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c6_AsOf31Dec2015_CommonStockMember" decimals="0">45976</us-
gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c7_AsOf31Dec2015_AdditionalPaidInCapitalMember" 
decimals="0">42589759</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c8_AsOf31Dec2015_RetainedEarningsMember" decimals="0">73243</us-
gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c9_AsOf31Dec2015_AccumulatedOtherComprehensiveIncomeMember" 
decimals="0">-41331858</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c10_AsOf31Dec2015_NoncontrollingInterestMember" decimals="0">-
1156064</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax unitRef="usd" 
contextRef="c11_From1Jan2016To30Jun2016_RetainedEarningsMember" decimals="0">-
37672</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax unitRef="usd" 
contextRef="c12_From1Jan2016To30Jun2016_NoncontrollingInterestMember" 
decimals="0">20618</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-17054</us-
gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries 
unitRef="usd" 
contextRef="c13_From1Jan2016To30Jun2016_AdditionalPaidInCapitalMember" 
decimals="0">8914</us-
gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries>
  <us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries 
unitRef="usd" 
contextRef="c12_From1Jan2016To30Jun2016_NoncontrollingInterestMember" 
decimals="0">-8914</us-
gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease unitRef="usd" 
contextRef="c13_From1Jan2016To30Jun2016_AdditionalPaidInCapitalMember" 
decimals="0">12513</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease unitRef="usd" 
contextRef="c12_From1Jan2016To30Jun2016_NoncontrollingInterestMember" 
decimals="0">-12513</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c14_From1Jan2016To30Jun2016_AccumulatedOtherComprehensiveIncomeMembe
r" decimals="0">-52468</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c12_From1Jan2016To30Jun2016_NoncontrollingInterestMember" 
decimals="0">43910</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" 
contextRef="c15_AsOf30Jun2016_CommonStockMember" decimals="INF">45975966</us-
gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c15_AsOf30Jun2016_CommonStockMember" decimals="0">45976</us-
gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c16_AsOf30Jun2016_AdditionalPaidInCapitalMember" 
decimals="0">42611186</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c17_AsOf30Jun2016_RetainedEarningsMember" decimals="0">35571</us-
gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c18_AsOf30Jun2016_AccumulatedOtherComprehensiveIncomeMember" 
decimals="0">-41384326</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" 
contextRef="c19_AsOf30Jun2016_NoncontrollingInterestMember" decimals="0">-
1112963</us-gaap:StockholdersEquity>
  <us-gaap:AmortizationOfDeferredCharges unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">0</us-
gaap:AmortizationOfDeferredCharges>
  <us-gaap:AmortizationOfDeferredCharges unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">24000</us-
gaap:AmortizationOfDeferredCharges>
  <us-gaap:ShareBasedCompensation unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">0</us-
gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">184000</us-
gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-7613</us-
gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-5323</us-
gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-4402</us-
gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">7834</us-
gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInDeferredCharges unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">46878</us-
gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredCharges unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">397301</us-
gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">0</us-
gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">19594</us-
gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-28035</us-
gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">102777</us-
gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-5664</us-
gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">0</us-
gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-16555</us-
gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">-3420</us-
gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">0</us-
gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">978076</us-
gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 
unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-341749</us-
gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 
unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" decimals="0">289055</us-
gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquireIntangibleAssets unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">18824</us-
gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">0</us-
gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-18824</us-
gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">0</us-
gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations 
unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-8073</us-
gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations 
unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" decimals="0">16944</us-
gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">-368646</us-
gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" 
contextRef="c5_From1Jan2015To30Jun2015" decimals="0">305999</us-
gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" 
contextRef="c20_AsOf31Dec2014" decimals="0">717144</us-
gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" 
contextRef="c21_AsOf30Jun2015" decimals="0">1023143</us-
gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockIssued1 unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" 
decimals="0">0</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" 
decimals="0">54000</us-gaap:StockIssued1>
  <us-gaap:InterestPaid unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016" 
decimals="0">0</us-gaap:InterestPaid>
  <us-gaap:InterestPaid unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015" 
decimals="0">0</us-gaap:InterestPaid>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c4_From1Jan2016To30Jun2016"
decimals="0">0</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c5_From1Jan2015To30Jun2015"
decimals="0">0</us-gaap:IncomeTaxesPaid>
  <dei:EntityRegistrantName contextRef="c4_From1Jan2016To30Jun2016">Bio-AMD 
Inc.</dei:EntityRegistrantName>
  <dei:DocumentType contextRef="c4_From1Jan2016To30Jun2016">10-
Q</dei:DocumentType>
  <dei:CurrentFiscalYearEndDate contextRef="c4_From1Jan2016To30Jun2016">--12-
31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" 
contextRef="c22_AsOf8Aug2016" 
decimals="INF">45975966</dei:EntityCommonStockSharesOutstanding>
  <dei:AmendmentFlag 
contextRef="c4_From1Jan2016To30Jun2016">false</dei:AmendmentFlag>
  <dei:EntityCentralIndexKey 
contextRef="c4_From1Jan2016To30Jun2016">0001370030</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus 
contextRef="c4_From1Jan2016To30Jun2016">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers 
contextRef="c4_From1Jan2016To30Jun2016">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory contextRef="c4_From1Jan2016To30Jun2016">Smaller 
Reporting Company</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer 
contextRef="c4_From1Jan2016To30Jun2016">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:DocumentFiscalYearFocus 
contextRef="c4_From1Jan2016To30Jun2016">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus 
contextRef="c4_From1Jan2016To30Jun2016">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentPeriodEndDate contextRef="c4_From1Jan2016To30Jun2016">2016-06-
30</dei:DocumentPeriodEndDate>
  <us-gaap:NatureOfOperations contextRef="c4_From1Jan2016To30Jun2016">&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Note 
1&amp;#160;&amp;#x2013; Nature of Operations and Continuance of 
Business&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY:
&apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;General&lt;/div&gt;&lt;br/&gt;&lt;div
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The accompanying unaudited 
condensed consolidated financial statements have been prepared pursuant to the 
rules and regulations of the Securities and Exchange Commission (the 
&amp;#x201c;SEC&amp;#x201d;).&amp;#160;Certain information and note disclosures 
normally included in annual consolidated financial statements prepared in 
accordance with generally accepted accounting principles have been condensed or 
omitted pursuant to those rules and regulations, although the Company believes 
that the disclosures made are adequate to make the information not 
misleading.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In the opinion of management, the unaudited condensed 
consolidated financial statements have been prepared on the same basis as the 
annual consolidated financial statements and reflect all adjustments, which 
include only normal recurring adjustments, necessary to present fairly the 
consolidated financial position as of June 30, 2016 and the results of 
operations and cash flows for the six month periods ended June 30, 2016 and 
2015. The financial data and other information disclosed in the notes to the 
interim condensed consolidated financial statements related to these periods are
unaudited.&amp;#160;The results for the three and six month period ended June 
30, 2016 are not necessarily indicative of the results to be expected for any 
subsequent quarter or the entire year ending December 31, 
2016.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;These unaudited condensed consolidated financial statements 
should be read in conjunction with our audited consolidated financial statements
and the notes thereto for the year ended December 31, 2015, included in the 
Company&amp;#x2019;s annual report on Form 10-K filed with the SEC&amp;#160;on 
March 30, 2016.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;Nature of 
Operations&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;Bio-AMD, Inc. (&amp;#x201c;Bio-AMD&amp;#x201d; the 
&amp;#x201c;Company&amp;#x201d;, &amp;#x201c;we&amp;#x201d;, 
&amp;#x201c;us&amp;#x201d;, &amp;#x201c;our&amp;#x201d;) (formerly known as Flex
Fuels Energy, Inc. and Malibu Minerals, Inc.) was incorporated in the State of 
Nevada on March 10, 2006 to engage in the business of exploration and discovery 
of gold, minerals, mineral deposits and reserves.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;On April 15, 2011, we 
entered into an Agreement and Plan of Merger (the &quot;Merger Agreement&quot;) 
pursuant to which we merged with our newly formed, wholly owned subsidiary, Bio-
AMD, Inc., a Nevada corporation (&quot;Merger Sub&quot; and such merger 
transaction, the &quot;Merger&quot;). Upon the consummation of the Merger, the 
separate existence of Merger Sub ceased and shareholders of the Company became 
shareholders of the surviving company named Bio-AMD, Inc. As permitted by 
Chapter 92A.180 of Nevada Revised Statutes, the sole purpose of the Merger was 
to effect a change of our name to Bio-AMD, Inc. to better reflect our core 
business area. Upon the filing of Articles of Merger (the &quot;Articles of 
Merger&quot;) with the Secretary of State of Nevada on April 15, 2011 to effect 
the Merger, our Articles of Incorporation were deemed amended to reflect the 
change in our corporate name.&amp;#160;&amp;#160;We are quoted on OTC Markets 
and the OTC Bulletin Board under the symbol 
&amp;#x201c;BIAD&amp;#x201d;.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;During the fourth quarter of our 2006 
fiscal year, for the purpose of diversifying our business, acquiring capital, 
gaining greater access to the capital markets and with the assistance of newly 
acquired capital, we entered into an Agreement with Flex Fuels Energy Limited 
(&amp;#x201c;FFE Ltd&amp;#x201d;) and the stockholders of FFE Ltd by which FFE 
Ltd became our wholly-owned subsidiary effective on May 29, 2007. FFE Ltd 
engaged in the development of the business of manufacturing and distributing Oil
Seed Rape (&amp;#x201c;OSR&amp;#x201d;) products.&lt;/div&gt;&lt;br/&gt;&lt;div
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Effective September 5, 2009,
after having carefully evaluated all options, we abandoned our proposed oil seed
business, as we no longer considered the business to be economically viable on 
either a go alone or partnered basis.&amp;#160;&amp;#160;The proposed project 
initiated by prior management involved building an oil seed crushing plant at 
Cardiff, Wales was compromised by delays, sub-optional design and substantial 
legal costs.&amp;#160;&amp;#160;We were unable to raise the necessary financing,
to locate a project partner, or to divest our interest in the project for 
value.&amp;#160;&amp;#160;Accordingly, we determined that our best course of 
action was to preserve value by winding down the oil seed operations of FFE 
Ltd.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;From our inception through the date of these unaudited 
condensed consolidated financial statements, we have not generated any revenues 
and have incurred significant expenses. The Company intends to fund its 
development of the currency risk technology, diagnostic technology and on-going 
operations through equity and/or debt financing 
arrangements.&amp;#160;&amp;#160;However, there can be no assurance that these 
arrangements will be sufficient to fund its ongoing capital expenditures, 
working capital, and other cash requirements. Consequently, our operations are 
subject to all the risks and uncertainties inherent in the establishment of a 
new business enterprise.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold;
COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;WOCU Limited 
Acquisition&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;On May 1, 2009, we entered into an Investment Agreement (the 
&amp;#x201c;Investment Agreement&amp;#x201d;) with WDX Organisation Limited, a 
corporation incorporated under the laws of England and Wales, and the founding 
shareholders of WDX Organisation Limited (the &amp;#x201c;Founders&amp;#x201d;),
the owners of all of the issued and outstanding shares of WDX Organisation 
Limited.&amp;#160;&amp;#160;On the same date, we entered into a related Loan 
Agreement (the &amp;#x201c;Loan Agreement&amp;#x201d;) and a related Option and 
Funding Agreement (the &amp;#x201c;Funding Agreement&amp;#x201d;) with WDX 
Organisation Limited.&amp;#160;&amp;#160;The Investment Agreement, Loan 
Agreement and Funding Agreement are hereinafter collectively referred to as the 
&amp;#x201c;Agreements&amp;#x201d;. Pursuant to the Agreements, we acquired 51% 
ownership of WDX Organisation Limited. WDX Organisation Limited changed its name
to WOCU Limited (&amp;#x201c;WL&amp;#x201d;) effective January 29, 
2013.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;WL is the developer of the WOCU technology, an algorithm and 
system of providing reference data for its WOCU global currency unit, designed 
to mitigate currency risk. On August 14, 2009, we provided a further 
&amp;#xa3;150,000 (approximately $247,800) to WL by way of a loan and have 
exercised certain call options. On November 20, 2009, we loaned an additional 
&amp;#xa3;150,000 (approximately $249,840) to WL and increased our equity 
position in WL.&amp;#160;WL has been working to develop contracts with a variety
of banks, currency exchange networks, data providers, and derivative exchanges 
in an effort to commercialize its WOCU technology through licensing 
agreements.&amp;#160;&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt;
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-
ALIGN: justify&quot;&gt;On March 8, 2010, we loaned an additional 
&amp;#xa3;150,000 (approximately $224,055) to WL and executed certain call 
options to further increase our equity position in WL. The loans were the result
of our ongoing investment in WL as contemplated by our May 1, 2009 Investment 
Agreement with WL.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-
ALIGN: justify&quot;&gt;Altogether, these transactions resulted
 in a total loan of &amp;#xa3;600,000 (approximately $904,000) to WL and the 
ownership of 93% of WL by the Company on March 8, 
2010.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN:
justify&quot;&gt;On July 23, 2010, we entered into a Subscription Agreement with
WL and the founders of WL under which we purchased 500,000 preference shares of 
WL (the &amp;#x201c;Preference Shares&amp;#x201d;) at a price of one British 
Pound per share (approximately $750,000). &amp;#160; The Preference Shares earn 
in priority to any other class of stock of WL, a cumulative dividend equal to 5%
of the subscription price of such Preference Shares per annum. These Preference 
Shares carry a preference over all other classes of WL stock in the event of a 
sale, liquidation or listing of WL. Upon liquidation, sale or listing and after 
repayment of the outstanding loans made by us to WL, other liabilities of WL and
related transaction costs, the holder of the Preference Shares is entitled to a 
payment equal to three times the subscription price (the &amp;#x201c;Preference 
Shares Payment&amp;#x201d;) paid for such Preference 
Shares.&amp;#160;&amp;#160;The Preference Shares are redeemable upon a sale, 
listing or winding down of WL.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;The Subscription Agreement also provided 
for WL to allot up to an aggregate of 16,900 C Ordinary Shares of WL to 
employees, directors and consultants of WL to secure their continued service to 
WL and incentivize them in the performance thereof.&amp;#160;&amp;#160;An 
aggregate of 14,061 C Ordinary Shares were issued, for nominal consideration, to
three employees and Robert Galvin, our former Chief Financial Officer on July 
23, 2010. The issuance of the 14,061 C Ordinary Shares reduced our ownership in 
WL from 93% to 77.54%.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;Effective June 30, 2011, WL agreed with all three 
of its employees to terminate existing employment agreements so as to reduce the
monthly cash outflows. As a result of the termination of employment contracts, 
and in accordance with the WL Articles of Association, terminated employees gave
up 9,243 C Ordinary Shares. This increased our ownership in WL to 
87.13%.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;During November 2011, we loaned an additional &amp;#xa3;50,000 
(approximately $77,000) to WL as a short-term unsecured intercompany loan. On 
July 12, 2012, it was agreed that this loan would be settled through the 
issuance of 5,000,000 common shares, increasing our ownership in WL to 
99.81%.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;Since January 2013, the Company has provided further advances 
totaling &amp;#xa3;196,000 (approximately $260,000) into WL to fund its 
operations based on the prospective pipeline of opportunities that have been 
generated.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 0.1pt; FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-RIGHT: 
0.1pt&quot;&gt;As at June 30, 2016, there were no commercial agreements in 
place, and no revenues had been generated by WL. Given the Company&amp;#x2019;s 
limited resources, it is unlikely that the Company can support WL operations 
going forward, as a contractor to WL vital to its technical operation has 
indicated it is not willing to continue to provide its services at the current 
much reduced rate of payment and accordingly further investment will be required
to support WL. The Company will consider any option that might preserve any 
value in WL.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; COLOR: 
#000000; TEXT-ALIGN: left&quot;&gt;Bio-AMD Holdings Limited 
Acquisition&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;On February 25, 2010, we entered into a Subscription and 
Shareholders Agreement with Bio-AMD Holdings Limited (&amp;#x201c;Bio-AMD 
Holdings&amp;#x201d;), a United Kingdom company, and the managers of Bio-AMD 
Holdings, under which we acquired a 63% interest in Bio-AMD Holdings for 
&amp;#xa3;865,000 British Pounds (approximately $1,335,000) through the purchase
of preferred shares.&amp;#160;&amp;#160;The preferred shares accrue dividends at
the rate of 5% per year and provide for a preference in liquidation equal to 
&amp;#xa3;865,000, plus accrued unpaid dividends (the preference on a sale is 
&amp;#xa3;850,000, plus accrued and unpaid dividends). Bio-AMD Holdings is a
development stage company, formed in February 2010, which, through its operating
subsidiary, Bio Alternative Medical Devices Ltd. (&amp;#x201c;Bio-
Medical&amp;#x201d;), principally operates in the Medical Point of Care 
(&amp;#x201c;POC&amp;#x201d;) diagnostic space. Where context requires, 
reference to Bio-AMD Holdings also includes reference to Bio-Medical. Bio-AMD 
Holdings owns a portfolio of patent applications on technologies, which it 
expects to enable it to develop highly accurate, low cost, hand held electronic 
diagnostic devices capable of reading certain third party assays. Since 2010 
Bio-AMD Holdings has been developing its technology into three initial product 
types (1) a digital strip reader targeted initially into the &amp;#x201c;over 
the counter&amp;#x201d; female well-being market (including digital pregnancy, 
ovulation and fertility testing, (2) a blood coagulation device and (3) early 
stage development work into a POC immunoassay detection system based on magnetic
nanoparticle manipulation.&amp;#160;&amp;#160;In addition, Bio-AMD Holdings is 
working to develop various commercial relationships with manufacturers, bio-
chemistry companies and sales distributions partners to enable commercialization
of its products through licensing agreements.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Since January 2014, the 
Company has provided additional working capital by way of cash injections via 
intercompany loans amounting to &amp;#xa3;100,000 (approximately $132,000) to 
Bio-AMD Holdings to further fund operations. These loans are secured against the
assets of Bio-AMD Holdings and its wholly owned operating subsidiary, Bio-
Medical.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY:
&apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;Restructuring of Bio-AMD Holdings and Bio-Medical 
operations&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 0px; FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;On June 1, 2016, the intellectual property
relating to the Company&apos;s DSR, COAG and MIDS projects (the &quot;IP&quot;) 
and depreciated physical equipment assets (together the IP, the 
&quot;Assets&quot;), formerly under the control of Bio-AMD Holdings and Bio-
Medical, were brought into the full control of Bio-AMD, Inc. under loan security
agreements put in place by the Company during 
2015.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 0px; FONT-SIZE: 
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;On June 17, 2016, the Company entered into a 
Subscription and Shareholders&apos; Agreement with Bio-AMD UK Holdings Limited 
(&quot;UKH&quot;), a United Kingdom company, and the managers of UKH, under 
which we acquired a 70% interest in UKH in exchange for the Assets. See exhibit 
10.1.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 0px; FONT-SIZE: 
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;UKH is a development stage company, formed in May 
2009 by the Company&apos;s two principal and key scientists formerly contracted 
to Holdings, Dr. Nasser Djennati and Dr. Andrew Mitchell. UKH was formerly 
dormant and has never traded. Immediately prior to the transaction UKH formed a 
new subsidiary, MIDS Medical Limited (&quot;MML&quot;) as a dedicated vehicle to
develop our MIDS universal immunoassay detection technology in a joint venture, 
further described below. UKH has taken over the operations of Holdings and Bio-
Medical.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 0px; FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;The 30% of UKH not owned by the Company is
owned by Dr. Nasser Djennati (15%) and Dr. Andrew Mitchell (15%), whose 
experience and qualifications were reported on Form 8K filed on March 3, 2010. 
The board of directors of both UKH and MML consists of Drs. Djennati and 
Mitchell, and Mr Barr, the Company&apos;s CEO.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New 
Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The 
effect of the restructuring was to beneficially increase the Company&apos;s 
interest in its UK medical operations from 63% to 70%, to simplify and gain 
better voting control of its UK subsidiaries, and to eliminate two employee 
profit share arrangements.&lt;/div&gt;&lt;br/&gt;&lt;div
 style=&quot;MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New 
Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;As a
result of the incremental increase in the ownership of the Assets, the Company 
recorded a charge to Additional Paid-in Capital and the Non-controlling Interest
of $12,513. The amount represents the Company&amp;#x2019;s additional interest 
in the net book value of the group of Assets determined by voting 
control.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 10pt; FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT:
bold; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;MIDS Medical Limited 
Operations&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 10pt; FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;On June 20, 2016, the Company and its UKH 
and MML subsidiaries entered into a joint venture by way of a Subscription and 
Shareholders&amp;#x2019; Agreement (&amp;#x201c;Agreement&amp;#x201d;) with a 
third party medical detection device developer (&amp;#x201c;Partner&amp;#x201d;)
a Nevada corporation, under which the Partner, in exchange for its participation
and funding to support MML during a Phase 1 development, owns a 40% interest in 
MML as of July 1, 2016, The Partner also prospectively agreed to fund a Phase 2 
development of our MIDS universal immunoassay detection technology within the 
MML vehicle. MML will have the right to use the MIDS Intellectual Property 
(&amp;#x201c;MIDS IP&amp;#x201d;) under license during the development and the 
MIDS IP will be transferred to MML in the event that MML concludes a commercial 
deal for MIDS with a third party. See exhibit 
10.2.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 10pt; FONT-SIZE: 
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;The Agreement provides for a series of payments 
(&amp;#x201c;Phase 1 Payments&amp;#x201d;) in an aggregate amount of 
&amp;#xa3;450,500 (approximately $650,000 based on the current rate of 
exchange). The Partner made a Phase 1 Payment to MML, of $130,000 (the 
&amp;#x201c;First Payment&amp;#x201d;), which was received on August 2, 2016 and
converted to &amp;#xa3;92,857. Subsequent Phase 1 Payments are expected to be 
received as follows; (a) on or before September 20, 2016, a payment 
&amp;#xa3;106,093, (b) on or before November 20, 2016, a payment of 
&amp;#xa3;100,640; (c) on or before January 20, 2017 a payment of 
&amp;#xa3;100,640; and (d) on or before March 20, 2016 a payment of 
&amp;#xa3;50,320.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 10pt;
FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;The Agreement also provides for a 
contingency funding (&amp;#x201c;Contingency&amp;#x201d;) to be made available 
by the Partner after March 31, 2017 in an aggregate amount of up to 
&amp;#xa3;45,000 (approximately $64,000) to be paid by the Partner within 20 
days of receiving a written notice from&amp;#160; 
MML.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 10pt; FONT-SIZE: 
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;The parties to the Agreement envisage a second 
phase of development (&amp;#x201c;Phase 2&amp;#x201d;) to follow Phase 1. This 
is expected to be broadly over a similar timeframe and at a similar cost. MML 
may independently obtain funding for Phase 2 at MML&amp;#x2019;s option, or 
invite the Partner to fund.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-
BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The Agreement contains 
various provisions to govern the funding obligations of the Partner: if any 
Phase 1 Payment is not made within 14 days of it falling due 
(&amp;#x201c;Default&amp;#x201d;), the Partner&amp;#x2019;s shareholding in MML 
may be reduced to zero; if no Contingency is drawn during Phase 1, UKH will be 
awarded an enduring 2.5% profit after tax right in MML 
(&amp;#x201c;Override&amp;#x201d;) which will increase to a 15% Override if the 
Partner declines to fund Phase 2; if the Partner declines to fund Phase 2 and 
any Contingency has been drawn, UKH will be awarded a 15% Override decreased by 
0.5% for each &amp;#xa3;7,500 tranche of Contingency drawn down during Phase 1. 
Any Override will convert pro rata into ordinary shares in the event of a sale 
of MML.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 10pt; FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;Provided that each Phase 1 Payment is made
within 14 days of falling due, the Partner also has additional control rights 
over MML, including representation on the MML board of directors, rights over
the appointment and employment of senior management persons, indebtedness, major
transactions, budget approval rights, accounting practices and general 
operational management supervisory rights.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New 
Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;As a 
condition of the Agreement, MML has entered into Supply of Services Agreements 
under which it receives the services of Drs. Djennati and Mitchell, being key 
personnel related to the MIDS development.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New 
Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Initial 
development project planning has commenced on the MIDS project, including the 
specification of a bench rig printed circuit board designed to support first 
stage testing of a sample of Hall Effect Sensors already supplied to MML in 
order to examine their behavior in the detection of magnetic nanoparticles 
&amp;#x2013; the core MIDS technology &amp;#x2013; and to determine how these 
Hall Effect Sensors should be optimized prior to integration in a micro fluidic 
test strip.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 10pt; FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;The Company has agreed, pursuant to a 
letter agreement (the &amp;#x201c;Warrant Agreement&amp;#x201d;), to 
prospectively issue 3,000,000 five year warrants in the Company exercisable at 
$0.10, to certain third parties (or their nominees) who have introduced the 
Partner to the Company (&amp;#x201c;Introducer Warrants&amp;#x201d;). The 
Warrant Agreement provides for the Introducer Warrants to be issued at the 
discretion of the Company at any time up to MML receiving the final Phase 1 
Payment, and may not be exercised prior to June 15, 2017. In the event the Phase
1 Payments are not made in full, the Company will have the right to cancel the 
issuance of the Introducer Warrants, or to negotiate revised terms, at the 
Company&amp;#x2019;s sole option. No other fees have been paid in regard to the 
Agreement. See exhibit 4.1.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE:
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold;
COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Going 
Concern&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The accompanying unaudited condensed consolidated financial 
statements have been prepared on a going concern basis, which contemplates the 
realization of assets and the satisfaction of liabilities in the normal course 
of business.&amp;#160;&amp;#160;The Company has not commenced its planned 
principal operations. As shown in the accompanying unaudited condensed 
consolidated financial statements, the Company has not generated any revenue and
has incurred recurring losses through June 30, 
2016.&amp;#160;&amp;#160;Additionally, the Company has recurring negative cash 
flows from operations and has an accumulated deficit of $41,384,326 as at June 
30, 2016.&amp;#160;&amp;#160;These factors raise substantial doubt about the 
Company&amp;#x2019;s ability to continue as a&amp;#160;going 
concern.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY:
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The Company&apos;s ability to continue its existence is 
dependent upon commencing its planned operations, management&apos;s ability to 
develop and achieve profitable operations and/or upon obtaining additional 
financing to carry out its planned business. The Company intends to fund the 
development of its diagnostic technology and on-going operations through equity 
and debt financing arrangements.&amp;#160; However, there can be no assurance 
that these arrangements will be sufficient to fund its ongoing capital 
expenditures, working capital, and other cash requirements.&amp;#160; The 
outcome of these matters cannot be predicted at this 
time.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;There can be no assurance that any additional financings will 
be available to the Company on satisfactory terms and conditions, if at 
all.&amp;#160; In the event we are unable to continue as a going concern, we may
elect or be required to seek protection from our creditors by filing a voluntary
petition in bankruptcy or may be subject to an involuntary petition in 
bankruptcy. To date, management has not considered this
alternative.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif;
 COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The accompanying unaudited 
condensed consolidated financial statements do not include any adjustments 
related to the recoverability or classification of asset-carrying amounts or the
amounts and classification of liabilities that may result should the Company be 
unable to continue as a going concern.&amp;#160;&lt;/div&gt;&lt;br/&gt;</us-
gaap:NatureOfOperations>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired unitRef="pure"
contextRef="c23_AsOf1May2009_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="2">0.51</us-
gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="gbp" 
contextRef="c24_From14Aug2009To14Aug2009_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="0">150000</us-
gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="usd" 
contextRef="c24_From14Aug2009To14Aug2009_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="0">247800</us-
gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="gbp" 
contextRef="c25_From20Nov2009To20Nov2009_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="0">150000</us-
gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="usd" 
contextRef="c25_From20Nov2009To20Nov2009_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="0">249840</us-
gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="gbp" 
contextRef="c26_From8Mar2010To8Mar2010_WOCULimitedWLFormerlyWDXOrganizationMembe
r" decimals="0">150000</us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="usd" 
contextRef="c26_From8Mar2010To8Mar2010_WOCULimitedWLFormerlyWDXOrganizationMembe
r" decimals="0">224055</us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedParties unitRef="gbp" 
contextRef="c27_AsOf8Mar2010_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="0">600000</us-gaap:LoansAndLeasesReceivableRelatedParties>
  <us-gaap:LoansAndLeasesReceivableRelatedParties unitRef="usd" 
contextRef="c27_AsOf8Mar2010_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="0">904000</us-gaap:LoansAndLeasesReceivableRelatedParties>
  <us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions unitRef="pure" 
contextRef="c26_From8Mar2010To8Mar2010_WOCULimitedWLFormerlyWDXOrganizationMembe
r" decimals="2">0.93</us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions>
  <biad:PreferenceSharesPurchasedInSubsidiary unitRef="shares" 
contextRef="c28_AsOf23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="INF">500000</biad:PreferenceSharesPurchasedInSubsidiary>
  <us-gaap:SaleOfStockPricePerShare unitRef="gbpPershares" 
contextRef="c28_AsOf23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="0">1</us-gaap:SaleOfStockPricePerShare>
  <us-
gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent unitRef="usd" 
contextRef="c29_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="0">750000</us-
gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent>
  <us-gaap:PreferredStockDividendRatePercentage unitRef="pure" 
contextRef="c29_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="2">0.05</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockRedemptionTerms
contextRef="c29_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMem
ber">Upon liquidation, sale or listing and after repayment of the outstanding 
loans made by us to WL, other liabilities of WL and related transaction costs, 
the holder of the Preference Shares is entitled to a payment equal to three 
times the subscription price (the &amp;#x201c;Preference Shares 
Payment&amp;#x201d;) paid for such Preference Shares.</us-
gaap:PreferredStockRedemptionTerms>
  <us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized unitRef="shares" 
contextRef="c30_AsOf23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember_SeriesC
PreferredStockMember" decimals="INF">16900</us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized>
  <us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od unitRef="shares" 
contextRef="c31_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMem
ber_SeriesCPreferredStockMember" decimals="INF">14061</us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od>
  <biad:NumberOfEmployees unitRef="pure" 
contextRef="c28_AsOf23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="0">3</biad:NumberOfEmployees>
  <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction unitRef="pure" 
contextRef="c29_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="2">0.93</us-
gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
  <us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions unitRef="pure" 
contextRef="c29_From23Jul2010To23Jul2010_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="4">0.7754</us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares unitRef="shares" 
contextRef="c32_From30Jun2011To30Jun2011_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="INF">9243</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions unitRef="pure" 
contextRef="c32_From30Jun2011To30Jun2011_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="4">0.8713</us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="gbp" 
contextRef="c33_From1Nov2011To30Nov2011_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">50000</us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="usd" 
contextRef="c33_From1Nov2011To30Nov2011_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">77000</us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" 
contextRef="c34_From12Jul2012To12Jul2012_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="INF">5000000</us-
gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions unitRef="pure" 
contextRef="c34_From12Jul2012To12Jul2012_WOCULimitedWLFormerlyWDXOrganizationMem
ber" decimals="4">0.9981</us-
gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="gbp" 
contextRef="c35_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">196000</us-
gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="usd" 
contextRef="c35_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">260000</us-
gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:Revenues unitRef="usd" 
contextRef="c35_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">0</us-gaap:Revenues>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired unitRef="pure"
contextRef="c36_AsOf25Feb2010_Bio-AMDHoldingsLimitedMember" 
decimals="2">0.63</us-
gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <us-gaap:PaymentsToAcquireBusinessesGross unitRef="gbp" 
contextRef="c37_From25Feb2010To25Feb2010_Bio-AMDHoldingsLimitedMember" 
decimals="0">865000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PaymentsToAcquireBusinessesGross unitRef="usd" 
contextRef="c37_From25Feb2010To25Feb2010_Bio-AMDHoldingsLimitedMember" 
decimals="0">1335000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PreferredStockDividendRatePercentage unitRef="pure" 
contextRef="c37_From25Feb2010To25Feb2010_Bio-AMDHoldingsLimitedMember" 
decimals="2">0.05</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockLiquidationPreferenceValue unitRef="gbp" 
contextRef="c36_AsOf25Feb2010_Bio-AMDHoldingsLimitedMember" 
decimals="0">865000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue unitRef="gbp" 
contextRef="c38_AsOf25Feb2010" decimals="0">850000</us-
gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="gbp" 
contextRef="c39_From1Jan2016To30Jun2016_Bio-AMDHoldingsLimitedMember" 
decimals="0">100000</us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions unitRef="usd" 
contextRef="c39_From1Jan2016To30Jun2016_Bio-AMDHoldingsLimitedMember" 
decimals="0">132000</us-gaap:LoansAndLeasesReceivableRelatedPartiesAdditions>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired unitRef="pure"
contextRef="c40_AsOf17Jun2016_BioAMDUKHoldingsLimitedMember" 
decimals="2">0.70</us-
gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" contextRef="c41_AsOf30Jun2016_BioAMDUKHoldingsLimitedMember" 
decimals="2">0.30</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" 
contextRef="c42_AsOf30Jun2016_DrNasserDjennatiMember_BioAMDUKHoldingsLimitedMemb
er" decimals="2">0.15</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" 
contextRef="c43_AsOf30Jun2016_DrAndrewMitchellMember_BioAMDUKHoldingsLimitedMemb
er" decimals="2">0.15</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" 
contextRef="c44_AsOf16Jun2016_InterestInUKMedicalOperationsMember" 
decimals="2">0.63</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" 
contextRef="c45_AsOf17Jun2016_InterestInUKMedicalOperationsMember" 
decimals="2">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease unitRef="usd" 
contextRef="c46_From1Jan2016To17Jun2016" decimals="0">12513</us-
gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" 
contextRef="c47_AsOf1Jul2016_ThirdPartyMedicalDetectionDeviceDevloperMember_MIDS
MedicalLimitedMember_SubsequentEventMember" decimals="2">0.40</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <biad:JointVentureAggregateProceedsProvidedByPartner unitRef="gbp" 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember" 
decimals="0">450500</biad:JointVentureAggregateProceedsProvidedByPartner>
  <biad:JointVentureAggregateProceedsProvidedByPartner unitRef="usd" 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember" 
decimals="0">650000</biad:JointVentureAggregateProceedsProvidedByPartner>
  <biad:ProceedsFromJointVenturePartner unitRef="usd" 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember" decimals="0">130000</biad:ProceedsFromJointVenturePartner>
  <biad:ProceedsFromJointVenturePartner unitRef="gbp" 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember" decimals="0">92857</biad:ProceedsFromJointVenturePartner>
  <biad:JointVenturePartnerFundingDescription 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember">Subsequent Phase 1 Payments are expected to be received as follows; 
(a) on or before September 20, 2016, a payment &amp;#xa3;106,093, (b) on or 
before November 20, 2016, a payment of &amp;#xa3;100,640; (c) on or before 
January 20, 2017 a payment of &amp;#xa3;100,640; and (d) on or before March 20, 
2016 a payment of &amp;#xa3;50,320.</biad:JointVenturePartnerFundingDescription>
  <biad:JointVenturePartnerProvisions 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember">The Agreement contains various provisions to govern the funding 
obligations of the Partner: if any Phase 1 Payment is not made within 14 days of
it falling due (&amp;#x201c;Default&amp;#x201d;), the Partner&amp;#x2019;s 
shareholding in MML may be reduced to zero; if no Contingency is drawn during 
Phase 1, UKH will be awarded an enduring 2.5% profit after tax right in MML 
(&amp;#x201c;Override&amp;#x201d;) which will increase to a 15% Override if the 
Partner declines to fund Phase 2; if the Partner declines to fund Phase 2 and 
any Contingency has been drawn, UKH will be awarded a 15% Override decreased by 
0.5% for each &amp;#xa3;7,500 tranche of Contingency drawn down during Phase 1. 
Any Override will convert pro rata into ordinary shares in the event of a sale 
of MML.</biad:JointVenturePartnerProvisions>
  <biad:ClassOfWarrantOrRightsGranted unitRef="shares" 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember" decimals="INF">3000000</biad:ClassOfWarrantOrRightsGranted>
  <biad:WarrantsTermOfWarrants 
contextRef="c48_From1Jul2016To1Jul2016_SubsequentEventMember_CorporateJointVentu
reMember">P5Y</biad:WarrantsTermOfWarrants>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 
unitRef="usdPershares" 
contextRef="c49_AsOf1Jul2016_SubsequentEventMember_CorporateJointVentureMember" 
decimals="2">0.10</us-
gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:SignificantAccountingPoliciesTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Note 2&amp;#160;&amp;#x2013; 
Summary of Significant Accounting Policies&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Use of 
estimates&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The preparation of consolidated financial statements in 
conformity with generally accepted accounting principles requires management to 
make estimates and assumptions that affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of 
the consolidated financial statements and the reported amounts of revenue and 
expenses during the reporting period. Actual results could differ from those 
estimates.&amp;#160;&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold;
COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Principles of 
consolidation&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The unaudited condensed consolidated financial statements 
include the accounts of Bio-AMD, Inc., WOCU Limited (a 99.81% owned subsidiary 
as of June 30, 2016), Bio-AMD Holdings Limited (a 63% owned subsidiary as of 
June 30, 2016), along with Bio-AMD Holdings Limited&amp;#x2019;s wholly owned 
subsidiary Bio-Medical, and&amp;#160;Bio-AMD UK Holdings Limited (a 70% owned 
subsidiary effective June 30, 2016), along with its then wholly owned subsidiary
MIDS Medical Limited. All significant intercompany transactions and balances 
have been eliminated in 
consolidation.&amp;#160;&amp;#160;&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The third party ownerships 
of 0.19% of WL, 37% of Bio-AMD Holdings, and 30% of UKH are recorded as non-
controlling interests in the unaudited condensed consolidated financial 
statements.&amp;#160;&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt;
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Patents&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Patents are stated at cost 
less accumulated amortization and are comprised of patent applications on 
technologies which the Company expects to enable it to develop highly accurate, 
low cost, hand held electronic diagnostic devices capable of reading third party
assays. The patents are amortized straight-line over the estimated useful life 
but not to exceed 17 years.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE:
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold;
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Revenue 
Recognition&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The Company recognizes revenue when the following criteria have
been met: persuasive evidence of an arrangement exists, no significant Company 
obligations remain, collection of the related receivable is reasonably assured, 
and the fees are fixed or determinable. The Company acts as a principal in its 
revenue transactions as it is the primary obligor in the 
transactions.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; COLOR: 
#000000; TEXT-ALIGN: left&quot;&gt;Deferred Revenue and Deferred 
Costs&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The Company defers revenue on contracts which contain a 
performance commitment until such time as the services have been completed and 
no significant Company obligations remain.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The costs associated with 
contracts for which revenue is deferred, including personnel costs and 
incremental contract costs, are initially capitalized as deferred costs. 
Subsequently these costs are recognized as a component of cost of revenue when 
the associated revenue is recognized.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;In May 2016, the Company 
received formal written notice of termination of its Master Agreement with 
Sysmex Corporation (&amp;#x201c;Sysmex&amp;#x201d;) in a letter dated April 22, 
2016. As a result of the termination, the Company has no further obligations 
with respect to the research agreement and related funding received.&amp;#160; 
Due to the unexpected termination by Sysmex, the Company recorded a gain from 
the contract termination of $248,074.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Foreign 
currency translation&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-
ALIGN: justify&quot;&gt;The Company&apos;s reporting and functional currency is 
US Dollars. The accounts of the Company&apos;s 99.81% owned subsidiary, WL, and 
the Company&apos;s 63% owned subsidiary, Bio-AMD Holdings, and Bio-AMD
Holdings&apos; wholly owned subsidiary, Bio-Medical, and the Company&apos;s 70% 
owned subsidiary UKH and its wholly owned subsidiary MML, are maintained using 
the local currency (Great British Pounds) as the functional currency. All assets
and liabilities are translated into US Dollars at the balance sheet date, equity
is translated at historical rates, and revenue and expense accounts are 
translated at the average exchange rate for the year or the reporting 
period.&amp;#160;The translation adjustments are recorded as accumulated other 
comprehensive income.&amp;#160;&amp;#160;Transaction gains and losses arising 
from exchange rate fluctuation on transactions denominated in a currency other 
than the functional currency are included in the unaudited condensed 
consolidated statements of operations.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The relevant translation 
rates are as follows: For the six month period ended June 30, 2016 closing rate 
at 1.3242 US$:GBP, average rate at 1.4319 US$:GBP and for the six month period 
ended June 30, 2015 closing rate at 1.5717 US$:GBP, average rate at 1.5233 
US$:GBP.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY:
&apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; COLOR: #000000; 
TEXT-ALIGN: justify&quot;&gt;Recently Issued Accounting 
Standards&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In February 2015, the FASB issued ASU No. 2015-02, 
Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is 
intended to improve targeted areas of consolidation guidance for legal entities 
such as limited partnerships, limited liability corporations, and securitization
structures (collateralized debt obligations, collateralized loan obligations, 
and mortgage-backed security transactions). The ASU focuses on the consolidation
evaluation for reporting organizations that are required to evaluate whether 
they should consolidate certain legal entities. In addition to reducing the 
number of consolidation models from four to two, the new standard simplifies the
FASB Accounting Standards Codification and improves current US GAAP by placing 
more emphasis on risk of loss when determining a controlling financial interest,
reducing the frequency of the application of related-party guidance when 
determining a controlling financial interest in a variable interest entity 
(&amp;#x201c;VIE&amp;#x201d;), and changing consolidation conclusions for 
companies in several industries that typically make use of limited partnerships 
or VIEs. The ASU will be effective for fiscal years, and interim periods within 
those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-
02 did not have any effect on our financial position, results of operations or 
cash flows.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In August 2014, the FASB issued ASU No. 2014-15, 
&quot;Presentation of Financial Statements - Going Concern (Subtopic 205-
40)&quot;. ASU 2014-15 provides guidance related to management&apos;s 
responsibility to evaluate whether there is substantial doubt about an 
entity&apos;s ability to continue as a going concern and to provide related 
footnote disclosure. ASU 2014-15 is effective for annual periods ending after 
December 15, 2016, and for interim and annual periods thereafter. Early 
application is permitted. We do not expect the adoption of ASU 2014-15 to have a
material effect on our financial position, results of operations or cash 
flows.&lt;/div&gt;&lt;br/&gt;&lt;div
 style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN: 0.1pt&quot;&gt;In June 2014,
the FASB issued ASU No. 2014-12, &amp;#x201c;Compensation &amp;#x2013; Stock 
Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of 
an Award Provide That a Performance Target Could Be Achieved after the Requisite
Service Period.&amp;#x201d; This ASU requires that a performance target that 
affects vesting and that could be achieved after the requisite service period be
treated as a performance condition. ASU 2014-12 is effective for fiscal years, 
and interim periods within those fiscal years, beginning after December 15, 
2015. The adoption of ASU 2014-12 did not have any effect on our financial 
position, results of operations or cash flows.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;In May 2014, the FASB issued
ASU No. 2014-09, &amp;#x201c;Revenue from Contracts with Customers (Topic 
606).&amp;#x201d; ASU 2014-09 affects any entity using US GAAP that either 
enters into contracts with customers to transfer goods or services or enters 
into contracts for the transfer of nonfinancial assets unless those contracts 
are within the scope of other standards (e.g., insurance contracts or lease 
contracts). ASU 2014-09 is effective for fiscal years, and interim periods 
within those fiscal years, beginning after December 15, 2016. We are still 
evaluating the effect of the adoption of ASU 2014-09. On April 1, 2015, the FASB
voted to propose to defer the effective date of the new revenue recognition 
standard by one year.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt;
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-
ALIGN: justify&quot;&gt;Recent accounting pronouncements issued by the FASB and 
the SEC did not or are not believed by management to have a material impact on 
the Company&apos;s present or future consolidated financial 
statements.&lt;/div&gt;&lt;br/&gt;</us-
gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c4_From1Jan2016To30Jun2016">&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Use of 
estimates&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The preparation of consolidated financial statements in 
conformity with generally accepted accounting principles requires management to 
make estimates and assumptions that affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of 
the consolidated financial statements and the reported amounts of revenue and 
expenses during the reporting period. Actual results could differ from those 
estimates.&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ConsolidationPolicyTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Principles of 
consolidation&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The unaudited condensed consolidated financial statements 
include the accounts of Bio-AMD, Inc., WOCU Limited (a 99.81% owned subsidiary 
as of June 30, 2016), Bio-AMD Holdings Limited (a 63% owned subsidiary as of 
June 30, 2016), along with Bio-AMD Holdings Limited&amp;#x2019;s wholly owned 
subsidiary Bio-Medical, and&amp;#160;Bio-AMD UK Holdings Limited (a 70% owned 
subsidiary effective June 30, 2016), along with its then wholly owned subsidiary
MIDS Medical Limited. All significant intercompany transactions and balances 
have been eliminated in 
consolidation.&amp;#160;&amp;#160;&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The third party ownerships 
of 0.19% of WL, 37% of Bio-AMD Holdings, and 30% of UKH are recorded as non-
controlling interests in the unaudited condensed consolidated financial 
statements.&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" 
contextRef="c50_AsOf30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="4">0.9981</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" 
contextRef="c51_AsOf30Jun2016_Bio-AMDHoldingsLimitedMember" 
decimals="2">0.63</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" 
contextRef="c40_AsOf17Jun2016_BioAMDUKHoldingsLimitedMember" 
decimals="2">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" 
contextRef="c50_AsOf30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="4">0.0019</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" contextRef="c51_AsOf30Jun2016_Bio-AMDHoldingsLimitedMember"
decimals="2">0.37</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" contextRef="c40_AsOf17Jun2016_BioAMDUKHoldingsLimitedMember" 
decimals="2">0.30</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Patents&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Patents are stated at cost 
less accumulated amortization and are comprised of patent applications on 
technologies which the Company expects to enable it to develop highly accurate, 
low cost, hand held electronic diagnostic devices capable of reading third party
assays. The patents are amortized straight-line over the estimated useful life 
but not to exceed 17 years.&lt;/div&gt;</us-
gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife 
contextRef="c4_From1Jan2016To30Jun2016">P17Y</us-
gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:RevenueRecognitionPolicyTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Revenue 
Recognition&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The Company recognizes revenue when the following criteria have
been met: persuasive evidence of an arrangement exists, no significant Company 
obligations remain, collection of the related receivable is reasonably assured, 
and the fees are fixed or determinable. The Company acts as a principal in its 
revenue transactions as it is the primary obligor in the 
transactions.&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:RevenueRecognitionDeferredRevenue 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Deferred Revenue and Deferred 
Costs&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The Company defers revenue on contracts which contain a 
performance commitment until such time as the services have been completed and 
no significant Company obligations remain.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The costs associated with 
contracts for which revenue is deferred, including personnel costs and 
incremental contract costs, are initially capitalized as deferred costs. 
Subsequently these costs are recognized as a component of cost of revenue when 
the associated revenue is recognized.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;In May 2016, the Company 
received formal written notice of termination of its Master Agreement with 
Sysmex Corporation (&amp;#x201c;Sysmex&amp;#x201d;) in a letter dated April 22, 
2016. As a result of the termination, the Company has no further obligations 
with respect to the research agreement and related funding received.&amp;#160; 
Due to the unexpected termination by Sysmex, the Company recorded a gain from 
the contract termination of $248,074.&lt;/div&gt;</us-
gaap:RevenueRecognitionDeferredRevenue>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Foreign currency 
translation&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The Company&apos;s reporting and functional currency is US
Dollars. The accounts of the Company&apos;s 99.81% owned subsidiary, WL, and the
Company&apos;s 63% owned subsidiary, Bio-AMD Holdings, and Bio-AMD 
Holdings&apos; wholly owned subsidiary, Bio-Medical, and the Company&apos;s 70% 
owned subsidiary UKH and its wholly owned subsidiary MML, are maintained using 
the local currency (Great British Pounds) as the functional currency. All assets
and liabilities are translated into US Dollars at the balance sheet date, equity
is translated at historical rates, and revenue and expense accounts are 
translated at the average exchange rate for the year or the reporting 
period.&amp;#160;The translation adjustments are recorded as accumulated other 
comprehensive income.&amp;#160;&amp;#160;Transaction gains and losses arising 
from exchange rate fluctuation on transactions denominated in a currency other 
than the functional currency are included in the unaudited condensed 
consolidated statements of operations.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The relevant translation 
rates are as follows: For the six month period ended June 30, 2016 closing rate 
at 1.3242 US$:GBP, average rate at 1.4319 US$:GBP and for the six month period 
ended June 30, 2015 closing rate at 1.5717 US$:GBP, average rate at 1.5233 
US$:GBP.&lt;/div&gt;</us-
gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:ForeignCurrencyExchangeRateTranslation1 unitRef="pure" 
contextRef="c52_AsOf30Jun2016_GBP" decimals="4">1.3242</us-
gaap:ForeignCurrencyExchangeRateTranslation1>
  <us-gaap:ForeignCurrencyExchangeRateTranslation1 unitRef="pure" 
contextRef="c53_AsOf30Jun2016_AverageRateMember_GBP" decimals="4">1.4319</us-
gaap:ForeignCurrencyExchangeRateTranslation1>
  <us-gaap:ForeignCurrencyExchangeRateTranslation1 unitRef="pure" 
contextRef="c54_AsOf30Jun2015_GBP" decimals="4">1.5717</us-
gaap:ForeignCurrencyExchangeRateTranslation1>
  <us-gaap:ForeignCurrencyExchangeRateTranslation1 unitRef="pure" 
contextRef="c55_AsOf30Jun2015_AverageRateMember_GBP" decimals="4">1.5233</us-
gaap:ForeignCurrencyExchangeRateTranslation1>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Recently Issued Accounting 
Standards&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In February 2015, the FASB issued ASU No. 2015-02, 
Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is 
intended to improve targeted areas of consolidation guidance for legal entities 
such as limited partnerships, limited liability corporations, and securitization
structures (collateralized debt obligations, collateralized loan obligations, 
and mortgage-backed security transactions). The ASU focuses on the consolidation
evaluation for reporting organizations that are required to evaluate whether 
they should consolidate certain legal entities. In addition to reducing the 
number of consolidation models from four to two, the new standard simplifies the
FASB Accounting Standards Codification and improves current US GAAP by placing 
more emphasis on risk of loss when determining a controlling financial interest,
reducing the frequency of the application of related-party guidance when 
determining a controlling financial interest in a variable interest entity 
(&amp;#x201c;VIE&amp;#x201d;), and changing consolidation conclusions for 
companies in several industries that typically make use of limited partnerships 
or VIEs. The ASU will be effective for fiscal years, and interim periods within 
those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-
02 did not have any effect on our financial position, results of operations or 
cash flows.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In August 2014, the FASB issued ASU No. 2014-15, 
&quot;Presentation of Financial Statements - Going Concern (Subtopic 205-
40)&quot;. ASU 2014-15 provides guidance related to management&apos;s 
responsibility to evaluate whether there is substantial doubt about an 
entity&apos;s ability to continue as a going concern and to provide related 
footnote disclosure. ASU 2014-15 is effective for annual periods ending after
December 15, 2016, and for interim and annual periods thereafter. Early 
application is permitted. We do not expect the adoption of ASU 2014-15 to have a
material effect on our financial position, results of operations or cash 
flows.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: justify; 
MARGIN: 0.1pt&quot;&gt;In June 2014, the FASB issued ASU No. 2014-12, 
&amp;#x201c;Compensation &amp;#x2013; Stock Compensation (Topic 718): Accounting
for Share-Based Payments When the Terms of an Award Provide That a Performance 
Target Could Be Achieved after the Requisite Service Period.&amp;#x201d; This 
ASU requires that a performance target that affects vesting and that could be 
achieved after the requisite service period be treated as a performance 
condition. ASU 2014-12 is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2015. The adoption of ASU 2014-
12 did not have any effect on our financial position, results of operations or 
cash flows.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In May 2014, the FASB issued ASU No. 2014-09, 
&amp;#x201c;Revenue from Contracts with Customers (Topic 606).&amp;#x201d; ASU 
2014-09 affects any entity using US GAAP that either enters into contracts with 
customers to transfer goods or services or enters into contracts for the 
transfer of nonfinancial assets unless those contracts are within the scope of 
other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is 
effective for fiscal years, and interim periods within those fiscal years, 
beginning after December 15, 2016. We are still evaluating the effect of the 
adoption of ASU 2014-09. On April 1, 2015, the FASB voted to propose to defer 
the effective date of the new revenue recognition standard by one 
year.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;Recent accounting pronouncements issued by the FASB and the SEC
did not or are not believed by management to have a material impact on the 
Company&apos;s present or future consolidated financial 
statements.&lt;/div&gt;</us-
gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<!-- [WMV4]
[XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAK3hbE
VTXOd1U7+9iHKYBy25QKV69HOl1N03x1pff3iAB1LqBqnr0sN+tqK1E0BcI73NmfgSIRh6iGD5vsrsl9
RYcsrtOTcfcOgZ61HMsrI5H6weu3eaqe30ytHlB/OS0tP9YRbqwN+ejXU/
+MJxMyfG6J1GyKXk8wUm10UUAzmUw==] CSR-->
  <us-gaap:IntangibleAssetsDisclosureTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;Note 3 &amp;#x2013; 
Patents&lt;/div&gt;&lt;br/&gt;&lt;table 
id=&quot;z05feb8420eb24d37b0fe0737aef813ff&quot; style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; WIDTH: 100%&quot; 
cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 20.75%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.09%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 15.65%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Cost&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Accumulated amortization&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px
solid&quot;&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Foreign currency translation adjustment&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.02%; VERTICAL-ALIGN: 
top&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.68%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;June 30,&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;2016&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;Net
carrying value&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN:
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;December 31,&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;2015&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;Net
carrying value&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 20.75%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.09%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 15.65%; VERTICAL-ALIGN: top&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.11%; VERTICAL-ALIGN: bottom&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: 
top&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.02%; VERTICAL-ALIGN: 
top&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.68%; VERTICAL-ALIGN: bottom&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: bottom&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 20.75%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Patents&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.09%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.63%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;174,810&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 2.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11.04%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: 
right&quot;&gt;&amp;#x2013;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px
double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;(9,237)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px
double; BACKGROUND-COLOR: #cceeff&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.66%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;165,573&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;165, 848&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;Bio-AMD currently has eight patent applications covering its 
three proprietary technology platforms, the Company having elected to abandon 
one redundant patent relating to DSR which was due for renewal in April 2016 
(other patents relating to DSR are being maintained).&amp;#160;We continue to 
review our intellectual property strategy with the intention of sufficiently 
protecting our key intangible assets, and that any new IP generated is reviewed 
as far as possible to optimize the novel nature of the IP and freedom to operate
in key jurisdictions.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt;
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-
ALIGN: justify&quot;&gt;In June 2015, Bio AMD Holdings Limited received a grant 
of U.S. patent dated June 2, 2015, under U.S. Patent No. US 9,046,512 protecting
twenty one claims central to the Company&amp;#x2019;s microfluidic strip and 
reader technology designed to test PT/INR by a POC 
device.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In January 2016, the Company received a grant of patent from 
the State Intellectual Property Office of the People&amp;#x2019;s Republic of 
China (&amp;#x201c;PRC&amp;#x201d;) for our MIDS technology. The Company has 
made similar MIDS technology patent applications in the U.K. and in more than 
145 Contracting States under the international Patent Cooperation Treaty, and 
separately in the USA, the European Union and 
India.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;In March 2016, the Company received notice of grant of patent
from the State Intellectual Property Office of the PRC relating to our 
microfluidic strip and reader technology designed to test PT/INR by a POC 
device.&lt;/div&gt;&lt;br/&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <biad:NumberOfLivePatents unitRef="pure" contextRef="c0_AsOf30Jun2016" 
decimals="0">8</biad:NumberOfLivePatents>
  <biad:NumberOfProprietaryTechnologyPlatforms unitRef="pure" 
contextRef="c4_From1Jan2016To30Jun2016" 
decimals="0">3</biad:NumberOfProprietaryTechnologyPlatforms>
  <biad:NumberOfPatentsNotRenewedAndAbandoned unitRef="pure" 
contextRef="c4_From1Jan2016To30Jun2016" 
decimals="0">1</biad:NumberOfPatentsNotRenewedAndAbandoned>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;table 
id=&quot;z05feb8420eb24d37b0fe0737aef813ff&quot; style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; WIDTH: 100%&quot; 
cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 20.75%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.09%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 15.65%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Cost&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Accumulated amortization&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px
solid&quot;&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Foreign currency translation adjustment&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.02%; VERTICAL-ALIGN: 
top&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.68%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;June 30,&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;2016&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;Net
carrying value&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
2px solid&quot; colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;December 31,&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;2015&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;Net
carrying value&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
$&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 20.75%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.09%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 15.65%; VERTICAL-ALIGN: top&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.11%; VERTICAL-ALIGN: bottom&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: 
top&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.02%; VERTICAL-ALIGN: 
top&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.68%; VERTICAL-ALIGN: bottom&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: bottom&quot; 
colspan=&quot;2&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 20.75%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Patents&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.09%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.63%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;174,810&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 2.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11.04%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: 
right&quot;&gt;&amp;#x2013;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px
double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;(9,237)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 3.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px
double; BACKGROUND-COLOR: #cceeff&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.66%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;165,573&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 
4px double; BACKGROUND-COLOR: #cceeff&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: right&quot;&gt;165, 848&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsGross unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">174810</us-
gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">0</us-
gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss 
unitRef="usd" contextRef="c56_From30Jun2016To30Jun2016" decimals="0">-9237</us-
gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
  <us-gaap:FiniteLivedIntangibleAssetsNet unitRef="usd" 
contextRef="c0_AsOf30Jun2016" decimals="0">165573</us-
gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">165848</us-
gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Note 4&amp;#160;&amp;#x2013; Related 
Party Transactions&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-
ALIGN: justify&quot;&gt;During the three months ended June 30, 2016, we paid 
$nil (2015 - $49,156), to The ARM Partnership (&amp;#x201c;ARM&amp;#x201d;), a 
partnership in which Robert Galvin, our former Chief Financial Officer and 
Treasurer is a partner, for services provided to us by Mr. Galvin in all 
capacities. During the six month period ended June 30, 2016, we paid an 
aggregate of $10,030 (2015 - $99,319) to ARM. Mr. Galvin owns 12.33% of the 
outstanding share capital of Bio-AMD Holdings. In addition, during the six 
months ended June 30, 2016, the Company paid $nil (2015 - $11,500 
(&amp;#xa3;7,500)) for the use of ARM&amp;#x2019;s offices in central London 
located at 3rd Floor, 14 South Molton Street, London, UK. The rental expense was
set at &amp;#xa3;500 per month for Bio-AMD Inc. (approximately $760), this 
ceased on July 31, 2015 and &amp;#xa3;750 per month for Bio-AMD Holdings 
(approximately $1,150), reduced to &amp;#xa3;500 (approximately $760) for each 
of the months of August and September 2015, and which ceased in October, 
2015.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;During the three month period ended June 30, 2016, we paid an 
aggregate of $24,138 (2015 - $36,461) to Thomas Barr, our Chief Executive 
Officer, for services provided to us by Mr. Barr in all 
capacities.&amp;#160;&amp;#160;During the six month periods ended June 30, 2016,
we paid an aggregate of $59,290 (2015 - $72,351) to Mr. 
Barr.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;MARGIN-BOTTOM: 0px; FONT-SIZE: 
10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; 
TEXT-ALIGN: justify; MARGIN-TOP: 12pt&quot;&gt;During the three month period 
ended June 30, 2016, we paid an aggregate of $15,733 (2015 - $23,614) to David 
Miller, our Chief Financial Officer, for services provided to us by Mr. Miller 
in all capacities.&amp;#160;During the six month period ended June 30, 2016, we 
paid an aggregate of $38,563 (2015 - $46,988) to Mr. 
Miller.&lt;/div&gt;&lt;br/&gt;</us-
gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c57_From1Apr2015To30Jun2015_AffiliatedEntityMember" 
decimals="0">49156</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd"
contextRef="c58_From1Jan2016To30Jun2016_AffiliatedEntityMember" 
decimals="0">10030</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c59_From1Jan2015To30Jun2015_AffiliatedEntityMember" 
decimals="0">99319</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners 
unitRef="pure" contextRef="c60_AsOf30Jun2016_ChiefFinancialOfficerMember" 
decimals="4">0.1233</us-
gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:CostsAndExpensesRelatedParty unitRef="usd" 
contextRef="c59_From1Jan2015To30Jun2015_AffiliatedEntityMember" 
decimals="0">11500</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:CostsAndExpensesRelatedParty unitRef="gbp" 
contextRef="c59_From1Jan2015To30Jun2015_AffiliatedEntityMember" 
decimals="0">7500</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="gbp" 
contextRef="c61_From1Jan2015To31Jul2015_AffiliatedEntityMember_BioAMDIncMember" 
decimals="0">500</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="usd" 
contextRef="c61_From1Jan2015To31Jul2015_AffiliatedEntityMember_BioAMDIncMember" 
decimals="0">760</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="gbp" 
contextRef="c62_From1Jan2015To31Jul2015_AffiliatedEntityMember_Bio-
AMDHoldingsLimitedMember_BioAMDIncMember" decimals="0">750</us-
gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="usd" 
contextRef="c62_From1Jan2015To31Jul2015_AffiliatedEntityMember_Bio-
AMDHoldingsLimitedMember_BioAMDIncMember" decimals="0">1150</us-
gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="gbp" 
contextRef="c63_From1Aug2015To30Sep2015_AffiliatedEntityMember_Bio-
AMDHoldingsLimitedMember_BioAMDIncMember" decimals="0">500</us-
gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals unitRef="usd" 
contextRef="c63_From1Aug2015To30Sep2015_AffiliatedEntityMember_Bio-
AMDHoldingsLimitedMember_BioAMDIncMember" decimals="0">760</us-
gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c64_From1Apr2016To30Jun2016_ChiefExecutiveOfficerMember" 
decimals="0">24138</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c65_From1Apr2015To30Jun2015_ChiefExecutiveOfficerMember" 
decimals="0">36461</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c66_From1Jan2016To30Jun2016_ChiefExecutiveOfficerMember" 
decimals="0">59290</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c67_From1Jan2015To30Jun2015_ChiefExecutiveOfficerMember" 
decimals="0">72351</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c68_From1Apr2016To30Jun2016_ChiefFinancialOfficerMember" 
decimals="0">15733</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c69_From1Apr2015To30Jun2015_PresidentMember" decimals="0">23614</us-
gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c70_From1Jan2016To30Jun2016_ChiefFinancialOfficerMember" 
decimals="0">38563</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" 
contextRef="c71_From1Jan2015To30Jun2015_ChiefFinancialOfficerMember" 
decimals="0">46988</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:DeferredRevenueDisclosureTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;MARGIN-BOTTOM: 0px; 
FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-TOP: 0px&quot;&gt;Note
5 &amp;#x2013; Deferred Revenue&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;Deferred revenue consists of funds 
received in advance of services being performed. The Company&amp;#x2019;s 
revenue recognition policy dictates that revenues will be recognized when the 
services have been completed and no significant Company obligations remain. As 
at June 30, 2016, the Company had $nil (December 31, 2015 - $950,402 
(&amp;#xa3;642,077)) of deferred revenues.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;The costs directly 
associated with the performance of services for which revenue has been deferred 
are initially capitalized as deferred costs. These costs will be recognized as a
component of cost of revenue when the associated revenue is 
recognized.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;As at June 30, 2016, the Company had $nil (December 31, 2015 - 
$645,534 (&amp;#xa3;436,113)) of deferred costs.&lt;/div&gt;&lt;br/&gt;&lt;div 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; COLOR: #000000; TEXT-ALIGN: justify&quot;&gt;In May 2016, the Company 
received notice of termination of its Master Agreement with Sysmex. Upon 
receiving notice, management has determined that the Company has no further 
material obligations under the research agreement. The net difference between 
the deferred revenues and deferred costs of $248,074 has been recognized as a 
gain on termination of research agreement in the statement of 
operations.&lt;/div&gt;&lt;br/&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
  <us-gaap:DeferredRevenueCurrent unitRef="gbp" contextRef="c1_AsOf31Dec2015" 
decimals="0">642077</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredCostsCurrentAndNoncurrent unitRef="usd" 
contextRef="c1_AsOf31Dec2015" decimals="0">645534</us-
gaap:DeferredCostsCurrentAndNoncurrent>
  <us-gaap:DeferredCostsCurrentAndNoncurrent unitRef="gbp" 
contextRef="c1_AsOf31Dec2015" decimals="0">436113</us-
gaap:DeferredCostsCurrentAndNoncurrent>
  <us-gaap:SegmentReportingDisclosureTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;Note&amp;#160;6&amp;#160;&amp;#x2013; Segmented 
Information&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;We currently operate in two segments: 1) the development of a 
technology designed to mitigate currency risk through our 99.81% owned 
subsidiary, WL as of June 30, 2016, and 2) the development of highly accurate, 
low cost, hand held, electronic medical diagnostic devices capable of reading 
third party assays through our 63% and 70% owned subsidiaries, Bio-AMD Holdings 
and Bio-AMD UK Holdings Limited, respectively. Segment information for the three
and six months ended June 30, 2016 and 2015 consists of the 
following:&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;Three months ended June 30, 
2016:&lt;/div&gt;&lt;br/&gt;&lt;table 
id=&quot;za5916a89e4b5433bb13a2c9eeaaed5a7&quot; style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; WIDTH: 75%&quot; 
cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; align=&quot;center&quot; 
border=&quot;0&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings &amp;amp; &lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD UK Holdings&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;427&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;63&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;490&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net income 
(loss)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(2,168&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;239,041&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(92,156&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; COLOR: #000000&quot;&gt;144,717&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;3,319&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;177,543&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;67,032&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;247,894&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;Three months ended June 30, 
2015:&lt;/div&gt;&lt;br/&gt;&lt;table 
id=&quot;zb89655d2886c416e8c52632fd0212a51&quot; style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; WIDTH: 75%&quot; 
cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; align=&quot;center&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot;
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;463&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;268&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left;
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;731&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net 
loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(12,025&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(20,213&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(321,894&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(354,132&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;2,672&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,168,133&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;483,272&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,654,077&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;Six months ended June 30 2016:&lt;/div&gt;&lt;br/&gt;&lt;table 
id=&quot;z4d16ef951bf2413ab42d38ccb77c1ffa&quot; style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; WIDTH: 75%&quot; 
cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; align=&quot;center&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings &amp;amp; &lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD UK&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;860&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;102&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;962&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net income 
(loss)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(4,018&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR:
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;226,444&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(230,984&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(8,558&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;3,319&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;177,543&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;67,032&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;247,894&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
left&quot;&gt;Six months ended June 2015:&lt;/div&gt;&lt;br/&gt;&lt;table 
id=&quot;zc4bd26c045b24edd8822a1d59ce1cb64&quot; style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; WIDTH: 75%&quot; 
cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; align=&quot;center&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;921&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;603&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,524&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net 
loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR:
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(33,524&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(36,459&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(506,989&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(576,972&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;2,672&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,168,133&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;483,272&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,654,077&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:NumberOfOperatingSegments unitRef="pure" 
contextRef="c4_From1Jan2016To30Jun2016" decimals="0">2</us-
gaap:NumberOfOperatingSegments>
<us-
gaap:DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues 
contextRef="c35_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er">development of a technology designed to mitigate currency risk through our 
99.81% owned subsidiary, WL</us-
gaap:DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" 
contextRef="c41_AsOf30Jun2016_BioAMDUKHoldingsLimitedMember" 
decimals="2">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">We currently operate in two segments: 1)
the development of a technology designed to mitigate currency risk through our 
99.81% owned subsidiary, WL as of June 30, 2016, and 2) the development of 
highly accurate, low cost, hand held, electronic medical diagnostic devices 
capable of reading third party assays through our 63% and 70% owned 
subsidiaries, Bio-AMD Holdings and Bio-AMD UK Holdings Limited, respectively. 
Segment information for the three and six months ended June 30, 2016 and 2015 
consists of the following:&lt;br /&gt;&lt;br /&gt;&lt;table 
id=&quot;za5916a89e4b5433bb13a2c9eeaaed5a7&quot; style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; WIDTH: 75%&quot; 
cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; align=&quot;center&quot; 
border=&quot;0&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings &amp;amp; &lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD UK Holdings&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;427&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;63&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;490&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net income 
(loss)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(2,168&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;239,041&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(92,156&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;144,717&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;3,319&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right;
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;177,543&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;67,032&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;247,894&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;table id=&quot;zb89655d2886c416e8c52632fd0212a51&quot; 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; WIDTH: 75%&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; 
align=&quot;center&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;463&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;268&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;731&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net 
loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(12,025&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(20,213&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(321,894&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(354,132&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;2,672&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,168,133&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;483,272&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,654,077&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;table id=&quot;z4d16ef951bf2413ab42d38ccb77c1ffa&quot; 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; WIDTH: 75%&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; 
align=&quot;center&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings &amp;amp; &lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD UK&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;860&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;102&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;962&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left;
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net income 
(loss)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(4,018&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;226,444&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(230,984&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(8,558&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;3,319&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;177,543&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;67,032&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;247,894&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;table id=&quot;zc4bd26c045b24edd8822a1d59ce1cb64&quot; 
style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, 
serif; WIDTH: 75%&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; 
align=&quot;center&quot;&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px&quot;
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;WL&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Bio-AMD Holdings&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Other&lt;/div&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center&quot;&gt;
(Corporate)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid&quot; valign=&quot;bottom&quot; colspan=&quot;3&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
center&quot;&gt;Consolidated&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-
ALIGN: left&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom&quot; 
valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;VERTICAL-ALIGN: bottom&quot; valign=&quot;bottom&quot; 
colspan=&quot;3&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left&quot; 
valign=&quot;bottom&quot; nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Interest and other 
income&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;921&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;603&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,524&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment net 
loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(33,524&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(36,459&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;,
Times, serif; COLOR: #000000&quot;&gt;(506,989&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#ffffff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;(576,972&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #ffffff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&quot;WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Segment total 
assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;2,672&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,168,133&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right;
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;483,272&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: 
#cceeff&quot; valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; 
valign=&quot;bottom&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;td style=&quot;WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot;&gt;
&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, 
Times, serif; COLOR: #000000&quot;&gt;1,654,077&lt;/div&gt;
&lt;/td&gt;
&lt;td style=&quot;WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; 
BACKGROUND-COLOR: #cceeff&quot; valign=&quot;bottom&quot; 
nowrap=&quot;nowrap&quot;&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c72_From1Apr2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">427</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c73_From1Apr2016To30Jun2016_Bio-AMDHoldingsLimitedMember" 
decimals="0">0</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c74_From1Apr2016To30Jun2016_CorporateMember" decimals="0">63</us-
gaap:InterestAndOtherIncome>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c72_From1Apr2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">-2168</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c73_From1Apr2016To30Jun2016_Bio-AMDHoldingsLimitedMember" 
decimals="0">239041</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c74_From1Apr2016To30Jun2016_CorporateMember" decimals="0">-
92156</us-gaap:NetIncomeLoss>
  <us-gaap:Assets unitRef="usd" 
contextRef="c75_AsOf30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="0">3319</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c76_AsOf30Jun2016_Bio-
AMDHoldingsLimitedMember" decimals="0">177543</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c77_AsOf30Jun2016_CorporateMember" 
decimals="0">67032</us-gaap:Assets>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c78_From1Apr2015To30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">463</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c79_From1Apr2015To30Jun2015_Bio-AMDHoldingsLimitedMember" 
decimals="0">0</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c80_From1Apr2015To30Jun2015_CorporateMember" decimals="0">268</us-
gaap:InterestAndOtherIncome>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c78_From1Apr2015To30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">-12025</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c79_From1Apr2015To30Jun2015_Bio-AMDHoldingsLimitedMember" 
decimals="0">-20213</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c80_From1Apr2015To30Jun2015_CorporateMember" decimals="0">-
321894</us-gaap:NetIncomeLoss>
  <us-gaap:Assets unitRef="usd" 
contextRef="c81_AsOf30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMember" 
decimals="0">2672</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c82_AsOf30Jun2015_Bio-
AMDHoldingsLimitedMember" decimals="0">1168133</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c83_AsOf30Jun2015_CorporateMember" 
decimals="0">483272</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c21_AsOf30Jun2015" 
decimals="0">1654077</us-gaap:Assets>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c84_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">860</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c85_From1Jan2016To30Jun2016_Bio-AMDHoldingsLimitedMember" 
decimals="0">0</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c86_From1Jan2016To30Jun2016_CorporateMember" decimals="0">102</us-
gaap:InterestAndOtherIncome>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c84_From1Jan2016To30Jun2016_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">-4018</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c85_From1Jan2016To30Jun2016_Bio-AMDHoldingsLimitedMember" 
decimals="0">226444</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c86_From1Jan2016To30Jun2016_CorporateMember" decimals="0">-
230984</us-gaap:NetIncomeLoss>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c87_From1Jan2015To30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">921</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c88_From1Jan2015To30Jun2015_Bio-AMDHoldingsLimitedMember" 
decimals="0">0</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome unitRef="usd" 
contextRef="c89_From1Jan2015To30Jun2015_CorporateMember" decimals="0">603</us-
gaap:InterestAndOtherIncome>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c87_From1Jan2015To30Jun2015_WOCULimitedWLFormerlyWDXOrganizationMemb
er" decimals="0">-33524</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c88_From1Jan2015To30Jun2015_Bio-AMDHoldingsLimitedMember" 
decimals="0">-36459</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" 
contextRef="c89_From1Jan2015To30Jun2015_CorporateMember" decimals="0">-
506989</us-gaap:NetIncomeLoss>
  <us-gaap:SubsequentEventsTextBlock 
contextRef="c4_From1Jan2016To30Jun2016">&lt;div style=&quot;FONT-SIZE: 10pt; 
FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; FONT-WEIGHT: bold; 
COLOR: #000000; TEXT-ALIGN: left&quot;&gt;Note&amp;#160;7 &amp;#x2013; 
Subsequent Event and Commitment&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-
SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify&quot;&gt;As previously described in Note 1, 
effective July 1, 2016, the Company has formed a joint venture agreement for the
Phase 1 development of MIDS technological 
application.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-
FAMILY: &apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify&quot;&gt;The Company has agreed, to prospectively issue 3,000,000 five 
year warrants in the Company exercisable at $0.10 per share, to certain third 
parties (or their nominees) who have introduced the joint venture partner to the
Company. The warrants may&amp;#160; be issued at any time up to MML receiving 
the final Phase 1 Payment and they may not be exercised prior to June 15, 
2017.&lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: 
&apos;Times New Roman&apos;, Times, serif; COLOR: #000000; TEXT-ALIGN:
justify&quot;&gt;Management evaluated all activities of the Company through the 
issuance date of the Company&apos;s interim unaudited condensed consolidated 
financial statements and concluded that no further subsequent events have 
occurred that would require adjustments or disclosure into the interim unaudited
condensed consolidated financial statements.&lt;/div&gt;&lt;br/&gt;</us-
gaap:SubsequentEventsTextBlock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>biad-20160630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by iC(tm) - CompSci Interactive Converter - 
http://www.compsciresources.com -->
<!-- Created: Mon Aug 15 16:32:52 EDT 2016 -->
<xs:schema xmlns:biad="http://www.bioamd.com/20160630" 
elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" 
targetNamespace="http://www.bioamd.com/20160630" 
xmlns:link="http://www.xbrl.org/2003/linkbase" 
xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-
types/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" 
xmlns:xs="http://www.w3.org/2001/XMLSchema" 
xmlns:xbrldt="http://xbrl.org/2005/xbrldt" 
xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="biad-20160630_lab.xml" 
xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" 
xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="biad-20160630_pre.xml" 
xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" 
xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="biad-20160630_def.xml" 
xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" 
xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="biad-20160630_cal.xml" 
xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" 
xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType 
roleURI="http://www.bioamd.com/role/ConsolidatedBalanceSheet" 
id="biad_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - CONDENSED CONSOLIDATED BALANCE 
SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/ConsolidatedBalanceSheet_Parentheticals" 
id="biad_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
(Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/ConsolidatedIncomeStatement"
id="biad_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF 
OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/ShareholdersEquityType2or3" 
id="biad_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF 
EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioamd.com/role/ConsolidatedCashFlow" 
id="biad_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF 
CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusin
ess" id="biad_r_Note1NatureofOperationsandContinuanceofBusiness">
        <link:definition>006 - Disclosure - Note 1 - Nature of Operations and 
Continuance of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolicies"
id="biad_r_Note2SummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Note 2 - Summary of Significant 
Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioamd.com/role/Note3Patents" 
id="biad_r_Note3Patents">
        <link:definition>008 - Disclosure - Note 3 - Patents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note4RelatedPartyTransactions" 
id="biad_r_Note4RelatedPartyTransactions">
        <link:definition>009 - Disclosure - Note 4 - Related Party 
Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioamd.com/role/Note5DeferredRevenue" 
id="biad_r_Note5DeferredRevenue">
        <link:definition>010 - Disclosure - Note 5 - Deferred 
Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformation" 
id="biad_r_Note6SegmentedInformation">
        <link:definition>011 - Disclosure - Note 6 - Segmented 
Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note7SubsequentEventandCommitment" 
id="biad_r_Note7SubsequentEventandCommitment">
        <link:definition>012 - Disclosure - Note 7 - Subsequent Event and 
Commitment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/AccountingPoliciesByPolicy" 
id="biad_r_AccountingPoliciesByPolicy">
        <link:definition>013 - Disclosure - Accounting Policies, by Policy 
(Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioamd.com/role/Note3PatentsTables" 
id="biad_r_Note3PatentsTables">
        <link:definition>014 - Disclosure - Note 3 - Patents 
(Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformationTables" 
id="biad_r_Note6SegmentedInformationTables">
        <link:definition>015 - Disclosure - Note 6 - Segmented Information 
(Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusin
essDetails" id="biad_r_Note1NatureofOperationsandContinuanceofBusinessDetails">
        <link:definition>016 - Disclosure - Note 1 - Nature of Operations and 
Continuance of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV4]
[XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAK3hbE
VTXOd1U7+9iHKYBy25QKV69HOl1N03x1pff3iAB1LqBqnr0sN+tqK1E0BcI73NmfgSIRh6iGD5vsrsl9
RYcsrtOTcfcOgZ61HMsrI5H6weu3eaqe30ytHlB/OS0tP9YRbqwN+eiBV4PhDt2/+n2P+5ydKpqU=] 
CSR-->
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPoliciesD
etails" id="biad_r_Note2SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>017 - Disclosure - Note 2 - Summary of Significant
Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioamd.com/role/Note3PatentsDetails" 
id="biad_r_Note3PatentsDetails">
        <link:definition>018 - Disclosure - Note 3 - Patents 
(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/ScheduleofFiniteLivedIntangibleAssetsTable" 
id="biad_r_ScheduleofFiniteLivedIntangibleAssetsTable">
        <link:definition>019 - Disclosure - Note 3 - Patents (Details) - 
Schedule of Finite-Lived Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note4RelatedPartyTransactionsDetails" 
id="biad_r_Note4RelatedPartyTransactionsDetails">
        <link:definition>020 - Disclosure - Note 4 - Related Party Transactions 
(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note5DeferredRevenueDetails" 
id="biad_r_Note5DeferredRevenueDetails">
        <link:definition>021 - Disclosure - Note 5 - Deferred Revenue 
(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformationDetails" 
id="biad_r_Note6SegmentedInformationDetails">
        <link:definition>022 - Disclosure - Note 6 - Segmented Information 
(Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/ScheduleofSegmentInformationTable" 
id="biad_r_ScheduleofSegmentInformationTable">
        <link:definition>023 - Disclosure -  Note 6 - Segmented Information  
(Details) - Schedule of Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/Note7SubsequentEventandCommitmentDetails" 
id="biad_r_Note7SubsequentEventandCommitmentDetails">
        <link:definition>024 - Disclosure - Note 7 - Subsequent Event and 
Commitment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType 
roleURI="http://www.bioamd.com/role/DocumentAndEntityInformation" 
id="DocumentAndEntityInformation">
        <link:definition>000 - Disclosure - Document And Entity 
Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" 
schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" 
schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2016-01-31" 
schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-
31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" 
schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" 
schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" 
schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="ScheduleOfFiniteLivedIntangibleAssetsAbstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfSegmentInformationAbstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_ScheduleOfSegmentInformationAbstract"/>
  <xs:element name="NatureOfOperationsAndContinuationOfBusinessNote1Abstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract"/>
  <xs:element name="SubsequentEventAndCommitmentNote7Abstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_SubsequentEventAndCommitmentNote7Abstract"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="NonCashInvestingAndFinancingActivitiesAbstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_NonCashInvestingAndFinancingActivitiesAbstract"/>
  <xs:element name="NoncontrollingOwnerDomain" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_NoncontrollingOwnerDomain"/>
  <xs:element name="Note1NatureofOperationsandContinuanceofBusinessDetailsTable"
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrldt:hypercubeItem" 
id="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable"/>
  <xs:element 
name="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems"
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems"/>
  <xs:element name="PreferenceSharesPurchasedInSubsidiary" 
type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_PreferenceSharesPurchasedInSubsidiary"/>
  <xs:element name="NumberOfEmployees" type="xbrli:integerItemType" 
abstract="false" xbrli:periodType="instant" nillable="true" 
substitutionGroup="xbrli:item" id="biad_NumberOfEmployees"/>
  <xs:element name="JointVentureAggregateProceedsProvidedByPartner" 
type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" 
xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" 
id="biad_JointVentureAggregateProceedsProvidedByPartner"/>
  <xs:element name="ProceedsFromJointVenturePartner" 
type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" 
xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" 
id="biad_ProceedsFromJointVenturePartner"/>
  <xs:element name="JointVenturePartnerFundingDescription" 
type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_JointVenturePartnerFundingDescription"/>
  <xs:element name="JointVenturePartnerProvisions" type="xbrli:stringItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_JointVenturePartnerProvisions"/>
  <xs:element name="ClassOfWarrantOrRightsGranted" type="xbrli:sharesItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_ClassOfWarrantOrRightsGranted"/>
  <xs:element name="WarrantsTermOfWarrants" type="xbrli:durationItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_WarrantsTermOfWarrants"/>
  <xs:element name="ForeignTranslationDomain" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_ForeignTranslationDomain"/>
  <xs:element name="Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrldt:hypercubeItem" 
id="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems"
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="NumberOfLivePatents" type="xbrli:integerItemType" 
abstract="false" xbrli:periodType="instant" nillable="true" 
substitutionGroup="xbrli:item" id="biad_NumberOfLivePatents"/>
  <xs:element name="NumberOfProprietaryTechnologyPlatforms" 
type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_NumberOfProprietaryTechnologyPlatforms"/>
  <xs:element name="NumberOfPatentsNotRenewedAndAbandoned" 
type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_NumberOfPatentsNotRenewedAndAbandoned"/>
  <xs:element name="Note4RelatedPartyTransactionsDetailsTable" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrldt:hypercubeItem" 
id="biad_Note4RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="Note4RelatedPartyTransactionsDetailsLineItems" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_Note4RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="Note6SegmentedInformationDetailsTable" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrldt:hypercubeItem"
id="biad_Note6SegmentedInformationDetailsTable"/>
  <xs:element name="Note6SegmentedInformationDetailsLineItems" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_Note6SegmentedInformationDetailsLineItems"/>
  <xs:element name="Note7SubsequentEventandCommitmentDetailsTable" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrldt:hypercubeItem" 
id="biad_Note7SubsequentEventandCommitmentDetailsTable"/>
  <xs:element name="Note7SubsequentEventandCommitmentDetailsLineItems" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_Note7SubsequentEventandCommitmentDetailsLineItems"/>
  <xs:element name="ForeignTranslationAxis" type="xbrli:stringItemType" 
abstract="true" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrldt:dimensionItem" id="biad_ForeignTranslationAxis"/>
  <xs:element name="NoncontrollingOwnerAxis" type="xbrli:stringItemType" 
abstract="true" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrldt:dimensionItem" id="biad_NoncontrollingOwnerAxis"/>
  <xs:element name="AverageRateMember" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_AverageRateMember"/>
  <xs:element name="Bio-AMDHoldingsLimitedMember" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_Bio-AMDHoldingsLimitedMember"/>
  <xs:element name="BioAMDIncMember" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_BioAMDIncMember"/>
  <xs:element name="BioAMDUKHoldingsLimitedMember" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_BioAMDUKHoldingsLimitedMember"/>
  <xs:element name="DrAndrewMitchellMember" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_DrAndrewMitchellMember"/>
  <xs:element name="DrNasserDjennatiMember" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_DrNasserDjennatiMember"/>
  <xs:element name="InterestInUKMedicalOperationsMember" 
type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_InterestInUKMedicalOperationsMember"/>
  <xs:element name="MIDSMedicalLimitedMember" type="nonnum:domainItemType" 
abstract="false" xbrli:periodType="duration" nillable="true" 
substitutionGroup="xbrli:item" id="biad_MIDSMedicalLimitedMember"/>
  <xs:element name="ThirdPartyMedicalDetectionDeviceDevloperMember" 
type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_ThirdPartyMedicalDetectionDeviceDevloperMember"/>
  <xs:element name="WOCULimitedWLFormerlyWDXOrganizationMember" 
type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" 
type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" 
nillable="true" substitutionGroup="xbrli:item" 
id="biad_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>biad-20160630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by iC(tm) - CompSci Interactive Converter - 
http://www.compsciresources.com -->
<!-- Created: Mon Aug 15 16:32:52 EDT 2016 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" 
xmlns:xlink="http://www.w3.org/1999/xlink" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.xbrl.org/2003/linkbase 
http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedBalanceSheet" 
roleURI="http://www.bioamd.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedIncomeStatement" 
roleURI="http://www.bioamd.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedCashFlow" 
roleURI="http://www.bioamd.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" 
order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredCostsCurrent"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" order="4" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Assets"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PropertyPlantAndEquipmentNet"/>
<calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_Liabilities" xlink:to="us-gaap_AccountsPayableCurrent" order="1" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_Liabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_Liabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:to="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_StockholdersEquity" xlink:to="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_StockholdersEquity" xlink:to="us-gaap_MinorityInterest" order="2" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" 
weight="1"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" 
order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SellingGeneralAndAdministrativeExpense" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_OperatingExpenses" xlink:to="us-
gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments"/>
<calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingExpenses" order="1"
weight="-1"/>
<!-- [WMV4]
[XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAK3hbE
VTXOd1U7+9iHKYBy25QKV69HOl1N03x1pff3iAB1LqBqnr0sN+tqK1E0BcI73NmfgSIRh6iGD5vsrsl9
RYcsrtOTcfcOgZ61HMsrI5H6weu3eaqe30ytHlB/OS0tP9YRbqwN+egH+p/WUBCZn7wWAJwuQ/VeXFVD
CjBPPjg==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetIncomeLoss" xlink:to="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnContractTermination" order="2" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestAndOtherIncome"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="3" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-
gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:to="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" 
weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_AmortizationOfDeferredCharges" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" 
weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_GainLossOnContractTermination" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredCharges"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="12" weight="-
1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInInvestingActivities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-
gaap_PaymentsToAcquireIntangibleAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1" 
weight="1"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-
gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
    <calculationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="3"
weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>biad-20160630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by iC(tm) - CompSci Interactive Converter - 
http://www.compsciresources.com -->
<!-- Created: Mon Aug 15 16:32:52 EDT 2016 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" 
xmlns:xlink="http://www.w3.org/1999/xlink" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.xbrl.org/2003/linkbase 
http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" 
xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedBalanceSheet" 
roleURI="http://www.bioamd.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedBalanceSheet_Parentheticals" 
roleURI="http://www.bioamd.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedIncomeStatement" 
roleURI="http://www.bioamd.com/role/ConsolidatedIncomeStatement"/>
<roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ShareholdersEquityType2or3" 
roleURI="http://www.bioamd.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedCashFlow" 
roleURI="http://www.bioamd.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note1NatureofOperationsandContinuanceofBusiness" 
roleURI="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusin
ess"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note2SummaryofSignificantAccountingPolicies" 
roleURI="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolicies"
/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note3Patents" 
roleURI="http://www.bioamd.com/role/Note3Patents"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note4RelatedPartyTransactions" 
roleURI="http://www.bioamd.com/role/Note4RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note5DeferredRevenue" 
roleURI="http://www.bioamd.com/role/Note5DeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note6SegmentedInformation" 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformation"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note7SubsequentEventandCommitment" 
roleURI="http://www.bioamd.com/role/Note7SubsequentEventandCommitment"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_AccountingPoliciesByPolicy" 
roleURI="http://www.bioamd.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note3PatentsTables" 
roleURI="http://www.bioamd.com/role/Note3PatentsTables"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note6SegmentedInformationTables" 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ScheduleofFiniteLivedIntangibleAssetsTable" 
roleURI="http://www.bioamd.com/role/ScheduleofFiniteLivedIntangibleAssetsTable"/
>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ScheduleofSegmentInformationTable" 
roleURI="http://www.bioamd.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note1NatureofOperationsandContinuanceofBusinessDetails" 
roleURI="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusin
essDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note2SummaryofSignificantAccountingPoliciesDetails" 
roleURI="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPoliciesD
etails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note3PatentsDetails" 
roleURI="http://www.bioamd.com/role/Note3PatentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note4RelatedPartyTransactionsDetails" 
roleURI="http://www.bioamd.com/role/Note4RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note5DeferredRevenueDetails" 
roleURI="http://www.bioamd.com/role/Note5DeferredRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note6SegmentedInformationDetails"
roleURI="http://www.bioamd.com/role/Note6SegmentedInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note7SubsequentEventandCommitmentDetails" 
roleURI="http://www.bioamd.com/role/Note7SubsequentEventandCommitmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#DocumentAndEntityInformation" 
roleURI="http://www.bioamd.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-
2005.xsd#dimension-default" 
arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-
2005.xsd#dimension-domain" 
arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-
2005.xsd#hypercube-dimension" 
arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-
2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-
member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-
2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-
gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="3" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" 
order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Assets"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-
gaap_OtherAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" 
order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Liabilities"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract" 
xlink:href="biad-
20160630.xsd#biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" 
xlink:to="biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract" 
order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_SubsequentEventAndCommitmentNote7Abstract" xlink:href="biad-
20160630.xsd#biad_SubsequentEventAndCommitmentNote7Abstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" 
xlink:to="biad_SubsequentEventAndCommitmentNote7Abstract" order="3" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" 
order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-
gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_MinorityInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_LiabilitiesAndStockholdersEquity" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-
gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockParOrStatedValuePerShare" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3"
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" 
order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" 
order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" 
order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" 
order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-
gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SellingGeneralAndAdministrativeExpense" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_OperatingExpensesAbstract" xlink:to="us-
gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" 
order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-
gaap_GainLossOnContractTermination" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestAndOtherIncome"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-
gaap_InterestAndOtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc"
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="5" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:to="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="8" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" 
order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" 
order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="us-gaap_StatementTable" xlink:to="us-
gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-
gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityComponentDomain" xlink:to="us-
gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" 
order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" 
order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax"
order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" order="4" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_MinorityInterestPeriodIncreaseDecrease" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-
gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_CashFlowsFromOperatingActivitiesAbstract" xlink:href="biad-
20160630.xsd#biad_CashFlowsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" 
xlink:to="biad_CashFlowsFromOperatingActivitiesAbstract" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member"
xlink:from="biad_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:to="us-gaap_GainLossOnContractTermination" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInPrepaidExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredCharges"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInDeferredCharges" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInAccountsPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInDeferredRevenue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_CashFlowsFromInvestingActivitiesAbstract" xlink:href="biad-
20160630.xsd#biad_CashFlowsFromInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" 
xlink:to="biad_CashFlowsFromInvestingActivitiesAbstract" order="2" 
xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:label="us-
gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-
gaap_PaymentsToAcquireIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInInvestingActivities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-
gaap_NetCashProvidedByUsedInInvestingActivities" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="3"
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="4" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_CashAndCashEquivalentsAtCarryingValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_NonCashInvestingAndFinancingActivitiesAbstract" 
xlink:href="biad-
20160630.xsd#biad_NonCashInvestingAndFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" 
xlink:to="biad_NonCashInvestingAndFinancingActivitiesAbstract" order="6" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_NonCashInvestingAndFinancingActivitiesAbstract" xlink:to="us-
gaap_StockIssued1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SupplementalCashFlowInformationAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc"
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_SupplementalCashFlowInformationAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestPaid"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid"
order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBu
siness">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" 
order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolici
es">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SignificantAccountingPoliciesTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note3Patents">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="us-
gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note4RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_RelatedPartyTransactionsAbstract" xlink:to="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note5DeferredRevenue">
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_DeferredRevenueDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note6SegmentedInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentReportingAbstract" xlink:to="us-
gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note7SubsequentEventandCommitment">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" 
order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc"
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock"
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_IntangibleAssetsFiniteLivedPolicy" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_RevenueRecognitionPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RevenueRecognitionDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RevenueRecognitionDeferredRevenue"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_RevenueRecognitionDeferredRevenue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="5" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="6" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note3PatentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note6SegmentedInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentReportingAbstract" xlink:to="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ScheduleofFiniteLivedIntangibleAssetsTabl
e">
    <loc xlink:type="locator" 
xlink:label="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract" 
xlink:href="biad-
20160630.xsd#biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract"/>
<!-- [WMV4]
[XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAK3hbE
VTXOd1U7+9iHKYBy25QKV69HOl1N03x1pff3iAB1LqBqnr0sN+tqK1E0BcI73NmfgSIRh6iGD5vsrsl9
RYcsrtOTcfcOgZ61HMsrI5H6weu3eaqe30ytHlB/OS0tP9YRbqwN+eqgbLEfN/UPx3qu7v0yP8qEiXSQ
1nAo3jQ==] CSR-->
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
</definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ScheduleofSegmentInformationTable">
    <loc xlink:type="locator" xlink:label="us-
gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" 
xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-
gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentDomain" xlink:to="biad_WOCULimitedWLFormerlyWDXOrganizationMember" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentDomain" xlink:to="biad_Bio-AMDHoldingsLimitedMember" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentDomain" xlink:to="us-gaap_CorporateMember" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestAndOtherIncome"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-
gaap_InterestAndOtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" 
order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Assets"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="3" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBu
sinessDetails">
    <loc xlink:type="locator" 
xlink:label="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItem
s" xlink:href="biad-
20160630.xsd#biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItem
s"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain_0" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-
gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-
gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="dei_LegalEntityAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_NoncontrollingOwnerAxis" 
xlink:href="biad-20160630.xsd#biad_NoncontrollingOwnerAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="biad_NoncontrollingOwnerAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_NoncontrollingOwnerDomain" 
xlink:href="biad-20160630.xsd#biad_NoncontrollingOwnerDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain"
xlink:from="biad_NoncontrollingOwnerAxis" 
xlink:to="biad_NoncontrollingOwnerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_NoncontrollingOwnerDomain_0" 
xlink:href="biad-20160630.xsd#biad_NoncontrollingOwnerDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="biad_NoncontrollingOwnerAxis" 
xlink:to="biad_NoncontrollingOwnerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_DrNasserDjennatiMember" 
xlink:href="biad-20160630.xsd#biad_DrNasserDjennatiMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_NoncontrollingOwnerDomain" 
xlink:to="biad_DrNasserDjennatiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_DrAndrewMitchellMember" 
xlink:href="biad-20160630.xsd#biad_DrAndrewMitchellMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_NoncontrollingOwnerDomain" 
xlink:to="biad_DrAndrewMitchellMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_ThirdPartyMedicalDetectionDeviceDevloperMember" 
xlink:href="biad-
20160630.xsd#biad_ThirdPartyMedicalDetectionDeviceDevloperMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_NoncontrollingOwnerDomain" 
xlink:to="biad_ThirdPartyMedicalDetectionDeviceDevloperMember" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateJointVentureMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_EntityDomain" xlink:to="us-gaap_CorporateJointVentureMember" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" 
xlink:to="biad_WOCULimitedWLFormerlyWDXOrganizationMember" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" xlink:to="biad_Bio-
AMDHoldingsLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_BioAMDUKHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDUKHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" 
xlink:to="biad_BioAMDUKHoldingsLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator"
xlink:label="biad_InterestInUKMedicalOperationsMember" xlink:href="biad-
20160630.xsd#biad_InterestInUKMedicalOperationsMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" 
xlink:to="biad_InterestInUKMedicalOperationsMember" order="3" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_MIDSMedicalLimitedMember" 
xlink:href="biad-20160630.xsd#biad_MIDSMedicalLimitedMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" xlink:to="biad_MIDSMedicalLimitedMember" 
order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedParties" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LoansAndLeasesReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" order="3" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_PreferenceSharesPurchasedInSubsidiary" xlink:href="biad-
20160630.xsd#biad_PreferenceSharesPurchasedInSubsidiary"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member"
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_PreferenceSharesPurchasedInSubsidiary" order="5" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-
gaap-2016-01-31.xsd#us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockDividendRatePercentage"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="8" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockRedemptionTerms" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockRedemptionTerms"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_PreferredStockRedemptionTerms" order="9" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_NumberOfEmployees"
xlink:href="biad-20160630.xsd#biad_NumberOfEmployees"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_NumberOfEmployees" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" 
order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="14" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DebtConversionConvertedInstrumentSharesIssued1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="15" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Revenues"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_Revenues" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PaymentsToAcquireBusinessesGross"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="17" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockLiquidationPreferenceValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockLiquidationPreferenceValue"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="18" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="20" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" order="21" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_JointVentureAggregateProceedsProvidedByPartner" 
xlink:href="biad-
20160630.xsd#biad_JointVentureAggregateProceedsProvidedByPartner"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_JointVentureAggregateProceedsProvidedByPartner" order="22" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_ProceedsFromJointVenturePartner"
xlink:href="biad-20160630.xsd#biad_ProceedsFromJointVenturePartner"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_ProceedsFromJointVenturePartner" order="23" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_JointVenturePartnerFundingDescription" xlink:href="biad-
20160630.xsd#biad_JointVenturePartnerFundingDescription"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_JointVenturePartnerFundingDescription" order="24" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_JointVenturePartnerProvisions" 
xlink:href="biad-20160630.xsd#biad_JointVenturePartnerProvisions"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_JointVenturePartnerProvisions" order="25" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_ClassOfWarrantOrRightsGranted" 
xlink:href="biad-20160630.xsd#biad_ClassOfWarrantOrRightsGranted"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_ClassOfWarrantOrRightsGranted" order="26" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_WarrantsTermOfWarrants" 
xlink:href="biad-20160630.xsd#biad_WarrantsTermOfWarrants"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="biad_WarrantsTermOfWarrants" order="27" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:label="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="29" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolici
esDetails">
    <loc xlink:type="locator" 
xlink:label="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_ForeignTranslationAxis" 
xlink:href="biad-20160630.xsd#biad_ForeignTranslationAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="biad_ForeignTranslationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_ForeignTranslationDomain" 
xlink:href="biad-20160630.xsd#biad_ForeignTranslationDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" 
xlink:from="biad_ForeignTranslationAxis" 
xlink:to="biad_ForeignTranslationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_ForeignTranslationDomain_0" 
xlink:href="biad-20160630.xsd#biad_ForeignTranslationDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="biad_ForeignTranslationAxis" 
xlink:to="biad_ForeignTranslationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain_0" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrencyAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CurrencyAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="us-gaap_CurrencyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" 
xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-
31.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" 
xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-
31.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_GBP" 
xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-
31.xsd#currency_GBP"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_AverageRateMember" 
xlink:href="biad-20160630.xsd#biad_AverageRateMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_ForeignTranslationDomain" xlink:to="biad_AverageRateMember" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" 
xlink:to="biad_WOCULimitedWLFormerlyWDXOrganizationMember" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" xlink:to="biad_Bio-
AMDHoldingsLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_BioAMDUKHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDUKHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc"
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" 
xlink:to="biad_BioAMDUKHoldingsLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="3" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_GainLossOnContractTermination" order="4" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ForeignCurrencyExchangeRateTranslation1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="5" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note3PatentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="biad_NumberOfLivePatents" 
xlink:href="biad-20160630.xsd#biad_NumberOfLivePatents"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="biad_NumberOfLivePatents" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_NumberOfProprietaryTechnologyPlatforms" xlink:href="biad-
20160630.xsd#biad_NumberOfProprietaryTechnologyPlatforms"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DisclosureTextBlockAbstract" 
xlink:to="biad_NumberOfProprietaryTechnologyPlatforms" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_NumberOfPatentsNotRenewedAndAbandoned" xlink:href="biad-
20160630.xsd#biad_NumberOfPatentsNotRenewedAndAbandoned"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DisclosureTextBlockAbstract" 
xlink:to="biad_NumberOfPatentsNotRenewedAndAbandoned" order="2" 
xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note4RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" 
xlink:label="biad_Note4RelatedPartyTransactionsDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note4RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note4RelatedPartyTransactionsDetailsTable" xlink:href="biad-
20160630.xsd#biad_Note4RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsLineItems" 
xlink:to="biad_Note4RelatedPartyTransactionsDetailsTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsTable" xlink:to="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain_0" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsTable" xlink:to="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsTable" 
xlink:to="dei_LegalEntityAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AffiliatedEntityMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AffiliatedEntityMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_RelatedPartyDomain" xlink:to="us-gaap_AffiliatedEntityMember" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChiefFinancialOfficerMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChiefExecutiveOfficerMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" 
order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresidentMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PresidentMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_RelatedPartyDomain" xlink:to="us-gaap_PresidentMember" order="3" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_BioAMDIncMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDIncMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_EntityDomain" xlink:to="biad_BioAMDIncMember" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
<definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" xlink:to="biad_Bio-
AMDHoldingsLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionAmountsOfTransaction" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_RelatedPartyTransactionAmountsOfTransaction" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="2" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CostsAndExpensesRelatedParty"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_CostsAndExpensesRelatedParty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OperatingLeasesRentExpenseMinimumRentals" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_OperatingLeasesRentExpenseMinimumRentals" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note5DeferredRevenueDetails">
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_DeferredRevenueCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredCostsCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_DeferredCostsCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_GainLossOnContractTermination" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note6SegmentedInformationDetails">
    <loc xlink:type="locator" 
xlink:label="biad_Note6SegmentedInformationDetailsLineItems" xlink:href="biad-
20160630.xsd#biad_Note6SegmentedInformationDetailsLineItems"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note6SegmentedInformationDetailsTable" xlink:href="biad-
20160630.xsd#biad_Note6SegmentedInformationDetailsTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" 
xlink:from="biad_Note6SegmentedInformationDetailsLineItems" 
xlink:to="biad_Note6SegmentedInformationDetailsTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note6SegmentedInformationDetailsTable" xlink:to="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain_0" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" 
xlink:to="biad_WOCULimitedWLFormerlyWDXOrganizationMember" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" xlink:to="biad_Bio-
AMDHoldingsLimitedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_BioAMDUKHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDUKHoldingsLimitedMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" 
xlink:to="biad_BioAMDUKHoldingsLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc"
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note6SegmentedInformationDetailsLineItems" xlink:to="us-
gaap_NumberOfOperatingSegments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-
01-31.xsd#us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note6SegmentedInformationDetailsLineItems" xlink:to="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note6SegmentedInformationDetailsLineItems" xlink:to="us-
gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note7SubsequentEventandCommitmentDetails"
>
    <loc xlink:type="locator" 
xlink:label="biad_Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note7SubsequentEventandCommitmentDetailsLineItems"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note7SubsequentEventandCommitmentDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note7SubsequentEventandCommitmentDetailsTable"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:to="biad_Note7SubsequentEventandCommitmentDetailsTable" order="0" 
xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsTable" 
xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsTable" xlink:to="us-
gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-
gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" 
xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-
gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateJointVentureMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_EntityDomain" xlink:to="us-gaap_CorporateJointVentureMember" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-
gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" 
order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_ClassOfWarrantOrRightsGranted" 
xlink:href="biad-20160630.xsd#biad_ClassOfWarrantOrRightsGranted"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:to="biad_ClassOfWarrantOrRightsGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="biad_WarrantsTermOfWarrants" 
xlink:href="biad-20160630.xsd#biad_WarrantsTermOfWarrants"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:to="biad_WarrantsTermOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_EntityRegistrantName" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol"
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" 
order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" 
order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" 
xlink:label="dei_EntityCommonStockSharesOutstanding" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" 
xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" 
order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" 
order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_AmendmentDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityVoluntaryFilers"/>
<definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory"
order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" 
xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" 
xlink:from="dei_DocumentInformationLineItems" 
xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>biad-20160630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by iC(tm) - CompSci Interactive Converter - 
http://www.compsciresources.com -->
<!-- Created: Mon Aug 15 16:32:52 EDT 2016 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" 
xmlns:xlink="http://www.w3.org/1999/xlink" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.xbrl.org/2003/linkbase 
http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-
2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-
2009-12-16.xsd#negatedLabel"
roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" 
xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of 
Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementOfFinancialPositionAbstract" xlink:to="us-
gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-
gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash, 
beginning of period</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-
gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash, end of 
period</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-
gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Amounts 
receivable</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AccountsReceivableNetCurrent" xlink:to="us-
gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred charges (Note 
1)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AssetsCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, 
net</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PropertyPlantAndEquipmentNet" xlink:to="us-
gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Patents (Note 
3)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-
gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Assets"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_Assets_lbl0" xml:lang="en-US">Segment total assets</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
<loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AccruedLiabilitiesCurrent" xlink:to="us-
gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other 
liabilities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-
gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue (Note 
1)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, 
Current</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Liabilities"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockValue"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, 10,000,000 
shares authorized, $0.001 par value, nil shares issued and outstanding</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockValue"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, 500,000,000 shares 
authorized, $0.001 par value, 45,975,966 shares issued and outstanding</label>
<labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par
Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-
gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares 
Authorized</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockSharesAuthorized" xlink:to="us-
gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares 
Issued</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares 
Outstanding</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockSharesOutstanding" xlink:to="us-
gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-
gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in 
Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockSharesOutstanding" xlink:to="us-
gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-
gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Balance (in 
Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockSharesOutstanding" xlink:to="us-
gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in 
capital</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" xlink:to="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Deficit</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-
gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings
(Accumulated Deficit) (in Dollars)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-
gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"
xml:lang="en-US">Total Bio-AMD, Inc. Stockholders&apos; Equity</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:to="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"
/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterest"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
<labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquity"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&apos; 
Equity</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-
gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-
gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities 
and Stockholders&apos; Equity</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-
gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement 
[Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SellingGeneralAndAdministrativeExpense" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and 
administrative charges (Note 4)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-
gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingExpenses"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Net loss before other 
income</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" xlink:to="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">Gain on termination of 
research agreement (Note 5)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_GainLossOnContractTermination" xlink:to="us-
gaap_GainLossOnContractTermination_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_GainLossOnContractTermination_lbl0" xml:lang="en-US">Gain on termination of
research agreement</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_GainLossOnContractTermination" xlink:to="us-
gaap_GainLossOnContractTermination_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_GainLossOnContractTermination_lbl1" xml:lang="en-US">Gain (Loss) on 
Contract Termination (in Dollars)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_GainLossOnContractTermination" xlink:to="us-
gaap_GainLossOnContractTermination_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-
gaap_GainLossOnContractTermination_lbl2" xml:lang="en-US">Gain (Loss) on 
Contract Termination</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_GainLossOnContractTermination" xlink:to="us-
gaap_GainLossOnContractTermination_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestAndOtherIncome"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest and other 
income</label>
    <labelArc xlink:type="arc"
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-
gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-
gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Segment net income (loss)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net
loss (income) attributable to the non-controlling interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net 
loss attributable to Bio-AMD, Inc. common shareholders</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment, net 
of tax</label>
<labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" xlink:to="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest_lbl" xml:lang="en-US">Total other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" 
xml:lang="en-US">Comprehensive (income)/loss attributable to the non-controlling
interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" 
xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss 
attributable to the Bio-AMD, Inc. common shareholders</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common 
share attributable to Bio-AMD, Inc. common shareholders - basic and diluted (in 
Dollars per share)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-
gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource"
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-
US">Weighted average number of common shares outstanding - basic and diluted (in
Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of 
Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-
gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Comprehensive 
income (loss)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-
gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components 
[Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-
gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in 
Capital [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AdditionalPaidInCapitalMember" xlink:to="us-
gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI 
Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-
gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NoncontrollingInterestMember" xlink:to="us-
gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows 
[Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementOfCashFlowsAbstract" xlink:to="us-
gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortization of prepaid
stock based fees</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AmortizationOfDeferredCharges" xlink:to="us-
gaap_AmortizationOfDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based consulting 
fees</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
<loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Amounts 
receivable</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-
gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid 
expenses</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-
gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredCharges"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Deferred 
charges</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-
gaap_IncreaseDecreaseInDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Security 
deposit and other assets</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts 
payable</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-
gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued 
liabilities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-
gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other 
liabilites</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred 
revenue</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-
gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" 
xml:lang="en-US">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-
gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent 
expenditures</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-
gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInInvestingActivities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash
used in Investing Activities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-
gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" 
xml:lang="en-US">Effects of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" 
xlink:to="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change 
in Cash</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockIssued1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued for prepaid 
services</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestPaid"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_InterestPaid_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income tax</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block
[Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="us-
gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies 
[Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract" 
xlink:href="biad-
20160630.xsd#biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract_lbl" 
xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract" 
xlink:to="biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party 
Transactions [Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RelatedPartyTransactionsAbstract" xlink:to="us-
gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DeferredRevenueDisclosureAbstract_lbl" xml:lang="en-US">Deferred Revenue 
Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_DeferredRevenueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting 
[Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_ScheduleOfSegmentInformationAbstract" xlink:href="biad-
20160630.xsd#biad_ScheduleOfSegmentInformationAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_ScheduleOfSegmentInformationAbstract_lbl" xml:lang="en-
US">Schedule of Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ScheduleOfSegmentInformationAbstract" 
xlink:to="biad_ScheduleOfSegmentInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementBusinessSegmentsAxis" xlink:to="us-
gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember_lbl" xml:lang="en-
US">WOCU Limited &quot;WL&quot;, formerly WDX Organization [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_WOCULimitedWLFormerlyWDXOrganizationMember" 
xlink:to="biad_WOCULimitedWLFormerlyWDXOrganizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="biad_Bio-
AMDHoldingsLimitedMember_lbl" xml:lang="en-US">Bio-AMD Holdings Limited 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Bio-AMDHoldingsLimitedMember" xlink:to="biad_Bio-
AMDHoldingsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CorporateMember_lbl" xml:lang="en-US">Corporate Segment [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events 
[Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AssetsAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES 
AND STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current 
Liabilities:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-
gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract" 
xlink:href="biad-
20160630.xsd#biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract_lbl" 
xml:lang="en-US">Nature of Operations and Continuation of Business (Note 
1)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract" 
xlink:to="biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_SubsequentEventAndCommitmentNote7Abstract" xlink:href="biad-
20160630.xsd#biad_SubsequentEventAndCommitmentNote7Abstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_SubsequentEventAndCommitmentNote7Abstract_lbl" xml:lang="en-
US">Subsequent Event and Commitment (Note 7)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_SubsequentEventAndCommitmentNote7Abstract" 
xlink:to="biad_SubsequentEventAndCommitmentNote7Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&apos; 
Equity:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-
gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, 
shares authorized</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockSharesAuthorized" xlink:to="us-
gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockParOrStatedValuePerShare" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred 
stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-
gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares 
issued</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockSharesIssued" xlink:to="us-
gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, 
shares outstanding</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockSharesOutstanding" xlink:to="us-
gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OperatingExpensesAbstract" xlink:to="us-
gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other 
income:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-
gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl" 
xml:lang="en-US">Comprehensive Loss:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:to="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ProfitLoss"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_lbl" 
xml:lang="en-US">Subsidiary preferred dividend</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:to="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in 
ownership interest of subsidiary</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="us-
gaap_MinorityInterestPeriodIncreaseDecrease_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_MinorityInterestPeriodIncreaseDecrease_lbl0" xml:lang="en-
US">Noncontrolling Interest, Period Increase (Decrease) (in Dollars)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="us-
gaap_MinorityInterestPeriodIncreaseDecrease_lbl0"/>
    <loc xlink:type="locator" 
xlink:label="biad_CashFlowsFromOperatingActivitiesAbstract" xlink:href="biad-
20160630.xsd#biad_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-
US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label"
xlink:from="biad_CashFlowsFromOperatingActivitiesAbstract" 
xlink:to="biad_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash 
used in operating activities:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:to="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in
operating assets and liabilities:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_CashFlowsFromInvestingActivitiesAbstract" xlink:href="biad-
20160630.xsd#biad_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-
US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_CashFlowsFromInvestingActivitiesAbstract" 
xlink:to="biad_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_NonCashInvestingAndFinancingActivitiesAbstract" 
xlink:href="biad-
20160630.xsd#biad_NonCashInvestingAndFinancingActivitiesAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NonCashInvestingAndFinancingActivitiesAbstract_lbl" 
xml:lang="en-US">Non-cash Investing and Financing activities:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NonCashInvestingAndFinancingActivitiesAbstract" 
xlink:to="biad_NonCashInvestingAndFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SupplementalCashFlowInformationAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary
disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-
gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NatureOfOperations"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text 
Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SignificantAccountingPoliciesTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant 
Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-
gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets
Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-
gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-
US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource"
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-
US">Patents</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl" 
xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" 
xlink:to="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related 
Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Revenue 
Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DeferredRevenueDisclosureTextBlock" xlink:to="us-
gaap_DeferredRevenueDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting
Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-
gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-
US">Schedule of Segment Reporting Information, by Segment [Table Text 
Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text 
Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SubsequentEventsTextBlock" xlink:to="us-
gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" 
xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock 
[Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementClassOfStockAxis" xlink:to="us-
gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SeriesCPreferredStockMember" xlink:to="us-
gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_BioAMDUKHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDUKHoldingsLimitedMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel"
xlink:label="biad_BioAMDUKHoldingsLimitedMember_lbl" xml:lang="en-US">Bio-AMD UK
Holdings Limited [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_BioAMDUKHoldingsLimitedMember" 
xlink:to="biad_BioAMDUKHoldingsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_NoncontrollingOwnerAxis" 
xlink:href="biad-20160630.xsd#biad_NoncontrollingOwnerAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_NoncontrollingOwnerAxis_lbl" xml:lang="en-US">Noncontrolling 
Owner [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NoncontrollingOwnerAxis" 
xlink:to="biad_NoncontrollingOwnerAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_DrNasserDjennatiMember" 
xlink:href="biad-20160630.xsd#biad_DrNasserDjennatiMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_DrNasserDjennatiMember_lbl" xml:lang="en-US">Dr. Nasser 
Djennati [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_DrNasserDjennatiMember" 
xlink:to="biad_DrNasserDjennatiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_DrAndrewMitchellMember" 
xlink:href="biad-20160630.xsd#biad_DrAndrewMitchellMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_DrAndrewMitchellMember_lbl" xml:lang="en-US">Dr. Andrew 
Mitchell [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_DrAndrewMitchellMember" 
xlink:to="biad_DrAndrewMitchellMember_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_InterestInUKMedicalOperationsMember" xlink:href="biad-
20160630.xsd#biad_InterestInUKMedicalOperationsMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_InterestInUKMedicalOperationsMember_lbl" xml:lang="en-
US">Interest in UK Medical Operations [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_InterestInUKMedicalOperationsMember" 
xlink:to="biad_InterestInUKMedicalOperationsMember_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_ThirdPartyMedicalDetectionDeviceDevloperMember" 
xlink:href="biad-
20160630.xsd#biad_ThirdPartyMedicalDetectionDeviceDevloperMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_ThirdPartyMedicalDetectionDeviceDevloperMember_lbl" 
xml:lang="en-US">Third Party Medical Detection Device Devloper [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ThirdPartyMedicalDetectionDeviceDevloperMember" 
xlink:to="biad_ThirdPartyMedicalDetectionDeviceDevloperMember_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_MIDSMedicalLimitedMember" 
xlink:href="biad-20160630.xsd#biad_MIDSMedicalLimitedMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_MIDSMedicalLimitedMember_lbl" xml:lang="en-US">MIDS Medical
Limited [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_MIDSMedicalLimitedMember" 
xlink:to="biad_MIDSMedicalLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type 
[Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity 
[Axis]</label>
<!-- [WMV4]
[XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAK3hbE
VTXOd1U7+9iHKYBy25QKV69HOl1N03x1pff3iAB1LqBqnr0sN+tqK1E0BcI73NmfgSIRh6iGD5vsrsl9
RYcsrtOTcfcOgZ61HMsrI5H6weu3eaqe30ytHlB/OS0tP9YRbqwN+eqgbLEfN/UPxey2ZDfnnzRq3NvC
1Dnr9oQ==] CSR-->
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateJointVentureMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CorporateJointVentureMember_lbl" xml:lang="en-US">Corporate Joint Venture 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CorporateJointVentureMember" xlink:to="us-
gaap_CorporateJointVentureMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrencyAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CurrencyAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CurrencyAxis" xlink:to="us-gaap_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_GBP" 
xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-
31.xsd#currency_GBP"/>
    <label xlink:type="resource"
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_GBP_lbl" 
xml:lang="en-US">United Kingdom, Pounds</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="currency_GBP" xlink:to="currency_GBP_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_ForeignTranslationAxis" 
xlink:href="biad-20160630.xsd#biad_ForeignTranslationAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_ForeignTranslationAxis_lbl" xml:lang="en-US">Foreign 
Translation [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ForeignTranslationAxis" 
xlink:to="biad_ForeignTranslationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_AverageRateMember" 
xlink:href="biad-20160630.xsd#biad_AverageRateMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_AverageRateMember_lbl" xml:lang="en-US">Average Rate 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_AverageRateMember" xlink:to="biad_AverageRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related 
Party [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AffiliatedEntityMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AffiliatedEntityMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AffiliatedEntityMember_lbl" xml:lang="en-US">Affiliated Entity 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AffiliatedEntityMember" xlink:to="us-gaap_AffiliatedEntityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChiefFinancialOfficerMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ChiefFinancialOfficerMember" xlink:to="us-
gaap_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_BioAMDIncMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDIncMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_BioAMDIncMember_lbl" xml:lang="en-US">Bio-AMD, Inc. 
[Member]</label>
    <labelArc xlink:type="arc"
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_BioAMDIncMember" xlink:to="biad_BioAMDIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChiefExecutiveOfficerMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ChiefExecutiveOfficerMember" xlink:to="us-
gaap_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresidentMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PresidentMember"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PresidentMember_lbl" xml:lang="en-US">President [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PresidentMember" xlink:to="us-gaap_PresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-
US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions_lbl" xml:lang="en-US">Loans
and Leases Receivable, Related Parties, Additions</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" xlink:to="us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedParties" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LoansAndLeasesReceivableRelatedParties"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedParties_lbl" xml:lang="en-US">Loans and 
Leases Receivable, Related Parties</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-
gaap_LoansAndLeasesReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions"/>
<label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Cumulative 
Percentage Ownership after All Transactions</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions" xlink:to="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_PreferenceSharesPurchasedInSubsidiary" xlink:href="biad-
20160630.xsd#biad_PreferenceSharesPurchasedInSubsidiary"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_PreferenceSharesPurchasedInSubsidiary_lbl" xml:lang="en-
US">Preference Shares Purchased in Subsidiary (in Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_PreferenceSharesPurchasedInSubsidiary" 
xlink:to="biad_PreferenceSharesPurchasedInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per 
Share (in Pounds per share)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-
gaap-2016-01-31.xsd#us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent_lbl" xml:lang="en-US">Consolidation, Less than Wholly 
Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by 
Parent (in Dollars)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent" xlink:to="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockDividendRatePercentage"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock,
Dividend Rate, Percentage</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockDividendRatePercentage" xlink:to="us-
gaap_PreferredStockDividendRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockRedemptionTerms" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockRedemptionTerms"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockRedemptionTerms_lbl" xml:lang="en-US">Preferred Stock, 
Redemption Terms</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockRedemptionTerms" xlink:to="us-
gaap_PreferredStockRedemptionTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based
Payment Award, Number of Shares Authorized (in Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized" xlink:to="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based 
Payment Award, Shares Issued in Period (in Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od" xlink:to="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_NumberOfEmployees" 
xlink:href="biad-20160630.xsd#biad_NumberOfEmployees"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NumberOfEmployees_lbl" xml:lang="en-US">Number of 
Employees</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfEmployees" xlink:to="biad_NumberOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_lbl" xml:lang="en-
US">Sale of Stock, Percentage of Ownership before Transaction</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_lbl"/>
<loc xlink:type="locator" xlink:label="us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Stock 
Repurchased and Retired During Period, Shares (in Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DebtConversionConvertedInstrumentSharesIssued1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt 
Conversion, Converted Instrument, Shares Issued (in Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-
gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Revenues"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_Revenues_lbl" xml:lang="en-US">Revenues (in Dollars)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to Acquire 
Businesses, Gross</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-
gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockLiquidationPreferenceValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred 
Stock, Liquidation Preference, Value (in Pounds)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-
gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"
xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling
Owners</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity 
Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-
gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_JointVentureAggregateProceedsProvidedByPartner" 
xlink:href="biad-
20160630.xsd#biad_JointVentureAggregateProceedsProvidedByPartner"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_JointVentureAggregateProceedsProvidedByPartner_lbl" 
xml:lang="en-US">Joint Venture, Aggregate Proceeds Provided by Partner</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_JointVentureAggregateProceedsProvidedByPartner" 
xlink:to="biad_JointVentureAggregateProceedsProvidedByPartner_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_ProceedsFromJointVenturePartner"
xlink:href="biad-20160630.xsd#biad_ProceedsFromJointVenturePartner"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_ProceedsFromJointVenturePartner_lbl" xml:lang="en-US">Proceeds
from Joint Venture Partner</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ProceedsFromJointVenturePartner" 
xlink:to="biad_ProceedsFromJointVenturePartner_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_JointVenturePartnerFundingDescription" xlink:href="biad-
20160630.xsd#biad_JointVenturePartnerFundingDescription"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_JointVenturePartnerFundingDescription_lbl" xml:lang="en-
US">Joint Venture, Partner Funding Description</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_JointVenturePartnerFundingDescription" 
xlink:to="biad_JointVenturePartnerFundingDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_JointVenturePartnerProvisions" 
xlink:href="biad-20160630.xsd#biad_JointVenturePartnerProvisions"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_JointVenturePartnerProvisions_lbl" xml:lang="en-US">Joint 
Venture, Partner Provisions</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_JointVenturePartnerProvisions" 
xlink:to="biad_JointVenturePartnerProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_ClassOfWarrantOrRightsGranted" 
xlink:href="biad-20160630.xsd#biad_ClassOfWarrantOrRightsGranted"/>
    <label xlink:type="resource"
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_ClassOfWarrantOrRightsGranted_lbl" xml:lang="en-US">Class of 
Warrant or Rights, Granted (in Shares)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ClassOfWarrantOrRightsGranted" 
xlink:to="biad_ClassOfWarrantOrRightsGranted_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" 
xlink:label="biad_ClassOfWarrantOrRightsGranted_lbl0" xml:lang="en-US">Class of 
Warrant or Rights, Granted</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ClassOfWarrantOrRightsGranted" 
xlink:to="biad_ClassOfWarrantOrRightsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="biad_WarrantsTermOfWarrants" 
xlink:href="biad-20160630.xsd#biad_WarrantsTermOfWarrants"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_WarrantsTermOfWarrants_lbl" xml:lang="en-US">Warrants, Term of
Warrants</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_WarrantsTermOfWarrants" 
xlink:to="biad_WarrantsTermOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-
US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars 
per share)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-
US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived 
Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-
gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ForeignCurrencyExchangeRateTranslation1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Foreign 
Currency Exchange Rate, Translation</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-
gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_NumberOfLivePatents" 
xlink:href="biad-20160630.xsd#biad_NumberOfLivePatents"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NumberOfLivePatents_lbl" xml:lang="en-US">Number of live 
patents</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfLivePatents" xlink:to="biad_NumberOfLivePatents_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_NumberOfProprietaryTechnologyPlatforms" xlink:href="biad-
20160630.xsd#biad_NumberOfProprietaryTechnologyPlatforms"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NumberOfProprietaryTechnologyPlatforms_lbl" xml:lang="en-
US">Number of proprietary technology platforms</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfProprietaryTechnologyPlatforms" 
xlink:to="biad_NumberOfProprietaryTechnologyPlatforms_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_NumberOfPatentsNotRenewedAndAbandoned" xlink:href="biad-
20160630.xsd#biad_NumberOfPatentsNotRenewedAndAbandoned"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NumberOfPatentsNotRenewedAndAbandoned_lbl" xml:lang="en-
US">Number of patents not renewed and abandoned</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfPatentsNotRenewedAndAbandoned" 
xlink:to="biad_NumberOfPatentsNotRenewedAndAbandoned_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionAmountsOfTransaction" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related 
Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-
gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CostsAndExpensesRelatedParty"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Costs and Expenses, 
Related Party</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CostsAndExpensesRelatedParty" xlink:to="us-
gaap_CostsAndExpensesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OperatingLeasesRentExpenseMinimumRentals" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingLeasesRentExpenseMinimumRentals"/>
<label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xml:lang="en-US">Operating 
Leases, Rent Expense, Minimum Rentals</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-
gaap_OperatingLeasesRentExpenseMinimumRentals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredCostsCurrentAndNoncurrent"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US">Deferred 
Costs</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-
gaap_DeferredCostsCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating 
Segments</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NumberOfOperatingSegments" xlink:to="us-
gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-
01-31.xsd#us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues_lbl" xml:lang="en-US">Segment Reporting Information, Description of
Products and Services</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues" xlink:to="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_UseOfEstimates"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text 
Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy
[Policy Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ConsolidationPolicyTextBlock" xlink:to="us-
gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, 
Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-
gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue 
Recognition, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-
gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RevenueRecognitionDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RevenueRecognitionDeferredRevenue"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US">Revenue 
Recognition, Deferred Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-
gaap_RevenueRecognitionDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" 
xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy 
Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New 
Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityComponentDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component 
[Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-
US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment 
Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-
gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name 
[Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_EquityMethodInvesteeNameDomain" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain_lbl"/>
<loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type 
[Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_SubsequentEventTypeDomain" xlink:to="us-
gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="biad_NoncontrollingOwnerDomain" 
xlink:href="biad-20160630.xsd#biad_NoncontrollingOwnerDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NoncontrollingOwnerDomain_lbl" xml:lang="en-
US">NoncontrollingOwner [Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NoncontrollingOwnerDomain" 
xlink:to="biad_NoncontrollingOwnerDomain_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable_lb
l" xml:lang="en-US">Note 1 - Nature of Operations and Continuance of Business 
(Details) [Table]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable_lbl"/
>
    <loc xlink:type="locator" 
xlink:label="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItem
s" xlink:href="biad-
20160630.xsd#biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItem
s"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItem
s_lbl" xml:lang="en-US">Note 1 - Nature of Operations and Continuance of 
Business (Details) [Line Items]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems
" 
xlink:to="biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems_l
bl"/>
    <loc xlink:type="locator" xlink:label="biad_ForeignTranslationDomain" 
xlink:href="biad-20160630.xsd#biad_ForeignTranslationDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label"
xlink:label="biad_ForeignTranslationDomain_lbl" xml:lang="en-
US">ForeignTranslation [Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ForeignTranslationDomain" 
xlink:to="biad_ForeignTranslationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" 
xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-
31.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies 
[Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="currency_AllCurrenciesDomain" 
xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable_lbl" 
xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies (Details) 
[Table]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems_lb
l" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies 
(Details) [Line Items]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/
>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note4RelatedPartyTransactionsDetailsTable" xlink:href="biad-
20160630.xsd#biad_Note4RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note4RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-
US">Note 4 - Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsTable" 
xlink:to="biad_Note4RelatedPartyTransactionsDetailsTable_lbl"/>
<loc xlink:type="locator" 
xlink:label="biad_Note4RelatedPartyTransactionsDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note4RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note4RelatedPartyTransactionsDetailsLineItems_lbl" 
xml:lang="en-US">Note 4 - Related Party Transactions (Details) [Line 
Items]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note4RelatedPartyTransactionsDetailsLineItems" 
xlink:to="biad_Note4RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note6SegmentedInformationDetailsTable" xlink:href="biad-
20160630.xsd#biad_Note6SegmentedInformationDetailsTable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note6SegmentedInformationDetailsTable_lbl" xml:lang="en-
US">Note 6 - Segmented Information (Details) [Table]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note6SegmentedInformationDetailsTable" 
xlink:to="biad_Note6SegmentedInformationDetailsTable_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note6SegmentedInformationDetailsLineItems" xlink:href="biad-
20160630.xsd#biad_Note6SegmentedInformationDetailsLineItems"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note6SegmentedInformationDetailsLineItems_lbl" xml:lang="en-
US">Note 6 - Segmented Information (Details) [Line Items]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note6SegmentedInformationDetailsLineItems" 
xlink:to="biad_Note6SegmentedInformationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note7SubsequentEventandCommitmentDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note7SubsequentEventandCommitmentDetailsTable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note7SubsequentEventandCommitmentDetailsTable_lbl" 
xml:lang="en-US">Note 7 - Subsequent Event and Commitment (Details) 
[Table]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsTable" 
xlink:to="biad_Note7SubsequentEventandCommitmentDetailsTable_lbl"/>
    <loc xlink:type="locator" 
xlink:label="biad_Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note7SubsequentEventandCommitmentDetailsLineItems"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_Note7SubsequentEventandCommitmentDetailsLineItems_lbl" 
xml:lang="en-US">Note 7 - Subsequent Event and Commitment (Details) [Line 
Items]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:to="biad_Note7SubsequentEventandCommitmentDetailsLineItems_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_ClassOfWarrantOrRightsGranted_lbl1" xml:lang="en-US">Aggregate
amount of each class of warrants or rights granted.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ClassOfWarrantOrRightsGranted" 
xlink:to="biad_ClassOfWarrantOrRightsGranted_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_JointVentureAggregateProceedsProvidedByPartner_lbl0" 
xml:lang="en-US">The aggregate proceeds provided, in a series of payments to 
fund the joint venture.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_JointVentureAggregateProceedsProvidedByPartner" 
xlink:to="biad_JointVentureAggregateProceedsProvidedByPartner_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_JointVenturePartnerFundingDescription_lbl0" xml:lang="en-
US">Description of the joint venture funding provided by the Partner.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_JointVenturePartnerFundingDescription" 
xlink:to="biad_JointVenturePartnerFundingDescription_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_JointVenturePartnerProvisions_lbl0" xml:lang="en-
US">Description of the provisions governing the funding obligations of the 
Partner.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_JointVenturePartnerProvisions" 
xlink:to="biad_JointVenturePartnerProvisions_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_NumberOfEmployees_lbl0" xml:lang="en-US">The number of 
employees, including officers, issued allotted shares.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfEmployees" xlink:to="biad_NumberOfEmployees_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_NumberOfLivePatents_lbl0" xml:lang="en-US">The number of live 
patents.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfLivePatents" xlink:to="biad_NumberOfLivePatents_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_NumberOfPatentsNotRenewedAndAbandoned_lbl0" xml:lang="en-
US">The number of patents  not renewed and abandoned.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfPatentsNotRenewedAndAbandoned" 
xlink:to="biad_NumberOfPatentsNotRenewedAndAbandoned_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_NumberOfProprietaryTechnologyPlatforms_lbl0" xml:lang="en-
US">The number of proprietary technology platforms.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NumberOfProprietaryTechnologyPlatforms" 
xlink:to="biad_NumberOfProprietaryTechnologyPlatforms_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_PreferenceSharesPurchasedInSubsidiary_lbl0" xml:lang="en-
US">The number of preference shares purchased in subsidiary.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_PreferenceSharesPurchasedInSubsidiary" 
xlink:to="biad_PreferenceSharesPurchasedInSubsidiary_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_ProceedsFromJointVenturePartner_lbl0" xml:lang="en-US">The 
amount of proceeds received from a joint venture partner to fund the joint 
venture.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ProceedsFromJointVenturePartner" 
xlink:to="biad_ProceedsFromJointVenturePartner_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_WarrantsTermOfWarrants_lbl0" xml:lang="en-US">Term of warrants
exercisable in &apos;PnYnMnDTnHnMnS&apos; format, for example, 
&apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and 
thirteen days.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_WarrantsTermOfWarrants" 
xlink:to="biad_WarrantsTermOfWarrants_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_ForeignTranslationAxis_lbl0" xml:lang="en-US">Foreign 
Translation [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ForeignTranslationAxis" 
xlink:to="biad_ForeignTranslationAxis_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_ForeignTranslationAxis_lbl1" xml:lang="en-US">Information by 
foreign translation.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ForeignTranslationAxis" 
xlink:to="biad_ForeignTranslationAxis_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_NoncontrollingOwnerAxis_lbl0" xml:lang="en-US">Noncontrolling 
Owner [Axis]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NoncontrollingOwnerAxis" 
xlink:to="biad_NoncontrollingOwnerAxis_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_NoncontrollingOwnerAxis_lbl1" xml:lang="en-US">Name of non-
controlling owner.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_NoncontrollingOwnerAxis" 
xlink:to="biad_NoncontrollingOwnerAxis_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_AverageRateMember_lbl0" xml:lang="en-US">Average Rate 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_AverageRateMember" xlink:to="biad_AverageRateMember_lbl0"/>
    <label xlink:type="resource"
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_AverageRateMember_lbl1" xml:lang="en-US">Average foreign 
exchange rate used to translate amounts denominated in functional currency to 
reporting currency.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_AverageRateMember" xlink:to="biad_AverageRateMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="biad_Bio-
AMDHoldingsLimitedMember_lbl0" xml:lang="en-US">Bio- AMD Holdings Limited 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Bio-AMDHoldingsLimitedMember" xlink:to="biad_Bio-
AMDHoldingsLimitedMember_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="biad_Bio-
AMDHoldingsLimitedMember_lbl1" xml:lang="en-US">Name of investment.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_Bio-AMDHoldingsLimitedMember" xlink:to="biad_Bio-
AMDHoldingsLimitedMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_BioAMDIncMember_lbl0" xml:lang="en-US">Bio AMD Inc 
[Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_BioAMDIncMember" xlink:to="biad_BioAMDIncMember_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_BioAMDIncMember_lbl1" xml:lang="en-US">All the names of the 
entities being reported upon in a document. Any legal structure used to conduct 
activities or to hold assets. Some examples of such structures are corporations,
partnerships, limited liability companies, grantor trusts, and other trusts. 
This item does not include business and geographical segments which are included
in the geographical or business segments domains.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_BioAMDIncMember" xlink:to="biad_BioAMDIncMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_BioAMDUKHoldingsLimitedMember_lbl0" xml:lang="en-US">Bio AMDUK
Holdings Limited [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_BioAMDUKHoldingsLimitedMember" 
xlink:to="biad_BioAMDUKHoldingsLimitedMember_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_BioAMDUKHoldingsLimitedMember_lbl1" xml:lang="en-
US">Description of equity method investment.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_BioAMDUKHoldingsLimitedMember" 
xlink:to="biad_BioAMDUKHoldingsLimitedMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_DrAndrewMitchellMember_lbl0" xml:lang="en-US">Dr Andrew 
Mitchell [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_DrAndrewMitchellMember" 
xlink:to="biad_DrAndrewMitchellMember_lbl0"/>
<label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_DrAndrewMitchellMember_lbl1" xml:lang="en-US">Name of non-
controlling owner.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_DrAndrewMitchellMember" 
xlink:to="biad_DrAndrewMitchellMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_DrNasserDjennatiMember_lbl0" xml:lang="en-US">Dr Nasser 
Djennati [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_DrNasserDjennatiMember" 
xlink:to="biad_DrNasserDjennatiMember_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_DrNasserDjennatiMember_lbl1" xml:lang="en-US">Name of non-
controlling owner.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_DrNasserDjennatiMember" 
xlink:to="biad_DrNasserDjennatiMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_InterestInUKMedicalOperationsMember_lbl0" xml:lang="en-
US">Interest In UK Medical Operations [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_InterestInUKMedicalOperationsMember" 
xlink:to="biad_InterestInUKMedicalOperationsMember_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_InterestInUKMedicalOperationsMember_lbl1" xml:lang="en-
US">Name of investments.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_InterestInUKMedicalOperationsMember" 
xlink:to="biad_InterestInUKMedicalOperationsMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_MIDSMedicalLimitedMember_lbl0" xml:lang="en-US">MIDS Medical 
Limited [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_MIDSMedicalLimitedMember" 
xlink:to="biad_MIDSMedicalLimitedMember_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_MIDSMedicalLimitedMember_lbl1" xml:lang="en-US">Name of 
investment.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_MIDSMedicalLimitedMember" 
xlink:to="biad_MIDSMedicalLimitedMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_ThirdPartyMedicalDetectionDeviceDevloperMember_lbl0" 
xml:lang="en-US">Third Party Medical Detection Device Devloper [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ThirdPartyMedicalDetectionDeviceDevloperMember" 
xlink:to="biad_ThirdPartyMedicalDetectionDeviceDevloperMember_lbl0"/>
<label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_ThirdPartyMedicalDetectionDeviceDevloperMember_lbl1" 
xml:lang="en-US">Description of non-controlling owner.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_ThirdPartyMedicalDetectionDeviceDevloperMember" 
xlink:to="biad_ThirdPartyMedicalDetectionDeviceDevloperMember_lbl1"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember_lbl0" xml:lang="en-
US">WOCU Limited WL Formerly WDX Organization [Member]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_WOCULimitedWLFormerlyWDXOrganizationMember" 
xlink:to="biad_WOCULimitedWLFormerlyWDXOrganizationMember_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/documentation" 
xlink:label="biad_WOCULimitedWLFormerlyWDXOrganizationMember_lbl1" xml:lang="en-
US">Name of investment.</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_WOCULimitedWLFormerlyWDXOrganizationMember" 
xlink:to="biad_WOCULimitedWLFormerlyWDXOrganizationMember_lbl1"/>
    <loc xlink:type="locator" 
xlink:label="biad_DocumentAndEntityInformationAbstract" xlink:href="biad-
20160630.xsd#biad_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="biad_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-
US">Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="biad_DocumentAndEntityInformationAbstract" 
xlink:to="biad_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central 
Index Key</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityCentralIndexKey" 
xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0" 
xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to 
Noncontrolling Interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" 
xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived 
Intangible Assets, Net</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
<loc xlink:type="locator" xlink:label="dei_AmendmentFlag" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public 
Float</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End
Date</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_DocumentPeriodEndDate" 
xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant 
Name</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase
(Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income
(Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash 
Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-
gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0" 
xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing
Operations</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:to="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal
Period Focus</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_DocumentFiscalPeriodFocus" 
xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity 
Current Reporting Status</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityCurrentReportingStatus" 
xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity 
Attributable to Parent</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource"
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal 
Year Focus</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_DocumentFiscalYearFocus" 
xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase 
(Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-
gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl0" 
xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation 
Gain (Loss)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" 
xlink:to="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInDeferredCharges_lbl0" xml:lang="en-US">Increase 
(Decrease) in Deferred Charges</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-
gaap_IncreaseDecreaseInDeferredCharges_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase 
(Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-
gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net 
Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <loc xlink:type="locator" 
xlink:label="dei_EntityCommonStockSharesOutstanding" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity
Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityCommonStockSharesOutstanding" 
xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and
Equity</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-
gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal 
Year End Date</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_CurrentFiscalYearEndDate" 
xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including 
Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0
" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to 
Noncontrolling Interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:to="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0
"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cash 
and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to 
Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-
gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource"
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary 
Filers</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityVoluntaryFilers" 
xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer 
Category</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-
US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from 
Continuing Operations before Equity Method Investments, Income Taxes, 
Noncontrolling Interest</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" xlink:to="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-
US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity 
Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_EntityWellKnownSeasonedIssuer" 
xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase 
(Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-
gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
<label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase 
(Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-
gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease)
in Prepaid Expense</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-
gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase 
(Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" 
xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment 
Description</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" 
xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" 
xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-
gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>biad-20160630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by iC(tm) - CompSci Interactive Converter - 
http://www.compsciresources.com -->
<!-- Created: Mon Aug 15 16:32:52 EDT 2016 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" 
xmlns:xlink="http://www.w3.org/1999/xlink" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.xbrl.org/2003/linkbase 
http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedBalanceSheet" 
roleURI="http://www.bioamd.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedBalanceSheet_Parentheticals" 
roleURI="http://www.bioamd.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedIncomeStatement" 
roleURI="http://www.bioamd.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ShareholdersEquityType2or3" 
roleURI="http://www.bioamd.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ConsolidatedCashFlow" 
roleURI="http://www.bioamd.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note1NatureofOperationsandContinuanceofBusiness" 
roleURI="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusin
ess"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note2SummaryofSignificantAccountingPolicies" 
roleURI="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolicies"
/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note3Patents" 
roleURI="http://www.bioamd.com/role/Note3Patents"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note4RelatedPartyTransactions" 
roleURI="http://www.bioamd.com/role/Note4RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note5DeferredRevenue" 
roleURI="http://www.bioamd.com/role/Note5DeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note6SegmentedInformation" 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformation"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note7SubsequentEventandCommitment" 
roleURI="http://www.bioamd.com/role/Note7SubsequentEventandCommitment"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_AccountingPoliciesByPolicy"
roleURI="http://www.bioamd.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note3PatentsTables" 
roleURI="http://www.bioamd.com/role/Note3PatentsTables"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note6SegmentedInformationTables" 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ScheduleofFiniteLivedIntangibleAssetsTable" 
roleURI="http://www.bioamd.com/role/ScheduleofFiniteLivedIntangibleAssetsTable"/
>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_ScheduleofSegmentInformationTable" 
roleURI="http://www.bioamd.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note1NatureofOperationsandContinuanceofBusinessDetails" 
roleURI="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusin
essDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note2SummaryofSignificantAccountingPoliciesDetails" 
roleURI="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPoliciesD
etails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note3PatentsDetails" 
roleURI="http://www.bioamd.com/role/Note3PatentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note4RelatedPartyTransactionsDetails" 
roleURI="http://www.bioamd.com/role/Note4RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note5DeferredRevenueDetails" 
roleURI="http://www.bioamd.com/role/Note5DeferredRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note6SegmentedInformationDetails" 
roleURI="http://www.bioamd.com/role/Note6SegmentedInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#biad_r_Note7SubsequentEventandCommitmentDetails" 
roleURI="http://www.bioamd.com/role/Note7SubsequentEventandCommitmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="biad-
20160630.xsd#DocumentAndEntityInformation" 
roleURI="http://www.bioamd.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0.0"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0"
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5.0"
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" 
order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Assets"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_LiabilitiesCurrentAbstract" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" 
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-
gaap_OtherAccruedLiabilitiesCurrent" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" 
order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Liabilities"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" 
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" 
xlink:label="NatureOfOperationsAndContinuationOfBusinessNote1Abstract"
xlink:href="biad-
20160630.xsd#biad_NatureOfOperationsAndContinuationOfBusinessNote1Abstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" 
xlink:to="NatureOfOperationsAndContinuationOfBusinessNote1Abstract" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" 
xlink:label="SubsequentEventAndCommitmentNote7Abstract" xlink:href="biad-
20160630.xsd#biad_SubsequentEventAndCommitmentNote7Abstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" 
xlink:to="SubsequentEventAndCommitmentNote7Abstract" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_StockholdersEquityAbstract" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0"
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" 
order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-
gaap_RetainedEarningsAccumulatedDeficit" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:label="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StockholdersEquityAbstract" xlink:to="us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" 
order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_MinorityInterest" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_StockholdersEquity" order="6.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-
gaap_LiabilitiesAndStockholdersEquity" order="7.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0.0"/>
<presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockParOrStatedValuePerShare" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_PreferredStockParOrStatedValuePerShare" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" 
order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" 
order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" 
order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" 
order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" 
order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended"
xlink:role="http://www.bioamd.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0.0"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SellingGeneralAndAdministrativeExpense" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_OperatingExpensesAbstract" xlink:to="us-
gaap_SellingGeneralAndAdministrativeExpense" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0"
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:label="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" 
order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-
gaap_GainLossOnContractTermination" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestAndOtherIncome"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-
gaap_InterestAndOtherIncome" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="4.0" 
preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"
xlink:to="us-gaap_ProfitLoss" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:to="us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" 
xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" 
order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" 
order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" 
order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" 
order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-
gaap_AdditionalPaidInCapitalMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" 
order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AccumulatedOtherComprehensiveIncomeMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-
gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementEquityComponentsAxis" xlink:to="us-
gaap_NoncontrollingInterestMember" order="5.0"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
<loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" 
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax"
order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_MinorityInterestPeriodIncreaseDecrease" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" 
preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CommonStockSharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" 
order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ConsolidatedCashFlow">
<loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" 
order="0.0"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" 
xlink:label="CashFlowsFromOperatingActivitiesAbstract" xlink:href="biad-
20160630.xsd#biad_CashFlowsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="CashFlowsFromOperatingActivitiesAbstract" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_NetIncomeLoss" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:to="us-gaap_GainLossOnContractTermination" order="1.0" 
preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" 
preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInPrepaidExpense" order="1.0" 
preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredCharges"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInDeferredCharges" order="2.0" 
preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingAssets" order="3.0" 
preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccountsPayable"/>
<presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInAccountsPayable" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInAccruedLiabilities" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-
gaap_IncreaseDecreaseInDeferredRevenue" order="7.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3.0"
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" 
xlink:label="CashFlowsFromInvestingActivitiesAbstract" xlink:href="biad-
20160630.xsd#biad_CashFlowsFromInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="CashFlowsFromInvestingActivitiesAbstract" 
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-
gaap_PaymentsToAcquireIntangibleAssets" order="0.0" 
preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NetCashProvidedByUsedInInvestingActivities" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-
gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" 
order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_CashAndCashEquivalentsAtCarryingValue" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_CashAndCashEquivalentsAtCarryingValue_0" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_CashAndCashEquivalentsAtCarryingValue_0" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" 
xlink:label="NonCashInvestingAndFinancingActivitiesAbstract" xlink:href="biad-
20160630.xsd#biad_NonCashInvestingAndFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" 
xlink:to="NonCashInvestingAndFinancingActivitiesAbstract" order="6.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="NonCashInvestingAndFinancingActivitiesAbstract" xlink:to="us-
gaap_StockIssued1" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SupplementalCashFlowInformationAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementLineItems" xlink:to="us-
gaap_SupplementalCashFlowInformationAbstract" order="7.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestPaid"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid"
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBu
siness">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolici
es">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SignificantAccountingPoliciesTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_SignificantAccountingPoliciesTextBlock" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note3Patents">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="us-
gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note4RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_RelatedPartyTransactionsAbstract" xlink:to="us-
gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note5DeferredRevenue">
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_DeferredRevenueDisclosureTextBlock" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note6SegmentedInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SegmentReportingAbstract" xlink:to="us-
gaap_SegmentReportingDisclosureTextBlock" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note7SubsequentEventandCommitment">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc"
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock"
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_IntangibleAssetsFiniteLivedPolicy" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_RevenueRecognitionPolicyTextBlock" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RevenueRecognitionDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RevenueRecognitionDeferredRevenue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_RevenueRecognitionDeferredRevenue" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" xlink:to="us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="6.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note3PatentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
<!-- [WMV4]
[XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAK3hbE
VTXOd1U7+9iHKYBy25QKV69HOl1N03x1pff3iAB1LqBqnr0sN+tqK1E0BcI73NmfgSIRh6iGD5vsrsl9
RYcsrtOTcfcOgZ61HMsrI5H6weu3eaqe30ytHlB/OS0tP9YRbqwN+euj37cr3gxvl1GwyFts6WGY=] 
CSR-->
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note6SegmentedInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SegmentReportingAbstract" xlink:to="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ScheduleofFiniteLivedIntangibleAssetsTabl
e">
    <loc xlink:type="locator" 
xlink:label="ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:href="biad-
20160630.xsd#biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsGross" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc"
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="ScheduleOfFiniteLivedIntangibleAssetsAbstract" xlink:to="us-
gaap_FiniteLivedIntangibleAssetsNet" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/ScheduleofSegmentInformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentInformationAbstract"
xlink:href="biad-20160630.xsd#biad_ScheduleOfSegmentInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="ScheduleOfSegmentInformationAbstract" xlink:to="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-
gaap_StatementBusinessSegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" 
order="0.0"/>
    <loc xlink:type="locator" 
xlink:label="WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementBusinessSegmentsAxis" 
xlink:to="WOCULimitedWLFormerlyWDXOrganizationMember" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementBusinessSegmentsAxis" xlink:to="Bio-AMDHoldingsLimitedMember" 
order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_CorporateMember" 
order="3.0"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-
gaap_SegmentReportingInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_InterestAndOtherIncome"/>
    <presentationArc xlink:type="arc"
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-
gaap_InterestAndOtherIncome" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" 
order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Assets"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="2.0"
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBu
sinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" 
xlink:label="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note1NatureofOperationsandContinuanceofBusinessDetailsTable"/>
    <loc xlink:type="locator" 
xlink:label="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItem
s"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DisclosureTextBlockAbstract" 
xlink:to="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" 
xlink:label="WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="WOCULimitedWLFormerlyWDXOrganizationMember" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Bio-AMDHoldingsLimitedMember"
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="Bio-AMDHoldingsLimitedMember" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioAMDUKHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDUKHoldingsLimitedMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="BioAMDUKHoldingsLimitedMember" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestInUKMedicalOperationsMember" 
xlink:href="biad-20160630.xsd#biad_InterestInUKMedicalOperationsMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="InterestInUKMedicalOperationsMember" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MIDSMedicalLimitedMember" 
xlink:href="biad-20160630.xsd#biad_MIDSMedicalLimitedMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="MIDSMedicalLimitedMember" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" 
order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" 
order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="dei_LegalEntityAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateJointVentureMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="dei_LegalEntityAxis" xlink:to="us-gaap_CorporateJointVentureMember" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="NoncontrollingOwnerAxis" 
xlink:href="biad-20160630.xsd#biad_NoncontrollingOwnerAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="NoncontrollingOwnerAxis" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncontrollingOwnerDomain" 
xlink:href="biad-20160630.xsd#biad_NoncontrollingOwnerDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="NoncontrollingOwnerAxis" xlink:to="NoncontrollingOwnerDomain" 
order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrNasserDjennatiMember" 
xlink:href="biad-20160630.xsd#biad_DrNasserDjennatiMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="NoncontrollingOwnerAxis" xlink:to="DrNasserDjennatiMember" 
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrAndrewMitchellMember" 
xlink:href="biad-20160630.xsd#biad_DrAndrewMitchellMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="NoncontrollingOwnerAxis" xlink:to="DrAndrewMitchellMember" 
order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" 
xlink:label="ThirdPartyMedicalDetectionDeviceDevloperMember" xlink:href="biad-
20160630.xsd#biad_ThirdPartyMedicalDetectionDeviceDevloperMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="NoncontrollingOwnerAxis" 
xlink:to="ThirdPartyMedicalDetectionDeviceDevloperMember" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsTable" 
xlink:to="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
order="6.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" 
order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_LoansAndLeasesReceivableRelatedPartiesAdditions" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_LoansAndLeasesReceivableRelatedParties" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_LoansAndLeasesReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" 
xlink:label="PreferenceSharesPurchasedInSubsidiary" xlink:href="biad-
20160630.xsd#biad_PreferenceSharesPurchasedInSubsidiary"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="PreferenceSharesPurchasedInSubsidiary" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_SaleOfStockPricePerShare" order="5.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-
gaap-2016-01-31.xsd#us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent" order="6.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockDividendRatePercentage"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="7.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockRedemptionTerms" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockRedemptionTerms"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_PreferredStockRedemptionTerms" order="8.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-
31.xsd#us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfEmployees" xlink:href="biad-
20160630.xsd#biad_NumberOfEmployees"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="NumberOfEmployees" order="11.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" 
order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <presentationArc xlink:type="arc"
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="13.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DebtConversionConvertedInstrumentSharesIssued1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="14.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_Revenues"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_Revenues" order="15.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PaymentsToAcquireBusinessesGross"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="16.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_PreferredStockLiquidationPreferenceValue" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PreferredStockLiquidationPreferenceValue"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="17.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="19.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestPeriodIncreaseDecrease" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems"
xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" order="20.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" 
xlink:label="JointVentureAggregateProceedsProvidedByPartner" xlink:href="biad-
20160630.xsd#biad_JointVentureAggregateProceedsProvidedByPartner"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="JointVentureAggregateProceedsProvidedByPartner" order="21.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromJointVenturePartner" 
xlink:href="biad-20160630.xsd#biad_ProceedsFromJointVenturePartner"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="ProceedsFromJointVenturePartner" order="22.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" 
xlink:label="JointVenturePartnerFundingDescription" xlink:href="biad-
20160630.xsd#biad_JointVenturePartnerFundingDescription"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="JointVenturePartnerFundingDescription" order="23.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="JointVenturePartnerProvisions" 
xlink:href="biad-20160630.xsd#biad_JointVenturePartnerProvisions"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="JointVenturePartnerProvisions" order="24.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightsGranted" 
xlink:href="biad-20160630.xsd#biad_ClassOfWarrantOrRightsGranted"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="ClassOfWarrantOrRightsGranted" order="25.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WarrantsTermOfWarrants" 
xlink:href="biad-20160630.xsd#biad_WarrantsTermOfWarrants"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="WarrantsTermOfWarrants" order="26.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems" 
xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="28.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolici
esDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" 
xlink:label="Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:href="biad-
20160630.xsd#biad_Note2SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" 
xlink:label="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_AccountingPoliciesAbstract" 
xlink:to="Note2SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ForeignTranslationAxis" 
xlink:href="biad-20160630.xsd#biad_ForeignTranslationAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="ForeignTranslationAxis" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignTranslationDomain" 
xlink:href="biad-20160630.xsd#biad_ForeignTranslationDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="ForeignTranslationAxis" xlink:to="ForeignTranslationDomain" 
order="0.0"/>
    <loc xlink:type="locator" xlink:label="AverageRateMember" xlink:href="biad-
20160630.xsd#biad_AverageRateMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="ForeignTranslationAxis" xlink:to="AverageRateMember" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" 
xlink:label="WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="WOCULimitedWLFormerlyWDXOrganizationMember" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
<presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="Bio-AMDHoldingsLimitedMember" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioAMDUKHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDUKHoldingsLimitedMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="BioAMDUKHoldingsLimitedMember" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrencyAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CurrencyAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="us-gaap_CurrencyAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" 
xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-
31.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_GBP" 
xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-
31.xsd#currency_GBP"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_CurrencyAxis" xlink:to="currency_GBP" order="1.0"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsTable" 
xlink:to="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_GainLossOnContractTermination" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ForeignCurrencyExchangeRateTranslation1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note2SummaryofSignificantAccountingPoliciesDetailsLineItems" 
xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="4.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note3PatentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfLivePatents" 
xlink:href="biad-20160630.xsd#biad_NumberOfLivePatents"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DisclosureTextBlockAbstract" xlink:to="NumberOfLivePatents" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" 
xlink:label="NumberOfProprietaryTechnologyPlatforms" xlink:href="biad-
20160630.xsd#biad_NumberOfProprietaryTechnologyPlatforms"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DisclosureTextBlockAbstract" 
xlink:to="NumberOfProprietaryTechnologyPlatforms" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" 
xlink:label="NumberOfPatentsNotRenewedAndAbandoned" xlink:href="biad-
20160630.xsd#biad_NumberOfPatentsNotRenewedAndAbandoned"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DisclosureTextBlockAbstract" 
xlink:to="NumberOfPatentsNotRenewedAndAbandoned" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note4RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" 
xlink:label="Note4RelatedPartyTransactionsDetailsTable" xlink:href="biad-
20160630.xsd#biad_Note4RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" 
xlink:label="Note4RelatedPartyTransactionsDetailsLineItems" xlink:href="biad-
20160630.xsd#biad_Note4RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_RelatedPartyTransactionsAbstract" 
xlink:to="Note4RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsTable" xlink:to="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="Bio-AMDHoldingsLimitedMember" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsTable" xlink:to="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AffiliatedEntityMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_AffiliatedEntityMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_AffiliatedEntityMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChiefFinancialOfficerMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_ChiefFinancialOfficerMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChiefExecutiveOfficerMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_ChiefExecutiveOfficerMember" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresidentMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_PresidentMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-
gaap_PresidentMember" order="4.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsTable" 
xlink:to="dei_LegalEntityAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioAMDIncMember" xlink:href="biad-
20160630.xsd#biad_BioAMDIncMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="dei_LegalEntityAxis" xlink:to="BioAMDIncMember" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsTable" 
xlink:to="Note4RelatedPartyTransactionsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_RelatedPartyTransactionAmountsOfTransaction" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_RelatedPartyTransactionAmountsOfTransaction" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty"
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CostsAndExpensesRelatedParty"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_CostsAndExpensesRelatedParty" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_OperatingLeasesRentExpenseMinimumRentals" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note4RelatedPartyTransactionsDetailsLineItems" xlink:to="us-
gaap_OperatingLeasesRentExpenseMinimumRentals" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note5DeferredRevenueDetails">
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_DeferredRevenueCurrent" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DeferredCostsCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_DeferredCostsCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_DeferredCostsCurrentAndNoncurrent" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_GainLossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_DeferredRevenueDisclosureAbstract" xlink:to="us-
gaap_GainLossOnContractTermination" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note6SegmentedInformationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" 
xlink:label="Note6SegmentedInformationDetailsTable" xlink:href="biad-
20160630.xsd#biad_Note6SegmentedInformationDetailsTable"/>
    <loc xlink:type="locator" 
xlink:label="Note6SegmentedInformationDetailsLineItems" xlink:href="biad-
20160630.xsd#biad_Note6SegmentedInformationDetailsLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SegmentReportingAbstract" xlink:to="Note6SegmentedInformationDetailsTable" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note6SegmentedInformationDetailsTable" xlink:to="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/us-
gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-
gaap_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" 
xlink:label="WOCULimitedWLFormerlyWDXOrganizationMember" xlink:href="biad-
20160630.xsd#biad_WOCULimitedWLFormerlyWDXOrganizationMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="WOCULimitedWLFormerlyWDXOrganizationMember" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Bio-AMDHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_Bio-AMDHoldingsLimitedMember"/>
<presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="Bio-AMDHoldingsLimitedMember" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioAMDUKHoldingsLimitedMember" 
xlink:href="biad-20160630.xsd#biad_BioAMDUKHoldingsLimitedMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" 
xlink:to="BioAMDUKHoldingsLimitedMember" order="3.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note6SegmentedInformationDetailsTable" 
xlink:to="Note6SegmentedInformationDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note6SegmentedInformationDetailsLineItems" xlink:to="us-
gaap_NumberOfOperatingSegments" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-
01-31.xsd#us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note6SegmentedInformationDetailsLineItems" xlink:to="us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_EquityMethodInvestmentOwnershipPercentage" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note6SegmentedInformationDetailsLineItems" xlink:to="us-
gaap_EquityMethodInvestmentOwnershipPercentage" order="2.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/Note7SubsequentEventandCommitmentDetails"
>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" 
xlink:label="Note7SubsequentEventandCommitmentDetailsTable" xlink:href="biad-
20160630.xsd#biad_Note7SubsequentEventandCommitmentDetailsTable"/>
    <loc xlink:type="locator" 
xlink:label="Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:href="biad-
20160630.xsd#biad_Note7SubsequentEventandCommitmentDetailsLineItems"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SubsequentEventsAbstract" 
xlink:to="Note7SubsequentEventandCommitmentDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note7SubsequentEventandCommitmentDetailsTable" 
xlink:to="dei_LegalEntityAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_CorporateJointVentureMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="dei_LegalEntityAxis" xlink:to="us-gaap_CorporateJointVentureMember" 
order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note7SubsequentEventandCommitmentDetailsTable" xlink:to="us-
gaap_SubsequentEventTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" 
order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-
gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" 
order="1.0"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note7SubsequentEventandCommitmentDetailsTable" 
xlink:to="Note7SubsequentEventandCommitmentDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightsGranted" 
xlink:href="biad-20160630.xsd#biad_ClassOfWarrantOrRightsGranted"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:to="ClassOfWarrantOrRightsGranted" order="0.0" 
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsTermOfWarrants" 
xlink:href="biad-20160630.xsd#biad_WarrantsTermOfWarrants"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note7SubsequentEventandCommitmentDetailsLineItems" 
xlink:to="WarrantsTermOfWarrants" order="1.0" 
preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" 
xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="Note7SubsequentEventandCommitmentDetailsLineItems" xlink:to="us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0"
preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" 
xlink:role="http://www.bioamd.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract"
xlink:href="biad-20160630.xsd#biad_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityRegistrantName" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" 
order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" 
order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_CurrentFiscalYearEndDate" order="4.0"/>
    <loc xlink:type="locator" 
xlink:label="dei_EntityCommonStockSharesOutstanding" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityCommonStockSharesOutstanding" order="5.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityPublicFloat" order="6.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" 
order="7.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_AmendmentDescription" order="8.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc"
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityCentralIndexKey" order="9.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityCurrentReportingStatus" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityVoluntaryFilers" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityFilerCategory" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_EntityWellKnownSeasonedIssuer" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_DocumentPeriodEndDate" order="14.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_DocumentFiscalYearFocus" order="15.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" 
xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-
31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" 
xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" 
xlink:from="DocumentAndEntityInformationAbstract" 
xlink:to="dei_DocumentFiscalPeriodFocus" order="16.0"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !2 / # 2(  A$! Q$!_\0
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M_J:SKK6Q#"?* #_PCJ%]_<UX>+Y)Q]IBM*:Z=9>B_K]1MF;KTMI;W#"Y)#X
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MO&MH0;B[#?9'F8CJ9/EP#Q]>*:]U<F[B\R2Y64S0@1K&=AC(7<3QZEN<\8%
MCH\T5S=G'*8+:"&282!YU9Y!DQM@XY(X[&F27=_+!#/-YMO%+(5<8*E-JX[
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)%% !1110!__9
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6816947776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 
200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Aug. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_DocumentAndEntityInformationAbstract', window );"><strong>Document 
and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bio-AMD Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End 
Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock,
Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,975,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001370030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this,
'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting 
Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known 
Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year 
Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period 
Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>If the value is true, then the document is an amendment to
previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>End date of current fiscal year in the format --MM-
DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>This is focus fiscal period of the document report. For a 
first quarter 2006 quarterly report, which may also provide financial 
information from prior periods, the first fiscal quarter should be given as the 
fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, 
CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>This is focus fiscal year of the document report in CCYY 
format. For a 2006 annual report, which may also provide financial information 
from prior periods, fiscal 2006 should be given as the fiscal year focus. 
Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);"
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The end date of the period reflected on the cover page if 
a periodic report. For all other reports and registration statements containing 
historical data, it is the date up through which that historical data is 
presented.  If there is no historical data in the report, use the filing date. 
The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 
485BPOS, etc). The document type is limited to the same value as the supporting 
SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities 
that have filed disclosures with the SEC. It is commonly abbreviated as 
CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name 
Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Indicate number of shares or other units outstanding of 
each of registrant's classes of capital or common stock or other ownership 
interests, if and as stated on cover of related periodic report. Where multiple 
classes or units exist define each class/interest by adding class of stock items
such as Common Class A [Member], Common Class B [Member] or Partnership Interest
[Member] onto the Instrument [Domain] of the Entity Listings, 
Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed 
all reports required to be filed by Section 13 or 15(d) of the Securities 
Exchange Act of 1934 during the preceding 12 months (or for such shorter period 
that registrants were required to file such reports), and (2) have been subject 
to such filing requirements for the past 90 days. This information should be 
based on the registrant's current or most recent filing containing the related 
disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Indicate whether the registrant is one of the following: 
(1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, 
(4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting 
Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of 
the Exchange Act. This information should be based on the registrant's current 
or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The exact name of the entity filing the report as 
specified in its charter, which is required by forms filed with the 
SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name 
Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required 
to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);"
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known 
seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form 
Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-
1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6817273696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 
200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 68,754<span></span>
</td>
<td class="nump">$ 437,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="nump">5,359<span></span>
</td>
<td class="nump">12,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">8,068<span></span>
</td>
<td class="nump">12,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DeferredCostsCurrent', window );">Deferred charges (Note 1)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">645,534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">82,181<span></span>
</td>
<td class="nump">1,108,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, 
net</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IntangibleAssetsNetExcludingGoodwill', window );">Patents (Note 3)</a></td>
<td class="nump">165,573<span></span>
</td>
<td class="nump">165,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_Assets', window );">Total Assets</a></td>
<td class="nump">247,894<span></span>
</td>
<td class="nump">1,274,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_LiabilitiesCurrentAbstract', window );"><strong>Current 
Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">34,114<span></span>
</td>
<td class="nump">62,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">17,575<span></span>
</td>
<td class="nump">23,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">17,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DeferredRevenueCurrent', window );">Deferred revenue (Note 1)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">950,402<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">52,450<span></span>
</td>
<td class="nump">1,053,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' 
Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockValue', window );">Preferred stock, 10,000,000 shares 
authorized, $0.001 par value, nil shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CommonStockValue', window );">Common stock, 500,000,000 shares authorized, 
$0.001 par value, 45,975,966 shares issued and outstanding</a></td>
<td class="nump">45,976<span></span>
</td>
<td class="nump">45,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">42,611,186<span></span>
</td>
<td class="nump">42,589,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">35,571<span></span>
</td>
<td class="nump">73,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit</a></td>
<td class="num">(41,384,326)<span></span>
</td>
<td class="num">(41,331,858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', 
window );">Total Bio-AMD, Inc. Stockholders' Equity</a></td>
<td class="nump">1,308,407<span></span>
</td>
<td class="nump">1,377,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(1,112,963)<span></span>
</td>
<td class="num">(1,156,064)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">195,444<span></span>
</td>
<td class="nump">221,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and 
Stockholders' Equity</a></td>
<td class="nump">$ 247,894<span></span>
</td>
<td class="nump">$ 1,274,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Carrying value as of the balance sheet date of liabilities
incurred (and for which invoices have typically been received) and payable to 
vendors for goods and services received that are used in an entity's business.
Used to reflect the current portion of the liabilities (due within one year or 
within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount due from customers or clients, within one year of 
the balance sheet date (or the normal operating cycle, whichever is longer), for
goods or services (including trade receivables) that have been delivered or sold
in the normal course of business, reduced to the estimated net realizable fair 
value by an allowance established by the entity of the amount it deems uncertain
of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Carrying value as of the balance sheet date of obligations
incurred and payable, pertaining to costs that are statutory in nature, are 
incurred on contractual obligations, or accumulate over time and for which 
invoices have not yet been received or will not be rendered. Examples include 
taxes, interest, rent and utilities. Used to reflect the current portion of the 
liabilities (due within one year or within the normal operating cycle if 
longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Accumulated adjustment, net of tax, that results from the 
process of translating subsidiary financial statements and foreign equity 
investments into the reporting currency from the functional currency of the 
reporting entity, net of reclassification of realized foreign currency 
translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 14<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-
108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-
108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-
108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> 
-SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32022-
110900<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-
108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> 
-SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-
110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustment
NetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Excess of issue price over par or stated value of the 
entity's capital stock and amounts received from other transactions involving 
the entity's stock or stockholders. Includes adjustments to additional paid in 
capital. Some examples of such adjustments include recording the issuance of 
debt with a beneficial conversion feature and certain tax consequences of equity
instruments awarded to employees. Use this element for the aggregate amount of 
additional paid-in capital associated with common and preferred stock. For 
additional paid-in capital associated with only common stock, use the element 
additional paid in capital, common stock. For additional paid-in capital 
associated with only preferred stock, use the element additional paid in 
capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);"
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date 
of all assets that are recognized. Assets are probable future economic benefits 
obtained or controlled by an entity as a result of past transactions or 
events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-
122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> 
-SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-
03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-
122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date 
of all assets that are expected to be realized in cash, sold, or consumed within
one year (or the normal operating cycle, if longer). Assets are probable future 
economic benefits obtained or controlled by an entity as a result of past 
transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-
107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-
107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of currency on hand as well as demand deposits with
banks or financial institutions. Includes other kinds of accounts that have the 
general characteristics of demand deposits. Also includes short-term, highly 
liquid investments that are both readily convertible to known amounts of cash 
and so near their maturity that they present insignificant risk of changes in 
value because of changes in interest rates. Excludes cash and cash equivalents 
within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Cash<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-
107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-
108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash 
Equivalents<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Aggregate par or stated value of issued nonredeemable 
common stock (or common stock redeemable solely at the option of the issuer). 
This item includes treasury stock repurchased by the entity. Note: elements for 
number of nonredeemable common shares, par value and other disclosure concepts 
are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date 
of deferred costs capitalized at the end of the reporting period that are 
expected to be charged against earnings within one year or the normal operating 
cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The carrying amount of consideration received or 
receivable as of the balance sheet date on potential earnings that were not 
recognized as revenue in conformity with GAAP, and which are expected to be 
recognized as such within one year or the normal operating cycle, if longer, 
including sales, license fees, and royalties, but excluding interest 
income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-
107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 
13.A.4(a).Q1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(b).Q2)<br> -URI
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(b))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(c).Q3)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Sum of the carrying amounts of all intangible assets, 
excluding goodwill, as of the balance sheet date, net of accumulated 
amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 
45<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-
109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> 
-SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br>
-URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-
109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date 
of all liabilities that are recognized. Liabilities are probable future 
sacrifices of economic benefits arising from present obligations of an entity to
transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of liabilities and equity items, including the 
portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-
122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> 
-SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-
03(a)(25))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-
122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of 
receivables from officers, directors, owners, and affiliates of the entity which
is directly or indirectly attributable to that ownership interest in subsidiary 
equity which is not attributable to the parent (that is, noncontrolling 
interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-
122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> 
-SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-
03(a)(24))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-
122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of expenses incurred but not yet paid classified as
other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 9<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-
107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary 
Current Liabilities<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 6<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-
107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-
107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Aggregate par or stated value of issued nonredeemable 
preferred stock (or preferred stock redeemable solely at the option of the 
issuer). This item includes treasury stock repurchased by the entity. Note: 
elements for number of nonredeemable preferred shares, par value and other 
disclosure concepts are in another section within stockholders' 
equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of asset related to consideration paid in advance 
for costs that provide economic benefits within a future period of one year or 
the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-
107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> 
-SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-
108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary 
Current Assets<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-
107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount after accumulated depreciation, depletion and 
amortization of physical assets used in the normal conduct of business to 
produce goods and services and not intended for resale. Examples include, but 
are not limited to, land, buildings, machinery and equipment, office equipment, 
and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br>
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> 
-SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-
03(a)(8))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-
122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The cumulative amount of the reporting entity's 
undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-
122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-
04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-
122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(30)(a)(3))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0"
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of 
receivables from officers, directors, owners, and affiliates of the entity which
are attributable to the parent. The amount of the economic entity's 
stockholders' equity attributable to the parent excludes the amount of 
stockholders' equity which is allocable to that ownership interest in subsidiary
equity which is not attributable to the parent (noncontrolling interest, 
minority interest). This excludes temporary equity and is sometimes called 
permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 
4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-
122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of stockholders' equity (deficit), net of 
receivables from officers, directors, owners, and affiliates of the entity,
attributable to both the parent and noncontrolling interests. Amount excludes 
temporary equity. Alternate caption for the concept is permanent 
equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
55<br> -Paragraph 4I<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-
111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-
111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-
111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
(e.nextSibling.style.display=='none') {
if
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6817027792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 
200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / 
shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares 
authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par 
value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockSharesIssued', window );">Preferred stock, shares 
issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares 
outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par Value 
(in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares 
Authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">45,975,966<span></span>
</td>
<td class="nump">45,975,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares 
Outstanding</a></td>
<td class="nump">45,975,966<span></span>
</td>
<td class="nump">45,975,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Face amount or stated value per share of common 
stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The maximum number of common shares permitted to be issued
by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Total number of common shares of an entity that have been 
sold or granted to shareholders (includes common shares that were issued, 
repurchased and remain in the treasury). These shares represent capital invested
by the firm's shareholders and owners, and may be all or only a portion of the
number of shares authorized. Shares issued include shares outstanding and shares
held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Number of shares of common stock outstanding. Common stock
represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-
112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Face amount or stated value per share of preferred stock 
nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The maximum number of nonredeemable preferred shares (or 
preferred stock redeemable solely at the option of the issuer) permitted to be 
issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Total number of nonredeemable preferred shares (or 
preferred stock redeemable solely at the option of the issuer) issued to 
shareholders (includes related preferred shares that were issued, repurchased, 
and remain in the treasury). May be all or portion of the number of preferred 
shares authorized. Excludes preferred shares that are classified as 
debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Aggregate share number for all nonredeemable preferred 
stock (or preferred stock redeemable solely at the option of the issuer) held by
stockholders. Does not include preferred shares that have been 
repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6817060288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 
200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND 
COMPREHENSIVE LOSS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OperatingExpensesAbstract', window );"><strong>Operating 
expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SellingGeneralAndAdministrativeExpense', window );">General and 
administrative charges (Note 4)</a></td>
<td class="nump">$ 103,847<span></span>
</td>
<td class="nump">$ 354,863<span></span>
</td>
<td class="nump">$ 257,594<span></span>
</td>
<td class="nump">$ 578,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">103,847<span></span>
</td>
<td class="nump">354,863<span></span>
</td>
<td class="nump">257,594<span></span>
</td>
<td class="nump">578,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments', window );">Net loss before other 
income</a></td>
<td class="num">(103,847)<span></span>
</td>
<td class="num">(354,863)<span></span>
</td>
<td class="num">(257,594)<span></span>
</td>
<td class="num">(578,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other 
income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_GainLossOnContractTermination', window );">Gain on termination of research 
agreement (Note 5)</a></td>
<td class="nump">248,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">248,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">144,717<span></span>
</td>
<td class="num">(354,132)<span></span>
</td>
<td class="num">(8,558)<span></span>
</td>
<td class="num">(576,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss 
(income) attributable to the non-controlling interest</a></td>
<td class="num">(48,574)<span></span>
</td>
<td class="nump">7,502<span></span>
</td>
<td class="num">(43,910)<span></span>
</td>
<td class="nump">13,554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss 
attributable to Bio-AMD, Inc. common shareholders</a></td>
<td class="nump">96,143<span></span>
</td>
<td class="num">(346,630)<span></span>
</td>
<td class="num">(52,468)<span></span>
</td>
<td class="num">(563,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', 
window );"><strong>Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">144,717<span></span>
</td>
<td class="num">(354,132)<span></span>
</td>
<td class="num">(8,558)<span></span>
</td>
<td class="num">(576,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax', window );">Foreign currency translation adjustment, net of 
tax</a></td>
<td class="num">(14,848)<span></span>
</td>
<td class="nump">26,402<span></span>
</td>
<td class="num">(17,054)<span></span>
</td>
<td class="num">(2,875)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">129,869<span></span>
</td>
<td class="num">(327,730)<span></span>
</td>
<td class="num">(25,612)<span></span>
</td>
<td class="num">(579,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', 
window );">Comprehensive (income)/loss attributable to the non-controlling 
interest</a></td>
<td class="num">(62,547)<span></span>
</td>
<td class="nump">19,990<span></span>
</td>
<td class="num">(64,529)<span></span>
</td>
<td class="nump">16,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to
the Bio-AMD, Inc. common shareholders</a></td>
<td class="nump">$ 67,322<span></span>
</td>
<td class="num">$ (307,740)<span></span>
</td>
<td class="num">$ (90,141)<span></span>
</td>
<td class="num">$ (563,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share 
attributable to Bio-AMD, Inc. common shareholders - basic and diluted (in 
Dollars per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', 
window );">Weighted average number of common shares outstanding - basic and 
diluted (in Shares)</a></td>
<td class="nump">45,975,966<span></span>
</td>
<td class="nump">45,103,998<span></span>
</td>
<td class="nump">45,975,966<span></span>
</td>
<td class="nump">44,906,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount after tax of increase (decrease) in equity from 
transactions and other events and circumstances from net income and other 
comprehensive income, attributable to parent entity. Excludes changes in equity 
resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> 
-URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 5<br> -URI
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-
108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net 
Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount after tax of increase (decrease) in equity from 
transactions and other events and circumstances from net income (loss) and other
comprehensive income (loss), attributable to noncontrolling interests. Excludes 
changes in equity resulting from investments by owners and distributions to 
owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 21<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613674-
111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-
111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-
111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount after tax of increase (decrease) in equity from 
transactions and other events and circumstances from net income and other 
comprehensive income. Excludes changes in equity resulting from investments by 
owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 19<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-
111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-
111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInte
rest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The amount of net income or loss for the period per each 
share in instances when basic and diluted earnings per share are the same amount
and reported as a single line item on the face of the financial statements.  
Basic earnings per share is the amount of net income or loss for the period per 
each share of common stock or unit outstanding during the reporting period.  
Diluted earnings per share includes the amount of net income or loss for the 
period available to each share of common stock or common unit outstanding during
the reporting period and to each share or unit that would have been outstanding 
assuming the issuance of common shares or units for all dilutive potential 
common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Gain (loss) related to the termination of a contract 
between the parties. The termination may be due to many causes including early 
termination of a lease by a lessee, a breach of contract by one party, or a
failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-
110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of income (loss) from continuing operations before 
deduction of income tax expense (benefit) and income (loss) attributable to 
noncontrolling interest, and addition of income (loss) from equity method 
investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-
122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncom
eLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The amount of interest income and other income recognized 
during the period. Included in this element is interest derived from investments
in debt securities, cash and cash equivalents, and other investments which 
reflect the time value of money or transactions in which the payments are for 
the use or forbearance of money and other income from ancillary business-related
activities (that is, excluding major activities considered part of the normal 
operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The portion of profit or loss for the period, net of 
income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Net Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-
109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-
04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-
122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-
04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-
122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other 
Comprehensive Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling
interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
55<br> -Paragraph 4J<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-
111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI
http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-
111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Net income after adjustments for dividends on preferred 
stock (declared in the period) and/or cumulative preferred stock (accumulated 
for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section
45<br> -Paragraph 11<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-
109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Generally recurring costs associated with normal 
operations except for the portion of these expenses which can be clearly related
to production and included in cost of sales or services. Includes selling, 
general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount after tax and reclassification adjustments of gain 
(loss) on foreign currency translation adjustments, foreign currency 
transactions designated and effective as economic hedges of a net investment in 
a foreign entity and intra-entity foreign currency transactions that are of a 
long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 
45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI
http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-
110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-
108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
entNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The consolidated profit or loss for the period, net of 
income taxes, including the portion attributable to the noncontrolling 
interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
55<br> -Paragraph 4K<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-
111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-
111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI
http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-
111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-
111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br>
-SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI
http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-
111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The aggregate total costs related to selling a firm's 
product and services, as well as all other general and administrative expenses. 
Direct selling expenses (for example, credit, warranty, and advertising) are 
expenses that can be directly linked to the sale of specific products. Indirect 
selling expenses are expenses that cannot be directly linked to the sale of 
specific products, for example telephone expenses, Internet, and postal charges.
General and administrative expenses include salaries of non-sales personnel, 
rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> 
-SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-
108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Average number of shares or units issued and outstanding 
that are used in calculating basic and diluted earnings per share 
(EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6817081376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 
200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF EQUITY (Unaudited) - 6 
months ended Jun. 30, 2016 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 221,056<span></span>
</td>
<td class="nump">$ 45,976<span></span>
</td>
<td class="nump">$ 42,589,759<span></span>
</td>
<td class="nump">$ 73,243<span></span>
</td>
<td class="num">$ (41,331,858)<span></span>
</td>
<td class="num">$ (1,156,064)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 
2015</a></td>
<td class="nump">45,975,966<span></span>
</td>
<td class="nump">45,975,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income 
(loss)</a></td>
<td class="num">$ (17,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries', 
window );">Subsidiary preferred dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in ownership 
interest of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,468)<span></span>
</td>
<td class="nump">43,910<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StockholdersEquity', window );">Balance at Jun. 30, 2016</a></td>
<td class="nump">$ 195,444<span></span>
</td>
<td class="nump">$ 45,976<span></span>
</td>
<td class="nump">$ 42,611,186<span></span>
</td>
<td class="nump">$ 35,571<span></span>
</td>
<td class="num">$ (41,384,326)<span></span>
</td>
<td class="num">$ (1,112,963)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 
2016</a></td>
<td class="nump">45,975,966<span></span>
</td>
<td class="nump">45,975,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>This element represents disclosure of the aggregate cash 
dividends paid to the entity by consolidated subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(b))<br> -URI
http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-
122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> 
-SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-
06)<br> -URI http://asc.fasb.org/extlink&amp;oid=6882215&amp;loc=d3e537971-
122884<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Number of shares of common stock outstanding. Common stock
represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-
112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling 
interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 16<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-
111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The portion of profit or loss for the period, net of 
income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Net Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-
109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-
04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-
122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-
04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-
122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other 
Comprehensive Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);"
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount after tax and reclassification adjustments of other
comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-
112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-
108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-
108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> 
-SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-
108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of 
receivables from officers, directors, owners, and affiliates of the entity which
are attributable to the parent. The amount of the economic entity's 
stockholders' equity attributable to the parent excludes the amount of 
stockholders' equity which is allocable to that ownership interest in subsidiary
equity which is not attributable to the parent (noncontrolling interest,
minority interest). This excludes temporary equity and is sometimes called 
permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 
4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-
122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-
gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-
gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-
gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-
gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-
gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-
gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-
gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-
gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-
gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-
gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6742727856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 
200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - 
USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_CashFlowsFromOperatingActivitiesAbstract', window );"><strong>Cash 
flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,558)<span></span>
</td>
<td class="num">$ (576,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract', window );"><strong>Adjustments to reconcile net loss to net cash 
used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AmortizationOfDeferredCharges', window );">Amortization of prepaid stock 
based fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_GainLossOnContractTermination', window );">Gain on termination of research 
agreement</a></td>
<td class="num">(248,074)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ShareBasedCompensation', window );">Stock based consulting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in 
operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInAccountsReceivable', window );">Amounts 
receivable</a></td>
<td class="nump">7,613<span></span>
</td>
<td class="nump">5,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">4,402<span></span>
</td>
<td class="num">(7,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred charges</a></td>
<td class="num">(46,878)<span></span>
</td>
<td class="num">(397,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Security deposit and 
other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(28,035)<span></span>
</td>
<td class="nump">102,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued 
liabilities</a></td>
<td class="num">(5,664)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other 
liabilites</a></td>
<td class="num">(16,555)<span></span>
</td>
<td class="num">(3,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">978,076<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', 
window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(341,749)<span></span>
</td>
<td class="nump">289,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_CashFlowsFromInvestingActivitiesAbstract', window );"><strong>Cash 
flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PaymentsToAcquireIntangibleAssets', window );">Patent expenditures</a></td>
<td class="num">(18,824)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in 
Investing Activities</a></td>
<td class="num">(18,824)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations', 
window );">Effects of exchange rate changes on cash</a></td>
<td class="num">(8,073)<span></span>
</td>
<td class="nump">16,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Change in 
Cash</a></td>
<td class="num">(368,646)<span></span>
</td>
<td class="nump">305,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, beginning of 
period</a></td>
<td class="nump">437,400<span></span>
</td>
<td class="nump">717,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, end of 
period</a></td>
<td class="nump">68,754<span></span>
</td>
<td class="nump">1,023,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_NonCashInvestingAndFinancingActivitiesAbstract', 
window );"><strong>Non-cash Investing and Financing 
activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StockIssued1', window );">Common stock issued for prepaid services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary 
disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_InterestPaid', window );">Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IncomeTaxesPaid', window );">Income tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_CashFlowsFromInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_CashFlowsFromInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_CashFlowsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_CashFlowsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_NonCashInvestingAndFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_NonCashInvestingAndFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitie
sAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The amount of amortization of deferred charges applied 
against earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of currency on hand as well as demand deposits with
banks or financial institutions. Includes other kinds of accounts that have the 
general characteristics of demand deposits. Also includes short-term, highly 
liquid investments that are both readily convertible to known amounts of cash 
and so near their maturity that they present insignificant risk of changes in 
value because of changes in interest rates. Excludes cash and cash equivalents 
within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Cash<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-
107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-
108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash 
Equivalents<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of increase (decrease) in cash and cash 
equivalents. Cash and cash equivalents are the amount of currency on hand as 
well as demand deposits with banks or financial institutions. Includes other 
kinds of accounts that have the general characteristics of demand deposits. Also
includes short-term, highly liquid investments that are both readily convertible
to known amounts of cash and so near their maturity that they present 
insignificant risk of changes in value because of changes in interest rates. 
Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 24<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-
108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> 
-SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-
110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData"
style="display: none;" id="defref_us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The effect of exchange rate changes on cash balances in 
continuing operations held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 24<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-
108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> 
-SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-
110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Gain (loss) related to the termination of a contract 
between the parties. The termination may be due to many causes including early 
termination of a lease by a lessee, a breach of contract by one party, or a 
failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-
110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br>
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The amount of cash paid during the current period to 
foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-
108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The increase (decrease) during the reporting period in the
aggregate amount of liabilities incurred (and for which invoices have typically 
been received) and payable to vendors for goods and services received that are 
used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The increase (decrease) during the reporting period in
amount due within one year (or one business cycle) from customers for the credit
sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The increase (decrease) during the reporting period in the
aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The increase (decrease) during the reporting period in the
value of expenditures made during the current reporting period for benefits that
will be received over a period of years. Deferred charges differ from prepaid 
expenses in that they usually extend over a long period of time and may or may 
not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);"
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The increase (decrease) during the reporting period, 
excluding the portion taken into income, in the liability reflecting revenue yet
to be earned for which cash or other forms of consideration was received or 
recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of increase (decrease) in operating assets 
classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">-
Definition</a><div><p>Amount of increase (decrease) in operating liabilities 
classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The increase (decrease) during the reporting period in the
amount of outstanding money paid in advance for goods or services that bring 
economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The amount of cash paid for interest during the 
period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-
108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of cash inflow (outflow) from investing activities,
including discontinued operations. Investing activity cash flows include making 
and collecting loans and acquiring and disposing of debt or equity instruments 
and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 24<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-
108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of cash inflow (outflow) from operating activities,
excluding discontinued operations. Operating activity cash flows include 
transactions, adjustments, and changes in value not defined as investing or 
financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 24<br> -URI
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-
108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The portion of profit or loss for the period, net of 
income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Net Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-
109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-
04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-
122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br>
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-
04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-
122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other 
Comprehensive Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The cash outflow to acquire asset without physical form 
usually arising from contractual or other legal rights, excluding 
goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-
108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary 
Investing Activities<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The aggregate amount of noncash, equity-based employee 
remuneration. This may include the value of stock or unit options, amortization 
of restricted stock or units, and adjustment for officers' compensation. As 
noncash, this element is an add back when calculating net cash generated by 
operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The fair value of stock issued in noncash financing 
activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 5<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-
108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-
108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6808129696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1
- Nature of Operations and Continuance of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Note 
1&#160;&#x2013; Nature of Operations and Continuance of Business</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">General</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">The accompanying unaudited condensed consolidated 
financial statements have been prepared pursuant to the rules and regulations of
the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&#160;Certain 
information and note disclosures normally included in annual consolidated 
financial statements prepared in accordance with generally accepted accounting 
principles have been condensed or omitted pursuant to those rules and 
regulations, although the Company believes that the disclosures made are 
adequate to make the information not misleading.</div><br/><div style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-
ALIGN: justify">In the opinion of management, the unaudited condensed 
consolidated financial statements have been prepared on the same basis as the 
annual consolidated financial statements and reflect all adjustments, which 
include only normal recurring adjustments, necessary to present fairly the 
consolidated financial position as of June 30, 2016 and the results of 
operations and cash flows for the six month periods ended June 30, 2016 and 
2015. The financial data and other information disclosed in the notes to the 
interim condensed consolidated financial statements related to these periods are
unaudited.&#160;The results for the three and six month period ended June 30, 
2016 are not necessarily indicative of the results to be expected for any 
subsequent quarter or the entire year ending December 31, 2016.</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">These unaudited condensed consolidated financial 
statements should be read in conjunction with our audited consolidated financial
statements and the notes thereto for the year ended December 31, 2015, included 
in the Company&#x2019;s annual report on Form 10-K filed with the SEC&#160;on 
March 30, 2016.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
justify">Nature of Operations</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">Bio-AMD, Inc. (&#x201c;Bio-AMD&#x201d; the &#x201c;Company&#x201d;, 
&#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;) (formerly known as 
Flex Fuels Energy, Inc. and Malibu Minerals, Inc.) was incorporated in the State
of Nevada on March 10, 2006 to engage in the business of exploration and 
discovery of gold, minerals, mineral deposits and reserves.</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">On April 15, 2011, we entered into an Agreement 
and Plan of Merger (the "Merger Agreement") pursuant to which we merged with our
newly formed, wholly owned subsidiary, Bio-AMD, Inc., a Nevada corporation 
("Merger Sub" and such merger transaction, the "Merger"). Upon the consummation 
of the Merger, the separate existence of Merger Sub ceased and shareholders of 
the Company became shareholders of the surviving company named Bio-AMD, Inc. As 
permitted by Chapter 92A.180 of Nevada Revised Statutes, the sole purpose of the
Merger was to effect a change of our name to Bio-AMD, Inc. to better reflect our
core business area. Upon the filing of Articles of Merger (the "Articles of 
Merger") with the Secretary of State of Nevada on April 15, 2011 to effect the 
Merger, our Articles of Incorporation were deemed amended to reflect the change 
in our corporate name.&#160;&#160;We are quoted on OTC Markets and the OTC 
Bulletin Board under the symbol &#x201c;BIAD&#x201d;.</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">During the fourth quarter of our 2006 fiscal year,
for the purpose of diversifying our business, acquiring capital, gaining greater
access to the capital markets and with the assistance of newly acquired capital,
we entered into an Agreement with Flex Fuels Energy Limited (&#x201c;FFE
Ltd&#x201d;) and the stockholders of FFE Ltd by which FFE Ltd became our wholly-
owned subsidiary effective on May 29, 2007. FFE Ltd engaged in the development 
of the business of manufacturing and distributing Oil Seed Rape 
(&#x201c;OSR&#x201d;) products.</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">Effective September 5, 2009, after having carefully evaluated all 
options, we abandoned our proposed oil seed business, as we no longer considered
the business to be economically viable on either a go alone or partnered 
basis.&#160;&#160;The proposed project initiated by prior management involved 
building an oil seed crushing plant at Cardiff, Wales was compromised by delays,
sub-optional design and substantial legal costs.&#160;&#160;We were unable to 
raise the necessary financing, to locate a project partner, or to divest our 
interest in the project for value.&#160;&#160;Accordingly, we determined that 
our best course of action was to preserve value by winding down the oil seed 
operations of FFE Ltd.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">From our 
inception through the date of these unaudited condensed consolidated financial 
statements, we have not generated any revenues and have incurred significant 
expenses. The Company intends to fund its development of the currency risk 
technology, diagnostic technology and on-going operations through equity and/or 
debt financing arrangements.&#160;&#160;However, there can be no assurance that 
these arrangements will be sufficient to fund its ongoing capital expenditures, 
working capital, and other cash requirements. Consequently, our operations are 
subject to all the risks and uncertainties inherent in the establishment of a 
new business enterprise.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
justify">WOCU Limited Acquisition</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On
May 1, 2009, we entered into an Investment Agreement (the &#x201c;Investment 
Agreement&#x201d;) with WDX Organisation Limited, a corporation incorporated 
under the laws of England and Wales, and the founding shareholders of WDX 
Organisation Limited (the &#x201c;Founders&#x201d;), the owners of all of the 
issued and outstanding shares of WDX Organisation Limited.&#160;&#160;On the 
same date, we entered into a related Loan Agreement (the &#x201c;Loan 
Agreement&#x201d;) and a related Option and Funding Agreement (the 
&#x201c;Funding Agreement&#x201d;) with WDX Organisation Limited.&#160;&#160;The
Investment Agreement, Loan Agreement and Funding Agreement are hereinafter 
collectively referred to as the &#x201c;Agreements&#x201d;. Pursuant to the 
Agreements, we acquired 51% ownership of WDX Organisation Limited. WDX 
Organisation Limited changed its name to WOCU Limited (&#x201c;WL&#x201d;) 
effective January 29, 2013.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">WL is the 
developer of the WOCU technology, an algorithm and system of providing reference
data for its WOCU global currency unit, designed to mitigate currency risk. On 
August 14, 2009, we provided a further &#xa3;150,000 (approximately $247,800) to
WL by way of a loan and have exercised certain call options. On November 20, 
2009, we loaned an additional &#xa3;150,000 (approximately $249,840) to WL and 
increased our equity position in WL.&#160;WL has been working to develop 
contracts with a variety of banks, currency exchange networks, data providers, 
and derivative exchanges in an effort to commercialize its WOCU technology 
through licensing agreements.&#160;</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On
March 8, 2010, we loaned an additional &#xa3;150,000 (approximately $224,055) to
WL and executed certain call options to further increase our equity position in 
WL. The loans were the result of our ongoing investment in WL as contemplated by
our May 1, 2009 Investment Agreement with WL.</div><br/><div style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">Altogether, these transactions resulted in a total loan of 
&#xa3;600,000 (approximately $904,000) to WL and the ownership of 93% of WL by 
the Company on March 8, 2010.</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On
July 23, 2010, we entered into a Subscription Agreement with WL and the founders
of WL under which we purchased 500,000 preference shares of WL (the 
&#x201c;Preference Shares&#x201d;) at a price of one British Pound per share
(approximately $750,000). &#160; The Preference Shares earn in priority to any 
other class of stock of WL, a cumulative dividend equal to 5% of the 
subscription price of such Preference Shares per annum. These Preference Shares 
carry a preference over all other classes of WL stock in the event of a sale, 
liquidation or listing of WL. Upon liquidation, sale or listing and after 
repayment of the outstanding loans made by us
 to WL, other liabilities of WL and related transaction costs, the holder of the
Preference Shares is entitled to a payment equal to three times the subscription
price (the &#x201c;Preference Shares Payment&#x201d;) paid for such Preference 
Shares.&#160;&#160;The Preference Shares are redeemable upon a sale, listing or 
winding down of WL.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Subscription 
Agreement also provided for WL to allot up to an aggregate of 16,900 C Ordinary 
Shares of WL to employees, directors and consultants of WL to secure their 
continued service to WL and incentivize them in the performance 
thereof.&#160;&#160;An aggregate of 14,061 C Ordinary Shares were issued, for 
nominal consideration, to three employees and Robert Galvin, our former Chief 
Financial Officer on July 23, 2010. The issuance of the 14,061 C Ordinary Shares
reduced our ownership in WL from 93% to 77.54%.</div><br/><div style="FONT-SIZE:
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">Effective June 30, 2011, WL agreed with all three of its employees to 
terminate existing employment agreements so as to reduce the monthly cash 
outflows. As a result of the termination of employment contracts, and in 
accordance with the WL Articles of Association, terminated employees gave up 
9,243 C Ordinary Shares. This increased our ownership in WL to 
87.13%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">During November 2011, we 
loaned an additional &#xa3;50,000 (approximately $77,000) to WL as a short-term 
unsecured intercompany loan. On July 12, 2012, it was agreed that this loan 
would be settled through the issuance of 5,000,000 common shares, increasing our
ownership in WL to 99.81%.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Since 
January 2013, the Company has provided further advances totaling &#xa3;196,000 
(approximately $260,000) into WL to fund its operations based on the prospective
pipeline of opportunities that have been generated.</div><br/><div 
style="MARGIN-BOTTOM: 0.1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-
RIGHT: 0.1pt">As at June 30, 2016, there were no commercial agreements in place,
and no revenues had been generated by WL. Given the Company&#x2019;s limited 
resources, it is unlikely that the Company can support WL operations going 
forward, as a contractor to WL vital to its technical operation has indicated it
is not willing to continue to provide its services at the current much reduced 
rate of payment and accordingly further investment will be required to support 
WL. The Company will consider any option that might preserve any value in 
WL.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Bio-AMD 
Holdings Limited Acquisition</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY:
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On 
February 25, 2010, we entered into a Subscription and Shareholders Agreement 
with Bio-AMD Holdings Limited (&#x201c;Bio-AMD Holdings&#x201d;), a United 
Kingdom company, and the managers of Bio-AMD Holdings, under which we acquired a
63% interest in Bio-AMD Holdings for &#xa3;865,000 British Pounds (approximately
$1,335,000) through the purchase of preferred shares.&#160;&#160;The preferred 
shares accrue dividends at the rate of 5% per year and provide for a preference 
in liquidation equal to &#xa3;865,000, plus accrued unpaid dividends (the 
preference on a sale is &#xa3;850,000, plus accrued and unpaid dividends). Bio-
AMD Holdings is a development stage company, formed in February 2010, which, 
through its operating subsidiary, Bio Alternative Medical Devices Ltd. 
(&#x201c;Bio-Medical&#x201d;), principally operates in the Medical Point of Care
(&#x201c;POC&#x201d;) diagnostic space. Where context requires, reference to 
Bio-AMD Holdings also includes reference to Bio-Medical. Bio-AMD Holdings owns a
portfolio of patent applications on technologies, which it expects to enable it 
to develop highly accurate, low cost, hand held electronic diagnostic devices 
capable of reading certain third party assays. Since 2010 Bio-AMD Holdings has
been developing its technology into three initial product types (1) a digital 
strip reader targeted initially into the &#x201c;over the counter&#x201d; female
well-being market (including digital pregnancy, ovulation and fertility testing,
(2) a blood coagulation device and (3) early stage development work into a POC 
immunoassay detection system based on magnetic nanoparticle 
manipulation.&#160;&#160;In addition, Bio-AMD Holdings is working to develop 
various commercial relationships with manufacturers, bio-chemistry companies and
sales distributions partners to enable commercialization of its products through
licensing agreements.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times
New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Since January 
2014, the Company has provided additional working capital by way of cash 
injections via intercompany loans amounting to &#xa3;100,000 (approximately 
$132,000) to Bio-AMD Holdings to further fund operations. These loans are 
secured against the assets of Bio-AMD Holdings and its wholly owned operating 
subsidiary, Bio-Medical.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
justify">Restructuring of Bio-AMD Holdings and Bio-Medical 
operations</div><br/><div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On
June 1, 2016, the intellectual property relating to the Company's DSR, COAG and 
MIDS projects (the "IP") and depreciated physical equipment assets (together the
IP, the "Assets"), formerly under the control of Bio-AMD Holdings and Bio-
Medical, were brought into the full control of Bio-AMD, Inc. under loan security
agreements put in place by the Company during 2015.</div><br/><div 
style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">On June 17, 2016, the Company
entered into a Subscription and Shareholders' Agreement with Bio-AMD UK Holdings
Limited ("UKH"), a United Kingdom company, and the managers of UKH, under which 
we acquired a 70% interest in UKH in exchange for the Assets. See exhibit 
10.1.</div><br/><div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">UKH is a 
development stage company, formed in May 2009 by the Company's two principal and
key scientists formerly contracted to Holdings, Dr. Nasser Djennati and Dr. 
Andrew Mitchell. UKH was formerly dormant and has never traded. Immediately 
prior to the transaction UKH formed a new subsidiary, MIDS Medical Limited 
("MML") as a dedicated vehicle to develop our MIDS universal immunoassay 
detection technology in a joint venture, further described below. UKH has taken 
over the operations of Holdings and Bio-Medical.</div><br/><div style="MARGIN-
BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">The 30% of UKH not owned by the Company is 
owned by Dr. Nasser Djennati (15%) and Dr. Andrew Mitchell (15%), whose 
experience and qualifications were reported on Form 8K filed on March 3, 2010. 
The board of directors of both UKH and MML consists of Drs. Djennati and 
Mitchell, and Mr Barr, the Company's CEO.</div><br/><div style="MARGIN-BOTTOM: 
0px; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">The effect of the restructuring was to 
beneficially increase the Company's interest in its UK medical operations from 
63% to 70%, to simplify and gain better voting control of its UK subsidiaries, 
and to eliminate two employee profit share arrangements.</div><br/><div 
style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">As a result of the 
incremental increase in the ownership of the Assets, the Company recorded a 
charge to Additional Paid-in Capital and the Non-controlling Interest of 
$12,513. The amount represents the Company&#x2019;s additional interest in the 
net book value of the group of Assets determined by voting 
control.</div><br/><div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; 
TEXT-ALIGN: left">MIDS Medical Limited Operations</div><br/><div style="MARGIN-
BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">On June 20, 2016, the Company and its UKH 
and MML subsidiaries entered into a joint venture by way of a Subscription and 
Shareholders&#x2019; Agreement (&#x201c;Agreement&#x201d;) with a third party 
medical detection device developer (&#x201c;Partner&#x201d;) a Nevada 
corporation, under which the Partner, in exchange for its participation and
funding to support MML during a Phase 1 development, owns a 40% interest in MML 
as of July 1, 2016, The Partner also prospectively agreed to fund a Phase 2 
development of our MIDS universal immunoassay detection technology within the 
MML vehicle. MML will have the right to use the MIDS Intellectual Property 
(&#x201c;MIDS IP&#x201d;) under license during the development and the MIDS IP 
will be transferred to MML in the event that MML concludes a commercial deal for
MIDS with a third party. See exhibit 10.2.</div><br/><div style="MARGIN-BOTTOM:
 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">The Agreement provides for a series of payments 
(&#x201c;Phase 1 Payments&#x201d;) in an aggregate amount of &#xa3;450,500 
(approximately $650,000 based on the current rate of exchange). The Partner made
a Phase 1 Payment to MML, of $130,000 (the &#x201c;First Payment&#x201d;), which
was received on August 2, 2016 and converted to &#xa3;92,857. Subsequent Phase 1
Payments are expected to be received as follows; (a) on or before September 20, 
2016, a payment &#xa3;106,093, (b) on or before November 20, 2016, a payment of 
&#xa3;100,640; (c) on or before January 20, 2017 a payment of &#xa3;100,640; and
(d) on or before March 20, 2016 a payment of &#xa3;50,320.</div><br/><div 
style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Agreement also provides 
for a contingency funding (&#x201c;Contingency&#x201d;) to be made available by 
the Partner after March 31, 2017 in an aggregate amount of up to &#xa3;45,000 
(approximately $64,000) to be paid by the Partner within 20 days of receiving a 
written notice from&#160; MML.</div><br/><div style="MARGIN-BOTTOM: 10pt; FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-
ALIGN: justify">The parties to the Agreement envisage a second phase of 
development (&#x201c;Phase 2&#x201d;) to follow Phase 1. This is expected to be 
broadly over a similar timeframe and at a similar cost. MML may independently 
obtain funding for Phase 2 at MML&#x2019;s option, or invite the Partner to 
fund.</div><br/><div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The 
Agreement contains various provisions to govern the funding obligations of the 
Partner: if any Phase 1 Payment is not made within 14 days of it falling due 
(&#x201c;Default&#x201d;), the Partner&#x2019;s shareholding in MML may be 
reduced to zero; if no Contingency is drawn during Phase 1, UKH will be awarded 
an enduring 2.5% profit after tax right in MML (&#x201c;Override&#x201d;) which 
will increase to a 15% Override if the Partner declines to fund Phase 2; if the 
Partner declines to fund Phase 2 and any Contingency has been drawn, UKH will be
awarded a 15% Override decreased by 0.5% for each &#xa3;7,500 tranche of 
Contingency drawn down during Phase 1. Any Override will convert pro rata into 
ordinary shares in the event of a sale of MML.</div><br/><div style="MARGIN-
BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: justify">Provided that each Phase 1 Payment is made 
within 14 days of falling due, the Partner also has additional control rights 
over MML, including representation on the MML board of directors, rights over 
the appointment and employment of senior management persons, indebtedness, major
transactions, budget approval rights, accounting practices and general 
operational management supervisory rights.</div><br/><div style="MARGIN-BOTTOM: 
10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">As a condition of the Agreement, MML has entered 
into Supply of Services Agreements under which it receives the services of Drs. 
Djennati and Mitchell, being key personnel related to the MIDS 
development.</div><br/><div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">Initial development project planning has commenced on the MIDS project,
including the specification of a bench rig printed circuit board designed to 
support first stage testing of a sample of Hall Effect Sensors already supplied 
to MML in order to examine their behavior in the detection of magnetic 
nanoparticles &#x2013; the core MIDS technology &#x2013; and to determine how 
these Hall Effect Sensors should be optimized prior to integration in a micro 
fluidic test strip.</div><br/><div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">The Company has agreed, pursuant to a letter agreement (the 
&#x201c;Warrant Agreement&#x201d;), to prospectively issue 3,000,000 five year 
warrants in the Company exercisable at $0.10, to certain third parties (or their
nominees) who have introduced the Partner to the Company (&#x201c;Introducer 
Warrants&#x201d;). The Warrant Agreement provides for the Introducer Warrants to
be issued at the discretion of the Company at any time up to MML receiving the 
final Phase 1 Payment, and may not be exercised prior to June 15, 2017. In the 
event the Phase 1 Payments are not made in full, the Company will have the right
to cancel the issuance of the Introducer Warrants, or to negotiate revised 
terms, at the Company&#x2019;s sole option. No other fees have been paid in 
regard to the Agreement. See exhibit 4.1.</div><br/><div style="FONT-SIZE: 10pt;
FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000;
TEXT-ALIGN: justify">Going Concern</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">The accompanying unaudited condensed consolidated financial statements 
have been prepared on a going concern basis, which contemplates the realization 
of assets and the satisfaction of liabilities in the normal course of 
business.&#160;&#160;The Company has not commenced its planned principal 
operations. As shown in the accompanying unaudited condensed consolidated 
financial statements, the Company has not generated any revenue and has incurred
recurring losses through June 30, 2016.&#160;&#160;Additionally, the Company has
recurring negative cash flows from operations and has an accumulated deficit of 
$41,384,326 as at June 30, 2016.&#160;&#160;These factors raise substantial 
doubt about the Company&#x2019;s ability to continue as a&#160;going 
concern.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company's ability to 
continue its existence is dependent upon commencing its planned operations, 
management's ability to develop and achieve profitable operations and/or upon 
obtaining additional financing to carry out its planned business. The Company 
intends to fund the development of its diagnostic technology and on-going 
operations through equity and debt financing arrangements.&#160; However, there 
can be no assurance that these arrangements will be sufficient to fund its 
ongoing capital expenditures, working capital, and other cash 
requirements.&#160; The outcome of these matters cannot be predicted at this 
time.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">There can be no assurance 
that any additional financings will be available to the Company on satisfactory 
terms and conditions, if at all.&#160; In the event we are unable to continue as
a going concern, we may elect or be required to seek protection from our 
creditors by filing a voluntary petition in bankruptcy or may be subject to an 
involuntary petition in bankruptcy. To date, management has not considered this 
alternative.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The accompanying 
unaudited condensed consolidated financial statements do not include any 
adjustments related to the recoverability or classification of asset-carrying 
amounts or the amounts and classification of liabilities that may result should 
the Company be unable to continue as a going 
concern.&#160;</div><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The entire disclosure for the nature of an entity's 
business, major products or services, principal markets including location, and 
the relative importance of its operations in each business and the basis for the
determination, including but not limited to, assets, revenues, or earnings. For 
an entity that has not commenced principal operations, disclosures about the 
risks and uncertainties related to the activities in which the entity is 
currently engaged and an understanding of what those activities are being 
directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-
108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-
108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6631435712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2
- Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting 
Policies [Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Note 
2&#160;&#x2013; Summary of Significant Accounting Policies</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Use of 
estimates</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The preparation of 
consolidated financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the consolidated financial 
statements and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Principles of 
consolidation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The unaudited 
condensed consolidated financial statements include the accounts of Bio-AMD, 
Inc., WOCU Limited (a 99.81% owned subsidiary as of June 30, 2016), Bio-AMD 
Holdings Limited (a 63% owned subsidiary as of June 30, 2016), along with Bio-
AMD Holdings Limited&#x2019;s wholly owned subsidiary Bio-Medical, and&#160;Bio-
AMD UK Holdings Limited (a 70% owned subsidiary effective June 30, 2016), along 
with its then wholly owned subsidiary MIDS Medical Limited. All significant 
intercompany transactions and balances have been eliminated in 
consolidation.&#160;&#160;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The third 
party ownerships of 0.19% of WL, 37% of Bio-AMD Holdings, and 30% of UKH are 
recorded as non-controlling interests in the unaudited condensed consolidated 
financial statements.&#160;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left">Patents</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Patents are stated at
cost less accumulated amortization and are comprised of patent applications on 
technologies which the Company expects to enable it to develop highly accurate, 
low cost, hand held electronic diagnostic devices capable of reading third party
assays. The patents are amortized straight-line over the estimated useful life 
but not to exceed 17 years.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left">Revenue Recognition</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The 
Company recognizes revenue when the following criteria have been met: persuasive
evidence of an arrangement exists, no significant Company obligations remain, 
collection of the related receivable is reasonably assured, and the fees are 
fixed or determinable. The Company acts as a principal in its revenue 
transactions as it is the primary obligor in the transactions.</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Deferred Revenue and Deferred 
Costs</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company defers revenue on
contracts which contain a performance commitment until such time as the services
have been completed and no significant Company obligations 
remain.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The costs associated with 
contracts for which revenue is deferred, including personnel costs and 
incremental contract costs, are initially capitalized as deferred costs. 
Subsequently these costs are recognized as a component of cost of revenue when 
the associated revenue is recognized.</div><br/><div style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">In May 2016, the Company received formal written notice of termination 
of its Master Agreement with Sysmex Corporation (&#x201c;Sysmex&#x201d;) in a 
letter dated April 22, 2016. As a result of the termination, the Company has no 
further obligations with respect to the research agreement and related funding 
received.&#160; Due to the unexpected termination by Sysmex, the Company 
recorded a gain from the contract termination of $248,074.</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Foreign currency 
translation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company's 
reporting and functional currency is US Dollars. The accounts of the Company's 
99.81% owned subsidiary, WL, and the Company's 63% owned subsidiary, Bio-AMD 
Holdings, and Bio-AMD Holdings' wholly owned subsidiary, Bio-Medical, and the 
Company's 70% owned subsidiary UKH and its wholly owned subsidiary MML, are 
maintained using the local currency (Great British Pounds) as the functional 
currency. All assets and liabilities are translated into US Dollars at the
balance sheet date, equity is translated at historical rates, and revenue and 
expense accounts are translated at the average exchange rate for the year or the
reporting period.&#160;The translation adjustments are recorded as accumulated 
other comprehensive income.&#160;&#160;Transaction gains and losses arising from
exchange rate fluctuation on transactions denominated in a currency other than 
the functional currency are included in the unaudited condensed consolidated 
statements of operations.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The 
relevant translation rates are as follows: For the six month period ended June 
30, 2016 closing rate at 1.3242 US$:GBP, average rate at 1.4319 US$:GBP and for 
the six month period ended June 30, 2015 closing rate at 1.5717 US$:GBP, average
rate at 1.5233 US$:GBP.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
justify">Recently Issued Accounting Standards</div><br/><div style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic
810): Amendments to the Consolidation Analysis, which is intended to improve 
targeted areas of consolidation guidance for legal entities such as limited 
partnerships, limited liability corporations, and securitization structures 
(collateralized debt obligations, collateralized loan obligations, and mortgage-
backed security transactions). The ASU focuses on the consolidation evaluation 
for reporting organizations that are required to evaluate whether they should 
consolidate certain legal entities. In addition to reducing the number of 
consolidation models from four to two, the new standard simplifies the FASB 
Accounting Standards Codification and improves current US GAAP by placing more 
emphasis on risk of loss when determining a controlling financial interest, 
reducing the frequency of the application of related-party guidance when 
determining a controlling financial interest in a variable interest entity 
(&#x201c;VIE&#x201d;), and changing consolidation conclusions for companies in 
several industries that typically make use of limited partnerships or VIEs. The 
ASU will be effective for fiscal years, and interim periods within those fiscal 
years, beginning after December 15, 2015. The adoption of ASU 2015-02 did not 
have any effect on our financial position, results of operations or cash 
flows.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">In August 2014, the FASB 
issued ASU No. 2014-15, "Presentation of Financial Statements - Going Concern 
(Subtopic 205-40)". ASU 2014-15 provides guidance related to management's 
responsibility to evaluate whether there is substantial doubt about an entity's 
ability to continue as a going concern and to provide related footnote 
disclosure. ASU 2014-15 is effective for annual periods ending after December 
15, 2016, and for interim and annual periods thereafter. Early application is 
permitted. We do not expect the adoption of ASU 2014-15 to have a material 
effect on our financial position, results of operations or cash 
flows.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN: 0.1pt">In June 2014, 
the FASB issued ASU No. 2014-12, &#x201c;Compensation &#x2013; Stock 
Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of 
an Award Provide That a Performance Target Could Be Achieved after the Requisite
Service Period.&#x201d; This ASU requires that a performance target that affects
vesting and that could be achieved after the requisite service period be treated
as a performance condition. ASU 2014-12 is effective for fiscal years, and 
interim periods within those fiscal years, beginning after December 15, 2015. 
The adoption of ASU 2014-12 did not have any effect on our financial position, 
results of operations or cash flows.</div><br/><div style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">In
 May 2014, the FASB issued ASU No. 2014-09, &#x201c;Revenue from Contracts with 
Customers (Topic 606).&#x201d; ASU 2014-09 affects any entity using US GAAP that
either enters into contracts with customers to transfer goods or services or 
enters into contracts for the transfer of nonfinancial assets unless those 
contracts are within the scope of other standards (e.g., insurance contracts or 
lease contracts). ASU 2014-09 is effective for fiscal years, and interim periods
within those fiscal years, beginning after December 15, 2016. We are still 
evaluating the effect of the adoption of ASU 2014-09. On April 1, 2015, the FASB
voted to propose to defer the effective date of the new revenue recognition 
standard by one year.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times
New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Recent accounting
pronouncements issued by the FASB and the SEC did not or are not believed by 
management to have a material impact on the Company's present or future 
consolidated financial statements.</div><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The entire disclosure for all significant accounting 
policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 6<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-
107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-
107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br>
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-
107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-
107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-
107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
}</script>
e.nextSibling.style.display='block';
} else
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6808149280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3
- Patents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets 
Disclosure [Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Note 3 
&#x2013; Patents</div><br/><table id="z05feb8420eb24d37b0fe0737aef813ff" 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 
100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.65%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Cost</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Accumulated amortization</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div>&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Foreign currency translation 
adjustment</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 13.68%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">June 30,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Net carrying value</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">December 31,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Net carrying value</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
</tr>
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.65%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.11%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 13.68%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Patents</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">174,810</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 2.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 11.04%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">&#x2013;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px double;
BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">(9,237)</div>
</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px double;
BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 1.66%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">165,573</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">165, 848</div>
</td>
</tr>
</table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif; COLOR: #000000; TEXT-ALIGN: justify">Bio-AMD currently has eight patent 
applications covering its three proprietary technology platforms, the Company 
having elected to abandon one redundant patent relating to DSR which was due for
renewal in April 2016 (other patents relating to DSR are being 
maintained).&#160;We continue to review our intellectual property strategy with 
the intention of sufficiently protecting our key intangible assets, and that any
new IP generated is reviewed as far as possible to optimize the novel nature of 
the IP and freedom to operate in key jurisdictions.</div><br/><div style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-
ALIGN: justify">In June 2015, Bio AMD Holdings Limited received a grant of U.S. 
patent dated June 2, 2015, under U.S. Patent No. US 9,046,512 protecting twenty 
one claims central to the Company&#x2019;s microfluidic strip and reader 
technology designed to test PT/INR by a POC device.</div><br/><div style="FONT-
SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-
ALIGN: justify">In January 2016, the Company received a grant of patent from the
State Intellectual Property Office of the People&#x2019;s Republic of China 
(&#x201c;PRC&#x201d;) for our MIDS technology. The Company has made similar MIDS
technology patent applications in the U.K. and in more than 145 Contracting 
States under the international Patent Cooperation Treaty, and separately in the 
USA, the European Union and India.</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">In
March 2016, the Company received notice of grant of patent from the State 
Intellectual Property Office of the PRC relating to our microfluidic strip and 
reader technology designed to test PT/INR by a POC 
device.</div><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The entire disclosure for all or part of the information 
related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 
50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-
109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br>
-SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-
109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> 
-SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-
109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6743117584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4
- Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party 
Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party 
Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Note 
4&#160;&#x2013; Related Party Transactions</div><br/><div style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">During the three months ended June 30, 2016, we paid $nil (2015 - 
$49,156), to The ARM Partnership (&#x201c;ARM&#x201d;), a partnership in which 
Robert Galvin, our former Chief Financial Officer and Treasurer is a partner, 
for services provided to us by Mr. Galvin in all capacities. During the six 
month period ended June 30, 2016, we paid an aggregate of $10,030 (2015 - 
$99,319) to ARM. Mr. Galvin owns 12.33% of the outstanding share capital of Bio-
AMD Holdings. In addition, during the six months ended June 30, 2016, the 
Company paid $nil (2015 - $11,500 (&#xa3;7,500)) for the use of ARM&#x2019;s 
offices in central London located at 3rd Floor, 14 South Molton Street, London, 
UK. The rental expense was set at &#xa3;500 per month for Bio-AMD Inc. 
(approximately $760), this ceased on July 31, 2015 and &#xa3;750 per month for 
Bio-AMD Holdings (approximately $1,150), reduced to &#xa3;500 (approximately 
$760) for each of the months of August and September 2015, and which ceased in 
October, 2015.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">During the three month 
period ended June 30, 2016, we paid an aggregate of $24,138 (2015 - $36,461) to 
Thomas Barr, our Chief Executive Officer, for services provided to us by Mr. 
Barr in all capacities.&#160;&#160;During the six month periods ended June 30, 
2016, we paid an aggregate of $59,290 (2015 - $72,351) to Mr. 
Barr.</div><br/><div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-
TOP: 12pt">During the three month period ended June 30, 2016, we paid an 
aggregate of $15,733 (2015 - $23,614) to David Miller, our Chief Financial 
Officer, for services provided to us by Mr. Miller in all 
capacities.&#160;During the six month period ended June 30, 2016, we paid an 
aggregate of $38,563 (2015 - $46,988) to Mr. Miller.</div><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The entire disclosure for related party transactions. 
Examples of related party transactions include transactions between (a) a parent
company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity 
and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-
122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-
107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-
107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-
107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-
107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-
107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6808170240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5
- Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue 
Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DeferredRevenueDisclosureTextBlock', window );">Deferred Revenue Disclosure
[Text Block]</a></td>
<td class="text"><div style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
justify; MARGIN-TOP: 0px">Note 5 &#x2013; Deferred Revenue</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">Deferred revenue consists of funds received in 
advance of services being performed. The Company&#x2019;s revenue recognition 
policy dictates that revenues will be recognized when the services have been 
completed and no significant Company obligations remain. As at June 30, 2016, 
the Company had $nil (December 31, 2015 - $950,402 (&#xa3;642,077)) of deferred 
revenues.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The costs directly associated
with the performance of services for which revenue has been deferred are 
initially capitalized as deferred costs. These costs will be recognized as a 
component of cost of revenue when the associated revenue is 
recognized.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">As at June 30, 2016, 
the Company had $nil (December 31, 2015 - $645,534 (&#xa3;436,113)) of deferred 
costs.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">In May 2016, the Company 
received notice of termination of its Master Agreement with Sysmex. Upon 
receiving notice, management has determined that the Company has no further 
material obligations under the research agreement. The net difference between 
the deferred revenues and deferred costs of $248,074 has been recognized as a 
gain on termination of research agreement in the statement of 
operations.</div><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The entire disclosure for deferred revenues at the end of 
the reporting period, and description and amounts of significant changes that 
occurred during the reporting period. Deferred revenue is a liability as of the 
balance sheet date related to a revenue producing activity for which revenue has
not yet been recognized. Generally, an entity records deferred revenue when it 
receives consideration from a customer before achieving certain criteria that 
must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(b).Q2)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(b).Q1(c))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.4(a).Q1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 
13.A.3(b).Q1(c),(b).Q2,(c).Q3)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-
107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(c).Q3)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6742966352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6
- Segmented Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting 
Disclosure [Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
justify">Note&#160;6&#160;&#x2013; Segmented Information</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">We currently operate in two segments: 1) the 
development of a technology designed to mitigate currency risk through our 
99.81% owned subsidiary, WL as of June 30, 2016, and 2) the development of 
highly accurate, low cost, hand held, electronic medical diagnostic devices 
capable of reading third party assays through our 63% and 70% owned 
subsidiaries, Bio-AMD Holdings and Bio-AMD UK Holdings Limited, respectively. 
Segment information for the three and six months ended June 30, 2016 and 2015 
consists of the following:</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Three 
months ended June 30, 2016:</div><br/><table 
id="za5916a89e4b5433bb13a2c9eeaaed5a7" style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" cellpadding="0" 
align="center" border="0">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings &amp; </div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD UK Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">427</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">63</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">490</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(2,168</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">239,041</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(92,156</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">144,717</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">3,319</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">177,543</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">67,032</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif; COLOR: #000000; TEXT-ALIGN: justify">Three months ended June 30, 
2015:</div><br/><table id="zb89655d2886c416e8c52632fd0212a51" style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">463</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">268</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">731</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(12,025</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(20,213</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(321,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(354,132</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">2,672</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,168,133</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">483,272</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,654,077</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif; COLOR: #000000; TEXT-ALIGN: left">Six months ended June 30 
2016:</div><br/><table id="z4d16ef951bf2413ab42d38ccb77c1ffa" style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings &amp; </div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD UK</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">860</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">102</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">962</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(4,018</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">226,444</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(230,984</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(8,558</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">3,319</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">177,543</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">67,032</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times,
serif; COLOR: #000000; TEXT-ALIGN: left">Six months ended June 
2015:</div><br/><table id="zc4bd26c045b24edd8822a1d59ce1cb64" style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">921</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">603</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,524</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(33,524</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(36,459</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(506,989</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000">(576,972</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">2,672</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,168,133</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">483,272</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,654,077</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The entire disclosure for reporting segments including 
data and tables. Reportable segments include those that meet any of the 
following quantitative thresholds a) it's reported revenue, including sales to 
external customers and intersegment sales or transfers is 10 percent or more of 
the combined revenue, internal and external, of all operating segments b) the 
absolute amount of its reported profit or loss is 10 percent or more of the 
greater, in absolute amount of 1) the combined reported profit of all operating 
segments that did not report a loss or 2) the combined reported loss of all 
operating segments that did report a loss c) its assets are 10 percent or more 
of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 34<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8981-
108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-
108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8971-
108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8595-
108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8380-
108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8933-
108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8844-
108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8984-
108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-
108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-
108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8538-
108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8864-
108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-
108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-
108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6603811712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7
- Subsequent Event and Commitment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text 
Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Note&#160;7 
&#x2013; Subsequent Event and Commitment</div><br/><div style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">As previously described in Note 1, effective July 1, 2016, the Company 
has formed a joint venture agreement for the Phase 1 development of MIDS 
technological application.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The 
Company has agreed, to prospectively issue 3,000,000 five year warrants in the
Company exercisable at $0.10 per share, to certain third parties (or their 
nominees) who have introduced the joint venture partner to the Company. The 
warrants may&#160; be issued at any time up to MML receiving the final Phase 1 
Payment and they may not be exercised prior to June 15, 2017.</div><br/><div 
style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: 
#000000; TEXT-ALIGN: justify">Management evaluated all activities of the Company
through the issuance date of the Company's interim unaudited condensed 
consolidated financial statements and concluded that no further subsequent 
events have occurred that would require adjustments or disclosure into the 
interim unaudited condensed consolidated financial 
statements.</div><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The entire disclosure for significant events or 
transactions that occurred after the balance sheet date through the date the 
financial statements were issued or the date the financial statements were 
available to be issued. Examples include: the sale of a capital stock issue, 
purchase of a business, settlement of litigation, catastrophic loss, significant
foreign exchange rate changes, loans to insiders or affiliates, and transactions
not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6807612688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 
200px;"><strong>Accounting Policies, by Policy 
(Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a"
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text 
Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Use of 
estimates</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman',
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The preparation of 
consolidated financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of 
contingent assets and liabilities at the date of the consolidated financial 
statements and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy 
Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Principles
of consolidation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The unaudited 
condensed consolidated financial statements include the accounts of Bio-AMD, 
Inc., WOCU Limited (a 99.81% owned subsidiary as of June 30, 2016), Bio-AMD 
Holdings Limited (a 63% owned subsidiary as of June 30, 2016), along with Bio-
AMD Holdings Limited&#x2019;s wholly owned subsidiary Bio-Medical, and&#160;Bio-
AMD UK Holdings Limited (a 70% owned subsidiary effective June 30, 2016), along 
with its then wholly owned subsidiary MIDS Medical Limited. All significant 
intercompany transactions and balances have been eliminated in 
consolidation.&#160;&#160;</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The third 
party ownerships of 0.19% of WL, 37% of Bio-AMD Holdings, and 30% of UKH are 
recorded as non-controlling interests in the unaudited condensed consolidated 
financial statements.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-
Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: 
left">Patents</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Patents are stated at
cost less accumulated amortization and are comprised of patent applications on 
technologies which the Company expects to enable it to develop highly accurate, 
low cost, hand held electronic diagnostic devices capable of reading third party
assays. The patents are amortized straight-line over the estimated useful life 
but not to exceed 17 years.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a"
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy 
[Policy Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Revenue 
Recognition</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company 
recognizes revenue when the following criteria have been met: persuasive 
evidence of an arrangement exists, no significant Company obligations remain, 
collection of the related receivable is reasonably assured, and the fees are 
fixed or determinable. The Company acts as a principal in its revenue 
transactions as it is the primary obligor in the 
transactions.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RevenueRecognitionDeferredRevenue', window );">Revenue Recognition, 
Deferred Revenue [Policy Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Deferred 
Revenue and Deferred Costs</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The 
Company defers revenue on contracts which contain a performance commitment until
such time as the services have been completed and no significant Company 
obligations remain.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The costs 
associated with contracts for which revenue is deferred, including personnel 
costs and incremental contract costs, are initially capitalized as deferred 
costs. Subsequently these costs are recognized as a component of cost of revenue
when the associated revenue is recognized.</div><br/><div style="FONT-SIZE: 
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">In May 2016, the Company received formal written notice of termination 
of its Master Agreement with Sysmex Corporation (&#x201c;Sysmex&#x201d;) in a 
letter dated April 22, 2016. As a result of the termination, the Company has no 
further obligations with respect to the research agreement and related funding 
received.&#160; Due to the unexpected termination by Sysmex, the Company 
recorded a gain from the contract termination of $248,074.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', 
window );">Foreign Currency Transactions and Translations Policy [Policy Text 
Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Foreign 
currency translation</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times 
New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Company's 
reporting and functional currency is US Dollars. The accounts of the Company's 
99.81% owned subsidiary, WL, and the Company's 63% owned subsidiary, Bio-AMD 
Holdings, and Bio-AMD Holdings' wholly owned subsidiary, Bio-Medical, and the 
Company's 70% owned subsidiary UKH and its wholly owned subsidiary MML, are 
maintained using the local currency (Great British Pounds) as the functional 
currency. All assets and liabilities are translated into US Dollars at the 
balance sheet date, equity is translated at historical rates, and revenue and 
expense accounts are translated at the average exchange rate for the year or the
reporting period.&#160;The translation adjustments are recorded as accumulated 
other comprehensive income.&#160;&#160;Transaction gains and losses arising from
exchange rate fluctuation on transactions denominated in a currency other than 
the functional currency are included in the unaudited condensed consolidated 
statements of operations.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY:
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The 
relevant translation rates are as follows: For the six month period ended June 
30, 2016 closing rate at 1.3242 US$:GBP, average rate at 1.4319 US$:GBP and for 
the six month period ended June 30, 2015 closing rate at 1.5717 US$:GBP, average
rate at 1.5233 US$:GBP.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New 
Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">Recently 
Issued Accounting Standards</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 
'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">In 
February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): 
Amendments to the Consolidation Analysis, which is intended to improve targeted 
areas of consolidation guidance for legal entities such as limited partnerships,
limited liability corporations, and securitization structures (collateralized 
debt obligations, collateralized loan obligations, and mortgage-backed security 
transactions). The ASU focuses on the consolidation evaluation for reporting 
organizations that are required to evaluate whether they should consolidate 
certain legal entities. In addition to reducing the number of consolidation 
models from four to two, the new standard simplifies the FASB Accounting 
Standards Codification and improves current US GAAP by placing more emphasis on 
risk of loss when determining a controlling financial interest, reducing the 
frequency of the application of related-party guidance when determining a 
controlling financial interest in a variable interest entity 
(&#x201c;VIE&#x201d;), and changing consolidation conclusions for companies in 
several industries that typically make use of limited partnerships or VIEs. The 
ASU will be effective for fiscal years, and interim periods within those fiscal 
years, beginning after December 15, 2015. The adoption of ASU 2015-02 did not 
have any effect on our financial position, results of operations or cash 
flows.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify">In August 2014, the FASB 
issued ASU No. 2014-15, "Presentation of Financial Statements - Going Concern 
(Subtopic 205-40)". ASU 2014-15 provides guidance related to management's 
responsibility to evaluate whether there is substantial doubt about an entity's 
ability to continue as a going concern and to provide related footnote 
disclosure. ASU 2014-15 is effective for annual periods ending after December 
15, 2016, and for interim and annual periods thereafter. Early application is 
permitted. We do not expect the adoption of ASU 2014-15 to have a material 
effect on our financial position, results of operations or cash 
flows.</div><br/><div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', 
Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN: 0.1pt">In June 2014, 
the FASB issued ASU No. 2014-12, &#x201c;Compensation &#x2013; Stock 
Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of 
an Award Provide That a Performance Target Could Be Achieved after the Requisite
Service Period.&#x201d; This ASU requires that a performance target that affects
vesting and that could be achieved after the requisite service period be treated
as a performance condition. ASU 2014-12 is effective for fiscal years, and 
interim periods within those fiscal years, beginning after December 15, 2015. 
The adoption of ASU 2014-12 did not have any effect on our financial position, 
results of operations or cash flows.</div><br/><div style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">In May 2014, the FASB issued ASU No. 2014-09, &#x201c;Revenue from 
Contracts with Customers (Topic 606).&#x201d; ASU 2014-09 affects any entity 
using US GAAP that either enters into contracts with customers to transfer goods
or services or enters into contracts for the transfer of nonfinancial assets 
unless those contracts are within the scope of other standards (e.g., insurance 
contracts or lease contracts). ASU 2014-09 is effective for fiscal years, and 
interim periods within those fiscal years, beginning after December 15, 2016. We
are still evaluating the effect of the adoption of ASU 2014-09. On April 1,
2015, the FASB voted to propose to defer the effective date of the new revenue 
recognition standard by one year.</div><br/><div style="FONT-SIZE: 10pt; FONT-
FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: 
justify">Recent accounting pronouncements issued by the FASB and the SEC did not
or are not believed by management to have a material impact on the Company's 
present or future consolidated financial statements.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Disclosure of accounting policy regarding (1) the 
principles it follows in consolidating or combining the separate financial 
statements, including the principles followed in determining the inclusion or 
exclusion of subsidiaries or other entities in the consolidated or combined 
financial statements and (2) its treatment of interests (for example, common 
stock, a partnership interest or other means of exerting influence) in other 
entities, for example consolidation or use of the equity or cost methods of 
accounting.  The accounting policy may also address the accounting treatment for
intercompany accounts and transactions, noncontrolling interest, and the income 
statement treatment in consolidation for issuances of stock by a 
subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-
107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-
111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-
03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-
122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-
02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-
122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Disclosure of accounting policy for (1) transactions 
denominated in a currency other than the reporting enterprise's functional 
currency, (2) translating foreign currency financial statements that are 
incorporated into the financial statements of the reporting enterprise by 
consolidation, combination, or the equity method of accounting, and (3) 
remeasurement of the financial statements of a foreign reporting enterprise in a
hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-
107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br>
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> 
-SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-
110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> 
-SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-
110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Disclosure of accounting policy for finite-lived 
intangible assets. This accounting policy also might address: (1) the 
amortization method used; (2) the useful lives of such assets; and (3) how the 
entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-
107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> 
-SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-
109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Disclosure of accounting policy pertaining to new 
accounting pronouncements that may impact the entity's financial reporting. 
Includes, but is not limited to, quantification of the expected or actual 
impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);"
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Disclosure of accounting policy for recognizing unearned 
income or deferred revenue related to transactions involving the sale of a 
product or performance of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-
107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Disclosure of accounting policy for revenue recognition. 
If the entity has different policies for different types of revenue 
transactions, the policy for each material type of transaction is generally 
disclosed. If a sales transaction has multiple element arrangements (for 
example, delivery of multiple products, services or the rights to use assets) 
the disclosure may indicate the accounting policy for each unit of accounting as
well as how units of accounting are determined and valued. The disclosure may 
encompass important judgment as to appropriateness of principles related to 
recognition of revenue. The disclosure also may indicate the entity's treatment 
of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section
50<br> -Paragraph 4<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-
107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.B.Q1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-
107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-
107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Disclosure of accounting policy for the use of estimates 
in the preparation of financial statements in conformity with generally accepted
accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 4<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-
108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-
108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br>
-SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-
108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6742941712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3
- Patents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule 
of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><table id="z05feb8420eb24d37b0fe0737aef813ff" style="FONT-SIZE:
10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0"
cellpadding="0">
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.65%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Cost</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Accumulated amortization</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div>&#160;</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Foreign currency translation 
adjustment</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 13.68%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">June 30,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2016</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Net carrying value</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px 
solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">December 31,</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">2015</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Net carrying value</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">$</div>
</td>
</tr>
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 15.65%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.11%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 13.68%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
<tr>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Patents</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">174,810</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 2.06%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 11.04%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">&#x2013;</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 13.1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px double;
BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">(9,237)</div>
</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 4px double;
BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 1.66%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">165,573</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 1.1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px 
double; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: right">165, 848</div>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Tabular disclosure of assets, excluding financial assets 
and goodwill, lacking physical substance with a finite life, by either major 
class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 
50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-
109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> 
-SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-
109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6743116896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6
- Segmented Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', 
window );">Schedule of Segment Reporting Information, by Segment [Table Text 
Block]</a></td>
<td class="text">We currently operate in two segments: 1) the development of a 
technology designed to mitigate currency risk through our 99.81% owned 
subsidiary, WL as of June 30, 2016, and 2) the development of highly accurate, 
low cost, hand held, electronic medical diagnostic devices capable of reading 
third party assays through our 63% and 70% owned subsidiaries, Bio-AMD Holdings 
and Bio-AMD UK Holdings Limited, respectively. Segment information for the three
and six months ended June 30, 2016 and 2015 consists of the following:<br 
/><br /><table id="za5916a89e4b5433bb13a2c9eeaaed5a7" style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center" border="0">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings &amp; </div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD UK Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">427</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">63</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">490</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(2,168</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">239,041</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(92,156</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">144,717</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">3,319</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">177,543</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">67,032</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><table id="zb89655d2886c416e8c52632fd0212a51" style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN:
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">463</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000">268</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">731</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(12,025</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(20,213</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(321,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(354,132</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">2,672</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,168,133</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">483,272</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000">1,654,077</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><table id="z4d16ef951bf2413ab42d38ccb77c1ffa" style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings &amp; </div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD UK</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">860</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">102</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">962</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net income (loss)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(4,018</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">226,444</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(230,984</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(8,558</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">3,319</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">177,543</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">67,032</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">247,894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><table id="zc4bd26c045b24edd8822a1d59ce1cb64" style="FONT-SIZE: 10pt; 
FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 75%" cellspacing="0" 
cellpadding="0" align="center">
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">WL</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid"
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Bio-AMD Holdings</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Other</div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">(Corporate)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" 
valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Consolidated</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: 
left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" 
nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Interest and other income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">921</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">603</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">$</div>
</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,524</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(33,524</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(36,459</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(506,989</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">(576,972</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">)</div>
</td>
</tr>
<tr>
<td style="WIDTH: 19%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; TEXT-ALIGN: left">Segment total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">2,672</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,168,133</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">483,272</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" 
valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-
COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000">1,654,077</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-
COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Tabular disclosure of the profit or loss and total assets 
for each reportable segment. An entity discloses certain information on each 
reportable segment if the amounts (a) are included in the measure of segment 
profit or loss reviewed by the chief operating decision maker or (b) are 
otherwise regularly provided to the chief operating decision maker, even if not 
included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 30<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-
108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-
108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-
108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> 
-SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-
109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br>
-SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-
108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6825271808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1
- Nature of Operations and Continuance of Business 
(Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2016 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 12, 2012 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2011 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 23, 2010 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 08, 2010 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Feb. 25, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2010 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Nov. 20, 2009 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 20, 2009 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Aug. 14, 2009 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 14, 2009 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Nov. 30, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2011 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jun. 17, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 16, 2016</div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2010 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2010 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th"><div>May 01, 2009</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, 
Liquidation Preference, Value (in Pounds) | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling 
Interest, Period Increase (Decrease) (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings 
(Accumulated Deficit) (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41,384,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41,331,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', 
window );">Subsequent Event [Member] | Corporate Joint Venture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_JointVentureAggregateProceedsProvidedByPartner', window );">Joint 
Venture, Aggregate Proceeds Provided by Partner</a></td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="nump">&#163; 450,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_ProceedsFromJointVenturePartner', window );">Proceeds from Joint
Venture Partner</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">&#163; 92,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_JointVenturePartnerFundingDescription', window );">Joint Venture, 
Partner Funding Description</a></td>
<td class="text">Subsequent Phase 1 Payments are expected to be received as 
follows; (a) on or before September 20, 2016, a payment &#xa3;106,093, (b) on or
before November 20, 2016, a payment of &#xa3;100,640; (c) on or before January 
20, 2017 a payment of &#xa3;100,640; and (d) on or before March 20, 2016 a 
payment of &#xa3;50,320.<span></span>
</td>
<td class="text">Subsequent Phase 1 Payments are expected to be received as 
follows; (a) on or before September 20, 2016, a payment &#xa3;106,093, (b) on or
before November 20, 2016, a payment of &#xa3;100,640; (c) on or before January 
20, 2017 a payment of &#xa3;100,640; and (d) on or before March 20, 2016 a 
payment of &#xa3;50,320.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_JointVenturePartnerProvisions', window );">Joint Venture, Partner 
Provisions</a></td>
<td class="text">The Agreement contains various provisions to govern the funding
obligations of the Partner: if any Phase 1 Payment is not made within 14 days of
it falling due (&#x201c;Default&#x201d;), the Partner&#x2019;s shareholding in 
MML may be reduced to zero; if no Contingency is drawn during Phase 1, UKH will 
be awarded an enduring 2.5% profit after tax right in MML 
(&#x201c;Override&#x201d;) which will increase to a 15% Override if the Partner 
declines to fund Phase 2; if the Partner declines to fund Phase 2 and any 
Contingency has been drawn, UKH will be awarded a 15% Override decreased by 0.5%
for each &#xa3;7,500 tranche of Contingency drawn down during Phase 1. Any 
Override will convert pro rata into ordinary shares in the event of a sale of 
MML.<span></span>
</td>
<td class="text">The Agreement contains various provisions to govern the funding
obligations of the Partner: if any Phase 1 Payment is not made within 14 days of
it falling due (&#x201c;Default&#x201d;), the Partner&#x2019;s shareholding in
MML may be reduced to zero; if no Contingency is drawn during Phase 1, UKH will 
be awarded an enduring 2.5% profit after tax right in MML 
(&#x201c;Override&#x201d;) which will increase to a 15% Override if the Partner 
declines to fund Phase 2; if the Partner declines to fund Phase 2 and any 
Contingency has been drawn, UKH will be awarded a 15% Override decreased by 0.5%
for each &#xa3;7,500 tranche of Contingency drawn down during Phase 1. Any 
Override will convert pro rata into ordinary shares in the event of a sale of 
MML.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_ClassOfWarrantOrRightsGranted', window );">Class of Warrant or 
Rights, Granted (in Shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_WarrantsTermOfWarrants', window );">Warrants, Term of 
Warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of
Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | 
$ / shares</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember', window );">WOCU Limited "WL", formerly WDX 
Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', 
window );">Business Acquisition, Percentage of Voting Interests
Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions', window );">Loans and 
Leases Receivable, Related Parties, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,055<span></span>
</td>
<td class="nump">&#163; 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,840<span></span>
</td>
<td class="nump">&#163; 150,000<span></span>
</td>
<td class="nump">$ 247,800<span></span>
</td>
<td class="nump">&#163; 150,000<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">&#163; 50,000<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">&#163; 196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_LoansAndLeasesReceivableRelatedParties', window );">Loans and Leases 
Receivable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions', window );">Subsidiary or Equity Method Investee, Cumulative Percentage 
Ownership after All Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.81%<span></span>
</td>
<td class="nump">87.13%<span></span>
</td>
<td class="nump">77.54%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_PreferenceSharesPurchasedInSubsidiary', window );">Preference 
Shares Purchased in Subsidiary (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in 
Pounds per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent', window );">Consolidation, Less than Wholly Owned 
Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent 
(in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend
Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockRedemptionTerms', window );">Preferred Stock, Redemption 
Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon liquidation, sale or listing and after repayment of the 
outstanding loans made by us to WL, other liabilities of WL and related 
transaction costs, the holder of the Preference Shares is entitled to a payment 
equal to three times the subscription price (the &#x201c;Preference Shares 
Payment&#x201d;) paid for such Preference Shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_NumberOfEmployees', window );">Number of Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Sale of 
Stock, Percentage of Ownership before Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a"
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock Repurchased
and Retired During Period, Shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt 
Conversion, Converted Instrument, Shares Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_Revenues', window );">Revenues (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember', window );">WOCU Limited "WL", formerly WDX 
Organization [Member] | Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized', window );">Share-based Compensation Arrangement by Share-based Payment 
Award, Number of Shares Authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od', window );">Share-based Compensation Arrangement by Share-based Payment 
Award, Shares Issued in Period (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember', window );">Bio-AMD Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', 
window );">Business Acquisition, Percentage of Voting Interests 
Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions', window );">Loans and 
Leases Receivable, Related Parties, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">&#163; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend
Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire 
Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,335,000<span></span>
</td>
<td class="nump">&#163; 865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, 
Liquidation Preference, Value (in Pounds) | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember', window );">Bio-AMD UK Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', 
window );">Business Acquisition, Percentage of Voting Interests 
Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember', window );">Bio-AMD UK Holdings Limited [Member] | Dr. 
Nasser Djennati [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember', window );">Bio-AMD UK Holdings Limited [Member] | Dr. 
Andrew Mitchell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_InterestI
nUKMedicalOperationsMember', window );">Interest in UK Medical Operations 
[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_MIDSMedic
alLimitedMember', window );">MIDS Medical Limited [Member] | Subsequent Event 
[Member] | Third Party Medical Detection Device Devloper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems', 
window );"><strong>Note 1 - Nature of Operations and Continuance of Business 
(Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_ClassOfWarrantOrRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Aggregate amount of each class of warrants or rights 
granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_ClassOfWarrantOrRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_JointVentureAggregateProceedsProvidedByPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The aggregate proceeds provided, in a series of payments 
to fund the joint venture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_JointVentureAggregateProceedsProvidedByPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_JointVenturePartnerFundingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);"
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Description of the joint venture funding provided by the 
Partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_JointVenturePartnerFundingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_JointVenturePartnerProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Description of the provisions governing the funding 
obligations of the Partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_JointVenturePartnerProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineItems"
>
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_Note1NatureofOperationsandContinuanceofBusinessDetailsLineIt
ems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The number of employees, including officers, issued 
allotted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_PreferenceSharesPurchasedInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The number of preference shares purchased in 
subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_PreferenceSharesPurchasedInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_ProceedsFromJointVenturePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The amount of proceeds received from a joint venture 
partner to fund the joint venture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_ProceedsFromJointVenturePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_WarrantsTermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Term of warrants exercisable in 'PnYnMnDTnHnMnS' format, 
for example, 'P1Y5M13D' represents the reported fact of one year, five months, 
and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_WarrantsTermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Percentage of voting equity interests acquired at the 
acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-
128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Exercise price per share or per unit of warrants or rights
outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-
122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0"
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Represents the purchase by the parent of an additional 
equity interest in a subsidiary during the period, thereby effecting a change in
total (consolidated) equity attributable to the parent. The purchase of the 
additional equity interest represented by this element increases the parent's 
controlling interest in the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
55<br> -Paragraph 4M<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591554-
111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-
111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-
122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPur
chaseOfInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The number of shares issued in exchange for the original 
debt being converted in a noncash (or part noncash) transaction. "Part noncash" 
refers to that portion of the transaction not resulting in cash receipts or 
payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 5<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-
108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The percentage of ownership of common stock or equity 
participation in the investee accounted for under the equity method of 
accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-
111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>For an unclassified balance sheet, reflects the carrying 
amount of unpaid loan amounts due from related parties at the balance sheet 
date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(e))<br> -URI
http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-
122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-
107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Reflects the amount of new advances made to related 
parties in the form of loan and lease receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(e))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-
122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-
107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_LoansAndLeasesReceivableRelatedPartiesAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The equity interest of noncontrolling shareholders, 
partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">-
Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling 
interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 16<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-
111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The cash outflow associated with the acquisition of 
business during the period. The cash portion only of the acquisition 
price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The percentage rate used to calculate dividend payments on
preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">-
Definition</a><div><p>Value of the difference between preference in liquidation 
and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The redemption terms of preferred stock of an entity that 
has priority over common stock in the distribution of dividends and in the event
of liquidation of the entity. The redemption features of this capital stock are 
solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-
112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-
112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The cumulative amount of the reporting entity's 
undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-
122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-
04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-
122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(30)(a)(3))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of revenue recognized from goods sold, services 
rendered, insurance premiums, or other activities that constitute an earning 
process. Includes, but is not limited to, investment and interest income before 
deduction of interest expense when recognized as a component of revenue, and 
sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Percentage of subsidiary's or equity investee's stock 
owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Per share amount received by subsidiary or equity investee
for each share of common stock issued or sold in the stock 
transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The maximum number of shares (or other type of equity) 
originally approved (usually by shareholders and board of directors), net of any
subsequent amendments and adjustments, for awards under the equity-based 
compensation plan. As stock or unit options and equity instruments other than 
options are awarded to participants, the shares or units remain authorized and 
become reserved for issuance under outstanding awards (not necessarily 
vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuth
orized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Number of share instruments newly issued under a share-
based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeri
od</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Number of shares that have been repurchased and retired 
during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-
04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-
122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-
112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-
02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-
122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Percentage of subsidiary's or equity method investee's 
stock owned by parent immediately after all stock transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransa
ctions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-
gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-
gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_LegalEntityAxis=us-
gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-
gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData"
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-
gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-
gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_NoncontrollingOwnerAxis=biad_DrNasserDjennatiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_NoncontrollingOwnerAxis=biad_DrNasserDjennatiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_NoncontrollingOwnerAxis=biad_DrAndrewMitchellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_NoncontrollingOwnerAxis=biad_DrAndrewMitchellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_InterestI
nUKMedicalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_InterestI
nUKMedicalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_MIDSMedic
alLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_MIDSMedic
alLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_NoncontrollingOwnerAxis=biad_ThirdPartyMedicalDetectionDeviceDev
loperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_NoncontrollingOwnerAxis=biad_ThirdPartyMedicalDetectionDevic
eDevloperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6817803920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2
- Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 17, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems', 
window );"><strong>Note 2 - Summary of Significant Accounting Policies (Details)
[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible 
Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_GainLossOnContractTermination', window );">Gain (Loss) on Contract 
Termination (in Dollars)</a></td>
<td class="nump">$ 248,074<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 248,074<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CurrencyAxis=currency_GBP', window );">United Kingdom, Pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems', 
window );"><strong>Note 2 - Summary of Significant Accounting Policies (Details)
[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign Currency 
Exchange Rate, Translation</a></td>
<td class="nump">1.3242<span></span>
</td>
<td class="nump">1.5717<span></span>
</td>
<td class="nump">1.3242<span></span>
</td>
<td class="nump">1.5717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember', window );">WOCU Limited "WL", formerly WDX 
Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems', 
window );"><strong>Note 2 - Summary of Significant Accounting Policies (Details)
[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="nump">99.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember', window );">Bio-AMD Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems', 
window );"><strong>Note 2 - Summary of Significant Accounting Policies (Details)
[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember', window );">Bio-AMD UK Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems', 
window );"><strong>Note 2 - Summary of Significant Accounting Policies (Details)
[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_ForeignTranslationAxis=biad_AverageRateMember', window );">Average 
Rate [Member] | United Kingdom, Pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems', 
window );"><strong>Note 2 - Summary of Significant Accounting Policies (Details)
[Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign Currency 
Exchange Rate, Translation</a></td>
<td class="nump">1.4319<span></span>
</td>
<td class="nump">1.5233<span></span>
</td>
<td class="nump">1.4319<span></span>
</td>
<td class="nump">1.5233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_Note2SummaryofSignificantAccountingPoliciesDetailsLineItems<
/td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The percentage of ownership of common stock or equity 
participation in the investee accounted for under the equity method of 
accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-
111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Useful life of finite-lived intangible assets, in 
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of
one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Foreign exchange rate used to translate amounts 
denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 
S99<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-
166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Gain (loss) related to the termination of a contract 
between the parties. The termination may be due to many causes including early 
termination of a lease by a lessee, a breach of contract by one party, or a 
failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-
110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The equity interest of noncontrolling shareholders, 
partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_ForeignTranslationAxis=biad_AverageRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_ForeignTranslationAxis=biad_AverageRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6722416048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3
- Patents (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_NumberOfLivePatents', window );">Number of live patents</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_NumberOfProprietaryTechnologyPlatforms', window );">Number of 
proprietary technology platforms</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_NumberOfPatentsNotRenewedAndAbandoned', window );">Number of 
patents not renewed and abandoned</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_NumberOfLivePatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The number of live patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_NumberOfLivePatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_NumberOfPatentsNotRenewedAndAbandoned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The number of patents  not renewed and 
abandoned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_NumberOfPatentsNotRenewedAndAbandoned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_NumberOfProprietaryTechnologyPlatforms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The number of proprietary technology platforms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_NumberOfProprietaryTechnologyPlatforms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6721864576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3
- Patents (Details) - Schedule of Finite-Lived Intangible Assets - USD 
($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract', 
window );"><strong>Schedule of Finite-Lived Intangible Assets 
[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">$ 174,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', 
window );">Patents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', 
window );">Patents</a></td>
<td class="num">(9,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_FiniteLivedIntangibleAssetsNet', window );">Patents</a></td>
<td class="nump">$ 165,573<span></span>
</td>
<td class="nump">$ 165,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_ScheduleOfFiniteLivedIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Accumulated amount of amortization of assets, excluding 
financial assets and goodwill, lacking physical substance with a finite 
life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 
50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-
109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of foreign currency translation gain (loss) which 
increases (decreases) assets, excluding financial assets and goodwill, lacking 
physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount before amortization of assets, excluding financial 
assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 
50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-
109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount after amortization of assets, excluding financial 
assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name
Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 
50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-
109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6815340720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4
- Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="2">7 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember',
window );">Affiliated Entity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note4RelatedPartyTransactionsDetailsLineItems', 
window );"><strong>Note 4 - Related Party Transactions (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party 
Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,156<span></span>
</td>
<td class="nump">$ 10,030<span></span>
</td>
<td class="nump">$ 99,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_CostsAndExpensesRelatedParty', window );">Costs and Expenses, Related 
Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">&#163; 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember',
window );">Affiliated Entity [Member] | Bio-AMD, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note4RelatedPartyTransactionsDetailsLineItems', 
window );"><strong>Note 4 - Related Party Transactions (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating Leases, 
Rent Expense, Minimum Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-
gaap_ChiefFinancialOfficerMember', window );">Chief Financial Officer 
[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note4RelatedPartyTransactionsDetailsLineItems', 
window );"><strong>Note 4 - Related Party Transactions (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party 
Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,563<span></span>
</td>
<td class="nump">46,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-
gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer 
[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note4RelatedPartyTransactionsDetailsLineItems', 
window );"><strong>Note 4 - Related Party Transactions (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party 
Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,138<span></span>
</td>
<td class="nump">36,461<span></span>
</td>
<td class="nump">$ 59,290<span></span>
</td>
<td class="nump">$ 72,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember', window
);">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note4RelatedPartyTransactionsDetailsLineItems', 
window );"><strong>Note 4 - Related Party Transactions (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party 
Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember', window );">Bio-AMD Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note4RelatedPartyTransactionsDetailsLineItems', 
window );"><strong>Note 4 - Related Party Transactions (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', 
window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling 
Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember', window );">Bio-AMD Holdings Limited [Member] | 
Affiliated Entity [Member] | Bio-AMD, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note4RelatedPartyTransactionsDetailsLineItems', 
window );"><strong>Note 4 - Related Party Transactions (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating Leases, 
Rent Expense, Minimum Rentals</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="nump">&#163; 750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_Note4RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_Note4RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Costs of sales and operating expenses for the period 
incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The equity interest of noncontrolling shareholders, 
partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>This element represents the payments that the lessee is 
obligated to make or can be required to make in connection with a property under
the terms of an agreement classified as an operating lease, excluding contingent
rentals and a guarantee by the lessee of the lessor's debt and the lessee's 
obligation to pay (apart from the rental payments) executory costs such as 
insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 
50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-
112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> 
-SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI 
http://asc.fasb.org/extlink&amp;oid=7661868&amp;loc=d3e34039-
112682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> 
-SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> 
-URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-
112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Amount of transactions with related party during the 
financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-
107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-
107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-
107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-
gaap_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_LegalEntityAxis=biad_BioAMDIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biad_BioAMDIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-
gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-
gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-
gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-
gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
(e.nextSibling.style.display=='none') {
{ e.nextSibling.style.display='none'; }
function toggleNextSibling (e) {
if
e.nextSibling.style.display='block';
} else
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6747046992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5
- Deferred Revenue (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue 
Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,402<span></span>
</td>
<td class="nump">&#163; 642,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645,534<span></span>
</td>
<td class="nump">&#163; 436,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_GainLossOnContractTermination', window );">Gain (Loss) on Contract
Termination</a></td>
<td class="nump">$ 248,074<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 248,074<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The carrying amount of consideration received or 
receivable as of the balance sheet date on potential earnings that were not 
recognized as revenue in conformity with GAAP, and which are expected to be 
recognized as such within one year or the normal operating cycle, if longer, 
including sales, license fees, and royalties, but excluding interest 
income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-
107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 
13.A.4(a).Q1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(b).Q2)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(b))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> 
-SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 
13.A.3(c).Q3)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-
122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Gain (loss) related to the termination of a contract 
between the parties. The termination may be due to many causes including early 
termination of a lease by a lessee, a breach of contract by one party, or a 
failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-
110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> 
-SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6746821264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6
- Segmented Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 17, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note6SegmentedInformationDetailsLineItems', window );"><strong>Note
6 - Segmented Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NumberOfOperatingSegments', window );">Number of Operating 
Segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember', window );">WOCU Limited "WL", formerly WDX 
Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note6SegmentedInformationDetailsLineItems', window );"><strong>Note
6 - Segmented Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues', window );">Segment Reporting Information, Description of Products
and Services</a></td>
<td class="text">development of a technology designed to mitigate currency risk 
through our 99.81% owned subsidiary, WL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="nump">99.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember', window );">Bio-AMD Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note6SegmentedInformationDetailsLineItems', window );"><strong>Note
6 - Segmented Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember', window );">Bio-AMD UK Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note6SegmentedInformationDetailsLineItems', window );"><strong>Note
6 - Segmented Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method 
Investment, Ownership Percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_Note6SegmentedInformationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_Note6SegmentedInformationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Description of the types of products and services from 
which the reportable segment derives its revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-
108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_DescriptionOfTypesOfProductsAndServicesFromWhichEachReportableSegmentDerive
sItsRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The percentage of ownership of common stock or equity 
participation in the investee accounted for under the equity method of 
accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 
50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-
111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Number of operating segments. An operating segment is a 
component of an enterprise: (a) that engages in business activities from which 
it may earn revenues and incur expenses (including revenues and expenses 
relating to transactions with other components of the same enterprise), (b) 
whose operating results are regularly reviewed by the enterprise's chief 
operating decision maker to make decisions about resources to be allocated to 
the segment and assess its performance, and (c) for which discrete financial 
information is available. An operating segment may engage in business activities
for which it has yet to earn revenues, for example, start-up operations may be 
operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_WOCULimit
edWLFormerlyWDXOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_Bio-
AMDHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biad_BioAMDUKH
oldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6746992944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6
- Segmented Information  (Details) - Schedule of Segment Information - USD 
($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting
Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 731<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 1,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLoss', window );">Segment net income (loss)</a></td>
<td class="nump">144,717<span></span>
</td>
<td class="num">(354,132)<span></span>
</td>
<td class="num">(8,558)<span></span>
</td>
<td class="num">(576,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_Assets', window );">Segment total assets</a></td>
<td class="nump">247,894<span></span>
</td>
<td class="nump">1,654,077<span></span>
</td>
<td class="nump">247,894<span></span>
</td>
<td class="nump">1,654,077<span></span>
</td>
<td class="nump">$ 1,274,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StatementBusinessSegmentsAxis=biad_WOCULimitedWLFormerlyWDXOrganizationMemb
er', window );">WOCU Limited "WL", formerly WDX Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting
Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLoss', window );">Segment net income (loss)</a></td>
<td class="num">(2,168)<span></span>
</td>
<td class="num">(12,025)<span></span>
</td>
<td class="num">(4,018)<span></span>
</td>
<td class="num">(33,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_Assets', window );">Segment total assets</a></td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StatementBusinessSegmentsAxis=biad_Bio-AMDHoldingsLimitedMember', 
window );">Bio-AMD Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting
Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLoss', window );">Segment net income (loss)</a></td>
<td class="nump">239,041<span></span>
</td>
<td class="num">(20,213)<span></span>
</td>
<td class="nump">226,444<span></span>
</td>
<td class="num">(36,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_Assets', window );">Segment total assets</a></td>
<td class="nump">177,543<span></span>
</td>
<td class="nump">1,168,133<span></span>
</td>
<td class="nump">177,543<span></span>
</td>
<td class="nump">1,168,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', 
window );">Corporate Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting
Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_NetIncomeLoss', window );">Segment net income (loss)</a></td>
<td class="num">(92,156)<span></span>
</td>
<td class="num">(321,894)<span></span>
</td>
<td class="num">(230,984)<span></span>
</td>
<td class="num">(506,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_Assets', window );">Segment total assets</a></td>
<td class="nump">$ 67,032<span></span>
</td>
<td class="nump">$ 483,272<span></span>
</td>
<td class="nump">$ 67,032<span></span>
</td>
<td class="nump">$ 483,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date 
of all assets that are recognized. Assets are probable future economic benefits 
obtained or controlled by an entity as a result of past transactions or 
events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-
122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> 
-SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-
03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-
122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The amount of interest income and other income recognized 
during the period. Included in this element is interest derived from investments
in debt securities, cash and cash equivalents, and other investments which 
reflect the time value of money or transactions in which the payments are for 
the use or forbearance of money and other income from ancillary business-related
activities (that is, excluding major activities considered part of the normal 
operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>The portion of profit or loss for the period, net of 
income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Glossary Net Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2:
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 
45<br> -Paragraph 28<br> -URI 
http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-
108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> 
-SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI 
http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-
109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-
04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-
122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> 
-SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-
04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-
122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> 
-Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other 
Comprehensive Income<br> -URI 
http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-
122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Line items represent financial concepts included in a 
table. These concepts are used to disclose reportable information associated 
with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_StatementBusinessSegmentsAxis=biad_WOCULimitedWLFormerlyWDXOrganizationMemb
er">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_StatementBusinessSegmentsAxis=biad_WOCULimitedWLFormerlyWDXOrganizationMemb
er</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_StatementBusinessSegmentsAxis=biad_Bio-AMDHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=biad_Bio-
AMDHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-
gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-
gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment 
*/</script><script type="text/javascript">
function toggleNextSibling (e) {
if
(e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else
{ e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" 
cellspacing="2" id="idp6605391520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7
- Subsequent Event and Commitment (Details) - Corporate Joint Venture [Member] -
Subsequent Event [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 01, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_Note7SubsequentEventandCommitmentDetailsLineItems', 
window );"><strong>Note 7 - Subsequent Event and Commitment (Details) [Line 
Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_ClassOfWarrantOrRightsGranted', window );">Class of Warrant or 
Rights, Granted | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 
'defref_biad_WarrantsTermOfWarrants', window );">Warrants, Term of 
Warrants</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" 
href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of
Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_ClassOfWarrantOrRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Aggregate amount of each class of warrants or rights 
granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_ClassOfWarrantOrRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" 
id="defref_biad_Note7SubsequentEventandCommitmentDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-
space:nowrap;">biad_Note7SubsequentEventandCommitmentDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_biad_WarrantsTermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Term of warrants exercisable in 'PnYnMnDTnHnMnS' format, 
for example, 'P1Y5M13D' represents the reported fact of one year, five months, 
and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biad_WarrantsTermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>biad_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Definition</a><div><p>Exercise price per share or per unit of warrants or rights
outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
References</a><div style="display: none;"><p>Reference 1: 
http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name 
Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 
S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI 
http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-
122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ 
Details</a><div style="display: none;"><table border="0" cellpadding="0" 
cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_dei_LegalEntityAxis=us-
gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-
gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" 
style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-
gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" 
onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- 
Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-
gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace 
Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>@"%,;X[)9J4@B,WHX*[O]C\ E!+ P04    " #!A@])>Q>T)50!  !8$
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M=A01[.U/.",U<T^S_GT>_P!02P,$%     @ P88/29;?K>44 P  F D   \
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MAKYWI"=RJ>4;ZU^HC2'1!@^L%N;K'2Y"LF:@^%Y#/F"L6C/V\">.+,U-P):
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MP+4($><QY6#75,!+%W6=G AZS(9ZL[%+*J"D4M?AB:#5L+A<)\[L2Z3<0\'
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MDJN2E)7^??F0%#LPD(NXNYJ9G>6CG-"\V1[ D7<EM3W0WKEASYBM>U#<WN$
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M-AY A^C M\\>]I0,_OULB83.A?"SCTVZ4BEQ.*X/9'NE]3]02P,$%     @
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M"!]\;-*52HG#87D@ZRNM_@-02P,$%     @ P88/2;&!R2:E 0  L0,  !D
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MWK^?-9'0NA!^\[%)5RHE#H?E@:ROM/H/4$L#!!0    ( ,&&#TD6;2"2I@$
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M"CR$9*[#+7(=D3%$X"'JO][]EO'O4_WQ2!RTG'6!$QV)F PHAH!B)B!@S*:
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M[1=DVC=E]K0'W_?IOG0T^1]02P,$%     @ P88/297*\%T6 P  ) X  !D
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M0!/(M"V"AU^0I840'7F+ &C8#(;-F'Y!P)YBS5@(C9GY"@V;(; 9TWN(PRN
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MN+V.UR(&5HV72[Z^-/5_4$L#!!0    ( ,&&#TF6S\\QRP$  .<$   9
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;(U46V^;,!3^*Q;OJ[F3102I9:JZ
MATE5'[9G)QR"51LSVPG=OY\OA"85;?*"[<-W.\:X'(5\51V 1F^<]6H3=%H/
M:XS5K@-.U)T8H#=O6B$YT68I]U@-$DCC2)SA. QSS GM@ZITM6=9E>*@&>WA
M62)UX)S(?P_ Q+@)HN!4>*'[3ML"KDH\\QK*H5=4]$A"NPGNHW6=6X0#_*8P
MJK,YLMFW0KS:Q<]F$X0V C#8::M S'"$&ABS0L;X[Z3Y;FF)Y_.3^J/KUJ3?
M$@6U8']HHSL3-@Q0 RTY,/TBQB>86LBLX$XPY9YH=U!:\!,E0)R\^9'V;AS]
MFU4XT98)\42(9T*4?DE()D+R@8!],M?7#Z))54HQ(C40^[&CM8%+*V*4D6E&
MF7URFM+M5%4>JSA/2GRT0A>8V&$>)LSGB-HCLGR&8!-@,45\F<(7[^,I17I=
M(+D42+U ,@EDER%[ARE\&QX3%>DJ"J_[I(L^Z5<^N??QF!LLLD6+[ 8+C_GV
M/4Z*ZS;YHDU^PXYY3)1G69%\#JMGV"I=?8B#S\[D0/;PB\@][17:"FV.MSN%
MK1 :C$QXEP6H,[?.O&#0:CLMS%SZ']$OM!A.U\I\MU7_ 5!+ P04    " #!
MA@])PJ=M*'(#  #[#P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R5
ME]MNHS 0AE\%\0 %FW-$D)I3DTHK57NQ>TT3)T$%G 6GZ;[]8CS0-#M0YR:
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M2Z<O#&V96<<$P\Q",6,V*X6086+3513VC-6T!&\.-;%0*3A$P[7,@0GLD>8
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MO52 J16)3Y[LQ0+^H5J O5R 1[TPC*L6I(;!KN4W,Q @Q^J43[TAC]1B>\G
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M.+RL\AAVQY81TB'2@FNH9KB&*9$N<GY8%1E; $O&&E@Q[)DA=TZ4X$X30_5
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MG-VHFKNCOL$(]"@B'LQ(;L"!"4 AR")5T%9!<_P$U&B@:Z)0B2IP*/B-T":
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M$9<TG-<9)Q>L;M<YK<?T9M#@V=8^4YKH[$H2RKC_PHL=D6YX2&T03RK*'@,
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MTH!8T,+?Y4HA[:+5W"3$:/:\C($ISK$34T'Z /G/9AAS'^R3SR?'M$QF;->
MY$42&6;C9IK \Y^(\_.K][=2_L,Q)Q+)681]/0.'4I>J>$T>S3*@GO6*J@38
M^8"FF56EV<C!YJAIY7 8)=,)[(!*'&")H^Z?8=TV6JFQMWJAR931!6OP?VO6
M>JG9BBX"5U+2.H\^*VJ;JWU^^'756*&.!Z2#6+M;4I T6*K'-Y=ZHX+D<\3R
M'3=BO97N!SW/="N_=D2->7B,9<25%87XDYV=[$'3FL$X+@+R.KK%J6@U1NS$
M1^$><PDP>;F"FN/:;2Z,CMM""C\>C2>&(95 (_A3R:@E#FI7BRX[7K'>#-FZ
MO'/716W]XS*D[FDAJ51Z2%UTC;BUV?QB:M'Q">P$NDF7C>US*][<+%Q8()V"
M4->B+<$@%BN5N).C(YCSX6S9V9D=B\PA3A6M)S"9U($Y^XIJX62D^6J5*E+B
M19 7;O--!O3-.E^JSS"RTR(3VUW38Y/,H3W+S*2Y:>)P:/PS&ZMDVUQ$)@/3
MI0I:#PRS$G-*4@'K=_RXM?0ZNJL!@N6MQ@P%^6S"VPXXP,[CW74FS5'^GVAA
MRM)-#:8OA^,#O[\_[GD;+]:I>G*L)BAI5C,=G]/? @U\N-&WPUB;3RMF166X
M#CW,YY8.25A[O4W9:JIG5>5(/_W=YKZK%<6J.FNK'J5S[QK% JZ6A/%)/&#(
M+>0NES+72C7VP'/@MOT-=IVLE>CM:*[5 FG6M[I,A$P9+.I@GT6+MB!$!?/H
MOEHQZL6WA,S=?H^5N2#%THP4/JHE\X60&Y:#17=M$3*IO@VH>HM#I>>R_-TT
M.][?JHY;G_*&,A<\ZB) &--)_J8B$08F>W0#T+8H^0-/4VW%,:;XVEBS*R!!
M%T@=33:P:.:5@,&8=.%5&'NUN?2#BJ=C$Z7S>D4,\AMU1V$V!WA<$DB:E\G@
M>HW,@.7D8SJ*H]E*_(NRCPIOT!L-QT.@M)>OOWESY1M<V]_'H\&A_IUYR./G
MF[3,-]D';6_#?)/A:*1_1WUPQB*0K]-SG1 WV!LER,(<Q99;KCEA/OOVZ.:-
MCJX=W7SPWJ4]^G6W#W+DN&+.;K]/5Z .'PSZ.Z\]<W5P;MV+[LM'@/NU$Y")
M<O$=LPLKPB:=&/72!7S88;C%A%Y@C2R>980G]^>D=BO(#$@'"FP1NZXG0]O)
M-T\U^UB[F;ARS*761ILC.KT= Z*HJV*W7-$]R!_M2$569IT7N+&2^P+%$^&@
M8V/9W6DP^Z1"6]SC'BN)CR+TYWAG+U_Z4G5_4)4PMW\E/VF:.6PDI79P/QEO
M>E (U[".5MTZ%O4<.:I8P<*./.?$F?AP%=:5*D+3HT.S?/<"-'?!RS3$CK_$
M9+#;,5'*?>I+OOF]EPMQZCS_2()U1)2M1'R<AM9-28**"2DW.:D@#KXY.KJB
M]K)Q0&M<8M: 6F)67D2PI5:?Z.3$.Y](\]-&!/N976/9FK[:;/:KNY]GI('.
MUEH/<"Q7UC")6>^RE6@(^LG3,L?%S#JVD_1CQ1=4HWKX_=FIE.8GT@]07*\.
M4C@QF7/RD(QLG6:$Q6=WE*$3)6&)*0[F&I'U2IH D\NP9(=FV\%#(0?+R"U-
MZWB$=='@M$Z+:].8A6^9T!=%F&QP]+A57[<7&W'NG+G&0(+S<O5%$$KO!:Q?
M@)4(7P/;GNZ%85.)G =2Y\*-P)LW>/@=UW2DF1/3I#.BTY)-Y6D'?QWOXE)?
M7%4RN]R>/S=6\.W6HNK;8/44Q(J'_<GNN+_SHJ>WA\/:M I#:T[LH!)<1*T>
M(QLVQMC&)ZC+46<HE;(:D0([ J+-&(!.UM'=$8S5D*9%[;J>ZL8P,[9"1'(?
MA7,92C=-[/E&+FM*X\S&RA"T71J@A_<3H@?".<V1T[F?.D1+S(8-&C[\39JC
MM1>23!-@"!"]+O%O2'525/,PS0U]?9D&Z%J\)XIE4/.VRF,1]ON# Q3VEA4C
M_*B:9O<-)7.:7)>/VH!^3^%$=A@=82ZH3J>$,TE)RE>.8^,]R7^8&N70&V 8
M'-?6W=YPO&O%K4^43N:3"^Y[6,U/&=.X1Q/A8/%7;>W%DSCAC-QSKS*C'V8Z
M(RQH+B$S2]"]Q429HXH0Q69 WO#92##5)>)ADXC_FS@A+>9OR G%1?(026*?
M5"!)[3\C7>&XVJ[T&#@JF#1@WPE1[O7W=@C[9BO]0X-8*71&-L1&J58(.)>7
M.]=3MFC.]F.M.>K,S(;:BI3[  -#1&#O/9,@VC6*N<5(?YMBVGAB82FV;9F0
M<YRQ:C]'S<TIA,IG &4"-BT\-YK0MNHM>NAHTVD!=@A2E0-WU)U>!5;_M32X
M9^[2@",'NH#68T5_JA:9ME)J_]"][<:OFR]WJ0@WN6V _?YS[5XW.W4CBZA^
M:BL_<]SH1B7%;JP)&^[:P*H&5],DQ>;F$K!CTI9J$UJ5]KC@54CZG*',DIQ
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M[(-Q-!YM[>V#P3?<HAO_#L</ 6/2"HQ?M67:*6YY")MYN;4_&E3VC'O=VAZ
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M0E5.>+4<2UMS%[99I"N&;-47"22C!C36[-8IO/AX_L*7/D[QVOMX\B_>I1,
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M=(,2 -,PV8QWDPNIFJ62+^MDT^@T:!P>12S'7TC$-*@*PR 8*8I9X%J-!O1
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MN,Z@H)MC\%!"PA>L=A/,'^,U__<NQ]^O]'BWN[9?Y7GQQ_\'4$L! A0#%
M  @ P88/2=;@/!Z7 0  NA$  !,              ( !     %M#;VYT96YT
M7U1Y<&5S72YX;6Q02P$"% ,4    " #!A@])2'4%[L4    K @  "P
M        @ '( 0  7W)E;',O+G)E;'-02P$"% ,4    " #!A@])>Q>T)50!
M  !8$   &@              @ &V @  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #!A@])T=&0NFX"  !1"   $
M@ %"!   9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,&&#TFSZ!:=/P$
M &D#   1              "  =X&  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( ,&&#TF97)PC$ 8  )PG   3              "  4P(  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ P88/2=_8A?-F @  K L   T
M             ( !C0X  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #!A@])
MEM^MY10#  "8"0  #P              @ $>$0  >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ P88/2:+N1@)F @  P @  !@              ( !7Q0
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,&&#TD'ZH"Y
ME ,  /\/   8              "  ?L6  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " #!A@])/C2PGA,"  !.!P  &
M@ '%&@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ P88/
M2;<845\!!   )1(  !@              ( !#AT  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( ,&&#TF?0??'R (  #8*   8
M      "  44A  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" #!A@])8%F>FLP#  !'$0  &               @ %#)   >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ P88/29T2PFNF 0  L0,  !@
M             ( !12@  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( ,&&#TE8<%Z^I0$  +$#   8              "  2$J  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #!A@])9'%J#Z4!  "Q
M P  &               @ '\*P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ P88/236C1O&F 0  L0,  !D              ( !URT
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #!A@])L8')
M)J4!  "Q P  &0              @ &T+P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( ,&&#TE^Y0AHI0$  +$#   9
M  "  9 Q  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MP88/219M()*F 0  L0,  !D              ( !;#,  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " #!A@])9K1T _@!   3!@  &0
M            @ %)-0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( ,&&#TFHKKM7I@$  +$#   9              "  7@W  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ P88/2>&Q4WNF 0
ML0,  !D              ( !53D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " #!A@])*WJL2PP&  " )   &0              @ $R
M.P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,&&#TF5
MRO!=%@,  "0.   9              "  75!  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ P88/2?)]X)/  0  =00  !D
M     ( !PD0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,&&#TG!6/.'K ,  /$0   9              "
M 4Q1  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ P88/
M28Y=G#2H 0  !P0  !D              ( !+U4  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " #!A@])-()O%:L[  #>\   %
M        @ $.5P  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P4&     "( (@ @
)"0  ZY(
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */
var Show = {};
Show.LastAR = null,
Show.hideAR = function(){
Show.LastAR.style.display = 'none';
};
Show.showAR = function ( link, id, win ){
if( Show.LastAR ){
Show.hideAR();
}
var ref = link;
do {
ref = ref.nextSibling;
} while (ref && ref.nodeName != 'TABLE');
if (!ref || ref.nodeName != 'TABLE') {
var tmp = win ?
win.document.getElementById(id) :
document.getElementById(id);
if( tmp ){
ref = tmp.cloneNode(true);
ref.id = '';
link.parentNode.appendChild(ref);
}
}
if( ref ){
ref.style.display = 'block';
Show.LastAR = ref;
}
};
Show.toggleNext = function( link ){
var ref = link;
do{
ref = ref.nextSibling;
}while( ref.nodeName != 'DIV' );
if( ref.style &&
ref.style.display &&
ref.style.display == 'none' ){
ref.style.display = 'block';
if( link.textContent ){
link.textContent = link.textContent.replace( '+', '-' );
}else{
link.innerText = link.innerText.replace( '+', '-' );
}
}else{
ref.style.display = 'none';
if( link.textContent ){
link.textContent = link.textContent.replace( '-', '+' );
}else{
link.innerText = link.innerText.replace( '-', '+' );
}
}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
/* table */
..report {
}
}
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
}
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>90</ContextCount>
  <ElementCount>137</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Disclosure - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - CONDENSED CONSOLIDATED BALANCE 
SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS 
(Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS 
(Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF 
OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND 
COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
<Position>4</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF EQUITY 
(Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF EQUITY 
(Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH 
FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 
(Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Nature of Operations and Continuance
of Business</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusiness
</Role>
      <ShortName>Note 1 - Nature of Operations and Continuance of 
Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Summary of Significant Accounting 
Policies</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolicies</Ro
le>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Patents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note3Patents</Role>
<ShortName>Note 3 - Patents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Related Party 
Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note4RelatedPartyTransactions</Role>
      <ShortName>Note 4 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note5DeferredRevenue</Role>
      <ShortName>Note 5 - Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Segmented Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note6SegmentedInformation</Role>
      <ShortName>Note 6 - Segmented Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Subsequent Event and 
Commitment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note7SubsequentEventandCommitment</Role>
      <ShortName>Note 7 - Subsequent Event and Commitment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accounting Policies, by Policy 
(Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      
<ParentRole>http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPolici
es</ParentRole>
      <Position>14</Position>
</Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 3 - Patents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note3PatentsTables</Role>
      <ShortName>Note 3 - Patents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioamd.com/role/Note3Patents</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 6 - Segmented Information 
(Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note6SegmentedInformationTables</Role>
      <ShortName>Note 6 - Segmented Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      
<ParentRole>http://www.bioamd.com/role/Note6SegmentedInformation</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 1 - Nature of Operations and Continuance
of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBusiness
Details</Role>
      <ShortName>Note 1 - Nature of Operations and Continuance of Business 
(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      
<ParentRole>http://www.bioamd.com/role/Note1NatureofOperationsandContinuanceofBu
siness</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 2 - Summary of Significant Accounting 
Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/Note2SummaryofSignificantAccountingPoliciesDeta
ils</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies 
(Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
<LongName>018 - Disclosure - Note 3 - Patents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note3PatentsDetails</Role>
      <ShortName>Note 3 - Patents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioamd.com/role/Note3PatentsTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 3 - Patents (Details) - Schedule of 
Finite-Lived Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/ScheduleofFiniteLivedIntangibleAssetsTable</Rol
e>
      <ShortName>Note 3 - Patents (Details) - Schedule of Finite-Lived 
Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioamd.com/role/Note3PatentsTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 4 - Related Party Transactions 
(Details)</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/Note4RelatedPartyTransactionsDetails</Role>
      <ShortName>Note 4 - Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      
<ParentRole>http://www.bioamd.com/role/Note4RelatedPartyTransactions</ParentRole
>
      <Position>21</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 5 - Deferred Revenue 
(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note5DeferredRevenueDetails</Role>
      <ShortName>Note 5 - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioamd.com/role/Note5DeferredRevenue</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 6 - Segmented Information 
(Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/Note6SegmentedInformationDetails</Role>
      <ShortName>Note 6 - Segmented Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
<ParentRole>http://www.bioamd.com/role/Note6SegmentedInformationTables</ParentRo
le>
      <Position>23</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure -  Note 6 - Segmented Information  (Details) - 
Schedule of Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioamd.com/role/ScheduleofSegmentInformationTable</Role>
      <ShortName>Note 6 - Segmented Information  (Details) - Schedule of Segment
Information</ShortName>
      <MenuCategory>Details</MenuCategory>
      
<ParentRole>http://www.bioamd.com/role/Note6SegmentedInformationTables</ParentRo
le>
      <Position>24</Position>
    </Report>
    <Report instance="biad-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 7 - Subsequent Event and Commitment 
(Details)</LongName>
      <ReportType>Sheet</ReportType>
      
<Role>http://www.bioamd.com/role/Note7SubsequentEventandCommitmentDetails</Role>
      <ShortName>Note 7 - Subsequent Event and Commitment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      
<ParentRole>http://www.bioamd.com/role/Note7SubsequentEventandCommitment</Parent
Role>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biad-20160630.xml</File>
    <File>biad-20160630.xsd</File>
    <File>biad-20160630_cal.xml</File>
    <File>biad-20160630_def.xml</File>
    <File>biad-20160630_lab.xml</File>
    <File>biad-20160630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001185185-16-005234-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001185185-16-005234-xbrl.zip
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M11=KG#D34]>[W[^='WT]]8<^*-MOIY^B>$CB8/+M^,_S>."$_C\.6D$[M<?
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MN+4(X.6*GP+TA>"\OB&:X[I,Z[ MSQE[/N8% "-Z>%](/V6A?%K?#X% OA,
M]/ %*Z)YX]P2K4=(J(WPKC&&YT;C. %2IEH::2G,$H\#PL@<D\$XX&0',N./
M5\0=Q\Q=@4^(TRJJPZ&?)'AU_QJ?R_G(?7_U\2C_TWO_9C]GMR,28X2-YH?]
M*!ZRJW\<-T2V]$ '!%$"+)C %S&JX D\B:G( +:/3P(/!C56G:T57P(DQAYE
MW3L_O=$&C %@:/B%C' ,A]W+()9',4SHCQ C.>IRA$>Q%@W]-)U"8Y3,0&1#
M<P+X>3RXH?CDVPB,&_CD%AY/;YR4_B*O?NAX0'T01?COWV-4=C#)T/E!Z),R
M\@!Q&A B( X:*OM;S]8G(5U"-/)#!!^X#,9U!I1N#?K3VO@\8E,E:'3WG,0'
MTB3TF]ILQ$C9#XB; A4#H(8H@ &KO[OQW1O!GC 9,!1C6G@%9"9&;BJ\$!(7
M="88*TA,@#+!#K!]QX_A301K!CR <I_)"15*V&:(9ND-#3<;"B&589*,@Y0^
M$!55MPLG<*T?1'>)!ES#,.+?:V#K@BR,Z!:8:&"0PIS30^/!9U]#593# _ Y
M],<(;X0*S,A9F,D=SH1BG0@]X^/9T!\N1-:8T,@W/@3(F("8M4;AG"(IF&L)
M&6*]Z4U," 6YO/+JA<<4\(Q>/M5"GN_2LO9",8I) +(>T<C]")@$5P%SHGPG
MXUX"HHLD!@&.8>4:AP:^\F&&"5A5.#VRR3',A"%RFF4P&+9?CJ\I-9:3U034
M8> AVF)06\@K\,Y?XY"6G&%*.AH#&O.A:\BIQ&[ E@3((L@O, UOEQ'=;!3V
M%TE!YQM8]WTB-$9,3P.H6#X!SP.Z]_X @ )XF0)-]TNQ]R$SPH-G3@Q:0O#6
MD]!U99.QPBK<>O[DWI,&=9]HKV7SA/\DFRA:V829X@(/P)$?N".S?QLGLW\#
MQB[81MIK5)\$]X ?>+A#+?\I(/?:IS$)$NTCV"J#"5\%LOF9$_B]L7;F4R,F
M8;^\T>[@->#D* 8&I7+"N9DV=T+2?2&WCN=H&4<:E"/U%NHO$@Y@!Q:O]+AQ
MCV^!6@NB.#?34,%'MP2V,/AQ *S4 .-#0,(_:1ZA6Y;8/H%Z8.=LOT8[#[5#
ML/X"#;4"$ <TQ!W5UH09DH H!QX9P%Z"6H>N[B)PJ US!E0"K<(L83HB_R9[
MG'W[IF U,@L")AGBPUZN^4)R!_Q &<-#0R-":Q68 YY)1,(.,$6!Q\'.%$06
M;$"-\P(X5^,>^YOMAF.8?LA^2?.B7\P,D]_CP.]K7T?<J$*=/![R;9_OB.Q9
M]G:"-ABR'KGWDY3P<V,.A>;B78K'P$!W&X_[%F/E9K*+YEO5(V IW_JWN'WR
M0Y(6PJ->$2O:88);/3?9>Q/MZ,89X6;<-0_WC8XNB<8EN?41).JS2I&+Z"Q1
M0)!H(S3P"PNE,H?20R_R /O\9(0F&-(0X8:?B^!0:R%% (1=B<\"P22Y@Z4Z
M$JIA@\%%PK"'<>J[>,2HY+CI7P7/Y9L3WF&ANPR?J5 -1?Z7%B>3%P&6YSH)
M97Z[ VD!#4"0$LZ0[;HPCE@MY1V&)U W?.U,9U&,[9<]$_CI&SL+X6J867]^
M?81J[ >1]G[\[L,X" @<X[0/D1.CF]\CW.*=#&'C*RCB#R>'A2U@^Q74\9B>
M*2A/ .: IIEER5B.ZO,^=:11HZ>1F4 2 \-:0(A@8,I4\);@.U @-"Z#2A1+
MRFEH SBLXQ>@QAR<"8_,26;1\\?@")?3(F,V)X$C5RI<1DREL1G0IA,3S%6Q
M=*RIW5 []8?4,"SLZI\^?=1.4Z^XN0KF2*34$H2&/XP*@2GA[ NF;Q O3.WN
ME=4N%PEZ$L#-=**97;J5MO>S4=B&FFW"'AST@VA$E\15B+S) G>,^Z!Z&7GY
M-LNJ/>$7YR"25P1&NW1&I+CF\ZO+XGI'<>2-W70'=MN/&1:OT =#C7*J=W3
MIM-'7H,C/>-%4!YCW %!3P5C:MW@83P:<?\*L)#3 [2A3YQ2#K PHJ?0"%"7
M(.HD'D_P^3#2@B@<,%\\$);R7X$N_%@'/T=#./GA]+<^C10&JA.?'GT=,($
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MW&L!V'9[OVG_O/T,F]_=R(%S8'<A(R#O\EM YB%$ @"&T.;.Z8"DX7W+>8P
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M\5\DQ#,.'0>_/PR]&%9^YJ=@X01@_B/LZ(+.1O7H35C*([P2+22W+/O2P^C
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MLGZFL+7UJ=7XN -,M6/&A_/VQOGWG)L:,'$R EB!R8/)OB9\,7Y.;@T^440
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M:TN"G>N7M_>].*!;ZO\'4$L#!!0    ( ,&&#TDQNA9,*0L  .-=   1
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M?6U^ZS-#I>2G9V9^W-[#6FF^D;SEFI^7#C)9*4+4>Z'4?ZG.P_F_4$L#!!0
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M@1B"4L+29O.OS.@Z8"'RDP1R.1]2RDEV@$)!&9R?GO 8&U$$8D-]PQ:Y.H2
MI9U$[-<BC*4X4^DV&T.2J")[$#,NRSZ^P@+J:W+L+IQ";,N,5B%(V8Y68?3$
MFV;WF*7]/;8,WB8520Y;M+ [C78LXO#!&$$#FXF0V;=N+:Q9F/%.\M9&SM8T
MI%)$B\FRZ-0T+-.TL&.&O+TK/T:JZ5:\SN#9W=KB,FS2C33EZCH2U@&C Y#>
MP@TP00Q(R9G#H%)?R\C3+I3=\&50Q+S)-@5K4'=F(7'\1> 88HJF<'FP<&U1
M^L4B' POPZ&VZ!. J4NU_F13YB[2VL,^F$O*N&(W\RT[CPQ5PS?[HCA>%S*
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M.+)^WU_A];Z<4UL>VW$ND]1DM^1;XHUM:2TGF3E;6RF:A"3,4*0#DK(UO_X
MO$@D18  B"8E12\SCB2BP>\#&HU&H_N7?SY/W;T9(@'VO??[QS\=[>\AS_8=
M[(W?[W\>'O2&9U=7^__\Q][>7W[YZ\'!W@?D(6*%R-E[F._AL_\)I_^[=[!W
MYD\?AS;>N_)"^JT=XAFBGWFT7?IO^OTD#!_?'1X^/3W]9-.?!C8F*/ C8J.
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MK0%8;[J:CEI;1KH']_X=HJ:&C5U4D'WOL]<8$)]M69W3^>> )8>3GDZFSO(
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M[V@;T"WQA@^ \QY<[&"+S/NDRK@X2U(9X1G*:2;FO@DF^+$WHJJIY[J%BG5
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M1HMA]V%JE 7W?GKXG/4.P16(J96Y#<:6/, 9LY!^MVM,9:<5IQ>G#5\L%Z8
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MS'F*8JGIS8JO%CM&"OOD#H\GK+ZJQ6J&2[$C;F%;V*G!*6-'X##282<5%[
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M'R(RPS:*JXY]G6![<F'9DSOTZ).0&;EIY\X1P70X7H4!9!%LJ*YV>MRF/5#
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M@I)Q8'![6Y25< Y"0;[I#=@8"'#)6!!N?/E'(+\<,D$/5H 8"O\/4$L#!!0
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M).HD# AX"KJ8<NS7:(88%G%2D"2,OW^V3?<>/&_SZVV&I%O#*+M:O@LB!*G
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M%TZ#@=25+8"<=&I,MU ,?4(LG9<?\\C8:[&S&ZHI%D0):K03J'JYW7TIJ%&
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M)97<'9 F.YR+(S]*+'(.3G'8'R+-3"\])LYX:;\(HA@GMR_325A+1*3(V3*
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MP0S9-&DN'NW5B9/\V'Q?(B/F:E\BD4EQ7Q*4>;#=VU<C!?+W)5T38P(M=)K
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MCJ!,X1?ZZ>KX8VXD/IV_BY,U3,+=IY.?KI('+PK^(,J7?YV80KD\?3H'!1&
MJ "6S#1V>.H#;JE2=ZYL'XCTY-->\?YC-<4>H-2?%)_DZIA'"UIG@PE/FM^G
M6>+Y6=%/^HI8B9 U5X:",(*GPD57<CM!.]<+YQ3]W1H ';U5IV_5:=%.E%#5
M:3E&]!,O/(L6\.D#E!2+URN=TR1K9W$1\I?7T\D; ](:H.8NSCF=*JG7U^$-
MT&*A*UP@,8$K&*7!(SR+_'@-+V%VM;SSGN99E@3WVPQ')=_%]4"LXGPL6M9K
M9 &E"YZ?QVGZ8@80 [Q,(!8SP#+!EZF-:,&"CZ,MW$"SQ&I^T(FW6W?F71"A
M-1&_.UN<X50&#P$2<$XNOI'HPEAGTFN/= -5/T [$C2XK"LB'Q1/<RK38&3(
MYVB-6.!UXEWH/?0WX'5R5@)A6FQ%"::+-@ W<E?^C#OCA7UN#\0@:U9EZ*^W
M]V'@OPMC+QMJ<69)6BUNQS"6K\BT(2 MG9P%I/-?7XF;@S+ZAHNMWC5,@ACM
M]A8G7B:I JNJ;SY9>YLQ+O^NG3QMC#;S"X";N]J,25520$ \0,W3786G&_@0
MX+U]E.&#\5#??(.JC?L'$7/YIU^U)?4+7=>XY&NC;@$XP[.[PSK/@_X"<2()
MIHG;^K&,(+Q=4FLHAHOG7>+A8*3;W?H^#OM_1'5RUC9%-;:"[R9O V@C=]\+
M=\:+#Z4]$,L9T-%1*8%>"D\@_?,LNL(!L/GM;/2@\ D5)'#6.?JW%SC,E= !
M)2' _])<?&H:8^9]BMI39M?H24["@[L7KKT$+?).ZUB*1ZOI)A@G+$2F*<3Y
MV$M753:TCR2= JWIBX T+T/CA8]!D6XP"7#-9!A[_I'FFW@!2DJ@(N7XVU,?
M,T]]NC,V 6V69J&2+:_"AA]@ED$PAAJNS&M%?@8J!DQ,EY/SXC"3HP$%K>G6
M+6'%GFS>!:GOA?1\\P[]+.V_F1*3MG4L$4K0=3:E'8HC*NGBR- HZ:AY3.6/
M5[]^#G,/01Z\9C?%"]C;S,N&P(B4NK7]MTR*CCLEV@>4G0#MY>H64E5CC5LF
M\<@-SV4%$N]0N^$L":%FR97)\NPR%[B-:_\5.]-->U".P<H752QII,PZ?OX(
MD_24/(#",KSB3"3;,L]/1#MT[=!=K/WM8?'6<]'@S8QPW;#_#+UDE#6Z(FS-
M] H$4%R@<?OV\NQV?6YIA[\ZUX?JW$V2U^!+K[U=40Q!PSE2] 9Y=[>^Q\[1
MJ;E!N%,RF3OU/-=37LMVQ^1\^L$+(NSLD%^Y ^&5>Y%^K"!=RT.&B>>^%,='
M[UYSHWESKSK9SC_C$YS5,H&+XY67/&C[.(O>(.\^M<^X,3JUSY@[)78_8ZYM
M2;9P8>Z.S@E,V@W='J2RX>5.CN6OZQ)FU*6*O^_YHQ>$-.0*EVB)(W:#=^2E
M@2]S>=5\T*"DA7>TE!I@R<T (>BZ'*OF^ 5>+?TI-'%CY>?8BBS-ZGNUS5)<
M50>=:0?S5<AX6$*HFC0=G@L&=S- .P.FMT-_E[HR&VZ,KLFPZ3]GK-<\6O"/
M@QTW^#38G;1V;0NZ1M-QQR^9 9.O/?=750>IP2*IA)0M?MDB&03?<^&"9(_$
MK: JZ]]PEXJ*+U<Z6)O?J^0J]:PHPG*-W:-Q9"7TO60*<JX&P?#3NL VF4;-
M2V]S35E\5-&VA$,"3.A+'092$W&Y#H6E(75AU;E._1*Y]12F&\X].GDSQP?$
MFL@\97#&9#G6R$M7:*N"_\!@>/1"G)N$WJ,VCZE" X^C&TC]4OP7ALRLN$[F
MG.@=VVR-87,-LO:T6;2VUWEARKMX[B/A$MCT[8D4><U4M,R[MKVE+F/%.D?&
MTY7B=/2)%?@Q#K<1KHKT+@B161WJX-TD:_NM:8.__'1=-@:TM?MX (%6ZB=H
MWAB-7S@0&L=H+_\0)X.].*X3M>YOJ;&70X T!45;MV^-N:JHJ[X],LO1AHRC
ML,?VE^-MU=WC.G>U&NYE#>?0XEI<B8<K=/$"&8\@+MU VZ'S'$PO@BA.R+:<
MRHSV&74J=-=^03+KGE4)Y237*0PV2$TT;G@IN">2%'$HE#Y@&,P*F!$Q9U,]
M.EF<<L'ECEV-VS1:D@OCN>]OUUM<8V0Q7^.#),T+8_H*GB$'6'I.C9;^\#5O
MW:63V",9RB<8AA^B^$MTBTXDN,CJ&:ZHG RU11&1M[Y9$0@BW[;@3GN_XUZ@
MZ 9H/]=O-#O45M_.R,9NTT:(PXIN2&'./L%6%84I7OTW!JD7<]6<G,D$UMS
M1QAM=556!M;DW:<:6).+IQ=84YL2UX$UUPG<>,'B]&D#([&33J"FO#/(>[MT
M[G2-3$U%O-FP:?W*YTNY!,)M>?7PJVCI<O);8O-F6S VMXM+_>FNW,&I^-"Y
MX>B<BLGBC53MHQ#/D9G7L\P$Q*2;[;^7Y%*U]7".Q[PS61/3UEDR'YDN6IF;
MFH/35W]UC8@.*>2E#;O5:2M_Z:7W9$QY1XR -_LPS-+B)R2')P,% 0>;5J;.
M6@"#LA'XA31SDD1>KH[ZO6]K3 8OW5K4SH,(GJ&_2BX]!H! Q<7RMK@M03<:
M<%- VCI+S=JM)BXTZH/4]C>TZ-WZ,/*2(&8K&8^"CQHCJX$M' %$",F;."QL
MKZ0@+C):XRM7CGP<"#J_YS!'/T'_N$<[#VRR_Q]02P,$%     @ P88/26V!
M$)J,(@  J2 " !4   !B:6%D+3(P,38P-C,P7W!R92YX;6SM75MSVSBR?M]?
MH?6^G%-3'M\2>YV:[)9LV8DWLJ5C.<GD;&VE:!*2,$.1"DC*UOSZ!7B12(H7
M7 E1HY<9QY:Z&U\W&HU&H_'+/U]G=F<!D ==Y_W!R<_'!QW@F*X%G<G[@\^C
MP^[H^N[NX)__Z'3^\LM?#P\['X #D.$#J_.\[,#K__%G_]LY[%R[L_G(A)T[
MQ\=_-7VX /AW#J:+_XW_/O7]^;NCHY>7EY]-_%'/A AX;H!,X)%?= X/,8-.
MPN,: <+A7>?>=3K=8-(Y>=LY.7]W=OKN[6GGIO?4.3T^.8^^\Y=?;.C\_FQX
MH(,'XGCO#U*L7I^1_;.+)D>GQ\=G1\D'#Z)/OGLEO\A\_N4L_/3)Y>7E4?C7
MU4<]6/1!3/;DZ-?[_LB<@IEQ"!W/-QR3,/#@.R_\9=\U#3^$ME:N3NDGR+\.
MDX\=DE\=GIP>GIW\_.I9!R%P?^ET?D&N#1[!N!-*_LY?SL'[ P_.YC81*/S=
M%('Q^X-G:%B'!,'C\[-C0N)OY#??T7>L,,^UH46POS)L,I31% #_H$-(?WZ\
MRPSB&;K&S"+:.R)_/BK]]M$_5 OX?6@@X/A3X$/3L#TQ>?/$U(A_A^?8#(Q\
M_/,,<V,7.4_@2)X=C*88@:EK6]@KW/P(H+]\PD1.771&)V;%]XF4TK&\-KSI
MK>V^L(.X^N91['YDB/;@^N#DP? #!-SQ8$Z\)78 GN%8F+4/G8"8FCN^"CSH
M (_26EF)2C0'POIT%,QF!EJZXQ&<.'",IX;C=TW3#0CSR1 #:D+ ,!9:@G@<
MT@9Q-L0Z=WP&*5??D SGFT=@$_O#K@9/#F1@19JA/NE%*R<ASV$1/F][8 P0
M M8C6  G /02;GQ3]B0['X$)\7W$&8Y=- NG!+U\Q5^7+>3%*'CVP(\ ,[K!
M,/CAC)W-H$_O]NO)R)HEFQ/P:AG^M*23M.+[TCQ_>EX^&<\VB]?)?4^F<RFT
M)E;YJHA( Y!$JU9@X]7B%CK0!WT<K&-^V*0F$'/J>AZ($:)<[NGIR0Q25EQC
MS/*(L0I?1D:FD3"LX#W@&Y VEN6D+7>EH%S2F0?&2%>V T]\!K/<^2_*1;MT
M_6>6LY:25->=CPJ8Q2TC(#E$*W3%S,)64I$L<66(P"PY%34I<ZWGF@$AVG6L
M&SRC_25S-%=)88WR' &/C(3\NH\ERL@*7O%DM8"52$L(\^4[XFF.&=JNF>%A
MDV20BQ(6MO$,[/<'@7<X,8SY]]5>?D 64DP/&O;0]2 1M_OL^22OEL4REBY,
M%HT-[SG,&,7DC@C&1\#VO>0W(>J'QR=QXNAO3'RC59!_3/&2K%#Z=80A)"@V
M#'"'?_24"KOFLIY".0OMHJS\!C(3D?"/&^:9S1C&GSB:A[FL0W,*[95ECY$[
MX[,ZWRW7K(LL@*($LJBMC$S@& BZW5>H5@L91BNI=2HA,TT*X<Z"(P'UF-YG
MQYL#$T=7P.JY,P,Z2I O9;;RTIH54&1[&3V4PQ7KXCC2Q1:,I=Z84LXNEOXT
MEI[+EJ*MGLJU*L=A.W#>6#+26.<Q25E)!PL=A;+]",=2H4*)0K!YISG)=./P
MB/R/I.07ADVV)EW_VD!HB7=17PP[4+(^TS%.F9P&31;;;5J+E/!)4&Z'=^Y%
M&V+O$9@ RX=G_@/PKP.$PC2C@IE8Q4]W4%.OT&JX4LMJDY-TB,#<@-;-ZQPX
M'E"HO&)&.B.@>HV5@)-:MP2F'(^VDCS$M>OYGD)E%?+1'"_5JZL8G5A;9T+:
MX@]-5/K##(,6., L(+%BWK KQG=]P^Z+N3UW#I"_'-I&E,/!*^R<!%8/0)'W
MJ^"W_9JKABM6Y-N&EZ[\>0^6Y>;5M -21_;!=:T7:-LJ=$G%=[L7-CKH8KV>
M-[_.15*I\YE;KIYD^+$"+D0])*<6^M!XAC;T(?#PG!_YKOE[IL1*Y:Z;FO>V
M9'$J=^3T2$K8!HCJ.EZ@&])NGIO.F<EJ\"4JW@!P"_;H0V-)=IP-[,YSG/2F
M6>K-NFB'G@=+AOXXE8<"S&EC$(KT5\),LXMEUF$99C)\*^<T'/A3@!I59PW'
M5NFT#CTY"1FAC$Q<&=) 3B;'J4W^M0PL&2D:P:!'<92S"V&-B /=V(\PZ2LJ
M,QRDR@R[ZS)#\N_!JLXP+$LL#EU+*IFXB;=-I?PHRO"O+/K.U8%UTW5@8:$8
MDX+IJ;5-HPPXZ7*QS68-JO,$K=(M#8#\&73AN&>8L OE4W:47\1&<P4&B_(*
M49*3#>"JR,#>P774:FR#A]XB-Q9M;<*CZ5"^:UEA,:1A#PUHW3G7QASB^$G)
MKK^$E>XS*3;-E0(F96?(F;H)9D%XR2'<O9)N!0A,@>/!!8@N4O==S[MU$8 3
M)]H)F=%5"#O"V?HM\/SXC&TP?C)>%25]I(O9,M-1H2AM-0>/Y):$ ZP; SG0
MF7BIT>'--S2ADK"+@FN+%FT:#.5$7G(":FRDT<GMT$4AJ+Z/X'/@DQ3VD_O@
M8AMV?,P;4YN$S5* UU#PS269]@,]L>B<3QO\)11BF95D'/?0<5$HO3K[V.#1
MUBW9)E@2*F#D^8-FYK;V95[NIEJDVB4W!5646N@HL=B>HP61K'4)G+)*:\@E
MSZ/\+<]_-'GY,]\\:G\7='\7='\75$ %^[N@%7#O[X(J5<#^+JC 7=!LMCUL
M">AU W^*@_4_U@NMNN.)#8[;8E4;BTKY&<4F:KJ*W[)RX2!G@,(!66%N?@A0
M**IZK99RWIJEDT&]Y3!J+(XKLL [SPN:F[,QMZU8@YDG:P*5MK..(J$&@4\Z
M$Y-$6%-*3+-LIR8SH&D[0T@=@S;I=6G8MF)!I<)/Q@&"H'*;")"JV.E-+S'K
MLC0R$LSZ2M&BNN6RC%4[HI]2H.3<;92C/,5K926_EJJQ:*7DR.7F=:DAE9MO
MJL][%SI#166^MHR5T!G6/DV[W6G:&ONBS\P*XK[/S>YSL_O<; MSL_&E$V<2
M-U-2VK*OG-FVV%)EM%.!E:YD[ B$!4O12UQVU[&ZU@PZD(A%'MZ*!57B%^@X
MZUX@:^T[,\DHT=2E[8W!-#))-2<$F#18@)"LRY'\X7]8IXS'%-_IP]*MK_I=
M@;&+XGKF)^,5>/DB-FR%62I1I<P]\*<N_LL"1#7.2DRA2?';D'5J5)T2+_7R
MF.Z#Z[C)9(HDCJ>4R@"AGJGN]83.4"C T]@;X0..?8GY#1QBPD2<)X#P0A<_
MLR!?K=4,M4;>U&:>5F\-@)KZ.J=<3'AC)AJ.FG6AD)->%\ZER3+,Y)RZ<_E=
MX*\7""4^-L.@)?XT"PK_$:R<6QD9<71=ZV$78CM2'/2*9KJBPW)B>QD9@P,F
M)-.?,@=Q8U@8T([D39V-Q#7N5X8'3?6F4"]"&V)M9E@E7M7B[B16<DDUVA7@
M_< 0($C"?!,!PP,]$/U?:<I-@EAM,!<I\.MKK#M$[ACZJI;\%'7-B5:)LR37
M!WL%GZ;HF_62>O2P(HX[&^\MH$A2G8=QBLQ*E4YU-1,N&$HBU+9<5I<MHM:8
M5Y%92E<C?RY*SGZJ8D!;:(<,W1*V/6H2!IZCQ*ML\R79<!HVBE8$R95PQ:K\
MNZ;]4]+5)2G%#G=U>"GM03OPU930UK'<BO*B2H76@A8K];+QRPI?<7 TQ2)T
M%P 9$_ 0S)X!&HQ#*5-%H@UHF5.2%B3+>#%.PD_1^H6&JG+#\63:1#QA0J<N
M.CN04-J*\6JX%2H-8_&*S'W);@F7K8G,:"R/H8!72 D1=Q(?N XI/U!>QUO(
M<#M\;GT-9C%:^8)JOC H2UI=76\QHZT(>:J,,1/]%&.5+>H5O ET#\BBJF@S
MD6.R)5L(6O@+4)+@DDI:QJK30S7#[7!)M"JI 2]?,"ZEE:DZS91P:MDT*<,K
M5<0@\ Y578]<A?.&FGFK%A4&3%.5!YP+37%:39W.*OEM36!,JZIJ]%+U %OB
M,1J_W/.G[4%*ES^IZ#_)D1J9A^<XF#/RA>X,[*^AJ[F&SG':*DNE5>> ND[Z
MM^+<7KRV9^/\HODV2]>&-^W!!;2 8WDD[GYRH]:O1&3#65XMTWT%R-M0T((&
M4O2XG8 T+9GL G!+Z=TDIY-[\;&_"HN@Y-P.[=/"J/$)KGT%?U&L7EC!SU&L
MNP#HV?6 6-W 9N3W_;C!T'C+=56,#G]Q;!1&W3B6LKA8C?9J(^,MUV,=8OS]
MF0HUJJ%)$XD%;FWWY4#@V9[5:5Q"3&D+C$I^^U9-?XYSWU)+V_=KVH8LW+Y?
MDU(%[/LU<<S@E<L@/2-674ZZIH]WPN%S.BPO;U,3VQ:3*0QSZ"'1][+OGV0O
MR&J=]3M##;I:W]3QGMQ'8+J."6V0$>_))2,=(I>DGZRKY6>/- JEGHZR"A84
MR*G%G8J8C1IM:7QMH3LC5W;^"'$?C'LQ[VN\<9NHR117,]2ZOJJ<BADCJL9<
M5Y^W?8.>YDV!KJ</BV,H[3+!MXF([W=@\W1GI*^-,F,HX:2WB*(I,RB#66.[
MKOSA1FI,<7V?XK;BM-SU6(A($,$"K;;SY4TANZ;I!G@FX'D X$)5PH^*K\Z4
M#OO$J-9]$:P<(8!<O[\IYA"!N0$MA;U]:WGJ70MDZST/J-2U7I+2&]@/U#/5
MG4*7K?BR@)_%QY=H7M)"3RJ?UFN:YP%EC7YI..^:_HOAY2@24FH$R;(T-);-
M+_4)TUU3_0:H_ 5#/D#I>A2)01X*L C0>(9V&,DVIOD\WQT+\C9@%6@=F-6]
M"J_?N &4L]\U)U !-'^UDR)WD,0JCV !G*"A52#/=-<,8 -4_I(H*6I_ #YE
M#JOH\0%%YXLB$K4O)22J GF]J;G+ Z)G)"25!U01:T]Y0"4D^IJ]X^@S3FEW
MS1\!)"^'^(8S@3@B5;?9JV>Z%64$%%:<:0%;#Z6\7)Y$WUXPS ;]>!'W+?#9
MC+IG@5;>LSI<[5W&8V#Z@_'-JSG%U@D>L5D-'")\UPFKF4F]_<*PB24WM<0+
MR[0=I7B%BX \W"4<__!>+MP4L;G+8TS\6V (;'C*"N;D:;Z+/1U"2VR<7PQ;
MS3:0CO&6]%3@4/8&A/RIOZ(+XKRQ()6PBBXZT6M\-W2>NOW$D?3;O/W$JO,'
M-UQ[U@&*8]U"QW!,_DT;(\FMN(I1J$A6;.0\VL%_C?3.\P)@G2BIQ$K3U^-P
M^2QUXS;I"B1]Y=VC8#ZW0[,S[&2S<>>,732+<%1YZ8^2=0OB)VH4^3.I0O'R
MJB^  95TD\[0UQP#L1ETT;.'$4IRYB3O.4?R4JXZC659Z$Y:BF@M!Y:4Q&5S
M-[<?7!^</!A^@( [7N^M#1RM15MNO*S@OUP%'O9 GG? YP%ZT#-MU\-,GK"$
M5_C#OZOT[57L^-\4#$$:C!6?[6QRT1WC4R@OD_@KP$E:A-'@K#@=!;.9@9;N
M> 0G#AQ#TW#\N$0E?,S'AB;)7O+W"<U14GH_K9P;[P7J*E!6AJ(D<J/CK'O:
MU"LX$\-1PBEE)C4[D<Z&.(C%^_T_\=J1/_<J8*(H,*YEJSGT8EQ<J("4\]ID
M@S/DS2,(FQL/#>2G7RT,%Q?.AN#%!%7.G%J>W-.GC')#TXB%O>Y5AU;QV6[H
M#/"V,91[FZ\IXTY8Y0BM$5*Z)-4R%=CMEQ)7.J4HN&I-O%'K.3V/:*!LW=IT
M/@(3DADAQ1NKC(A ;[>(VB.8DUO^SD1IBK>,%W>?M!S!AB8+#5O=&;0:M6:V
M.C0HMG"?<T'Z&H,? :9ZLR"D20YM-H/A#7G>-$&.IMH^B&6\N.=+CJ#:65+*
M3/?<J%%A]BBG%+&6S8C-+,;5,OQI*?!"9-N39I\],!C?>#[$RZB:FM(<![UM
M8I@R8'EL])U*K[O98JPBFU7JN2KYZ=Y0LBFQ&CI99V/"^;=;Z$ ?].$"[WHC
MG]1 ]FV3:;MT2P&BMGXL\9:+-"&:.+"A>5O/M%T*I@!1RF,=<A3<P.7+>J9M
M5W#994NQ-SIX%'SK(@ GSG6 &3IF-G?I6.$_[>@XN8&9S2^,YHYL3.8@ #E_
MH:Y8%\8'\)(:(W(=_*,95N[$,C9@',PRM,M)L$,LI=I7SYETV"N<NX9CZXZF
M?_GKX6'GWU_OO[SYS[]_->?!ZS?G[:7UQ\5B\FWI?.X%+Q\NT.7%I]/?/C\M
M/?MB8?YQ;/_+OPP6C]Z_GGZ]!_?@I;_\>/GQTV_G=^?SYX79>_VMW_UT-GV^
M^?+TZ\ Z^7SQTR7\^.G;U?+T[?]]^G)^^7%@GSP<G[V>S,?C,]B].NG_N/KA
MH&/OX2?_QZ>3F^,K\^[B[&$VGHSN'J?G\$/O[<)#GGWY^,WTD#]X,L?F8/+_
MYR<?[SUT]_;C^0L(SH#Q YP=+_V/]M718'3L#R^_/3[_>'GX"02_G5V8Z&SR
MNK!//KPL;WWO_.N';^__T[D>/1X>\J:IS"FP AMO/U,A;3[:#2U%;0*+0PR=
M5P88C^ZY4);4[5?W><G:S?PICTU6FL^33D%TM8S_V- <8Q-%=PJ9Y7B%%^V6
M)9B3<;JU_H2Q\(S*43'= V.CR)^XK*#^ 2EZ[**6IYX=$9<2,YNC6BQES1>9
M:L:1>S +PG*>=!_]AA5?)H4F+ZK2%DH!%^AID>E:)=E BO;\T28_:;;?L*U0
M"*0CR%5I,S0ZX,^D2VA_6"'[ U 2<]9PW$''$0(IT,LB[R0:C[KB #*_RV'-
MI6R$J[7W?VN#K I"W*\%,L74RI[[Y!"#=\3E#/I*'PFEX:MW0:BW4X'M6/&[
MHH(OBR:W-V,FGO(71@L9ZKU)SS^#"Y^0+(94PKND$3V%;Y%F&.@^FJ RT8+B
MT9+'1YD@_SJX_MR',[Q 6U_[.":; 60OO_9^':")X<1Q_#V8/0-$M?XPD-N2
M/DUUF+, )&N[PZ3!*^@>=N]['UV;/)_NQ;(RZ*R20&OF1C4,TG82G+5T"/M9
M/) BK<@JG\NRT)VK975I&Q"E=@7:;5#2LDD538J\Q9PJ4@N[J'0=*^PD'_7G
M4%3>5\1)LV]G"-N+FL_D8=/UVN:?Y(UF4;45O]/,]4B6+Y1Q5-<9>]W^NG7:
MR?6X%FQ3NYT-@7K -Z#-?U%]ZTIH&,; !U5!=JBT?20_?5;'R\>K)!4D=3R9
MM(]6+TU9\")D%AN9'[%T)6FWZB_O@3\EK91)OTCBR39_"\"#,0/*\D(B\F@*
MYR5,[N(T((]*<E;!U>6^A(&Z3%,-1]W;- ES)-/-O@;?;*9JGZ=J3D-:TEC[
M/)9T/3:5YF)5'9;I\R<AW550V))#$V'-58$DZQ2<57=)TN/.^?SI'EC0-.SU
M0L^@01HZ.[+:44$FZ]E6%EW>W_5&L4#L4[#TRSLQ^\JAD?;&*N\^)=OMX@E_
M1=D6I(25KL51]O:B#,E\3EV:HA2>4)<RT^U$J\VU1A]E1]8R%*+N<*V8D=9L
M++<6"H)\&=4UU[;A>8-Q^*:&\LJ:#68[DAXI!S-W&LIU")TBJLYO%7#1OO6J
ML]',.70!2G*<%4#D:=YA$F&$'!2ZK IV6U)Y0Z..2M3R+HQ%+1: W_M@8M@W
M>*+ZRVJ7Y0'SYXF[.,)?(AIX0WX@P+]) 5]$4$OD+,DI%0*4VM1P(1[1JO,^
MM'!GJ.E8C2N,*($P.^(-3R)63O0O%SK^%RP<UG4#I44%[/2XDAK<J7 2.F-Z
M<!T33R8LIDU>8WUQ -KT(.7OX15^M^6;L%)(=.VO"P0J<CST6M*[_ZHQN1(5
MR"@1[J$'O%!C6K\!Q\%#9<@IE7Q5VXN!=0B6#57/B4@/=1T+@9=[Z)M38-M,
MP!=^=8N!+QZJGKK=IRE$T4L <<H0.SU@1JW"%M $^+^VBSTE@T(82>J(9BC4
MQ J,M$.-]JZ*@A5%J;92O!O_A'C7_!% +VII")!)@)R P?B+&Y7S16<:T:?0
MNE9.9B3)*4F+#*!?50K)JPAM/1;ZKA%VP>N31^>]1V "N" 6GGHKA?11LZQP
M+$IR?JPBZ%KAI!L+,_82^@JKLQ%]IM&R?94$FY#3@9CW0 9:T$#+ 2HZF+V.
MNH3 !4CY/1)G>%,X[XZQX^O:=N;I+T6'.7*%U!.L2;<N!=J3TBF9S1:C5#'
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M\0G!+T>$XK/A ?*O_P)02P$"% ,4    " #!A@])T5F/H0]G   Y[P0 $0
M            @ $     8FEA9"TR,#$V,#8S,"YX;6Q02P$"% ,4    " #!
MA@]),;H63"D+  #C70  $0              @ $^9P  8FEA9"TR,#$V,#8S
M,"YX<V102P$"% ,4    " #!A@])WS3  ;\(  #A7   %0
M@ &6<@  8FEA9"TR,#$V,#8S,%]C86PN>&UL4$L! A0#%     @ P88/2:?I
M^ -&(@  4!H" !4              ( !B'L  &)I860M,C Q-C V,S!?9&5F
M+GAM;%!+ 0(4 Q0    ( ,&&#TG22,)?BC@  !2P @ 5              "
M 0&>  !B:6%D+3(P,38P-C,P7VQA8BYX;6Q02P$"% ,4    " #!A@]);8$0
MFHPB  "I( ( %0              @ &^U@  8FEA9"TR,#$V,#8S,%]P<F4N
9>&UL4$L%!@     &  8 B@$  'WY      $!
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>